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ABSTRACf 
Malaria remains one of the most devastating tropical diseases, with staggering infection and mortality 
statistics. Over 200 million clinical cases of malaria (resulting in 1 - 3 million deaths) are reported 
annually. Africa bears the greatest burden of this disease. with the vast majority of malaria cases 
(>85%). and malaria-related deaths (>90%). being reported in sub-Saharan Africa. The main challenge 
to malaria control has been the development of clinically significant resistance Of the parasite to most 
known antimalarial drugs. This suggests that the development of new, highly efficadous drugs and/or 
treatment regimens for the management of malaria remains a key priority. 
This study applied molecular hybridization as a strategy in the development of novel potential 
antimalarial agents. The aim was to try and identify novel hybrid compounds containing scaffolds that 
are structurally related to the natural product curcumin, and which exhibit in vitro and in vivo 
antimalarial activity. Part of the study involved investigations into the pharmacokinetics and possible 
antimalarial mechanisms of action of selected target compounds. 
This work was carried out in three phases: 
A: 
Series of hybrid compounds containing chalcones and dienones (curcumin-related scaffolds) linked to 
either 3'-azido-2',3'-dideoxythymidine (AZT. an azide-bearing. relatively hydrophilic nucleoside analog 
with intrinsic anti-HIV activity) or 7-chloroquinoline (a known antimalarial pharmacophore present in 
several clinically available antimalarials) were designed and synthesized as novel hybrid antimalarial 
compounds. Hybridization was effected by application of the experimentally simple and robust Cu(l) 
catalyzed 1,3-dipolar cydoaddition reaction of azides and terminal alkynes (click chemistry), 
In vitro testing revealed that the acetylenic chalcone and dienone intermediates, as well as the chalcone-
AZT. dienone-chloroquinoline and dienone-AZT hybrid compounds, showed moderate antiplasmodial 
activity, exhibiting lower micromolar ICso values against three different strains of P. falciparum. 
However. the chaicone-chloroquinoline hybrid compounds 3.1Sb. 3.1Sc and 3.17b showed notably high 
in vitro antimalarial activity. all three exhibiting submicromolar ICso values. Compound 3.tSb was the 
most active, with ICso values of 0.04 f.lM. 0.07 f.lM and 0.09 f.lM against the Dl0, Dd2 and W2 strains 
of P. faldparum, respectively. The presence of the chloroquinoline moiety on the three more active 
compounds was most likely responsible for the improved activity that these compounds exhibited, 
though this significant improvement in activity was not universal. 
A limited mechanistic investigation carried out on the chakone-chloroquinoline hybrid compounds 
suggested that inhibition of hemozoin formation was likely to be a primary mechanism of antimalarial 
activity. particularly for the hybrid compounds 3.1Sb, 3.1Sc and 3.ISe. which were all comparably or 
more potent than chloroquine in inhibiting ~-hematin formation. The moderate inhibition of Faldpain 
2 suggested that this mechanism could also contribute to the overall observed antimalarial activities of 
these compounds, albeit to a limited extent. Inhibition of parasite-induced new permeability pathways 
(NPPs) did not appear to be a notable mechanism of action for these compounds. 
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B: 
The next phase was to identify analogs of 3.15b (and intermediate 3.19) with improved predicted 
physicochemical and pharmacokinetic parameters, factors which could potentially translate into 
improved oral bioavailability. To this end. three software packages with varying but complementary 
capabilities were applied for use in the in silico prediction of various physicochemical and ADME 
parameters. By the rational replacement of the triazole linkers in 3.15b and 3.19. several analogs were 
proposed that had improved predicted solubilities relative to their parent compounds, particularly at 
lower pH. The analogs also maintained acceptably high predicted Cac02 permeability. The main alert 
was their possible metabolic instability, primarily due to N-dealkylation of their nitrogen-containing 
linkers. The in silico solubility and metabolism predictions were supported by experimental solubility 
determinations and in vitro metabolism studies. 
All the target analogs exhibited notable antimalarial activity. with ICso values in the lower micromolar 
to mid-nanomolar range, though none were as active as 3.1Sb. The related analogs 5.13 and 5.15. both 
of which were analogs of 3.1Sb that bore piperazinyl linkers. were the most active of the analogs. These 
compounds had ICso values between 0.3 - 0.6 nM against three strains of P. faldparum. The analogs 
were also very potent inhibitors of ~-hematin formation, more potent than chloroquine. Compounds 
s.n and S.tS were extremely potent, with the lowest ICso values of 0.2 equivalents. This suggested that 
inhibition of hemozoin formation could contribute substantially to the antimalarial action of these 
compounds. The analogs showed moderate to poor inhibition of Fakipain 2. and were poor inhibitors 
of parasite-induced new permeability pathways. 
C: 
Compounds 3.l5b and SJ3 were selected for preliminary PK profiling and in vivo antimalarial testing in 
mice, and were administered in different formulations and at varying doses. The DMSO-water 
formulation afforded notably higher oral bioavailability for both 3.1Sb and 5.13 relative to the other 
formulations used for the PK studies. Compound 3.1Sb exhibited a bi-phasic PK profile after oral 
administration as a DMSO-water formulation. which was most likely due to staggered absorption in 
separate sections of the GI tract. Also. significantly higher exposure and drculating concentrations were 
observed for 3JSb compared to 5.13 after oral administration. The rapid decline in the drculating 
concentrations of both compounds after IV administration indicated an extremely effldent clearance of 
the compounds. possibly a combination of both hepatic (metabolic) and renal clearance. The two 
compounds did not exhibit significant in vivo antimalarial activity. showing only marginal improvement 
to the untreated cqntrols in terms of suppression of parasitemia, decline in average mouse weights and 
-, 
overall mouse survival. This activity was significantly inferior to that observed for chloroquine. 
Compound 3.1Sb showed slightly better efficacy that 5.13. with a notably slower rise in parasitemia in 
the middle and later stages of the study as well as more mice surviving for longer (relative to their 
respective untreated controls). 
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CHAPTER ONE 
INTRODUCTION 
1.1 Preamble 
This chupter introduces malar ia: rhe aetiology. geographi<al distribution. impact and 
pre~entation of the di~ea5e. II then goes on to highl ight some or the measures available 
to control the disease, focusing on available antimalarial drugs and the main challenges 
associated with their use. 
1.2 Malaria 
M alaria refers to the clinical disease caused by infect ion of humans by prelawu of the 
Plasmodium genus. Four species of Plasmodium are known to infed humans: 
PlaJmodium faldparum. P. vivax. P. ova/e and P. malariae. Other species of 
Plasmodium are pri rnarily parasites of monkeys. birds and apes. uffecting man on ly 
rarely .:md no t seriously [1.2J. 
1.3 Geograph ical Distribution of the Plasmodium Species 
Malaria risk 
_ StOtbie 
_ Unsta/:>loj 
M;>Ianal,,,,, 
t" .,,_,. ' .... '" So.". (11)00) "loS_. ~' 1) ,,' l. """,,&,,, ... 120(1)_. """-..... I 17 
r...,.,.. ..... (LWII;PI<>S_. I017)_ 
t ...... '11"" ' ____ 10 ... ____ "'-" I""'" """" ....,,,. .. '"' ) _. CI_ CoroMono 
_ ....... ~Gl __ I"""" ... ..,._<'Il) 
Figure 1.1 : Map $howing 'h~ global d istribution o f malaria [3] 
As can be deduced from the map above (Figure 1.1 ), malaria is predominantly a 
trOpical dilease, being highly endemic in sub-Saharan Africa. Central and South 
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America. and Asia. However. parts of the Middle East and the Western Pacific also 
bear some of the global burden of malaria. albeit to a much lesser degree [2.4]. 
P. falciparum is the predominant species in Africa though P. vivax and P. ova/e also 
occur. P. ova/e seems to be restricted to western Africa [2]. P. vivax is thought to be 
responsible for approximately 1-20% of malaria infections in tropical Africa. and also 
for 50% of the global non-African malaria burden [5]. 50-70%_of malaria infections 
in south Asia. the western Pacific. and South America. rising to ao-l00% in the 
subtropical and more temperate regions of Central America. the eastern 
Mediterranean. the Middle East, and south-central Asia, are also attributed to P. vivax 
[6]. Both P. vivax and P. faldparum are found in South America. other parts of Asia 
and the western Pacific. P. ma/ariae is made out to be in only a few pockets around 
the world. but is probably more wide spread than has been hitherto anticipated [21. 
1.4 Impact of Malaria 
Approximately 2 - 3 billion people, representing a significant proportion of the world's 
population, are at risk of infection in over 109 malarious countries and territories, and 
it is estimated that, at anyone time. 1 billion of these people are carrying the malaria 
parasite [4,7]. 
Malaria remains one of the most devastating tropical diseases [8], with staggering 
infection and mortality statistics. The WHO Malaria Report 2008 estimated that 247 
million clinical cases of mala ia were reported in 2006. 80-90% of these being caused 
by P. falciparum [4.9J. The vast majority of malaria cases (86%) were reported in 
sub-Saharan Africa, with East Asia and the eastern M~iterranean accounting for just 
9% and 3% of the reported cases.. res~ttiveiy [41: This pattern of geographical 
distribution of the disease. which has Africa bearing the greatest burden. has been 
conSistently replicated in other global heafthreports over the years [9-11], 
P. falciparum is responsible for practically all mortality and most of the morbidity 
associated with malaria [2]. and. with the bulk of P. faldparum infections being 
reported in sub-Saharan Africa [5], it comes as no surprise that by far the majority of 
malaria deaths (in excess of 90%) occur in tropical Africa [4.10]. However. the 
proportion of malaria burden is somewhat lower in the southern Africa sub-region 
than in the high transmission regions [12] of the central. eastern and western sub-
regiOns of Africa [10]. 
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In the year 2000. the WHO Expert Committee on Malaria reported an annual death 
rate from malaria of between 1.1 and 2.7 million people [9]; these figures have since 
been reviewed downwards, and current reports put the tally at between 0.6 - 1.2 
million deaths a year, with 85% of these deaths being children below the age of 5 
years in sub-Saharan Africa [4]. Occurring mainly in rural areas [12], this corresponds to 
about 18 - 25% of the total mortality of children under the age of 5 years in this 
region, with death resulting mainly from cerebral malaria and anaemia [9,10.12]. 
Fatalities of 10 - 30% have been reported among children referred to hospital with 
severe malaria. especially in rural areas where patients have restricted access to 
adequate health care [9]. Even more worrying are the reports indicating that as low as 
one in five malaria deaths are actually reported [4]. 
Though the malaria toll in terms of human life is rather obvious from these statistics, 
the attendant economic burden resulting from treatment and prevention initiatives. 
though less obvious, is also equally staggering. Annually, it is estimated that affected 
African countries spend in excess of USD 12 million in malaria treatment and 
prevention programs [5]. Studies in several sub-Saharan African countries have 
reported that as much as 28% of household incomes in less-privileged populations 
may be spent on malaria treatment, with costs ranging from $4 to as high as $60 per 
patient for in-patient treatment; out-patient treatment costs are somewhat lower, in 
the range of $1 to $3 per patient [13J. 
Malaria also poses a great burden to health care facilities in endemic countries, being 
responsible for 20 - 35% of all out-patient clinic visits as well as 20 - 45% of hospital 
admissions. It is a major contributor to in-patient deaths in these countries. mainly due 
to late presentation. inadequate clinical management and the unavailability or stock-
outs of effective antimalarial drugs [10]. 
1.5 Transmission and life Cycle 
Knowledge of the life-cycle of the malaria parasite. particularly the human phase of the 
cycle. IS,., necessary for the understanding of, among other things, the clinical 
presentation ofthe disease (Section 1.6). the microbiological diagnosis of the disease. as 
well as certain aspects of in vitro antimalarial testing (Chapter Four). 
The malaria parasite is spread by the female Anopheles mosquito [2,14]. Sixty species 
of this mosquito have been identified as vectors of human malaria. and their 
distribution varies from country to country [2]. 
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The life cycle of all Plasmodium species is complex (Figure 1.2). involving both sexual 
and asexual repl ication. Infection in humans begins with the bite of an infected female 
Anopheles mosquito. As the mosquito bites to get a blood meal to nourish her eggs, 
she injects sporozoi tes in her saliva into thf> blood~tream of her victim. Sporozoi tes 
represent the termin(l l st(lge of the parasite's life cycle in the mosquito (15.16). 
-- -. 
i 
i 
o 
Figure 1.2: Schematic; diagram outlining the asexual life cycle of the Plasmodium parasite [17J 
The injected sporozoites quickly invade liver cells (hepatocytes). and have been 
re ported 10 disappear from peripheral circulation within 30 minutes to 1 hour after the 
mosquito bite. This liver-stage. also caBed tissue phase or pre-palent period. lasts for 
different periods depending on the infecting species: S - 25 days for P. falciparum and 
S - 27 days for P. vivax [2 1, During Ihis phase the parasites dilterentlilte ilnd undergo 
asexua l multiplkation resulting in tens of thousands of rnerozoites. The invaded 
hepatocytes. now filled wilh merozoites and referred 10 as hepalk sc.hizonlS. lyse 10 
releilse the merozoile~ inlo circulation 12.15J. In the casc of P. vivaxand P. ova/e. some 
sporozoites may go into hibernation w ithin hepatocytes. and in this stale are referred 
to as hypnozoites. This latent phase is sometimes lermed the cryptobiot ic phase. and 
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the hypnozoites can lie dormant for month~ or yean. and on reactivution can caU5e 
clinical r(! l ap~(! 121. 
Upon release from the hep..lfocyfes, individual merozoites attach onto the red blood 
cell (erythrocyte) membranes and, by a prCK:ess of invagination. invade them. Here. 
asexual multipliciltion continues. ilnd each merozoite repl icate~ producing 12 - 16 
progeny merozoiles. Parasitic development within the erythrocytes can be 
microscopically characterized as prCK:eeding through the stages of rings. trophozoites. 
E.><Iriy schl.lOnts and mature schiLOllts (Figure 1.3); each mature schiLont contains tem of 
erythrocytic merozoites [2.15], 
Mature erythrocytic schizonts then lyse to releiue thele merozoites into the 
bloodstream. These merozoites immediately invade other un infected red cell~. and the 
erythrocytic cycle of invasion - mult iplication - release - invasion begins again, The 
lengtl1 of this intra-erythrocytic cycle depend5 again on the infecting 5pecies: about 48 
ho..m in P. vivJx. P. ov,11(' and P. falciparum inrectiom and 72 Ilours in GHe of P. 
m,llariae infection. It occurs synchronously ilnd tile merozoites are released at 
approximately the same fi rne of the day. Tile contenh of the infected cells that are 
released upon their lysis s!imulate the release of Tumour Neaosis Factor (TN F) and 
other cytokines, which resulr in rhe characteristic clinical manifestations of the disease -
fever and chills 12.151. 
( 
Figure 1.3: Tr-tin blood smear micrographs ~howing intra-erythrocytic development of P. 
(J/ciparum through the r ing (A). trophozoite IS) and schizont (C)stages [l6J. 
It should be noted. however. that not all o f the merozoites divide inlo schizonls. Some 
differentiate into Ihe sexual forms of the parasite. i.e. male and female gametocytes. 
Mature gametocytes appear in the peripheral blood after a variable period (8 - II days 
for P. (aldparnm). and it is theie gametocytes that are tilken up by a female Anopheles 
mosquito during a blood meal. whereupon the parasite commences fhe sexUill part of 
ils life cycle. Gamelocytes may persis! in circulation for several weeks [2.15[. 
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Within the mosquito mid-gut. the male gametocyte undergoes a rapid nudear division, 
each producing eight flagellated microgametes. These then fertilize the female 
macrogamete resulting in an ookinete that traverses the mosquito gut wall and encysts 
on the exterior of the gut wall as an oocyst. Sporozoites rapidly develop asexually 
within the oocyst. which soon ruptures. releasing hundreds of sporozoites into the 
mosquito body cavity. These sporozoites eventually migrate to the mosquito salivary 
gland. and during the mosquito's next blood meal. get injected into the victim's 
-
bloodstream along with mosquito saliva [2.15]. 
1.6 The Clinical Disease 
The initial phase of infection. during which sporozoites invade and develop within 
hepatocytes. is accompanied by few symptoms. if any. Rarely, vague aches and pains, 
headache and nausea may be present. Such symptoms are usually atypical. and may 
resemble any febrile illness; this is termed the primary attack [2]. 
Clinical features of malaria occur during the subsequent erythrocytic phase of the 
infection. and are more profound and severe in the case of P. fa/dparum malaria. 
Upon invasion of the erythrocytes. the parasite rapidly and efficiently degrades and 
consumes intracellular components. principally hemoglobin. Hemoglobin degradation 
is an important source of free amin  adds for the parasite. useful in the synthesis of 
parasitic proteins (section 1.7) [18,19]. This metabolic process results in the formation of 
hemozoin (malaria pigment) which. coupled to parasite-induced alterations of the red-
blood cell membranes. eventually leads to the lysis of the erythrocytes [2.20]. 
This rupture of erythrocytes releases certain factors and toxins such as 
phospholipoproteins. erythrocyte membrane products, malaria pigment and malarial 
toxins. which in turn directly induce the release of cytokines such as TNf and 
interleukin-1 from macrophages. resulting in chills and high grade fever. This is why 
malaria is essentially a febrile illness characterised by fever and related symptoms [2]. 
Due to the relatively synchronised lysis of erythrocytic schizonts and the subsequent 
release of pyrogenic substances. the febrile symptoms of malaria follow a similarly 
regular pattern, recurring and escalating in intervals of 48 - 72 hours (depending on 
the infecting species). In malaria due to P. vivax and P. ova/e. this typical pattern of 
fever recurs once every 48 hours (Benign Tertian malaria). However. in P. falciparum 
infection (malignant tertian malaria). this pattern may often not be seen and the febrile 
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episodes tend to be more frequent. In P. malariae infection, the relapses occur once 
every 72 hours (quartan malaria) [2]. 
The typical ··text book" presentation of malaria would involve the above described 
febrile episodes. which would ideally be characterised by three phases [2]: 
• Cold phase. characterized by shaking chills usually at around mid-day and lasting 
for 15 minutes to 1 hour: 
• Hot phase. evidenced by a high grade fever which lasts 2 to 6 hours; 
• Sweating phase, characterised by profuse sweating and the gradual subsiding of the 
fever over 2 - 4 hours. 
These febrile episodes are usually accompanied by head aches. vomiting. delirium. 
anxiety and restlessness. which are. as a rule, transient and disappear with 
normalization of body temperature [2]. 
However. this classical presentation is rarely observed as described, and malaria is also 
known to present with a myriad of atypical symptoms such as atypical fever. 
headache. body aches. back ache and joint pains. vertigo. altered behaviour. acute 
psychosis. altered sensorium. convulsions, coma. cough. breathlessness. chest pain. 
acute abdomen. weakness. vomiting and diarrhoea. jaundice. pallor. puffiness of 
eyelids. hepato-splenomegaly and combinations of the above. This picture is usually . 
further complicated by the common presence of secondary infections as well as 
symptoms of adverse drug r actions to administered antimalarials [2]. 
1. 7 Hemoglobin Degradation 
Of special interest among the parasite's many metabolic pathways is the process of 
hemoglobin degradation. by which the erythrocytic parasite breaks down the host cell 
hemoglobin and utilises the resulting amino acids and iron for its own metabolic 
processes. Interest in this process stems from the fact that it is essential for the parasite's 
.,.,.. 
survival [18,2'0,21]. 
Though the malaria parasite has the ability to synthesize asparagine. glutamine, glycine. 
proline. aspartate and glutamate [22]. hemoglobin degradation appears to be a critical 
source of amino adds for parasite utilisation in protein synthesis and energy 
metabolism [18]. Hemoglobin is also an important source of parasitic iron. which it 
utilises in the synthesis of iron-dependent proteins such as the enzymes ribonucleotide 
reductase, superoxide dismutase and cytochromes [20.21]. 
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However, hemoglobin is a poor source of the amino acids methionine. cysteine and 
glutamine and contains no isoleucine at all - these have to be taken up by the parasite 
from the host cell cytosol. The entry of these amino acids into infected erythrocytes is 
facilitated by the presence of parasite induced transport channels, dubbed new 
permeability pathways (NPPs), on the erythrocyte membrane [23]. Upon entering the 
infected erythrocyte. uptake of isoleucine by the parasite has two components: one 
component involves the influx of isoleucine via a saklrable. A TP-independent 
,'" 
transporter capable of exchanging intracellular leucine for isofeiJcine; the second 
component involves the glucose/ATP-dependent active accumulation of the amino 
acid within the parasite [24] 
Hemoglobin uptake is primarily by trophozoites and early schizonts, and has been 
shown to involve the process of micropinocytosis. Host cell (erythrocyte) cytoplasm is 
taken up by the invagination of the parasitophorous vacoular membrane and the 
parasite plasma membrane resulting in the formation of large. double-membraned 
cytostomes. Smaller, double-membraned vesicles then form by budding from the 
cytostomes. and these migrate and fuse with the acidic food vacuole of the parasite. 
These digestive vacuoles have an internal pH of 5.18±0.05 [25]. and are the definitive 
site of hemoglobin degradation [20.21]. 
The process of hemoglobin dissociation and metabolism within the parasite has been 
demonstrated to be a semi-ordered. enzymatic process involving distinct classes of 
enzymes (Figure 1.4) [21.26]. Initial deavage of hemoglobin into its heme and globulin 
components has b en demonstrated to be effected by aspartic proteases. specifically 
the four highly homologous Plasmepsins I. 11. III (more commonly referred to as histo-
aspartic protease [HAP]) and IV. Cysteine proteases may also play an albeit unclear 
role in this initial cleavage. either directly in a so far undefined role. or indirectly via 
participating in the processing of aspartic proteases [20.21.26-30]. 
The subsequent breakdown of the globulin component into smaller globin fragments is 
known to involve the activity of cysteine proteases. principally Falcipain 2 and 
Faldpain 3 [27.29.31]. This process proceeds quite rapidly. with the Faldpains deaving 
the polypeptide at multiple sites [32]. Aspartic proteases have also been demonstrated 
to playa role at this stage as well. with HAP being the most efficient of them [28]. 
The smaller globin fragments are then substrates for the metalloprotease Faldlysin. 
which breaks them down to even smaller peptides. usually containing 6 - 8 amino add 
residues [33]. These are then substrates of dipeptidyl aminopeptidase 1 (DPAP1). a 
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pla ~modial ort r1ologue o f Cathep~in C. which further reduces these small peptid es to 
dipept idcs (3 41 . small enough 10 exit the paras i te'~ food vacuole. In the cytoplasm, 
these dipept ides are sutxl rates for neutral aminopeptidases such as M l alanyl 
aminopeptidase (PfM 1AAP) and M17 leucine aminopepl idase (PfMI7lAP). These are 
zinc melalloenzymes that concl ude rhe globulin catabolism, releasing free amino acids 
available fo r parasite uti lization (1 7). 
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Figure 1.4: Hemoglo bin degradation pathway in PfaJmooium food vacuole 11 7) 
Heme is toxic to the malaria parasite. and is efficiently d etoxified by conve~ ion into 
the crystalline Ilemozoin, an almost inert fo rm of heme. The course o f detoxifica tion 10 
hemozoin has been reported to be a two-step process involv ing histidine-rich pro teins 
and lipids [35J. Thi s hemozoin consists of chaim of dimeric heme units fo rmed tty i ron-
carboxylate bonds invo lving the central ferric iron o f one heme unit and the 
propiona te side chain o f the adjacent heme unit (Figure 1.5) . These dime ric Ilclne unih 
then interact via hydrogen bonding to fo rm the chaim that constitute (ry~ta ltine 
hemozoip [35 ,391 , 
In v iew o f (he above description, it can be seen that Ihe hemoglobin degradation 
proces~ offer~ a pletho ra o f pot ential antimalarial drug targeh. £~t abli\hed antimalari al 
drug~ (c,g, the quinoline·based antimalarials chloroquine and amodiaquine) ad by 
inter fering with hemozoin fo rma tion (Section 1.9 .1.4). The myriad o f enzymes 
involved o ffer al ternative antimalarial ta rgets, and Plasmepsin inhibito rs (40 ], Falcipain 
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inhibitors [31] and even inhibitors of plasmodial neutral aminopeptidases [17] have all 
been studied as potential antimalarial agents. 
Figure 1.S: Partial structure of a p-hemeatin chain. clearly showing the dimeric heme units linked 
by ferric iron-propionate linkages [38] 
Interestingly. another aspartic protease. Plasmepsin V. does not seem to be involved in 
hemoglobin catabolism. This plasmodial aspartic protease is located in the endoplasmic 
retirulum rather than in the addic food varuole and appears to be involved in the 
processing of the over 300 proteins exported from the parasite into the host 
cell/erythrocyte. These proteins are usually destined for the erythrocyte membrane or 
cytoskeleton. where they play roles audal for parasite survival in the host cell [41.42]. 
This enzyme is therefore essential for parasite survival. and offers yet another novel 
target for therapeutic intervention. 
1.8 Strategies for the control of malaria 
The control of malaria can be considered on two levels. i.e. pre-infection (before the 
infected mosquito bites and infects the human host) or post-infection (after the 
infectious bite by the vector). 
The main strategies towards pre-infection control involve preventing access of the 
vector to human hosts. These include: 
.. Indoor residual spraying: this is the application of insectiddes to the inner surfaces 
of dwellings. where mosquitoes are likely to rest after taking a blood meal [4]. 
.. Use of insectidde-treated nets OlNs): there is strong evidence that the widespread 
use of ITNs can significantly reduce the inddence and effects of malaria in endemic 
areas [43]. 
.. Use of insect repellents: certain chemicals, when applied on the human skin. 
strongly discourage the approach by mosquitoes and other arthropods. Such 
chemicals are therefore useful in preventing mosquito bites, and examples include 
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diethyl toluamide (DEfT). which has been used for a long time and is considered 
safe and reliable [44]. 
After an infectious bite of a human by the vector (i.e. post-infection). the only recourse 
is the use of antimalarial drugs. The drugs may be applied to: 
• Prevent the clinical establishment of the infection, referred to as chemoprophylaxis; 
• Eradicate the parasite and manage the disease after the establishment of clinical 
manifestations, referred to as chemotherapy. 
• Prevent maturation of the parasite and onward infection of the vector -
prevention of transmission. 
These are elaborated in detail in the following section. 
Chloroquine Amodiaquine 
Dihydroartemisinin 
Artesunate 
Proguanil 
o 
CF3 Mefloquine 
CI 
Atovaquone 
Figure 1.6: Examples of drugs that are currently in use as antimalarials 
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1.9 Current Therapy 
1.9.1 Classification o f available antimalarial agents 
Antimalarials may be classed based on their: 
• Chemical structures; 
• Stage of the parasite life-cycle upon which they act: 
• Clinical application; 
• Mechanism of antimalarial action. 
1.9.1.1 Classification based on chemical structure 
Table 1.1 : The various classes of available antimalarial drugs (based on chemical structure) 
[2,45.46J 
Class I Examples 
4-am in CXju inoli nes : Chloroquine. amodiaquine 
---- _ ... _- '.-•.. -_._.. , ...... , -,---.-.--.-.- ,-"~ ---~-, ._ .. '--~---.~- -_ .. -
- ----
8-aminoquinolines 
• 
Primaquine 
: . ---_ .. - -'-"'-
-
, - " .. -- .. ,'''" .. 
- --
Acyl amino alcohols 
, Quinine. meflCXjuine. 
- - ----_. __ ._--_._---- - - - -_. __ .. - ---_._- - ------_._--_.-
Phenanthrene methanols ! Halofantrine. lumefantrine 
- -_._---_._.- ----_ .. __ .. -- - - ----_ .... _._ ... - - -'- - "._._--
----
----.. __ .--_._-----
Diaminopyrimidines Pyrimethamine 
-----_ .. -
- _.-
--
Sulfones Dapsone 
- -
Sulfonamides Sul fadoxine. sulfadiazine. sulfalene 
------ --- -
- - - _._._--.- --- _._._._. __ .- -
-
---- _ .. - -
--_ .. _- ._._,"m 
"'"'--
- -
8iguanides , Proguanil. chloroproguanil 
--
_._._._---_.-
- -- _ .-
- ----
-- - --_.-
Peroxides/sesquiterpene lactones Artemisinin (Qinghaosu) derivatives and analogues· 
artemether. artesunate 
- _._.-
---- - - -_._.-
-_._---._ .. _._- - -_ .. __ . __ ._--
- -- _._.- - - _._--- - -.... _ .... _-- .. .. .. " .... _-_.".-
Naphthoquin one, Atovaquone 
-
-------_._----- -- -_._---
- -
Miscellaneous 
Antibiotics (tetracycline. doxycycline) ; Iron che/aring agents 
(desferrioxamine) 
1.9.1.2 Classification based on the stage of the parasite life-cycle upon which they act 
The various stages of the asexual (human) phase of the malaria parasite life cycle are 
distinct from each other not on ly by way of their morphology and metabolism. but 
a lso in their drug sensitivity [47]. and this has been used as a basis for the classification 
of antimalarials. 
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prevention (suppression) of acute clinical symptoms. The slow onset. longer acting 
blood schizonticides pyrimethamine. atovaquone. sulfonamides. and sulfones are 
useful for malaria cases presenting with less severe symptoms. or for combination 
therapy with the rapid-onset blood schizonticides [2.48.49]. 
Anti-relapse antimalarial drugs are essentially those that have hypnozoiticidal 
activity/activity against the exo-erythrocytic phase of P. tJtvax~ and P. ma/ariae 
-infections in the liver. Primaquine is useful for this purpose. usually being administered 
after the treatment of the primary attack in order to effect radical cure by eradicating 
the hypnozoites of P. vivax and P. ova/e, which are responsible for relapsing infections 
[2.47.49]. 
1.9.1.4 Classification based on mechanism of antimalarial action 
Inhibitors of nucleic add synthesis - folate antagonists 
The folate pathway is involved in the generation of tetrahydrofolate. a necessary co-
factor for the biosynthesis of purine nudeotides, thymidylate and certain amino adds. 
Antimalarial drugs that inhibit this pathway therefore cause a decrease in purine (and 
hence DNA). serine and methionine synthesis by the parasite. Traditionally. antifolates 
are classified into two classes based on their target enzyme: dihydrofolate reductase 
(DHFR) inhibitors and dihydropteroate synthase (DHTS) inhibitors. These two enzymes 
are essential components of the folate pathway. 
The sulfonamides (sulfadoxine, sulfadiazine, sulfalene) and the sulfones (dapsone) 
mimic palO-aminobenzoic acid (PABA). thereby competitively inhibiting DHTS and 
interfering with the conversion of dihydropteroate from hydroxymethyldihydropterin. 
Pyrimethamine and the biguanides (proguanil. chloproguanil) inhibit DHFR, thus 
preventing the NADPH-dependent reduction of dihydrofolate to tetrahydrofolate 
[50.51]. 
Inhibitors of mitochondrial respiration 
Atovaquone. a hydroxynaphthoquinone. has been shown to act on the mitochondrial 
electron transfer chain. where it interferes with the functions of the parasite's 
mitochondrial cytochrome bel complex by mimicking the natural substrate ubiquinone 
(co-enzyme Q) [52-54]. 
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There is evidence that artemisinins could also possibly exert their antimalarial activity 
by interfering with mitochondrial function. Based on experiments carried out in yeasts. 
it has been proposed that the mitochondrial electron transport chain activates the 
artemisinins. causing the local generation of free radicals/reactive oxygen species that 
subsequently damage the mitochondria and cause its depolarization [55]. This proposal 
is further supported by the fact that artemisinin has been shown to inhibit the 
mitochondrial respiratory chain of both sexual and asexual stages of P. faldparum [56]. 
Inhibitors of hemozoin 03-hematin) formation 
As mentioned previously. heme is a by-product of hemoglobin metabolism by the 
malaria parasite. and is efficiently detoxified by conversion into the crystalline 
hemozoin. an almost inert form of heme [35]. Hemozoin formation is a validated 
target for most of the well-known antimalarial drugs, including the 4-aminoquinoline. 
quinoline methanol and phenanthrene methanol antimalarials (chloroquine. 
amodiaquine. quinine. mefloquine. halofantrine. and primaquine) [57-59]. 1l-1l 
interactions between the quinoline (or the equivalent polycyclic) nucleus and the 
electronic system of heme monomers or dimers appears to be the basis for this 
inhibition. resulting in the inhibition of hemozoin formation either directly by 
inhibiting heme aggregation or indirectly by enzymatic inhibition of a protein that 
catalyses hemozoin crystallization. The resulting ad ducts and/or the accumulating free 
heme are lethal to the parasites. inducing oxidative stress and leading to the oxidative 
damage of vital intracellular components [37.60,61]. 
Inhibitors of P. faldparum ATPase (PfATP6) activity 
Artemisinins have been shown to inhibit PfA TP6, a plasmodial sarco/endoplasmic 
reticulum Ca2+-A TPase (SERCA). This observation was made possible by transfection 
studies. where the PfA TP6 was expressed in Xenopus laevis oocytes. Thapsigargin. a 
sesquit~rpene lactone and a known highly specific SERCA inhibitor. has also been 
shown to oompetitively antagonize the parasiticidal activity of artemisinin. This 
inhibition of SERCA by artemisinins was proposed to occur after the activation of the 
artemisinins by iron when it was shown that chelation of iron by desferrioxamine 
diminishes the antiparasitic activity of artemisinins and correspondingly attenuates their 
inhibition of PfATP6 [62]. Some controversy still surrounds this proposed mechanism 
of action. largely because many aspects of this hypothesis still need to be examined 
[63] and the fact that results are often dependent on the methodologies used to study 
this inhibition [64]. 
. . 
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1.9.2 Resistance to rurrentiy available antimalarial drugs 
Current therapy of malaria faces major challenges such as poor toxicity profiles and, 
partiruiarly. the development of dinically significant resistance of the parasite to most 
known antimalarial drugs. P. fa/dparum has been observed to have developed 
resistance to all the major dasses of drugs (amodiaquine. dlloroquine. mefloquine. 
quinine and sulfadoxine-pyrimethamine) [65,66]. There have been disturbing reports 
of possible artemisinin-resistant malaria in Southeast Asia; a recent study in western 
Cambodia reported reduced in vivo susceptibility of P. falciparum to artesunate that 
could not be explained by pharmacokinetic or other host factors [67,68], with the 
most likely explanation being a degree of resistance of the parasite to artesunate arising 
from the prolonged and inappropriate use of artemisinin mono-therapies in the 
country [69]. 
Chloroquine. which was the mainstay of antimalarial therapy for nearly half a century. 
has been rendered ineffective in vast zones of malaria endemic areas due to the 
development of resistance; this has led to health bodies recommending alternative 
therapies, which are commonly more expensive and less safe than chloroquine [65,66]. 
Reports of the emergence of chloroquine resistant malaria began in South America in 
the 1950s [70] and in the late 1970s in Africa [71]. with the levels of resistance rising so 
rapidly that within the next 10 years chloroquine began to be replaced as the first-line 
treatment for malaria in African countries. Malawi was the first African country to do 
this in 1993 [72]. Unfortunately. the emergence of chloroquine resistance has been 
global. and it is estimated that in excess of 500/0 of malaria infections globally are 
resistant to chloroquine [73]. This situation has led to the intense and concerted efforts 
to understand the molerular mechanisms of chloroquine resistance, as well as to 
discover and/or develop new drug entities devoid of this shortcoming. 
Chloroquine resistance has been associated with reduced lysosomal accumulation of 
chloroquine [71.74-76]. There also appears to be evidence of chloroquine efflux from 
the acidic food varuole. accompanied by a H+ 'leak' (acidic food vacuole 
alkalinization). that seems to be enhanced in chloroquine-resistant (CQR) strains [77]. 
Strong association has been shown between chloroquine resistance and mutations on 
the pfert gene. This gene codes for the protein PfCRT (P. fa/dparum Chloroquine 
Resistance Transporter). a 424 amino add. 48.6kDa protein that localizes on the 
membrane of the parasite addic food varuole. Pfert mutations that code for the 
replacement of lysine residue 76 in the first transmembrane domain of PfCRT [78] by 
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either threonine (K76T) [78-80] or. to a lesser extent. isoleucine (K761) and asparagine 
(K76N). have been associated with the CQR phenotype [81]. An association has also 
been demonstrated between chloroquine resistance and mutations of the P. faldparum 
gene pfmdrl, which codes for the glycoprotein PGHl (P-glycoprotein homologue 1). 
also a lysosomal membrane protein [82]. Studies have shown that pfcrtpolymorphisms 
are more strongly associated with chloroquine resistance than pfmdrl polymorphisms 
[82.83], though combinations of the two may result in higher levels of chloroquine 
resistance [82.84.85]. Chloroquine resistance reversal shall be discussed in Chapter 
Two as one of the approaches to antimalarial drug discovery. 
Resistance to sulfadoxine-pyrimethamine was first noted on the Thai-Cambodian 
border in the mid-1960s. and is now commonplace in Asia and South America [86]. P. 
vivax has developed resistance rapidly to sulfadoxine-pyrimethamine. though it still 
remains sensitive to chloroquine in south-east Asia. the Indian sub-continent and the 
Korean peninsula [66]. The 5ulfadoxine-pyrimethamine combination replaced 
chloroquine as the first-line treatment for malaria in most African countries. though 
sensitivity started declining in the late 1980s and rapidly gained ground on this 
continent. more so in the east than in the west [65.86.87]. The molecular basis of 
resistance to DHFR and DHPS inhibitors (such as sulfadoxine-pyrimethamine) is single 
mutations on the genes encoding for the respective enzymes, resulting in amino acid 
substitutions on the enzymes themselves. Mutations at codons 108, 51, 59, 164, and 
also occasionally 50. 140. and the •• Bolivian repeat" of the DHFR gene. and codons 
436. 437. 540. 581. and 613 of the DHPS gene. have been shown to be associated 
with reduced susceptibility to antimalarial folate antagonists [50.86.88,89]. 
Mefloquine resistance was also first observed near the Thai-Cambodian border in the 
late 19805. and is now common in Thailand and neighboring countries such as 
Cambodia. Bangladesh and India. Though reported. the degree and scope of 
mefJoquine resistance in South America are stm far below that of Southeast Asia. 
Clinical-..mefJoquine resistance is rare in Africa [86]. Gene mutation and over-expression 
"" of the pfmdfl gene may be associated with the mechanism of mefloquine resistance 
[82,90]. 
Reports of clinical resistance to quinine, especially from the Thai-Cambodian border, 
began to accumulate during the mid-1960s. This situation was further compounded by 
the widespread use of quinine in Thailand in the early 19805 as an interim therapy due 
to the declining efficacy of sulfadoxine-pyrimethamine. Pfmdrl mutations similar to 
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those associated with chloroquine resistance may also account for reduced 
susceptibility to quinine [86]. 
With the number of reports of resistant malaria strains emerging from Southeast Asia. it 
is unsurprising that multidrug resistance of P. falciparum. which is defined as resistance 
to more than two operational antimalarial compounds of different chemical classes, is 
well established in this region. particularly around the borderi:egions of Thailand [86]. 
"" 
Despite its possible novel mode of action, resistance occurs readily with atovaquone 
monotherapy. For this reason. it is recommended that atovaquone be used as a fixed-
ratio combination with the antifolate drug proguanil (Malarone®) [50.91]. 
Atovaquone resistance may be the result of mutations in the plasmodial genes coding 
for the putative cytochrome b product. resulting in changes in the amino acid sequence 
such as V284T, M1331 and U44S [53]. 
Studies that have tried to shed light on the molecular basis of diminished artemisinin 
susceptibility [86,92] have not yielded convincing results so far. No mutations of the 
candidate genes suggested by earlier studies have been found to confer artemisinin 
resistance. 
1.10 Summary 
The high levels of morbidity and mortality associated with malaria and the 
shortcomings associated with currently available antimalarial drugs suggest that the 
development of new, highly efficacious drugs and/or treatment regimens for the 
management of malaria remains a key priority [93J. 
This project therefore seeks to contribute to this aspect. and is an attempt to design 
and develop new (and cost effective) antimalarial agents. Chapter Two provides a 
discussion of some of the possible approaches for antimalarial drug discovery. 
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CHAPTER TWO 
APPROACHES TO ANTIMAlARIAL DRUG DISCOVERY 
2.1 Preamble 
Having introduced malaria as a disease and the drugs available for its treatment in 
Chapter One. this chapter follows on to present some of the general strategies that 
have been. and continue to be. exploited for the discovery of antimalarial drugs. 
Representative examples are given for the various approaches. and the discussion is 
concluded by a brief account of some of the more modern techniques that can be 
applied to augment antimalarial drug discovery. 
Some of the strategies that have been applied in this study are then highlighted. 
2.2 Introduction 
As has been alluded to in the previous Chapter. the development of new, highly 
efficacious drugs and/or treatment regimens for the management of malaria remains a 
key priority [1]. This must take into account specific concerns. in particular the 
requirement for affordable and simple to use new therapies [2]. Various strategies are 
available for this purpose. and include: 
• Applying available drugs in new treatment regimens; 
• Identification of antimalarial compounds arising from research on other diseases: 
• Reversal of antimalarial drug resistance; 
• Development of analogs of existing antimalarial chemotherapeutic agents; 
• Discovery of uniquely novel antimalarial agents: 
o Identification and validation of novel antimalarial pharmacophores for 
further development; 
o De novo design of novel antimalarial compounds; 
o Application of high-throughput screening and virtual screening techniques; 
b~ Discovery and development of natural product-based therapeutic agents . 
... 
2.3 Applying available drugs in new treatment regimens 
One of the strategies for evading the development of resistance to antimalarials is the 
use of combination therapies. which basically involves the co-administration of two or 
more antimalarial agents. The WHO defines antimalarial combination therapy as "the 
simultaneous use of two or more blood schizontocidal drugs with independent modes 
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It is for these reasons that ACTs generally combine the artemisinin-based antimalarials 
with longer-acting antimalarial agents. Examples of ACTs constituted in this way 
include artemether + lumefantrine (Co-Artem®). which was the first clinically available 
fixed combination of an artemisinin-based antimalarial and a longer-acting 
antimalarial. Other ACTs currently also recommended by WHO on the strength of 
clinical trials include artesunate + amodiaquine (Coarsucam®). artesunate + 
mefloquine (Artequin®). artesunate + sulfadoxine-pyrimethamine • and DHA + 
piperaquine (Duo-Cotecxin®). Sulfametopyrazine-pyrimethamine is considered an 
alternative to sulfadoxine-pyrimethamine [7]. Other antimalarial drugs that have been 
considered as partner drugs in ACTs include pyronaridine [4], chlorproguanil-dapsone 
and atovaquone-proguanil [3]. 
These ACTs take advantage of the rapid reduction in parasitemia afforded by the 
artemisinin antimalarial, with the additional agent(s) ensuring complete elimination of 
the parasite by essentially mopping up what's left of it. In this way rapid cure is 
achieved. with minimal risk of the survival of any strains of the parasite that may 
emerge as resistant to either of the administered agents. When given in combination 
with these slowly eliminated antimalarials. short courses of treatment (6 dose/3 day 
regimens) are effective. This is because a 3-day course of the artemisinin is required to 
eliminate at least 900/0 of the parasitemia; the partner medidne only has to clear the 
remaining 100/0 of the parasitemia. thus redudng the potential for development of 
resistance [3,7]. 
However, implementation of ACT has had its fair share of ethical and logistic 
considerations [11]. and it has been argued that access to this form of therapy is still 
beyond the reach of the majority of the impoverished population that is heavily 
affected by malaria. the major barrier being cost [6]. 
2.3.2 Non-artemisinin based combination therapy (non-ACT) 
These ind\J.de combinations such as chloroquine + sulfadoxine-pyrimethamine and 
... 
amodiaquine + sulfadoxine-pyrimethamine [3]. However. the prevailing high levels of 
resistance to these drugs as monotherapy have compromised their efficacy even in 
combinations. As a result of this. and the fact that these combinations are still less 
effective that ACTs. WHO no longer recommends non-ACTs for the treatment of 
uncomplicated malaria [7]. 
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2.4 Antimalarial compounds arising from research on other diseases 
Antimalarial drug discovery has benefited immensely from research aimed at 
discovering new therapies for other unrelated diseases. 
For example. development of antifolates as therapeutic agents began with efforts to 
treat acute leukemias and other cancers, and which were based 0", th~~ observed anti-
proliferative effects of creating a folate deficient state. Antifolate anticancer agents such 
as methotrexate were the fruits of these efforts. Subsequent screens of antifolates 
against other rapidly dividing cells led to a demonstration of hitherto unknown 
antibacterial and antiparasitic activities. including antimalarial activity [12]. This led to 
the development of antifolate antimalarial agents. such as the dihydrofolate reductase 
(DHFR) inhibitors proguanil. chlorproguanil and pyrimethamine [12.13] as well as the 
dihydropteroate synthase (DHFS) inhibitors dapsone. sulfadoxine and 
sulfametopyrazine [12]. The combination of DHFR and DHPS inhibitors is markedly 
synergistic. and hence these agents are invariably used in combination in the treatment 
of malaria. e.g. as pyrimethamine + sulfadoxine (Fansidar®) and pyrimethamine + 
sulfametopyrazine (Metakelfin®) combinations. These drugs tend to have long 
elimination profiles with half-lives >80 hours. hence enabling effective single-dose 
therapy. Chlorproguanil-dapsone combination is also available [12]. and novel 
antifolate drug combinations continue to be tested [14]. As mentioned previously. the 
pyrimethamine + sulfadoxine and pyrimethamine + sulfametopyrazine combinations 
have also been successfully incorporated into ACTs. 
Atovaquone (Mepron®) was initially identified as a broad spectrum anti-infective [15]. 
but its development was expedited by the discovery of its potential to treat 
Pneumocystis carinii pneumonia (PCP). one of the main opportunistic infections in 
HIV/AIDS patients [16]. Its antimalarial activity has been demonstrated [17], and its 
potential as an antimalarial has since been re-explored following the demonstration of 
its in vitro antimalarial synergy with proguanil [18.19] as well as its efficacy and safety 
when administered as the fixed dose antimalarial combination of atovaquone-
proguanil (Malarone®) [20]. 
Iron chelators have been developed mainly for the treatment of iron overload 
particularly in patients suffering from blood disorders such as thalassemias, and who 
receive regular blood transfusions. These compounds sequester and allow for the 
elimination of iron. thereby preventing the complications (damage to the liver, heart 
and endocrine organs) that would arise from the inevitable accumulation of iron 
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resulting from the repeated transfusions. Classic examples of iron chelators used for this 
purpose are desferrioxamine (DFO) and deferiprone [21·23]. DFO is the most widely 
used iron chelator. and is a naturally occurring trihydroxamic add derived from 
cultures of Streptomyces pi/osus that has been used extensively for many years; it is 
remarkably safe and nontoxic [24]. Interestingly. these and other iron chelators have 
been shown to exhibit antimalarial activity in vitro [24.25]. This is possibly due to 
either their ability to withhold iron (thereby making it inaccessible for vital. iron-
dependent metabolic pathways of the intra·erythrocytic parasite). or by the formation 
of complexes with iron that are toxic to the parasite. Following these observations in 
vitro. animal and human trials have subsequently been carried out on some of these 
agents. DFO has been shown to be effective as a single agent in reducing P. fa/dparum 
parasitemia in uncomplicated malaria in humans. and these findings suggest that iron 
chelation may be a potentially viable strategy for the chemotherapy of malaria [26]. 
2.5 Reversal of drug resistance 
One of the main shortcomings of most of the currently available antimalarial drugs is 
the development of resistance by the malaria parasite; it therefore follows that the 
reversal of this resistance could potentially restore the efficacy of these agents [27]. 
This strategy has been actively pursued. with chloroquine resistance (CQR) reversal 
agents the subject of most of the reported studies of this nature. A range of structurally 
diverse compounds have been identified that act as CQR reversal agents. ranging from 
natural products and clinically available drugs to novel synthetic compounds. 
2.5.1 Natural products as CQR reversal agents 
In the mid-1980s. ethnobotanical studies in Madagascar revealed the application by 
traditional healers and local populations of extracts from various local plants as 
chloroquine adjuvants: these decoctions and infusions were co-administered with 1 - 2 
tablets (100-- 200 mg) of chloroquine with the aim of reinforcing the antimalarial 
effects of chloroquine [28]. Two of the plants used for this purpose, namely Hernandia 
voyronii (also known as Hazomalania voyronil) and Strychnos myrtoides. have had 
their possible chloroquine potentiating activities investigated further [28-301. 
A series of dimeric, structurally-related. pavine-benzyltetrahydroisoquinoline (pavine· 
BTIQ) alkaloids have been isolated from H. voyronii. and are designated as Herveline 
A. B. C and D. Reticuline. the precursor of the BTIQ component of these alkaloids. has 
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resulting from the repeated transfusions. Classic examples of iron chelators used for this 
purpose are desferrioxamine (DFO) and deferiprone [21-23]. DFO is the most widely 
used iron chelator. and is a naturally occurring trihydroxamic acid derived from 
cultures of Streptomyces pi/os us that has been used extensively for many years; it is 
remarkably safe and nontoxic [24]. Interestingly, these and other iron chelators have 
been shown to exhibit antimalarial activity in vitro [24.25]. This is possibly due to 
either their ability to withhold iron (thereby making it inaccessible for vital, iron-
dependent metabolic pathways of the intra-erythrocytic parasite). or by the formation 
of complexes with iron that are toxic to the parasite. Following these observations in 
vitro. animal and human trials have subsequently been carried out on some of these 
agents. DFO has been shown to be effective as a single agent in reducing P. faldparum 
parasitemia in uncomplicated malaria in humans. and these findings suggest that iron 
chelation may be a potentially viable strategy for the chemotherapy of malaria [26]. 
2.5 Reversal of drug resistance 
One of the main shortcomings of most of the currently available antimalarial drugs is 
the development of resistance by the malaria parasite; it therefore follows that the 
reversal of this resistance could potentially restore the efficacy of these agents [27]. 
This strategy has been actively pursued, with chloroquine resistance (CQR) reversal 
agents the subject of most of the reported studies of this nature. A range of structurally 
diverse compounds have been identified that act as CQR reversal agents. ranging from 
natural products and clinically available drugs to novel synthetic compounds. 
2.5.1 Natural products as CQR reversal agents 
In the mid-1980s. ethnobotanical studies in Madagascar revealed the application by 
traditional healers and local populations of extracts from various local plants as 
chloroquine adjuvants; these decoctions and infusions were co-administered with 1 - 2 
tablets 000- 200 mg) of chloroquine with the aim of reinforcing the antimalarial 
effects of chloroquine [28]. Two of the plants used for this purpose, namely Hernandia 
voyronii (also known as Hazomalania voyronil) and Strychnos myrtoides, have had 
their possible chloroquine potentiating activities investigated further [28-30]. 
A series of dimeric. structurally-related, pavine-benzyltetrahydroisoquinoline (pavine-
BTIQ) alkaloids have been isolated from H. voyronii. and are designated as Herveline 
A. B. C and D. Reticuline. the precursor of the BTIQ component of these alkaloids. has 
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also been isolated, characterized and derivatized (by de methylation) to yield the semi* 
synthetic derivative laudanosine [30] (see Figure 2.1 for structures). These compounds 
showed moderate to weak in vitro antimalarial activity (lC50 values of 1 - 30 JlM 
against the CQR P. fa/dparum FCM29 strain). Herveline Band C, and to a lesser 
extent laudanosine. showed significant chloroquine potentiating effects in vitro against 
the same CQR strain (FCM29): retiruline showed weak synergism with chloroquine. 
Herveline A showed only additive effects, while Herveline 0 mow~d mild antagonism 
with chloroquine [30]. 
A study of S. myrtoides showed that crude extracts from the plant lacked any intrinsic 
antimalarial activity in vitro, but reversed CQR in a dose~ependent manner against 
the CQR P. fa/dparum strain FCM29; they also potentiated the effects of chloroquine 
in vivo in mice infected with CQR P. yoe/ii nigeriensis. Bioassay guided fractionation 
yielded two indole alkaloids, malagashanine and strychnobrasiline (Fig. 2.1). which 
exhibited similar activities [29]. Malagashanine, the parent compound of a class of 
indole alkaloids. has also been reported to enhance the susceptibility of other CQR 
strains. such as W2 and K1. to chloroquine in vitro [31.32]. This chloroquine 
sensitization was not observed with the chloroquine sensitive (CQS) strain NS [31]. 
Malagashanine has also shown notable in vitro synergy with quinine and mefloquine, 
as well as the aminoacridines quinacrine and pyronaridine [30]. lcajine and isoretuline 
(Figure 2.1). two indole alkaloids also isolated from Strychnos species, have been 
shown to potentiate chloroquine in vitro against the CQR strains W-2 and PFB, though 
this activity is absent against the CQS FCA strain of P. fa/dparum [33]. 
Other plant species have also yielded compounds with chloroquine potentiating 
activity. Bisbenzylisoquinoline alkaloids. isolated from plants of the Annonaceae and 
Menispermaceae species, also exhibit moderate intrinsic antimalarial activity (ICso 
values in the lower micromolar to high nanomolar range). and show in vitro synergy 
with chloroquine against the CQR strains FcBl [34] and W2 [35]; the more potent of 
this class of alkaloids are fangchinoline [34] and cepharanthine [35] (Figure 2.1). 
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Figure 2.1: Chemical structures of some compounds of natural origin with CQ potentiating 
activity 
2.5.2 Clinically available drugs as CQR reversal agents 
A wide range of clinically available drugs have been eXperimentally shown to 
potentiate the antimalarial activity of chloroquine in vitro (Figure 2.2A). The clinically 
available Ca2+ channel blocker verapamil is probably the most widely known CQR 
reversal agent, and is regularly used as the reference compound in many CQR-reversal 
studies. It shows weak intrinsic antimalarial activity (lCso of 2.5~ and 7.2~ against 
010 (CQS) and Od2 (CQR). respectively); at non-toxic concentrations, verapamil has 
been shown i'o enhance chloroquine susceptibility of CQR Od2 but not CQS 010 P. 
fa/ciparom. though it enhances chloroquine accumulation in both strains [36]. The 
actual mechanism of verapamil-mediated CQR reversal is yet to be established. but 
appears to be diminished in vitro in the presence of a.l-gJycoprotein. a plasma protein 
that interacts with basic compounds [37]. 
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Figure 2.1: Chemical structures of some compounds of natural origin with CQ potentiating 
activity 
2.5.2 Clinically available drugs as CQR reversal agents 
A wide range of clinically available drugs have been experimentally shown to 
potentiate the antimalarial activity of chloroquine in vitro (Figure 2.2A). The clinically 
available Ca2+ channel blocker verapamil is probably the most widely known CQR 
reversal agent. and is regularly used as the reference compound in many CQR-reversal 
studies. It shows weak intrinsic antimalarial activity (ICso of 2.5~ and 7.2~ against 
010 (CQS) and Od2 (CQR). respectively): at non-toxic concentrations. verapamil has 
"" 
been shown to enhance chloroquine susceptibility of CQR Od2 but not CQS 010 P. 
falciparum. though it enhances chloroquine accumulation in both strains [36]. The 
actual mechanism of verapamil-mediated CQR reversal is yet to be established. but 
appears to be diminished in vitro in the presence of a.l-glycoprotein. a plasma protein 
that interacts with basic compounds [37]. 
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Other clinically available drugs with reported CQR-reversal activity include selected 
antihistamines [3840]. antiretroviral protease inhibitors [41]. antidepressants [42.43] 
and antibiotics [44]. The use of combinations of chemosensitizers has also been 
suggested based on encouraging in vitro results; combinations of verapamil-
trifluoperazine and verapamil-desipramine-trifluoperazine have been shown to lower 
the chloroquine ICso of the CQR RSAll strain to levels comparable with those of the 
CQS 010 strain [45]. 
Chlorpheniramine Promethazine Cyproheptadine 
NC 
F1uoxetine F 
Citalopram 
o 
c¢o 
2·5 .I) 
/'NA' 0=3-8 
) 
Figure 2.2: A: Chemical structures of selected clinically available drugs with CQ potentiating 
aCtIvity; B: structures of selected synthetic CQR reversal agents of various classes: biphenyl (2.1), 
arylbromide (2.2). biaryl-ether (2.3), diarylethane (2.4), acridone (2.5), and benzylamino (2.6) 
derivatives. 
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2.5.3 Synthetic CQR reversal agents and reversed chloroquines 
The CQR reversal activity of a very diverse range of synthetic compounds has been 
reported. Some of these have been developed based on SAR analysis of known CQR 
reversal agents. as well as possible chloroquine chemosensitizing pharmacophores 
derived from such agents. Some examples of synthetic CQR reversal agents that have 
been identified are highlighted below. 
A series of aryl bromide. biphenyl and biaryl-ether compounds were designed as 
potential chemosensitizers. and were based on N-phenyl-l.3-diaminopropane. a 
possible chloroquine chemosensitizing pharmacophore derived from malagashanine 
and chlorpromazine. All compounds exhibited moderate (lCso 1 - 5~) to weak (lCso 
>5~) in vitro antimalarial activity against the CQR FCM29 strain of P. faldparum. 
Some of the compounds (such as compounds 2.1. 2.2 and 2.3. Figure 2.2B) also 
showed notable synergistic effects with chloroquine in vitro [46]. Another series of 
potential CQR reversal agents were designed exploiting an imipramine-based 
pharmacophore. namely a diarylmethane moiety linked by a 3-carbon chain to a 
secondary or tertiary nitrogen. These compounds were shown to possess notable in 
vitro CQR reversal activity. with some of them (such as compound 2.4. Figure 2.2B) 
rendering the CQR W2 strain fully sensitive to chloroquine [47]. 
Other classes of potential CQR-reversaI agents include 9H-xanthenes [48], lO-N 
substituted acridones [49]. dibenzosuberanylpiperazine derivatives [50] and 
benzylamine derivatives [51]. 
Reversed chloroquines are compounds in which chloroquine (or a chloroquine-like 
molecule) has been covalently linked to a proposed CQR reversal pharmacophore 
(usually derived from recognized CQR reversal agents). The rationale for this is that the 
presence of the additional pharmacophore may enable the chloroquine-like 
component evade the CQR mechanism(s) [52]. Such a molecule (compound 2.7, 
Figure 2.3) \Alas designed and synthesized. with the CQR reversal pharmacophore 
derived from imipramine. a well studied CQR reversal agent. The compound was 
shown to be just as active as chloroquine against the CQS strain 06 (lC5O 2.9nM), but. 
more importantly. retained comparable activity against the CQR strain Dd2 (lCso 
5.3nM) [52]. 
Postulated reversed chloroquines have also been synthesized based on the 4-aryl-3.4-
dihydropyrimidin-2U"'--one (DHPM) scaffold. Selected for their easy synthetic 
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accessibility via the Biginelli multicomponent reaction. one of these compounds 
(compound 2.8. Figure 2.3), and its citrate salt. showed high activity against both the 
CQS 3D7 (ICso 28nM) and CQR Kl (ICso 4nM) strains of P. falciparum [53]. A similar 
approach has been used to design reversed acridone-based antimalarials: the most 
active compound (compound 2.9. Fig 2.3), though not as potent as chloroquine is 
against the CQS D6 strain, was equipotent across the CQR (Dd2) and CQS (D6) strains 
of P. falciparum. [54]. 
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Figure 2.3: Figure showing a imipramine-based (2.7) and DHPM-based (2.8) reversed CQs. as well as 
the general structure of reversed acridone-based antimalarials (2.9) 
2.6 Development of analogs of existing antimalarials 
-,~-~- <-.<-~------------------
The late Sir James Black. joint winner of the 1988 Nobel Prize in Physiology and 
Medicine. has been quoted as saying that "The most fruitful basis for the discovery of a 
new drug is to start with an old drug" [55]. This has been underscored by an analysis 
of the origins of recently launched drugs, which revealed that most were derived by 
modification of the chemical structure of known drugs or lead structures derived from 
scientific literature [56]. 
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Pharmacophores/substructural motifs that are thought to be largely responsible for the 
observed antimalarial activity of known antimalarial drugs can be derived from the 
structures of these compounds. Such scaffolds can then be used as templates for the 
rational design of various derivatives of the parent drugs which may then be 
synthesized and tested for antimalarial activity [2]. In this way, new. potent 
antimalarial agents that are analogs of the parent drug may be identified. Some 
examples of this are highlighted below. 
The 7-chloro-4-aminoquinoline moiety. derived from chloroquine. is arguably the 
most widely used template for the design of new antimalarial compounds [2]. The 
generation of chloroquine analogs by derivatization of this central moiety has been 
driven by structure-activity relationship (SAR) studies focusing on the effects of 
modifications of the chloroquine side-main and. to a lesser extent. replacement of the 
7 -chloro group. For example, a study of the antimalarial activities of several 4-
aminoquinolines with shortened side chains found that the derivatives studied. such as 
2.10. 2.11 and 2.12 (Figure 2.4) retained significant antimalarial activity in vitro. with 
ICso values in the lower nanomolar range. These compounds were somewhat less 
active against the CQR Kl strain of P. fa/dparum than against the CQS N F54 strain. 
suggesting that they retain a degree of cross-resistance with chloroquine [57]. It has 
also been demonstrated that replacement of the 7 -chloro group with either the 7-
bromo or the 7 -iodo groups is assodated with retention of antimalarial activity for a 
variety of aminoquinolines [58.59]. mainly thought to be due to their moderately 
strong electron-withdrawing capadty and strong lipophilidty [59]. 
Additionally. the degree of resistance to 4-aminoquinolines was inversely correlated 
with the lipid solubility of the compounds [60] which is largely determined by the 
lipophilidty of their corresponding side-chains. This may suggest that an increase in the 
lipophilidty of quinoline and related antimalarials relative to chloroquine renders them 
less susceptible to the CQR mechanism [60.61]. This argument is further supported by 
the identification of chloroquine-like molecules that bear highly lipophilic side chains 
'. 
that not only retain chloroquine-like potency against CQS P. falciparum strains. but 
also completely lack any in vitro cross resistance with chloroquine against CQR strains. 
Ferroquine. ruthenoquine and (ortho)-phenylequine (Figure 2.4) are examples of such 
compounds, all of which show remarkable activity against P. falciparum strains. with 
ICso of <30nM against both CQS 010 and CQR Kl strains [62-65]. 
FIl!I(" M r.IlAI\ITAf _ Ph n TI-lnl( ?mr 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
'I. 
mHN~N~ 1./ b (I 
2.10 
Ferroquine 
mHN~C 1./ .".,; a N 
2.11 
Ruthenoquine (ortho }Phenylequine 
Figure 2.4: Figure showing selected chloroquine analogs. including the chloroquine analogs 
with lipophilic side chains (o)-phenylequine, ferroquine and ruthenoquine 
Derivatization of the side<hains of other aminoquinoline antimalarials has also been 
attempted. A series of Mannich base derivatives of amodiaquine. for example. 
identified analogs that were more active than chloroquine in vitro. These analogs were 
also found to be more efficacious than amodiaquine in vivo against CQR P. berghei. 
irrespective of the route of administration (oral or intraperitoneal) [66]. 
2.7 Development of uniquely novel antimalarial chemotherapeutic agents 
The identification of new chemical entities that possess antimalarial activity is an 
attractive strategy for the development of new antimalarial drugs. This may be by the 
identification and validation of new antimalarial pharmacophores for use as templates 
in the design of new antimalarial agents. the rational (de novo) design of compounds 
based on known molecular targets/mechanisms of action. high-throughput screening 
(HTS) of compound libraries. structure-based or ligand-based virtual screening of 
virtual compound libraries and/or the discovery of natural products with antimalarial 
activity. This approach to antimalarial drug discovery borrows heavily from more 
modern drug discovery strategies. particularly computational techniques. 
2.7.1 Identification of new antimalarial phannacophores/chemical scaffolds 
One of the ways by which new antimalarial phannacophores may be identified is by 
the targeting of chemical motifs that are structurally similar to known pharmacophores. 
For example. acridones and quinoxalines. both of which bear distinct structural 
similarities to the quinoline nucleus present in chloroquine and other quinoline-based 
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antimalarials. have been used as templates in the design of potential antimalarials. An 
acridone derivative coded T3.5 (Figure 2.5) was reportedly more active than 
chloroquine in vitro against the CQR Dd2. 7G8 and Tm90-C2B strains of P. 
falciparum. though it was less active against the CQR 06 strain [67]. Compound 2.13 
(Figure 2.5). a bispyrrolo[1.2-a]quinoxaline. was extremely active. with (Cso values of 
50 nM against the CQS Thai and the CQR Kl P. falciparum [68]. 
2.14 (I 
\. 
N a 2.16 
2.15 
Figure 2.5: Examples of highly active antimalarial compounds based on novel chemical scaffolds 
Similarly. the highly active artemisinin antimalarials have been used to inspire the 
design of related compounds as potential novel antimalarial compounds. For example. 
studies of epoxy-endoperoxides and bicydic epoxy-endoperoxides identified several 
potent compounds that exhibited sub-micromolar IC50 values against both CQS and 
CQR P. fa/dparum [69.70]. The activities of bicydic epoxy-endoperoxides such as 2.14 
and 2.15 (Figure 2.5) were significantly better than those of similarly substituted 
monocyclic versions [70]. 
Novel antimalarial scaffolds unrelated to known antimalarials can be derived from 
miscellaneous compounds that have been shown to possess antimalarial activity. 
Clotrimazole is an antifungal azole has been shown to exhibit significant antimalarial 
activity in vitro (W2. ICso 0.55 J.lM) [71.72]. This compound was used to derive a 
polycyclic antimalarial pharmacophore that was then applied in the design of potential 
antimalarial clotrimazole analogs. Compound 2.16 (Figure 2.5) was the most potent 
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compound identified from the series. and was more active than chloroquine or 
dotrimazole in vitro, with ICso values <10 nM against 307 and Kl P. faldparum [73]. 
2.7.2 De novo design of novel antimalarial compounds 
The potential of de novo design in the discovery of potential antimalarials is 
exemplified by the following examples. 
Plasmepsin II (PII) is a malaria parasite aspartic protease involved in the hemoglobin 
degradation process that takes place in an addic vacuole, and has been identified as a 
potential target for antimalarial therapy (section 1.7). A new class of non-peptidic PI! 
inhibitors that display single-digit micromolar ICso values and good selectivity towards 
(the mammalian aspartic protease) renin have been reportedly developed with the 
help of structure-based de novo design guided by molecular modeling of the active site 
of PIt. Compound 2.17 (Figure 2.6) was the most active of the derivatives studied [74]. 
Oihydroorotate dehydrogenase (OHOOH) is the fourth enzyme in the pyrimidine 
biosynthetic pathway, and catalyses the oxidation of dihydroorotate (OHO) to orotate 
in the presence of the co-factors flavin mononucleotide (FMN) and ubiquinone. The 
selective inhibition of P. faldparum OHOOH (PfDHOOH) offers itself as an attractive 
strategy for the development of novel antimalarial agents. In what was essentially a 
proof-of-principle study, the de novo design of potential PfDHOOH inhibitors was 
attempted. guided by the molecular design program SPROUT. The designed inhibitors. 
which were simple and readily prepared amides of anthranilic add. showed only 
modest enzyme affinities. but were considered as excellent starting points for further 
optimization [75]. 
2.7.3 High-throughput screening for the discovery of novel antimalarial compounds 
High-throughput screening (HTS) involves the rapid. large scale. usually automated 
testing of physical libraries of compounds for activity against a particular 
microorganism or druggable target. The libraries of compounds used for this purpose 
may have been designed and synthesized based on the particular target of interest (e.g. 
by combinatorial chemistry). though for the most part these libraries have usually been 
previously synthesized during other non-related chemistry or drug discovery 
endeavors. In this way, compounds that may not have hitherto been known to possess 
certain biological activities may be identified. Growth inhibition assays [76], hematin 
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polymerization assays [77] and a variety of enzyme-based assays are examples of 
assays that have been adapted for the HTS of potential antimalarial compounds. 
1039 compounds initially designed and synthesized as potential Cathepsin D inhibitors 
were screened against PI! using a high-throughput fluorogenic peptide-substrate assay. 
13 compounds showed greater than 50% inhibitory activity against PIt. Of these, 
compounds 2.18 and 2.19 (Rgure 2.6) were synthesized and evaluated for inhibition of 
PII. and were shown to exhibit sub-micromolar Kivalues against Pit [78]. 
The Plasmodium falciparum dihydroorotate dehydrogenase (PJOHODH) inhibitor 
DSM 1 (Figure 2.6) that is potent (I\i = 15nM) and spedes-selective (>SOOO-foid over 
the human enzyme) was also identified by high-throughput screening [79]. 
An efficient and robust high-throughput cell-based screen {l,536- ell format) based on 
proliferation of P. faldparum in erythrocytes was applied in the screening of 1. 7 million 
compounds. 17,000 compounds were identified that showed significant antimalarial 
activity. Most known antimalarials were identified in this screen. though many novel 
chemical scaffolds. which likely act through both known and novel pathways. were 
also identified. In silico compound activity profiling also revealed the cellular pathways 
and/or protein targets for a number of these compounds [80]. 
2.7.4 Virtual screening for the identification of novel antimalarial compounds 
Virtual screening can be considered as a form of HTS which computationally screens 
virtual (rather than physical) chemical libraries for potential active agents. This 
technique may be structure-based (where the search is aimed at finding compounds 
that are structurally similar to, or share common 3-D molecular interaction fields with. 
known pharmacophores/active compounds) or ligand-based (where the search is 
aimed at identifying compounds with complementary 3-D molecular interaction fields 
to those described for the active site of a particular enzyme target, and which are 
therefore Hkeiy to interact with it). 
In an attempt to identify novel non-peptide inhibitors of malarial cysteine proteases, 
the Chern Bridge database consisting of approximately 241 000 compounds was 
screened against homology models of Faldpain-2 and Fakipain-3 in three consecutive 
stages of docking. Eighty four of the most promising compounds were procured and 
subjected to both enzymatic and cell-based biological evaluations. Of these 
compounds. twenty two were shown to experimentally inhibit the Faicipains. with 
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ICso values ranging from 1 - 63 jIl'Vt; twelve compounds showed dual activity. 
Compounds 2.20. 2.21 and 2.22 (Figure 2.6) exhibited single..cJigit micromolar ICso 
values against both D6 and W2 P. faldparom [81]. A similar search was carried out on 
The Available Chemical Directory. which comprises nearly 355.000 compounds. One 
hundred compounds were subsequently selected for biological screening. from which 
twenty two cysteine protease inhibitors were identified. eighteen of which were found 
to be low micromolar inhibitors of Faldpain-2. Unforkmately. only one of these 
Faldpain-2 inhibitors also exhibited in vitro antiplasmodial activity (W2. ICso 9.5 jIl'Vt); 
the others did not show noticeable antiplasmodial activity at concentrations of up to 
20 jIl'Vt [82]. 
,-..",., " 
~ i~~ 
Ul 
Figure 2.6: Examples of highly active antimalarial compounds derived by de novo design or 
from HTS and virtual screening efforts. 
2.7.5 Natural products as a source of novel antimalarial compounds 
Nature is. as ever. an extremely rich source of potential antimalarial agents [83.84]. 
with the antimalarial drugs quinine and artemisinin being outstanding examples of 
therapeutic natural products. Following the serendipitous or rational discovery of a 
biologically active natural material, the conventional approach to natural product 
j 
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development has been the bioassay-guided fractionation of extracts derived from such 
material, and the subsequent isolation and characterization of pure, active compounds. 
Identification of promising compounds in this way usually triggers medicinal chemistry 
efforts geared towards the total synthesis of the identified compounds and/or the 
generation of analogs. and which are aimed at providing a supplementary source of 
the product for further study, revealing structure-activity relationships, identifying more 
potent analogs and/or overcoming challenging physicochemical and biological 
properties. 
A classic example of this approach is the discovery of artemisinin. Based on age-old 
reports in Chinese traditional medicine of the antipyretic effects of extracts of the 
Chinese herb Qinghao (Artemisia annua L). scientific studies went on to demonstrate 
significant antimalarial activity of the ethanolic extracts of this plant against both 
chloroquine-sensitive (CQS) and chloroquine-resistant (CQR) strains of P. fa/dparom 
[85]. Further studies led to the isolation and characterization of a highly active 
sesquiterpene lactone, artemisinin, in 1971 [86.87}; artemisinin has since been 
derivatized to yield a very diverse range of semi-synthetic analogues [88]. Using 
comparable approaches. the continuing search for new antimalarial drugs from natural 
sources. and in particular from plant. marine and fresh-water sources. has led to the 
identification of an impressive range of structurally diverse compounds from a variety 
of chemical classes. some of which are highlighted in Figure 2.7 [87.89-911. 
Cryptolepine 
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Figure 2.7: Chemical structures of some antimalarial natural products 
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Upon the elucidation of the structure of a novel antimalarial compound from natural 
sources, and possibly informed by preliminary SAR data. it may be possible to reduce 
this structure to its basic pharmacophoric unit(s). Pharmacophores derived in this way 
can be utilized in much the same way as pharmacophores derived from synthetic 
compounds (see above): they may be useful in the design of novel analogs, or be used 
as templates in the structure-based virtual screening of databases and libraries of known 
compounds (from both natural and synthetic sources) for structural analogs. These may 
then be acquired/synthesized and assayed alongside the primary compound and 
possibly even lead to the identification of additional active compounds. 
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Figure 2.8: Chemical structures of OZ439 (a synthetic peroxide antimalarial drug candidate) as 
well as febrifugine and some of its highly active analogs 
For example. artemisinin has inspired the design and synthesis of very promising, 
longer-acting analogs that are now in clinical development such as OZ439 (Figure 2.8). 
a promising synthetic peroxide antimalarial drug candidate [92,93]. Another example 
of this relates to febrifugine (Figure 2.8), a highly potent antimalarial alkaloid isolated 
from the roots. stem and leaves of the plant Dichroa febrifuga Lour .• a Chinese herb 
locally referred to as Chang Shan [94]. The piperidinyl-(acetonyl)quinazoline moiety. a 
structural unit derived from febrifugine, was used as a template in the search for 
analogs in the Walter Reed Army Institute of Research (WRAIR) Chemical Information 
System (CIS) database. This yielded 133 analogs. of which 35 were selected for in vitro 
antimalarial assays. Some of these compounds had been previously reported in 
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literature (e.g. halofuginone); other potent analogs were also identified. though these 
were less active that febrifugine. These included the 5<hloro analog (2.23) and the 
6.7.8-trichloro analog (2.24) of febrifugine (Figure 2.8). both of which had ICso values 
of <5nglml against the 06 (CQS) and W2 (CQR) strains of P. faldparum. as well as 
significantly reduced in vitro cytotoxidty against a variety of mammalian cell lines [95]. 
An impressively large number of novel naturally-derived compounds have been 
isolated and characterized over the years. The volume and variety of these compounds 
looks set to increase particularly with the current consdous effort to expand the range 
of biodiversity sampled for this purpose by. for example, the exploration of extreme 
habitats not routinely considered [96]. The creation of virtual and/or physical 
repositories of these compounds helps to keep track of these compounds and 
simultaneously create a rich resource that can be tapped for drug discovery efforts. 
Examples of such databases already exist, such as the Dictionary of Natural Products 
[97] and a marine natural products database that reportedly holds approximately 
6000 chemical compounds [98]. Such databases can be valuable for structure-based or 
ligand-based virtual screening. as well as for ligand docking studies on a variety of 
known protein targets: physical repositories of purified natural products can provide 
compound libraries for HTS. 
As mentioned earlier. one of the strategies for evading the development of resistance 
to antimalarials is the use of combination therapies, which basically involves the co-
administration of two or more antimalarial agents. Although the emphasis is currently 
on ACTs [4-6]. the identification of new and efficadous combinations remains a 
priority. and the identification of new. active, naturally-derived compounds could 
provide additional possibilities. The potential of combinations of established 
antimalarial drugs with new bioactive compounds derived from natural sources has 
already been demonstrated experimentally. When a mixture of febrifugine and 
isofebrifugine. isolated from the leaves of Hydrangea macrophylla Seringe var. Otsaka 
Makino, was administered concurrently with chloroquine (20 mglkg once a day orally 
for 2 days) in mice infected with P. berghei NK65. no parasites could be detected 
microscopically after the end of the treatment period. and all mice treated in this way 
survived. This was in contrast to the observations made for those P. berghei NK65 
infected mice treated solely with either chloroquine or the alkaloid mixture, whereby 
recrudescence was observed after the treatment period, and was subsequently 
followed by the death of all the mice [99]. 
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2.8 Application of conventional and modem techniques to augment antimalarial drug 
discovery 
2.8. t Development of dual drugs 
Dual drugs. also known as hybrid compounds, refer to single chemical entities that 
consist of two drugs/active compounds/pharmacophoric units linked together 
covalently by a linker [100]. The selection of the two principles in the dual drug is 
usually based on their observed (or anticipated) synergistic or additive pharmacological 
activities, with their combination into one unit being aimed at taking advantage of this 
synergy and possibly enabling the identification of highly active novel chemical entities. 
A typical example of this approach is exemplified by a study of chalcone-
chloroquinoline hybrid compounds. The study of chalcones as potential antimalarials 
mainly stems from the identification of Ucochalcone A (Figure 2.9A) , a naturally 
occurring chalcone isolated from the Chinese licorice roots locally called Can Cao that 
showed significant dose-dependent inhibition of parasite viability in vitro against P. 
faldparom 307 (CQS) and Dd2 (CQR) strains. with an ICso of approximately 0.6 
pg/mL for both strains [101.102]. The study of chaicone-chloroquinoline hybrid 
compounds identified several analogs (compounds 2.25 - 2.28. Figure 2.9A) that 
showed inhibition of j3-hematin formation comparable with that exhibited by 
chloroquine. Unfortunately the study did not report the in vitro antimalarial activities 
of these compounds against P. faldparom [103]. 
2.8.2 Metabolism and metabolite identification studies 
In silica (computational) and in vitro metabolism studies are primarily aimed at 
assessing the metabolic stability of promising hit and lead compounds, and are usually 
geared at providing useful information to guide and/or help in the interpretation of 
the results from subsequent pharmacokinetic studies and in vivo assays. In addition, 
such information also enables the drug discovery scientists to design and synthesize 
analogs of the primary compound.(s) that are potentially more stable to metabolism 
and are likely to have improved bioavailability profiles - this is particularly so for 
compounds administered orally as metabolic stability is a key determinant of oral 
bioavailability [104]. 
However. and probably just as importantly. the generation and identification of 
primary metabolites of a compound can be an effective way of generating chemical 
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diversity and augmenting the efforts aimed at identifying novel active compounds 
based on an identified hit. This approach is well justified by the fact that. in a variety 
of cases, pharmacologically active metabolites have been found to contribute 
significantly to the overall observed in vivo antimalarial activity of a compound. A 
typical example of this is N-desethylchloroquine, the primary metabolite of 
chloroquine. which exhibits potent antimalarial activity comparable to that of 
chloroquine [105.106]. This concept of pharmacologically active metabolites is just as 
applicable to antimalarial hits derived from natural sources. For example. Y. Oshima 
and co-workers (2003) reported the isolation and structural elucidation of two 
primary metabolites of febrifugine after its incubation for 1 hour with mouse liver S9 
(in the presence of cofactor for the NAOPH-regenerating system) in phosphate buffer 
at 3rc. The two metabolites. designated feb-A and feb-B (Figure 2.9B). were then 
synthesized to afford enough material for antimalarial testing. Feb-A. as well as its 
synthetic isofebrifugine analog isofeb-A. showed extremely potent in vitro antimalarial 
activity against the FCR-3 strain of P. faldparum. with isofeb-A being even more 
potent than febrifugine (EC50 == 0.27 nM) and having a significantly higher selectivity 
index. Feb-A. however. was more potent than isofeb-A in vivo in mice infected with P. 
berghei [107] 
In addition, metabolism studies may be useful in understanding the in vivo toxicity of a 
particular compound; this is because any toxic effects observed after the administration 
of a particular compound could very well be due to the generation of toxic 
metabolites. Such information derived from metabolism studies would then be crucial 
in the design of potent compounds devoid of the unwanted toxicity of the parent 
compound. S. Zhu and co-workers (2006. 2009) drew upon prior studies on the SAR. 
toxicity and metabolism of febrifugine to design a series of febrifugine analogs with the 
aim of identifying compounds with enhanced potency and/or attenuated toxicity 
relative to febrifugine. Their first study focused only on modifications of the 
quinazoUnone ring of febrifugine that targeted the eUmination of the tendency to form 
chemically reactive and toxic intermediates and metabolites such as the arene oxide 
2.29. Compounds 2.30 (5.6-difluoro analog) and 2.31 (5-trifluoromethyl analog) 
(Figure 2.9B) showed antimalarial activity superior to that of febrifugine in vitro, with 
ICso values of tess than 1 nM against both the 06 (CQS) and W2 (CQR) strains of P. 
faldparom. and were over 100 times less toxic than febrifugine based on an in vitro 
cytotoxicity assay on rat hepatocytes. Introduction of an extra nitrogen at either 
position 5, 6, 7, or 8, or fluoro substitution at only position 5. did not enhance 
antimalarial potency. but yielded analogs with significantly reduced cytotOXicity (and 
hence improved therapeutic indices). The study therefore concluded that selected 
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substitutions at the 5- and 6- positions. as well as an increase in the oxidation potential 
of the quinazolinone ring (by the introduction of electron-withdrawing s,-,bstituents or 
extra nitrogens) are assodated with a reduction in cytotoxidty [108]. Their subsequent 
study considered similarly substituted/modified analogs of febrifugine. but in which the 
piperidine ring had now been replaced with a pyrrolidine ring like in compound 2.32 
(Figure 2.9B); antimalarial activity was retained. with a similar activity/toxidty pattern 
observed between both sets of analogs [109]. 
o 
HO H 
Licochalcone A . I W
HN 
0 
CI 2.25: R1=H; R2=H; R3=N(CH3)2 
2.26: R1=H; R2=H; R3=CI 
2.27: R,=H; Rl=F; R3=H 
2.28: R,=CI; R2=H; R3=H 
H 
~rXJ:) 
o H Dt" N'1HOVOYl HO " NJ~N) 
Feb-B 
H 
Isofeb-A 
Figure 2.9: A: structure of Ucochakone A. and chalcone hybrid compounds with antimalarial 
activity: B: some metabolites of febrifugine. and examples of compounds designed to be more 
stable to metabolism. 
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CHAPTER TWO: APPROACHES TO ANfIMALARIAL DRUG DISCOVERY 
2.8.3 Identification of novel targets and reverse phannarology 
The mechanisms of action of many antimalarial oompounds are usually unknown at 
the time of their discovery. and generally tend to remain so for extended periods of 
their development as potential lead compounds. This is particularly so because most 
antimalarial compounds are usually assessed in whole-cell parasite cultures. The 
implication of this is that chemical derivatization and attendant SAR studies. which 
could benefit immensely from a dear understanding of how the particular compounds 
exert their antimalarial activity and (where possible) their actual molecular targets. are 
usually carried out without this knowledge. 
However. it is acknowledged that the identification of the mechanisms of action of a 
novel antimalarial compound is indeed quite challenging considering the myriad of 
possible molecular targets (induding unknown targets). the cost and complexities 
involved in actually testing compounds against a variety of targets. and the possibility 
of the overall obselVed antimalarial activity being the result of the action of the 
compound on multiple targets. However. where possible. it is well advised to try and 
identify the actual targets of the active compounds. induding natural products and 
their derivatives. 
Metabolic profiling offers an exdting approach to the identification of (oftentimes 
new) molecular targets of biologically active molecules, and involves the assessment of 
the metabolic response of an organism/celVparasite following exposure to a bioactive 
molecule. The majority of biologically active molecules elidt their responses by 
interfering with protein function (e.g. by enzyme inhibition/over-activation or protein-
protein interaction inhibition). and this typically leads to a perturbation in the normal 
metabolic activity of the parasite that may be detectable via post-exposure metabolic 
profiling. In this way. the pathway/function that the molecule interferes with may be 
revealed. along with its actual molecular target(s) [nO]. Such an approach may be 
adapted for the high-throughput phenotypic screening of libraries of compounds [In]. 
and bioactiv~ natural products. by virtue of their chemical diversity. are particularly 
suited to act as probes for the identification of new molecular targets in this way 
[110.111]. The metabolic profiling of the malaria parasite has been reported [112.113], 
which would suggest the latent potential in this approach. 
Activity-Based Protein Profiling (ABPP) is another useful approach for the identification 
of druggable targets. Synthetic or naturally-derived molecules (or privileged structures 
derived from them) that may have a high affinity for active sites of individual enzymes 
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and that are equipped with a tag either for the purpose of visualization/detection or 
enrichment. could be incubated with proteomes from. for example. two different 
slilges of the malaria pathogen. These small probes would then bind in the target 
emyme(s) ;Jnd provide a practical meam for their isolation and identification by 
techniques such as gel electrophoresis and fluorescence detection. Proteins/enzymes 
identified in this way can then be investigated further as potential therapeutic targets 
by both classical mechanism of action studies o r reverse pharmaCOlogy (see below) 
(tT4]. The application of comparative ABPP has been successful in identifying 
irrevenible inhibHors of a specific papain cysteine protease in the ma laria parasite and 
used to demonstrate a role for the enzyme in the parasite invasion processes [115]. 
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Figure 2. 10: Schematic repre~lalion of the various approaches 10 antimalarial drug discovery. 
including K>me of the more modem approaches 
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vitro physicochemical and ADME prediction to guide in the design and selection of 
target compounds for synthesis. 
The natural product basis of the study is introduced in section 2.9.1 below; the 
approach to molecular hybridization and the selection of the hybrid components will 
be introduced and discussed in Chapter Three; the use of in silico and in vitro 
physicochemical and ADME predictions to guide target compound design is elaborated 
in Chapter Five. 
2.9.1 Curcumin and dlalcones 
2.9.1.1 Introduction 
As mentioned above. nature continues to be a rich source of chemical diversity for 
drug discovery [83,84]. Curcumin [diferuloylmethane; 1.7-bis(4-hydroxy-3-
methoxyphenyl)-1.6-heptadiene-3,5-dione] is one such example of a bioactive 
compound of natural origin. It is the major one of three phenolic diketone molecules 
isolated from turmeric. the rhizomes of Curcuma longa L (Zingiberaceae). the other 
two being demethoxycurcumin and bis-demethoxycurcumin [122]. These three 
compounds (as well as other structurally related synthetic and semi-synthetic 
compounds) are usually collectively referred to as curcuminoids. 
In solution, these compounds exist as equilibrium mixtures of the symmetrical keto 
(diene-dione) and unsymmetrical enol tautomers (Rgure 2.11); the enol tautomer 
predominates due to the dual stabilization effects of the resultant extended conjugation 
and intra-molecular hydrogen-bonding [123]. Interestingly. curcumin could also exist as 
a quinone-methide radical - the product of photo-catalyzed auto-oxidation in basic 
aqueous media [124]. 
Curcuma longa has for centuries been cultivated in India and other parts of Asia. and 
its rhizome (turmeric) used to impart colour and flavour to food as well as for 
medicinal purposes in the treatment of diabetic wounds, hepatic disorders, jaundice, 
anorexia. coryza. cough. rheumatoid arthritis among numerous other maladies [125]. 
These medicinal properties of turmeric have since been attributed to the curcuminoids 
present in it [126]. and subsequent extensive studies of curcumin. the principle 
curcuminoid. have demonstrated a very diverse range of biological activities. as 
discussed below. 
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Keto 
(urcumin. R, :: R2 :: OMe 
Demethoxycurcumin, R, :: H; R2 :: OMe 
Bis-demethoxycurcumin, R,:: R2 :: H 
-
Quinone methide 
Enol 
o 0 
Figure 2.U: Structures of curcumin. demethoxycurcumin. and bis-demethoxycurcumin. showing 
their 'k.eto· and 'enol' forms [122.1231 and the structure of the curcumin quinone-methide 
radical [124] 
On the other hand. chalcones are 1.3-diarylprop-2-ene-l-ones. i.e. compounds 
containing two aromatic rings linked by an a.,f3-unsaturated carbonyl system in the 
form of a propenone chain. or compounds that contain this basic sub-structure [127]. 
The structural similarity of chalcones (and dienones) to curcumin is obvious (see Figure 
2.12) both having two aryl rings linked by a chain that contains an a..f3-unsaturated 
carbonyl system. It comes as no surprise. therefore. that curcumin and chalcones 
possess overlapping biological activity profiles. 
o o 
Curcumin 
o o 
Ring A 
Chalcone Dlenone 
Figure 2.12: General structures of curcumin-related compounds cha\cooes and dienooes 
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Reverse pharmacology offers an alternative means by which the molecular targets of 
biologically active compounds may be identified. and represents a major paradigm 
shift in drug discovery. Rather than apply a bioactive molecule in the identification of a 
molecular target. reverse pharmacology begins with the initial identification of 
potential protein targets (such as enzymes and receptors) by the application of 
bioinformatics tools that exploit the vast DNA·sequence databases provided by 
intensive genomic research. This process has been termed 'target mining'. The potential 
targets identified in this way are then cloned and exposed to candidate ligands. which 
may include natural products. in what has been termed as 'ligand fishing'. High· 
throughput screening (HTS) as well as virtual screening systems can also be designed 
based on such potential targets. and these can be used to screen physical and virtual 
libraries of both synthetic and naturally~erived molecules in the search for possible 
ligands [116]. As far as antimalarial drug discovery is concerned. this approach has 
been rendered quite feasible by the successful sequencing of the genome of the human 
malaria parasite P. faldparom [117]. now available as a database for vacdne 
development and drug discovery applications [118]. 
It has been argued that libraries of natural products and their derivatives are actually 
better suited for such screens simply because they span a much broader chemical space 
than most synthetic compound libraries currently available for this purpose, and which 
are usually composed of collections of existing drugs or combinatorial libraries of 
'drug-like' molecules [119]. This diversity evolves primarily from differences in the 
levels of chirality, degree of unsaturation. presence of complex ring systems and the 
ratios of heteroatoms such as nitrogen. oxygen, sulfur and halogens [120]. It has even 
been proposed that screening libraries should be intentionally optimized by adding to 
them molecules with biogenic or natural-product-like scaffolds [121]. 
Figure 2.10 schematically summarizes the inter-relationships between the various 
approaches to antimalarial drug discovery outlined in this Chapter. including some of 
the more modern approaches 
2.9 Antimalarial drug discovery strategies applied in this study 
This study applied some of the strategies outlined above in an attempt to identify 
novel. highly active antimalarial compounds. For example. natural product-inspired 
scaffolds were used in the design of the target compounds. Molecular hybridization 
was another of the strategies applied in this study - majority of the target compounds 
were designed as dual drugs. The study also utilized in silico (computational) and in 
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vitro physicochemical and ADME prediction to guide in the design and selection of 
target compounds for synthesis. 
The natural product basis of the study is introduced in section 2.9.1 below: the 
approach to molecular hybridization and the selection of the hybrid components will 
be introduced and discussed in Chapter Three; the use of in silico and in vitro 
physicochemical and ADME predictions to guide target compound design is elaborated 
in Chapter Five. 
2.9.1 Curcumin and chalcones 
2.9.1.1 Introduction 
As mentioned above. nature continues to be a rich source of chemical diversity for 
drug discovery [83.84]. Curcumin [diferuloylmethane; 1.7-bis(4-hydroxy-3-
methoxyphenyl)-1.6-heptadiene-3,5-dione] is one such example of a bioactive 
compound of natural origin. It is the major one of three phenolic diketone molecules 
isolated from turmeric. the rhizomes of CurQJma longa L (Zingiberaceae). the other 
two being demethoxycurcumin and bis-demethoxycurcumin [122]. These three 
compounds (as well as other structurally related synthetic and semi-synthetic 
compounds) are usually collectively referred to as curcuminoids. 
In solution. these compounds exist as eqUilibrium mixtures of the symmetrical keto 
(diene-dione) and unsymmetrical enol tautomers (figure 2.n); the enol tautomer 
predominates due to the dual stabilization effects of the resultant extended conjugation 
and intra-molecular hydrogen-bonding [123]. Interestingly. curcumin could also exist as 
a quinone-methide radical - the product of photo-catalyzed auto-oxidation in basic 
aqueous media [124]. 
CurQJma longa has for centuries been cultivated in India and other parts of Asia, and 
its rhizome (turmeric) used to impart colour and flavour to food as well as for 
medicinal purposes in the treatment of diabetic wounds. hepatic disorders. jaundice. 
anorexia. coryza, cough. rheumatoid arthritis among numerous other maladies [125]. 
These medicinal properties of turmeric have since been attributed to the curcuminoids 
present in it [126], and subsequent extensive studies of curcumin. the principle 
curcuminoid. have demonstrated a very diverse range of biological activities, as 
discussed below . 
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Keto 
CUfcumin, R, :: R2 :: OMe 
Demethoxycurcumin, R,:: H; R2 ::: OMe 
Bis-demethoxycurcumin, R,::: R2 :: H 
-
Enol 
o 
Quinone methide 
o 
Figure 2.11: Structures of curcumin. demethoxycurcumin. and bis..cfemethoxycurcumin. showing 
their 'keto' and 'enol' forms [122.123] and the structure of the curcumin quinone-methide 
radical [124] 
On the other hand. chalcones are 1,3-diarylprop-2-ene-l-ones, i.e. compounds 
containing two aromatic rings linked by an a..j3-unsaturated carbonyl system in the 
form of a propenone chain. or compounds that contain this basic sub-structure [127]. 
The structural similarity of chalcones (and dienones) to curcumin is obvious (see Figure 
2.12) both having two aryl rings linked by a chain that contains an (l,j3-unsaturated 
carbonyl system. It comes as no surprise. therefore. that curcumin and chalcones 
possess overlapping biological activity profiles. 
o o 
Curcumin 
o o 
Chalcone Dienone 
Figure 2.12: General structures of curcumin-related compounds chakones and dienones 
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Scientific studies have shown curcumin to possess a variety of biological activities. 
including antioxidant [123]. antiangiogenic [128] and anti-cancer [129] activity. as well 
as promotion of wound healing [125]. It has also been shown to possess anti-
inflammatory [130.131] and anti-protozoal activity against Trypanosoma [132]. 
Leishmania [133] and Plasmodium [134,135] parasites. Chakones appear to be a 
privileged class of compounds. exhibiting a very diverse range of biological activities 
including anticancer [136,137], antioxidant [138]. antibacterial [139], antiviral [140]. 
anti-HIV [141]. anti-TB [142]. and antiprotozoal activity against Giardia [143], 
Leishmania [144.145] and Plasmodium [146.147] species. 
2.9.1.2 Antimalarial activity of curcumin and chalcones 
With regard to its antiplasmodial activity. in vitro studies have shown curcumin to 
inhibit the growth CQR P. faldparom in a dose-dependent manner. with an ICso of 
-5J.1M [134]. The current study reproduced these in vitro antimalarial results against 
both the CQR (Od2) and the CQS (010) strains (Chapter Four). However. the 
development of curcumin as an antimalarial is hampered by its relatively low potency 
and its poor oral bioavailability [148]: in vivo studies show up to 75% of orally 
administered curcumin is unabsorbed and excreted in faeces [126]. 
The study of chalcones as potential antimalarial agents was largely inspired by the 
discovery of the naturally occurring antimalarial chalcone. licochalcone A [101.102]. 
Extensive SAR studies on the antimalarial activity of chalcones. such as those by 
Glutteridge et al. [149] and Go et al. [146]. have led to the identification of a very 
diverse range of synthetic chakones with notable antimalarial activities. including 
halogenated. hydroxylated. alkoxylated and qui no Ii nyl chalcones. These studies have 
suggested that: 
.. electron-withdrawing groups on ring A (e.g. 4-chloro. 2.3-dichloro, 2,4-dichloro 
and 2,4-difluoro substitutions) and electron-donating groups on the ring B (e.g. 
2.4-dimethoxy and 2.3,4-trimethoxy substitutions) were associated with an 
increased in vitro antimalarial potency; 
.. replacement of ring A with a quinoline ring further enhanced antimalarial activity; 
.. alkoxylated chalcones were generally more active than hydroxylated chakones; 
.. the a-~unsaturated enone linker was essential for activity [146.147.149-151]. 
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2.9.1.3 Proposed mechanisms of antimalarial action 
Curcumin has been experimentally shown to inhibit various mammalian isoforms of 
Sarcoplasmic Reticulum Calcium ATPase (SERCA) pumps. possibly by stabilizing the 
interaction between the nucleotide binding and phosphorylation domains, precluding 
ATP binding [152]. Inhibition of the P. faldparom SERCA (PfATP6) could therefore be 
a possible basis for its observed antimalarial activity. which is similar to one of the 
proposed mechanisms of action of the highly active artemisinin-derived antimalarials. 
Other possible mechanisms of action of both curcumin and chalcones have been 
proposed based on the empirical evaluation of their structures. For example. these 
compounds may interfere with hemozoin formation by interacting with heme to 
prevent polymerization. This could be by 'THC stacking interactions facilitated by the 
two phenyl ring systems. and which could allow for stacking interactions with heme. In 
the case of curcumin (and hydroxylated chakones). inhibition of hemozoin formation 
could also result from hydrogen bonding between the enolic and phenolic hydroxyl 
groups on curcumin and the terminal carboxylate groups on heme. or from iron 
chelation involving the coordination of the central iron of the haem by the 13-
diketonate group on curcumin [153]. 
Another possible mechanism of action is the inhibition of the cysteine proteases 
involved in the hydrolysis of globulin. This non-reversible inhibition would be the 
result of curcumin or chalcones covalently binding with the enzymes via a 1.4-
conjugate addition reaction, in which the thiol group of the cysteine residue within the 
enzyme's active site. in its thiolate form. acts as a nucleophile and attacks the 0..13-
unsaturated carbonyl system of curcumin as shown in figure 2.13 [154]. 
MeO 
-
HO 
Enzyme, 
5 OH 0 
Figure 2.13: Schematic representation of the proposed lA-conjugate addition of the thiolate 
group of an enzyme and the a.{3- unsaturated carbonyl system of curcumin 
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Other probable antimalarial mechanisms of action of chalcones include inhibition of 
the P. fa/dparum cyclin-dependent kinase PfMRK [1551 or possible inhibition of 
protozoal fumarate reductase [156]. 
In spite of its low antimalarial potency. curcumin remains an attractive potential lead 
compound for the design and (semi)synthesis of potential antimalarial compounds 
[135]. Curcumin in itself was not applied in the synthesis of hybrid compounds in this 
study. but rather the two classes of structurally related compounds. chalcones and 
dienones, were used for this purpose. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
2.10 Research questions. Aims and Objectives 
Research question 
The research question that this study aimed to answer was whether it would be 
possible to identify novel curcumin-related hybrid compounds with in vitro and in 
vivo antimalarial activity. An attendant question was whether it would be possible to 
elucidate the pharmacokinetics and mechanism(s) of action of selected target 
compounds. 
Objective 
The overall objective was to identify novel hybrid compounds containing scaffolds that 
are structurally related to the natural product curcumin. and which possess in vitro and 
in vivo antimalarial potency. 
Specific aims 
.. To design and synthesize novel hybrid compounds as potential antimalarial agents 
which contain scaffolds that are structurally related to the natural product curcumin 
(Chapter Three). 
.. To pharmacologically evaluate the synthesized compounds in vitro for antimalarial 
activity and possible mechanisms of action (Chapter Four). 
.. To apply in silico (computational) techniques to guide the design of derivatives of 
the more active compounds with potentially superior physicochemical and/or 
ADMET properties for subsequent synthesis. in vitro antimalarial testing and 
mechanistic studies (Chapter FIVe). 
.. To elucidate the pharmacokinetic profiles and evaluate the in vivo antimalarial 
activities of the most promising compounds using the mouse model (Chapter Six). 
ERIC M.GUANTAI - Ph.D THESIS /Iml 
" 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
C1IAl'TLR 1\,\/0' ,\f'I'!~O,\C: 11:5 10 ,\:--':Wvl,\i ... \RI,\L DRUG :)ISCO\'U~) 
References 
1. R G Ridley. Medical need. scientific opportunity and the drive for antimalarial drugs. Nature (2002) 415 
686-693. 
2. C Biot and K Chibale. Novel approaches to antimalarial drug disrovery. Infed. Di!ord. Drug Target! (2006) 
6173-204. 
3. WHO. Guidelines for the treatment of malaria. wtO (2006) 
4. G Edwards and G A Biagini. Resisting resistance: dealing with the irrepressible problem of malaria. Brit. 1. 
Clin. Pharmacal. (2006) 61 (6) 690-693. 
5. N White. Antimalarial drug resistance and combination chemotherapy. Phil. Trans. R . .soc. Land. (1999) 
B354 739-749. 
6. T K Mutabingwa. Artemisinin-based combination therapies (ACTs): Best hope for malaria but inaccessible to 
the needy. Acta Trap. (2005) 95 305-315. 
7. WHO. Guidelines for the treatment of malaria - 2nd Edition. WHO (2010) 
8. N J White. Qinghaosu (Artemisinin): The Price of Success. Science (2008) 320330-334. 
9. K I Barnes and N J White. Population biology and antimalarial resistance: The transmission of antimalarial 
drug resistance in Plasmodium faldparom. Ada Trap. (2005) 94 230-240. 
10. N J White. Assessment of the Pharmacodynamic Properties of Antimalarial Drugs In 1I1K1. Antimicrob. 
Agents Chemother. (1997) 41 (7) 1413-1422. 
11. D N Durrheim. Artemisinin-dass comb nation therapy for malaria - unresolved ethical and technical issues. 
Trap. Med. Infect. Dis. (2004) 2 185-188. 
12. A Nzila. The past. present and future of antifolates in the treatment of Plasmodium faldparom infection. 1. 
Antimicrab. Chemother. (2006) 571043-1054. 
13. H C Carrington. A F Crowther. D G Davey. A A Levi. and F L Rose. A metabolite of paludrine with high 
antimalarial activity. Nature (1951) 168 1080. 
14. P A Winstanley. E K Mberu. I S F Szwandt. A M Breckenridge. and W M Watkins. In Vitro Activities of Novel 
Antifolate Drug Combinations against Plasmodium faldparom and Human Granulocyte CFUs. Antimicrob. 
Agents Chemother. (1995) 39 (4) 948-952. 
15. A T Hudson. Atovaquone - a novel broad-spectrum anti-infective drug. Parasitol. Today (1993) 9 (2) 66-
68. 
16. W T Hughes. The role of Atovaquone tablets in treating Pneumcx:ysti! Giilrimipneumonia. 1. A«juir. Immune 
Getie. Syndr. Hum. Retroviral. (1995) 8 247-252. 
17. I K Srivastava. H Rottenberg. and A B Vaidya. Atovaquone. a Broad Spectrum Antiparasitic Drug. Collapses 
Mitochondrial Membrane Potential in a Malarial Parasite. J. BioI. Chem. (1997) 212 (7) 3961-3966. 
clUe M GUANf AJ- ph.D THESIS 2010 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
-- ---------
18. I K Srivastava and A B Vaidya. A Medlanism for the Synergistic Antimalarial Action of Atovaquone and 
Proguanil. Antimicrob. Agents Cheroother'. (1999) 43 (6) 1334-1339. 
19. C ) Canfield. M Pudney. and W E Gutteridge. Interactions of atovaquone with other antimalarial drugs 
against P. faldpelUm in vitro. Experim. Parasitol. (1995) 80 373-381. 
20. P D Radloff. J Phillips. M Nkeyi, D Hutchinson. and P G Kremsner. Atovaquone and proguanil for 
Plasmodium faldpelUm malaria. liJncet (1996) 3471511-1514. 
21. N Olivieri. G M Brittenham, D matsui, M Berkovitch. l M Blendis. R G Cameron. R A McClelland, P P Uu. D 
M Templeton. and G Koren. lron<helation therapy with oral deferiprone in patients with thalassemia 
major. New Engl. 1. Med. (1995) 332 (14) 918-922. 
22. N Olivieri and G M Brittenham. lron-Chelating Therapy and the Treatment of Thalassemia. Blood (1997) 
89 (3) 739-761. 
23. C B Modell and J Beck. long-tenn desfenioxamine therapy in thalassemia. Ann. New York Acad. Sci. 
(2006) 232 201-210. 
24. G F Mabeza, M loyevsky, V R Gordeuk. and G Weiss. Iron Chelation Therapy for Malaria: A Review. 
Pharmacol. Therap. (1999) 81 (1) 53-75. 
25. D G Heppner, P E Hallaway. G J Kontoghiorghes, and J W Eaton. Antimalarial Properties of Orally A4ive 
Iron Chelators. Blood (1988) 72 (1) 358-361. 
26. V Gordeuk. P E Thuma, G M Brittenham, S Zulu, G Simwanza, A Mhangu, G Flesch. and D Parry. Iron 
Chelation With Desferriolmmine B in Adults With Asymptomatic Plasmodium faldpelUm Parasitemia. Blood 
(1992) 79 (2) 308-312. 
27. T ) Egan and C H Kaschula. Strategies to reverse drug resistance in malaria. CUff. Opin. Infect. Dis. (2007) 
20 (6) 598-604. 
28. P Rasoanaivo. D Ramanitrahasimbola. and S Ratsimamanga-Urverg. leads and botanicals from plants in 
Madagascar. Personal communication (2010) 
29. P Rasoanaivo. S Ratsimamanga-Urverg. R Milijaona. H Rafatro. A Rakoto-Ratsimamanga, C Galeffi. and M 
Nicoletti. In vitro and in IIii,.v chloroquine-potentiating action of Strychnos myrtoides alkaloids against 
chloroquine-resistant strains of ~asmodtUm resistant malaria. Planta Medica (1993) 60 13-16. 
30. P Rasoanaivo. S Ratsimamanga-Urverg. H Rafatro. D Ramanitrahasimbola. G Palazzino, C Galeffi, and M 
Nicoletti. Alkaloids of Hemandia voyronii: chlorquine-potentiating activity and structure elucidation of 
Herveline D. Planta Medica (1998) 64 58-62. 
31. D Ramanitrahasimbola. P Rasoanaivo. and H Vial. Malagashanine potentiates chloroquine antimalarial 
activity in drug resistant Plasmodium malaria by modifying both its efflux and influx, Mol Biochem. 
Parasitol (2006) 146 58-67. 
32. H Rafatro. D Ramanitrahasimbola, P Rasoanaivo, S Ratsimamanga-Urverg. A Rakoto-Ratsimamanga. and F 
Frappier. Reversal Activity of the Naturally Oa:urring Chemosensitizer Malagashanine in Plasmodium 
Malaria. Biochem. Pharmacol (2000) 59 1053-1061. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
I ,:11APT[R T\X10: ,\PPROi\CI1LS 10 ANTllv1t\L·\Rf,\l DRUG DISCOV[Rl 
33. M Fredt1rich. M Hayatte. M TIts. P de Mol. and l Angenot. Reversal of chloroquine and mefloquine 
resistance in Plasmodium fakiparom by two monoindole alkaloids. lcajine and lsoretuline. Planta Medica 
(2001) 67523-527. 
34. F Frappier. A Jossang. J Soudon. F Calvo. P Rasoanaivo. S Ratsimamanga-Urverg. J. Saez. and J Schrevel. 
Bisbenzylisoquinolines as Modulators of Chloroquine Resistance in Plasmodium faldparom and Multidrug 
Resistance in Tumor Cells. Antimicrob. Agents Chernether. (1996) 40 (6) 1476-1481. 
35. P A Tamez. D lantvit. E Urn. and J M Pezzuto. Chemosensitizing action of cepharanthine against drug-
resistant human malaria. Plasmodium faldparom. 1. Ethnopharrnaro/. (2005) 98 137-142. 
36. J A Martiney. A Cerami. and A F G Slater. Verapamil Reversal of Chloroquine Resistance in the Malaria 
Parasite Plasmodium faldparom Is Specific for Resistant Parasites and Independent of the Weak Base Effect. 
1. BioI. Chem. (1995) 270 (38) 22393-22398. 
37. G 0 Gbotosho. 0 A Ogundahunsi. C T Happi. D E Kyle. l Gerena. W K Milhous. A Sowunmi. AM J 
Oduola. and l A Salako. The effects of a.l-add glywprotein on the reversal of chloroquine resistance in 
Plasmodium faldparom. Annal. Tropic. Med. Paras/tol. (2006) 100 (7) 571-578. 
38. AM J Oduola. A Sowunmi. W K Milhous. T G Brewer. D E Kyle. l Gerena. R N Rossan, LA Salako. and B G 
Schuster. In vitro and in vi&lO reversal of chloroquine resistance in Plasmodium faldparom with 
promethazine. Am. 1. Trop. Med. Hyg. (1998) 58 (5) 625-629. 
39. G 0 Gbotosho. C T Happi. A.Sijuade. 0 A T Ogundahunsi. A Sowunmi. and A M J Oduola. Comparative 
study of interactions between chloroquine and chlorpileniramine or promethazine in healthy volunteers: a 
potential wmbination-therapy phenomenon for resuscitating chloroquine for malaria treatment in Africa. 
Annal. Tropic. Med. Paras/tol. (2008) 102 (t) 3-9. 
40. W Peters. R Ekong. B L Robinson, D C Warhurst. and Xing-Qing Pan. Antihistaminic drugs that reverse 
chloroquine resistance in Plasmodium faldparom. lancet (1989) 334-335. 
41. Z He. L Chen, J You. L Qin. and X Chen. Antiretroviral protease inhibitors potentiate chloroquine 
antimalarial activity in malaria parasites by regulating intracellular glutathione metabolism. 
Experim.Parasito/. (2009) 123 122-127. 
42. M F M Khairul. T H Min, J H Low. C H Che Nasriyyah. A N A'shikin, M N Norazmi, M Ravichandran, and S 
S Raju. Fluoxetine potentiates Chloroquine and Mefloquine effects on multi-drug resistant Plasmodium 
faldparom in &.1'tro. Jap.1. Inf. Dis. (2009) 59329-331. 
43. S G Evans, N Butkow. C Stilwell. M Berk, N Kirchmann. and I Havlik. Citalopram Enhances the Activity of 
Chloroquine in Resistant Plasmodium in I4tro and in 14&10. 1. Pharrnacol. Experim. Therapeut. (1998) 286 
(1) 172-174. 
44. T H Min. M F M.Khairul. J H Low. C H Che Nasriyyah. AN A'shikin, M N Norazmi. M Ravichandran, and S 
S Raju. Roxithromydn potentiates the effects of chloroquine and mefloquine on multidrug-resistant 
Plasmodium faldparom in vitro. Experim. Parasitol. (2007) 115 387-392. 
ERIC M C.UANTAI - Ph.D THESIS 2010 
59 
liliiii 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
45. A D van Schalkwyk. J C Walden. and P J Smith. Reversal of Chloroquine Resistance in Plasmodium 
fa/dparum using Combinations of Chemosensitizers. Antimicrob. Agents Chemother. (2001) 45 (n) 3171· 
3174. 
46. F Chouteau. D Ramanitrahasimbola. P Rasoanaivo. and K Chibale. Exploiting a basic chemosensitizing 
pharmacophore hypothesis. Part t: Synthesis and biological evaluation of novel arylbromide and bicydic 
chemosensitizers against drug-resistant malaria parasites. Bioorg. Moo. Chem. Lett. (2005) 15 3024-3028. 
47. A K Bhattacharjee. DE Kyle. and J l Vennerstrom. Structural Analysis of Chloroquine Resistance Reversal by 
Imipramine Analogs. Antimicrob. Agents Chemother. (2001) 45 (9) 2655-2657. 
48. Chung-Pu Wu. D A van Schalkwyk, D Taylor. P J Smith. and K Chibale. Reversal of chloroquine resistance in 
Plasmodium fa/dparumby 9Hxanthene derivatives. Int. J. Antimicrob. Agents (2005) 26170-175. 
49. J X Kelly. M J Smilkstein. R A Cooper. K D lane. R A Johnson. A Janowsky. R A Dodean. D J Hinrichs. R 
Winter. and M Riscoe. Design.. Synthesis, and Evaluation of 10-N-Substituted Acridones as Novel 
Chemosensitizers in Plasmodium faldparom. Antimicrob. Agents Chemother. (2007) 51 (11) 41334140. 
50. Y OSCI. S Kobayashi. Y Sato. Y Suzuki. K Takino. T Takeuchi. Y Miyata. M Sakaguchi. and H Takayanagi. 
Structural Properties of Dibenzosuberanylpiperazine Derivatives for Efficient Reversal of Chloroquine 
Resistance in Plasmodium dllJbaudi. 1. Moo. Chem (2003) 461948-1956. 
51. S Yeh. P J Smith. and K Chlbale. Dual-ading diamine antiplasmodial and chloroquine resistance modulating 
agents. Biochem. Pharmacol. (2006) 72 156-165. 
52. S J Burgess. A Selzer. J X Kelly. M J Smilkstein. M K Riscoe. and D H Peyton. A Chloroquine-like Molerule 
Designed to Reverse ResistaOO! in Plasmodium faldparum. J. Med. Chem (2006) 49 5623-5625. 
53. N October. N D Watermeyer. V Yardley. T J Egan, K Ncokazi. and K Chibale. Reversed chloroquines based 
on the 3.4-diilydropyrimidin-2(1n,-one scaffold: synthesis and evaluation of antimalarial. f'-hematin 
inhibition and cytotoxic activity. ChemMedChem (2008) 3 (11) 1649-1653. 
54. J X Kelly. M J Smilkstein. R Brun. S Wittlin. R A Cooper. K D lane. A Janowsky, R A Johnson, R A Dodean. 
R Winter. D J Hinrichs. and M K Riscoe. Discovery of dual function acridones as new antimalarial 
chemotype. Nature (2009) 459 (7244) 270-273. 
55. T N K Raju. The Nobel Chronides: 1988 - James \XIhyte Black. (b 1924). Gertrude Elion (1918-99). and 
George H Hitchings (1905-98). lancet (2000) 355 1022. 
56. J R Proudfoot. Drugs. Leads, and Drug-Ukeness: An Analysis of Some Recently launched Drugs. Bioorg. 
Med Chem. Lett. (2002) 12 1647-1650. 
57. R GRidley. W Hofheinz. H Matile. C Jaquet. A Dam. R Masciadri. S Jolidin. W F Richter. A Guenzi. M-A 
Girornetta, H Urwyler, W Huber, S Thaithong, and W Peters. 4-Aminoquinoline Analogs of Chloroquine 
with Shortened Side Chains Retain Activity against Chloroquine-Resistant Plasmodium faldparom. 
Antimicrob. Agents Chemother. (1996) 40 (8) 1846-t854. 
58. D De. F M Krogstad. l D Byers. and D J Krogstad. Structure-Activity Relationships for Antiplasmodial 
Activity among 7-Substituted 4-Aminoquinolines. J. Moo. Chern. (1998) 41 4918-4926. 
ERIC M GUANT AI - Ph.D THESIS 2010 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
59. C H Kaschula. T J Egan. R Hunter, N Basiliro, S Parapini. D Taramelli, E Pasini. and D Monti. Strud1.lre-
Activity Relationships in 4-Aminoquinoline Antiplasmodials. The Role of the Group at the 7-Position. J. 
Med Chem. (2002) 45 353t-3539. 
60. P G Bray. S R Hawley. M Mungthin. and S A Ward. Physicochemical properties correlated with drug 
resistance and the reversal of drug resistance in Plasmodium fa/dparom. Malec. Pharmacol. (1996) 50 1559-
1566. 
61. DC Warhurst. Understanding resistance to antimalarial4-aminoquinolines. cinchona alkaloids and the highly 
hydrophobic arylaminoalcohols. CUff. Sci. (2007) 92 (11) 1556-1560. 
62. MAL Blackie. V Yardley. and K Chibale. Synthesis and evaluation of phenylequine for antimalarial activity 
in vitro and in viltO. B/corg. Med. Chem. lett. (2010) 20 1078-1080. 
63. P Beagley. MAL Blackie, K Chibale, C Clarkson, R Meijboom. J R Moss, P J Smith. and H Suo Synthesis and 
antiplasmodial activity in vitro of new ferrocene-chloroquine analogues. Dalton Trans. (2003) 3046-3051. 
64. P Beagley. MAL Blackie. K Chibale. C Clarkson, J R Moss. and P J Smith. Synthesis and antimalarial activity 
in vitro of new ruthel'lC::l(Ene-chloroquine analogues. Dalton Trans. (2002) 4426-4433. 
65. MAL Blackie. P Beagley, S L Croft. H Kendrick. J R Moss. and K Chibale. Metallocene-based antimalarials: 
An exploration into the influence of the ferrocenyl moiety on in vitro antimalarial activity in chloroquine-
sensitive and chloroquine-resistant strains of Plasmodium fa/dparom. Bioorg. Med. Chem. (2007) 15 6510-
6516. 
66. K J Raynes. P A Stocks. P M O'Neill. B K Park. and S A Ward. New 4-Aminoquinoline Mannich Base 
Antimalarials. 1. Effect of an Alkyl Substituent in the Sf·Position of the 4'-Hydroxyanilino S"!de Chain. 1. Med. 
Chem. (1999) 422747·2751. 
67. J X Kelly. M J Smilkstein. R Bnm. S \XIittlin. R A Cooper. K D Lane. A Janowsky. R A Johnson, R A Dodean, 
R \XIinter. D J Hinrichs. and M K Riscoe. Discovery of dual function acridones as new antimalarial 
chemotype. Nature (2009) 459 (7244) 27()'273. 
68. J Guillon. P Grellier.M Labaied, P Sonnet. J-M Leger. R Deprez·Poula!n. I Forfar-Bares. P Dallemagne. N 
Lemaitre. F pehourcq. J Rochette. C Sergheraert. and C Jarry. Synthesis. Antimalarial Activity. and Molecular 
Modeling of New PyrroIo[t,2-a]quinoxalines. BispyrroloU,2-alquinoxalines. Bispyrido[3,2-e]pyrrolo[1,2-
a]pyrazines. and Bispyrrolo[1,2·ajthieno[3,2-e]pyrazines. J. Med Chem. (2004) 471997-2009. 
69. D K Taylor. T D Avery. B W Greatrex. E R T Tiekink. I G Macreadie. P I Macreadie. A D Humphries. M 
Kalkanidis, E N Fox. N K1onis. and L Tilley. Novel Endoperoxide Antimalarials: Synthesis. Heme Binding, 
and Antimalarial Activity. J. Moo. Chern. (2004) 471833-1839. 
70. M P Crespo. TO Avery, E Hanssen. E Fox, T V Robinson. P Valente. 0 K Taylor. and l TIlley. Artemisinin 
and a Series of Novel Endoperoxide Antimalarials Exert Early Effects on Digestive Vacuole Morphology. 
Antimicrob. Agents Chemother. (2008) 52 (1) 98-109. 
71. K J Saliba. and K Kirk. Clotrimazole inhibits the growth of Plasmodium fa/dparom in vitro. Trans. R. Soc 
Trap. Moo. Hyg. (1998) 92 (6) 666-667. 
ERIC M GUANfAI- Ph.D THESIS 2010 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
, \;~: < 
72. T TIffert. H Ginsburg. M Krugliak, B C Elford. and V L Lew. Potent antimalarial activity of dotrimamle in in 
Liftrorultures of Plannodium faldparom. Proc. Natl Acad Sd. USA. (2000) 97 (1) 331-336. 
73. S Gemma. G Camp1ani. S Butini. G Kukreja. B P Joshi. M Persico. B Catalanotti. E Novellino. E Fattorusso. V 
Nacd. L Savini. D Taramelli. N Basilico. G Morace. V Yardley. and C Fattorusso. Design and Synthesis of 
Potent Antimalarial Agents Based on Clotrimamle Scaffold: Exploring an Innovative Phannaoophore. 1. 
Moo. Chem. (2007) 50595-598. 
74. D A Carache. S R H6rtner. A Bertogg. C Binkert. D Bur. H P Miirki. A Dom. and F Diederich. De Noll'O 
Design, Synthesis, and In i-ftro Evaluation of a New Class of Nonpeptidic Inhibitors of the· Malarial Enzyme 
Plasmepsin n. ChemBioChem. (2002) 11 1137·1141. 
75. T Heikillii. S Thirumalairajan. M Davies. M R Parsons. A G McConkey. C W G Fishwick. and A P johnson. 
The first de 17011'0 designed inhibitors of Plasmodium faldparom dihydroorotate dehydrogenase. Bioorg. 
Moo. Chem. Lett. (2006) 16 88-92. 
76. M L Baniecki. D F Wirth. and J Clardy. High-Throughput Plasmodium faldparomGrowth Assay for Malaria 
Drug Discovery. Antimicrob. Agents Chemother. (2007) 51 (2) 716-723. 
77. Y Kurosawa. A Dom. M Kitsuji-Shirane. H Shimada. T Satoh. H Matile. W Hofheinz. R Masdadri. M Kansy. 
and R G Ridley. Hematin Polymerization Assay as a High-Throughput Screen for Identification of New 
Antimalarial Phannaoophores. Antimicrob. Agents Chemother. (2000) 44 (10) 2638-2644. 
78. T S Haque. A G Skillman. C E lee. H Habashita. I Y Gluzman. T J A Ewing. D E Goldberg. I D Kuntz. and J A 
Ellman. Potent. low-Molea.llar-Weight Non-Peptide Inhibitors of Malarial Aspartyl Protease Plasmepsin II. 1. 
Moo. Chem. (1999) 42 1428-1440. 
79. M A Phillips. R Gujjar. N A Malmquist. J White. F E Mamuni. J Baldwin. and P K Rat hod. 
Triamlopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitors with Potent and Selective Activity 
against the Malaria Parasite Plasmodium faldparom. J. Moo. Chem. (2008) 51 3649-3653. 
80. D Plouffe. A Brinker. C McNamara. K Henson. N Kato. K Kuhen. A Nagle. F Adrian. J T Madzen. P 
Anderson. T Nam. N S Gray. A Chatterjee. J Janes. S F Van. R Trager. J S Caldwell. P G Schultz. Y Zhou. and 
E A Winzeler. In silko activity profiling reveals the mechanism of action of antimalarials discovered in a 
high-throughput screen. Proc. Natl. Acad. Sci. USA. (2008) 105 (26) 9059-9064. 
81. P V Desai. A Patny. Y Sabnis. B Tekwani. J Gut. P J Rosenthal. A Srivastava, and M Avery. Identification of 
Novel Parasitic Cysteine Protease Inhibitors Using Virtual Screening. 1. The ChemBridge Database. 1. Med. 
Chem. (2004) 47 6609-6615. 
82. P V Desai. A Patny. J Gut. P J Rosenthal. B Tekwani, A Srivastava. and M Avery. Identification of Novel 
Parasitic Cysteine Protease Inhibitors by Use of Virtual Screening. 2. The Available Chemical Directory. J. 
Med. Chem. (2006) 491576-1584. 
83. H Itokawa. S L Morris-Natschke. T Akiyama, and K-H Lee. Plant-derived natural product research aimed at 
new drug discovery. 1. Nat. Moo. (2008) 62 263-280. 
84. D J Newman, G M Cragg. and K M Snader. Natural Products as Sources of New Drugs over the Period 1981-
2002. J. Nat. Prod. (2003) 661022-1037. 
ERIC M. GUANT Ai - Ph.D THESIS 2010 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
85. M-W Wang. X Hao. and K Chen. Biological screening of natural products and drug innovation in China. 
Phil. Trans. R. Soc. B. (2007) 362 1093-1105. 
86. D L Klayman. Quinghaosu (artemisinin): An antimalarial drug from China. Science (1985) 228 1049-1055. 
87. S Saxena. N Pant. DC Jain. and R S Bhakuni. Antimalarial agents from plant sources. CUff. Sci. (2003) 85 
(9) 1314-1329. 
88. R K Haynes. From Artemisinin to New Artemisinin Antimalarials: Biosynthesis. Extraction, Old and New 
Derivatives, Stereochemistry and Medicinal Chemistry Requirements. CUff. Top. Med. Chem. (2006) 6 509-
537. 
89. K Kaur. M Jain, T Kaur. and R Jain. Antimalarials from nature. Bioorg. Med. Chem. (2009) 17 3229-3256. 
90. K Gademann and J Kobylinska. Antimalarial Natural Products of Marine and Freshwater Origin. Chem. 
Record (2009) 9 187-198. 
91. R Batista, A J Silva Jnr. and A B Oliviera. Plant-Derived Antimalarial Agents: New leads and Efficient 
Phytomedicines. Part II. Non-Alkaloidal Natural Products. Mol. (2009) 143037-3072. 
92. S A Charman, S Arbe-Barnes, I Bathurst. R Brun. M Campbell. W N Charman, F C Chiu. J Challet. J C Craft. 
D J Creek, Y Dong. H Matile. M Maurer. J Morizzi. T Nguyen. P Papastogiannidis. C Scheurer. D M 
Shackleford. K Sriraghavan. L Stingelin. Y Tang. H Urwyler. X Wang. K L White. S Wittlin, L Zhou. and J L 
Vennerstrom. Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of 
uncomplicated malaria. Proc. Natl. Acad Sci. (2011) 108 (11) 4400-5. 
93. J L Vennerstrom. S Arbe-Barnes. R Brun. S A Charman. F C Chiu. J Chollet. Y Dong. ADorn. D Hunziker. H 
Matile. K Mcintosh. M Padmanilayam. T J Santo. C Scheurer. B Scomeaux. Y Tang. H Urwyler. S Wittlin. 
and W N Charman. Identification of an antimalarial synthetic trioxolane drug development candidate. 
Nature (2002) 430 (7002) 900-904. 
94. F A Kuehl, Jr. C F Spencer, and K Folkers. Alkaloids of Dk:hroa febrifuga Lour. 1. Am. Chem. Soc (1948) 10 
2091-2093. 
95. S Jiang. Q Zeng. M Gettayacamin. A Tungtaeng. S Wannaying. A Um. P Hansukjariya. C 0 Okunji. S Zhu. 
and D Fang. Antimalarial Activities and Therapeutic Properties of Febrifugine Analogs. Antimicrob. Agents 
Chemother. (2005) 49 (3) 1169-1176. 
96. R K Pettit. Culturability and Secondary Metabolite Diversity of Extreme Microbes: Expanding Contribution 
of Deep Sea and Deep-Sea Vent Microbes to Natural Product Discovery. Mar. Biotechnol. (2010) Online 
publication DOl 1O.1OO7/s10126-010-9294-y. 
97. Dictionary of Natural Products. (2010) (httD://dnD.chemnetb<l~~,I::()r.T11intro/mC!,"v ocr) 
98. J lei and J Zhou. A Marine Natural Product Database. 1. Chem. Inl Comput. Sci. (2002) 42742-748. 
99. A IsHih. T Suzuki. M Watanabe. T Miyase, and M Terada. Combination Effects of ChloroquMle with the 
Febrifugine and lsofebrifugine Mixture against a Blood-induced Infection with Chloroquine-resistant 
Plasmodium be1J'he{NK65 in ICR Mice. Phytother. Res. (2003) 17 1234-1236. 
!:RIC M. GUANT AI - Ph.D THESIS 2010 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
::1 1,\P[r:R T\-'(IO: ,\PPROACI U:S ro ,\~T:M,\IJ\RIAL DRUG DISCO'v'LR', 
100.J J Walsh and A Bell. Hybrid Drugs for Malaria. CUrT. Pharm. Des. (2009) 15 2970-2985. 
101. M Chen. T G Theander. 5 B Christensen. L Hviid. L Zhai. and A Kharazmi. Ucochaloone A. a New 
Antimalarial Agent. Inhibits In Vitro Growth of the Human Malaria Parasite Plasmodium faldparum and 
Protects Mice from P. yoeIlllnfedion. Antimia'Ob. Agents Chemother. (1994) 38 (7) 1470-1475. 
102.A Kharazmi. Discovery of oxygenated chaloones as novel antimalarial agents. Ann. Trap. Med. Parasotol. 
(1997) 91 (l) 5-91-5-95. 
103.R Ferrer. G Lobo, N Gamboa. J Rodrigues. C Abramjuk. K Jung. M lein. and J E Charris. Synthesis of [(1-
Chloroquioolin4-yl)amioolchaloones: Potential Antimalarial and Anticancer Agents. Sci. Pharm. (2009) 71 
725-741. 
104.E K Kerns and l Di. Drug-like Properties: Concepts. Structure. Design and Methods: from ADME to Toxicity 
Optimization. Academic PresslBseMer (2008) (1st Edition) 
105.D Prejean. B Saune. R Farinotti. J-P Flinois. P Beaune. A-M Taburet. and A Ducharme. In vitro metabolism 
of chloroquine: identification of CYP2C8. CYP3M and CYP2D6 as the main isoforms catalyzing N-
desethylchloroquine formation. Drug Met. Disp. (2003)31 (6) 748-754. 
106.5 Fu. A Bjorkman. B WAhlin. D Ofori-Adjei, 0 Ericsson. and F 5j6qvist. In vitro activity of chloroquine. the 
two enantiomers of chloroquine. desethylchloroquine and pyronaridine aiilinst Plasmodium faldparum. Br. 
1. Clin. Pharmacal. (1986) 22 93-96. 
107.5 Hirai. H Kikuchi. H-5 Kim, K Begum. Y Wataya. H Tasaka. Y Miya:zawa. K Yamamoto. and Y Oshima. 
Metabolites of Febrifugine and Its Synthetic Analogue by Mouse Uver S9 and Their Antimalarial Activity 
against Plasmodium Malaria Parasite. 1. Moo. Chern. (2003) 46 4351-4359. 
108.5 Zhu, l Meng. Q Zhang, and L Wei. 5ynthesis and evaluation of febrifugine analogues as potential 
antimalarial agents. Bioorg. Med. Chem. lett. (2006) 16 1854-1858. 
109.5 Zhu, Q Zhang, C Gudise. lWei, E 5mith, and Y Zeng. Synthesis and biological evaluation of febrifugine 
analogues as potential antimalarial agents. Bioorg. Med. Chem. (2009) 174496-4502. 
110. M Pucheault. Natural products: chemical instruments to apprehend biological symphony. Org. Biomol. 
Chem. (2008) 6424-432. 
m. G G Harrigan, 0 J Brackett. and l G Bores. Medicinal Chemistry. Metabolic Profiling and Drug Target 
Discovery. A Role for Metabolic Profiling in Reverse Pharmacology and Chemical Genetics. Mini-Rev. Med. 
Chem. (2005) 5 13-20. 
112. M B Cassera. E F Merino. V J Peres. E A Kimura. G \lfIunderlich. and A M Katzin. Effect of fosmidomydn on 
metabolic and transcript profiles of the methylerythritol phosphate pathway in Plasmodium faldparum. 
Mem. Ins!. Oswaldo Cruz (2007) 102 (3) -377. 
113. R Teng. P R Junankar, W A Bubb. C Rae. P Mercier, and K Kirk. Metabolite profiling ofthe intraerythrocytic 
malaria parasite Plasmodium faldparum by lH NMR spectroscopy. NMR Biomed. (2009) 22 292-302. 
114. T Bottcher, M Pltscheider. and S A Sieber. Natural Products and Their Biological Targets: Proteomic and 
Metabolomic labeling Strategies. A~. Chern. Int. Ed. (2010) 49 2680-2698. 
ERIC M GUANTAI- Ph.D THESIS 2010 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
iii 
':IIAPTER T'.x/O: .\PPRO,\CI1I:S 10 ANTlM,\I..ARIAl DRUG DISCOVERY 
115. D C Greenbaum. A Baruch. M Grainger. Z Bozdech. K F Medzihradszky. J Engel. JDeRisi. A A Holder. and 
M Bogyo. A role for the protease Faldpain 1 in host cell invasion by the human malaria parasite. Science 
(2002) 298 2002-2006. 
116. T Takenaka. Classical \IS reverse pharmacology in drug discovery. B. J. U. International. (2001) 88 (2) 7-10. 
117. M J Gardner. N Hall. E Fung. 0 White. M Bemman. R W Hyman. J M Carlton. A Pain. K E Nelson. S 
Bowman. I T Paulsen. K James. J A Eisen. K Rutherford. S L Salzberg. A Craig. S Kyes. M-S Chan. V Nene. S J 
Shallom. B Suh. J Peterson. S Angiouli. M Pertea. J Allen. J Selengut. D Haft. M W Mather. A B Vaidya. D M 
A Martin. A H Fairlamb. M J Fraunholz, D S Roes. S A Ralph. G I McFadden. G M Subramanian. C MungaU. 
J C Venter. D J Carrud, S L Hoffman. C Newbold. R W Davis. C M Fraser. and B Barrell. Genome sequence 
ofthe human malaria parasite Plasmodium faldpamm. NlIture(2002) 419498-511. 
11S. The Plasmodium Genome Database Collaborative. PlasmoDB: An integrative database of the Plasmodium 
faldpamm genome. Tools for accessing and analyzing finished and unfinished sequence data. Nudeic Acids 
Res. (2001) 29 (1) 66-69. 
119. R A Bauer. J M Wurst. and D S Tan. Expanding the range of 'drugaable' targets with natural product-based 
libraries: an academic perspective. CUlT. Opin. Chem. BioI. (2010) 14301-314. 
120.M Feher and J M Schmidt. Property Distributions: Differences between Drugs. Natural Products. and 
Molecules from Combinatorial Chemistry. 1. Chem. Inl Comput. Sci. (2003) 43218-227. 
12t.J Hert. J J Irwin. C Laggner. M J Keiser. and B K Shoichet. Quantifying Biogenic Bias in Screening Ubraries. 
Nat. Chem. BioI. (2009) 5 (7) 479-483. 
122.H B Rasmussen. S B Christensen. L P Kvist. and A Karazmi. A simple and efficient separation of Wl'Cl.lmins, 
the antiprotomal constituents of CUmlmll Ionga. Planta Med. (2000) 66 396-398. 
123.W M Weber, L A Hunsaker. S F Abcouwer, L M Deck, and D L Vander Jagt. Anti-oxidant activities of 
wl'Cl.lmin and related enones. Bioorg. Med. Chem. (2005) 13 3811-3820. 
124.M Griesser. V Pistis. T Suzuki. N Tejera, D A Pratt, and C Schneider. Autoxidative and cydooxygenase-2 
cataly:red transformation of the dietary chemopreventive agent wrwmin. J. Bioi. Chem. (2011) 286 1114-
1124. 
125.H P T Ammon and M A Wahl. Pharmacology of CUmin» Ionga. Planta Med. (1991) 57 
126.R K Maheshwari. A K Singh. J Gaddipati. and R C Srimal. Multiple biological activities of wl'Cl.lmin: A short 
review. Ufe Sci. (2006) 78 2081-20S7. 
127.Z Nowakowska. A review of anti-infective and anti-inflammatory chalcones. fur. J. Med. Chem. (2007) 42 
125-137. 
128.T P Robinson. T Ehlers. R B Hubbard IV. X Bai. J L Arbiser. D J Goldsmith. and J P Bowen. Design, synthesis 
and biological evaluation of angiogenesis inhibitors: aromatic enone and dienone analogues of wrwmin. 
Bioorg. Med. Chem. lett. (2003) 13115-tl7. 
129. B B Aggarwal. A Kumar. and A C Bharti. Anticancer potential of curwmin: preclinical and dinical studies. 
Anticancer Res. (2003) 23363-398. 
"rue M GUANf Af - Ph.D THESIS 2010 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
CllAPflR 1\':1/0 ,.\FPRO,\CI1[5 fO A:'-JTI,\'INARI,\L DRUG DISCOVERY 
130.A N Nurfina. M S Reksohadiprodjo. H llmmermen. U A Jenie. 0 Sugfyanto. and H van der Coot. Synthesis 
of some symmetrical curcumin derivatives and their antiinflammatory activity. Fur. 1. Moo. Chem. (1997) 
32321-328. 
131. t Camacho-Barquero. I Villegas. J M sanchez-Calvo. E Talero, S sanchez-fidalgo, V Motilva, and C A Lastra. 
Curcumin. a CUlWmtI longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS 
expression in chronic experimental colitis. Int. ImmunophanT'lllcol. (2007) 7 333-342. 
132.M Nose, T Koide, Y Ogfhara. Y Yabu. and N Ohta. Trypanosomal effeda of curcumin in vitro.. Bioi. Phatm. 
Bull. (1998) 21 (6) 643-645. 
133.T Koide. M Nose. Y Ogfhara. and N Ohta. leishmaniddal effed: of curcumin in vitro. Bioi. Phatm. Bull. 
(2002) 25 (1) 131-133. 
134.R C Reddy. P G Vatsala. V G Keshamouni, G Padmanaban. and P N Rangarajan. Curcumin for malaria 
therapy. Biochem. Bioph. Res. Co. (2005) 326472474. 
135.0 N Nandakumar. V A Nagaraj. P G Vathsala. P Rangarajan. and G Padmanaban. Curcumin-Artemisinin 
combination therapy for malaria. Antimicrob. Agents Chemother. (2006) 50 (5) 1859-1860. 
136.N J Lawrence. R P Patterson. L-L Ooi. 0 Cook, and S Ducki. Effects of a-substitutions on structure and 
bioiogfcal activity of anticancer chalcones. Bioorg. Med. Chem. Lett. (2006) 16 5844-5848. 
137.A Modzelewska. C. Pettit. G Achanta. N E Davidson. P Huang. and S R Khan. Anticancer activities of novel 
chalcone and bis-chalcone derivatives. Bioorg. Med. Chem. (2006) 143491-3495. 
138.0 P Sharma. Antioxidant activity of curcumin and related compounds. Biochem. PhsnT'IlIcol. (1976) 25 lBll-
1812. 
139.5 F Nielsen. T Boesen. M Larsen, K Sdwsnning, and H Kromann. Antibacterial chalcones-bioisosteric 
replacement ofthe 4'-hydroxy group. Bioorg. Med Chem. (2004) 12 3047-3054. 
140.8 Malhotra. J C Onyilagha. A Bohm. G H N Towers, 0 James, J B Harbome. and C J French. Inhibition of 
tomato ringspot virus by ftavonoids. Phytochem. (1996) 43 (6) 1271-1276. 
141.Q Wang. Z-H Ding. J-K tiu. and YeT Zheng. Xanthohumol. a novel anti-HIV-l agent purified from Hops 
Humulus lupulus. Antiviral Res. (2004) 64 189-194. 
142.Y-M Un. Y Zhou. M T Flavin. L-M Zhou. W Nie. and F-C Chen. Chalcones and Flavonoids as Anti-
Tuberculosis Agents. Bioorg. Moo. Chern. (2002) 102795-2802. 
l43.L Perez-Arriaga. M L Mendoza-Magana. R Cortes-Zarate. A Corona-Rivera. L Bobadilla-Morales. R Troyo-
Sanroman. and M N Ramfrez-Herrera. Cytotoxic effects of curcumin on Giardia lamb/ia trophozoites. Ada 
Trop. (2006) 98 152-161. 
144.P Boeck., CAB Faldlo. PC teal. R A Yunes. V C Filho. E C Torres-Santos. and B Rossi-Bergman. Synthesis of 
chalcone analogs with increased antileishmanial activity. Bioorg. Moo. Chern. (2006) 141538-1545. 
ERIC M. GUANTAI - Ph.D THESIS 2010 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
:':1 'AP', U"- 11.'(70: .\I'PROr\CI-lLS 10 .'NT 1 ,\1r\l.A RIAL DRUG DISCOVERY 
145.M Chen. S B Christensen. T G Theander. and A Kharazmi. Antileishmanial Activity of Uaxhalcone A in Mice 
Infected with Leishmania major and in Hamsters Infected with i.eimmaria dooovari. Antimicrob. Agents 
Chemother. (1994) 38 (6) 1339-1344. 
146.M tiu. P Wilairat. and M-l Go. Antimalarial alkoxylated and hydroxylated chalcones: strudure-activity 
relationship analysis. 1. Med. Chem. (2001) 44 4443-4452. 
147.R ti. G L Kenyon. F E Cohen. X Chen. B Gong. J N Dominguez. E Davidson. G Kurzban. R E Miller. EO 
Nuzum, P J Rosenthal. and J H McKerrow. In Vitro Antimalarial Activity of Chalcones and Their 
Derivatives. 1. Med. Chem. (1995) 38 5031-5037. 
148.P Anand. A B Kunnumakkara. R A Newman. and B B Aggarwal. Bioavailability of Currumin: Problems and 
Promises. Mol Pharm. (2007) 4 (6) 807-818. 
149.C E Gutteridge. D A Nichols. S M Curtis. D S Thota. J V Vo. L Gerena. G Montip. C 0 Asher. D S Diaz. C A 
DiTusa. K Smith. and A K Bhattacharjee. In vi'troand in viKlefficacy and in vitro metabolism of t-phenyl-3-
aryl-2-propen-l-ones against Plasmodium faldparum. Bioorg. Med. Chem. Lett. (2006) 16 5682-5686. 
150J N Dominguez. J E Charris. G Lobo. N G de Dominguez. M M Moreno. F Riggione. E Sanchez. J Olson. and 
P J Rosenthal. Synthesis of quinolinyl chalmnes and evaluation of their antimalarial activity. cur. 1. Med. 
Chem. (2001) 36 555-560. 
151. M tiu. P Wilairat. S L Croft. A L-C Tan. and M-L Go. Structure-Adivity Relationships of Antileishmanial and 
Antimalarial Chalcones. Bioorg. Med. Chem. (2003) 1l 2729-2738. 
152.J G BHmen. S Z Khan. M Javed. and F Mkhelangeli. Inhibition oHhe SERCA Ca2+ pumps by currumin. cur. 1. 
Biochem. (2001) 268 6318-6327. 
153.Y Jiao. J Wilkinson IV. E C Pietsch. J L Buss. W Wang. R Planalp. F M Torti. and S V Torti. Iron chelation in 
the biological activity of wrrumin. Fff!e Radical Bio. Med. (2006) 40 1152-1160. 
154.Z Kunakbaeva. R Carrasco. and I Rozas. An approximation of the mechanism of inhibition of cysteine 
proteases: nucleophilic sulphur addition to Michael acceptor type compounds. 1. Mol. Strud-Theochem 
(2003) 626 209-216. 
155.J A Geyer. S M Keenan, C L Woodard, P A Thompson. L Gerena. D A Nichols. C E Gutteridge. and N C 
Waters. Selective inhibition of Pfmric. a Plasmodium faldparum CDK. by anti~farial 1.3-diaryl-2-
propenones. Bioorg. Moo. Chem. lett. (2009) 191982-1985. 
156.M Chen. l Zhai. S B Christensen, T G Theander, and A Kharazmi. Inhibition of Fumarate Reductase in 
Leishmania majorand L dooovanit:1y Chalcones. Antimicrob. Agents Chemother. (2001) 45 (7) 2023-2029. 
ERJC M. GUANT AI - Ph.D 1 HESIS 20H) 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
-
In the context of trying to circumvent antimalarials drug resistance, hybridization is 
quite an attractive strategy particularly when the pharmacophores/active molecules 
being merged possess independent modes of antimalarial action. Application of dual 
drugs developed in this way would be akin to applying the individual bioactive 
molecules in combination [2], thereby borrowing from the highly rated combination 
therapy approach which advises against mono-therapy and advocates for the co-
administration of two (or more) antimalarial agents [3] (see Chapter One). In addition. 
such an approach would avoid the frequent problem of having to consider the 
different pharmacokinetic profiles of individual drugs when administered as simple 
combinations [2]. 
Although there are no examples of antimalarial dual drugs in clinical use so far. a 
number of highly active molecules have been identified using this approach. For 
example. compounds named trioxaquines have been developed by covalently linking a 
1.2.4-trioxane motif (borrowed from the highly active natural sesquiterpene 
artemisinin. Figure 3.1) to a 4-aminoquinoline moiety (borrowed from chloroquine 
and other aminoquinoline-based antimalarials) via an appropriate spacer. This strategy 
combined the potential heme-alkylating peroxide entity with the 4-aminoquinoline 
entity. known to enhance accumulation in the acidic food vacuole of the parasite and 
act by interfering with hemozoin formation. The most active of these were ODC 182 
and ODC 188 (Figure 3.1) with ICso values <40 nM against FcSl (CQR) and FcM29 
(also CQR) P. faldparom strains [4]. Another set of dual drugs was designed to target 
both the glutathione (GSH) regeneration system and the heme detoxification pathway. 
Compounds GRQt and GRQ2 (Figure 3.1) were therefore prepared by linking a 
glutathione reductase (GR) inhibitor to a 4-aminoquinoline moiety via an ester bond 
that was revealed to be sufficiently stable in biological compartments but prone to acid 
hydrolysis in the food vacuole of the parasite. These compounds were found to be 
quite active. with ED50 values <30 nM against CQR P. falciparom [5]. 
These examples. along with others such as antimalarial primaquine-statin double-drugs 
(that inhibit the malarial parasite Plasmepsin II enzyme. one of the aspartic proteases 
involved in haemoglobin degradation) [6], illustrate the potential of molecular 
hybridization as a strategy for the development of novel antimalarial agents. This study 
therefore sought to exploit this potential, investigating the antimalarial activity of 
hybrid compounds consisting of curcumin-related compounds linked to other 
rationally selected entities, as described in the sections that follow. 
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CHAPTER THREE 
DESiGN AND SYNTHESIS OF CHAlCONE- AND DIENONE-BASED HYBRID COMPOUNDS 
3.1 Preamble 
This chapter contains the work done to address the first specific aim of the study, 
which was: To design and synthesize novel hybrid compounds as potential antimalarial 
agents which contain scaffolds that are structurally related to the natural product 
curcumin. 
The chapter begins by introducing the concept of hybrid compounds/dual drugs and its 
application as a strategy for (antimalarial) drug discovery. It goes on to examine the 
1.3-dipolar cycloaddition reaction of azides and acetylenes as a convenient molecular 
hybridization strategy. What follows is an account of the rational selection of 
chalcones, dienones. AZT and chloroquinoline as suitable entities in the design of target 
antimalarial hybrid compounds. after which the synthesis and lH-NMR characterization 
of the target compounds is reported and discussed. 
3.2 Hybrid compounds/dual drugs 
As mentioned in Chapter One. the development of resistance by the malaria parasite 
to the bulk of therapeutic agents available clinically has become one of the leading 
impediments in the efforts to control this disease. As a direct result of this. great efforts 
have been made towards the development of new. highly efficacious therapeutic 
agents that do not suffer from this liability. 
One of the strategies employed in this quest for novel drugs is molecular hybridization 
(see section 2.S.1), which is the rationa\ design of ne'\lll mo\ecu\es involving the 
adequate fusion of pharmacophoric sub-units recognized and derived from two or 
more known bioactive molecules [1]. Such pharmacophoric units would consist of the 
molecular frameworks that bear those structural features thought to be responsible for 
the observed pharmacological activity of the original compounds; their selection 
would therefore be aimed at maintaining the said pharmacological characteristics. with 
their subsequent fusion. usually via a covalent linker. potentially transferring and 
combining these characteristics into the final target molecules (referred to as hybrid 
compounds or dual drugs) [t.2]. 
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molerules in combination [2], thereby borrowing from the highly rated combination 
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such an approach would avoid the frequent problem of having to consider the 
different pharmacokinetic profiles of individual drugs when administered as simple 
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number of highly active molerules have been identified using this approach. For 
example. compounds named trioxaquines have been developed by covalently linking a 
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(also CQR) P. fa/dparom strains [4]. Another set of dual drugs was designed to target 
both the glutathione (GSH) regeneration system and the heme detoxification pathway. 
Compounds GRQ1 and GRQ2 (Figure 3.1) were therefore prepared by linking a 
glutathione reductase (GR) inhibitor to a 4-aminoquinoline moiety via an ester bond 
that was revealed to be sufficiently stable in biological compartments but prone to acid 
hydrolysis in the food vacuole of the parasite. These compounds were found to be 
quite active. with ED50 values <30 nM against CQR P. falciparom [5]. 
These examples. along with others such as antimalarial primaquine-statin double-drugs 
(that inhibit the malarial parasite Plasmepsin II enzyme. one of the aspartic proteases 
involved in haemoglobin degradation) [6]. illustrate the potential of molecular 
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Artemisinin 
o 
x 0 
GRQ1: n = 5. X = H 
GRQ2:n = 4. X= OH 
ODC188:n=2 
Figure 3.1: Structures of artemisinin and selected antimalarial hybrid compounds [4.5] 
3.3 Selection of a suitable hybridization strategy 
3.3.1 Introduction to CUck Chemistry 
Click chemistry is a modular approach to chemical transformations that applies 
practical and reliable chemical reactions to connect a diversity of structures bearing a 
wide variety of functional groups [7.8]. It encompasses several groups of reactions 
including cycloaddition reactions. nucleophilic ring-opening reactions. carbonyl 
chemistry of the non-aldol type and addition to carbon-carbon multiple bonds (Figure 
3.2). As described by Sharpless et al. [8], dick reactions must be of wide scope, give 
consistently high yields with a variety of starting materials. be easy to perform. be 
insensitive to oxygen or water. use only readily available reagents and offer simple 
reaction work-up and product isolation. Robust chemistry of this nature offered a 
convenient hybridization strategy for application in this study. and the 1.3-dipolar 
cycloaddition reactions were considered for this purpose. 
1.3-Dipolar cydoadditions are exergonic fusion processes that involve the reaction of 
1.3-dipoles and dipolarophiles to yield a variety of 5 -membered heterocycles [9,10]. 
As the name suggests. a 1.3-dipole is a molecule that has both a nucleophilic site and an 
electrophilic site in a 1.3-relation; this generally refers to molecules containing one or 
more heteroatoms and which possess at least one mesomeric structure in the form of a 
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charged dipole (in a 1.3-relation). A typical example of such a structure is an azide 
(Figure 3.3A). 
RIOO-Q-R1 
~ 
o R'~ 
Diers-Alder '" 
Cycloadditlon Catalyst 
(=( Additions 
J Nuc 
R' 
;= 
Natural sources R
IO
-%3 
Cuel) ! [0] 
R"/ 
N,;;.N 
1- ~R' N.J' 
1,3-Dlpolar Cycloaddition 
Cu(l) catalyzed Huisgen 
r - - - - - - --I 
, 0 ' 
:A: , , 
'R' '~ 
'.--------: ".ow ~ 
R"ONH2 
Figure 3.2: A selection of clkk chemistry reactions [11] 
Nucleophilic 
Ring opening 
R"O 
'N 
R'~ 
Non-Aldol Carbonyl 
Chemistry 
The second reaction component, the dipolarophile. is a source of two n-electrons. and 
generally refers to a structure with a double or triple bond e.g. an alkyne. alkene or 
carbonyl group [9]. Th  cycloaddition of azides and alkynes to yield t.2.3-triazoles is 
arguably the most widely applied member of this class of reactions. largely due to the 
ease with which the azide can be introduced and subsequently carried unscathed 
through many synthetic steps. It also appears to be the only 1.3-dipole that is 
practically devoid of any side reactions. However. there are always concerns about the 
safety of working with organic azides due to their potentially explosive nature [12,13]. 
This type of reaction was first described by R. Huisgen [10] and classically involves the 
concerted movement of six electrons in a suprafadal manner - 4 n-electrons from the 
l,3-dipole and 2 n-electrons from the dipolarophile [9,10]. Figure 3.3B illustrates the 
mechanism of the classical (non-catalyzed) Huisgen 1.3-dipolar cydoaddition reaction 
using the azide and alkyne as the t.3-dipole and dipolarophile. respectively. to yield a 
mixture of the 1.4- and l,5-substituted-1.2.3-triazoles. 
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3.3.2 Cu(l) catalyzed cydoaddition reaction of azides and terminal alkynes 
A 
Under thermal (non-catalyzed) conditions. this l,3-dipolar cydoaddition reaction of 
alkynes and azides requires extended reaction times (hours to days). significant heating. 
and affords a mixture of both 1.4- and 1.5-regioisomers (Figure 3.3C): this is because 
the activation energy barriers for the concerted process leading to the generation of 
both isomers are very close, 25.7 and 26.0 kcal/mol for the 1.4- and 1.5-regioisomers. 
respectively [7.12.14.15]. However. this reaction has since been revolutionalized by the 
independent discoveries by the research groups led by Sharpless [12] and Meldal [16] 
that the use of Cu(l) catalysis resulted in higher yields. stability to various solvents 
(including water) and pH. tolerance to most functionalities. faster reactions under 
milder reaction conditions. and. unlike the prior uncatalyzed reaction, yielded only the 
l,4-disubstituted regioisomer [7,8,17]. As a result, the Cu(l)-catalyzed 1.3-dipolar 
cycloaddition reaction of azides and terminal alkynes now met the general 
requirements of a click chemistry reaction (as defined in Section 3.3.1). 
... 
Electrophilic site Nuceophilic site 
c 
R \ (f) e 
N=N=N ca. 1:1 
--==--H 
Figure 3.3: A: mesomeric forms of the azide showing the l,3--dipole; B: mechanism of the 
classical Huisgen cycloaddition reaction showing the concerted movement of electrons and the 
resultant regioisomers; C: products of the azide-alkyne cydoaddition reaction under thermal (i) 
and Cu(l)-catalyzed (iO conditions: 0) 80 - 120 "c. 12-60 hrs; eii) Cu(l). rt. 12-24 hrs [1] 
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Sharpless and coworkers (2002) [12] indicated that the generation of the Cu(l) catalyst 
in situ by the reduction of Cu(ll) salts (such as Cu(OAch. but more commonly 
CuS04.5H20) is the preferable approach as Cu(ll) salts tend to be less costly and are 
often purer that CuO) salts; ascorbic acid or sodium ascorbate have proven to be 
excellent reducing agents for this purpose. Oirect sources of Cu(l) such as CuOTf.C6H6 
[12]. Cui [18]. [Cu(NCCH3)4][PF6] [19], Cu(OEthl and Cu(PPh3hBr [20] can be used 
directly in the absence of a reducing agent. However. these reactions usually require 
acetonitrile as co-solvent and one equivalent of a nitrogen base (for example 2.6-
lutidine. triethylamine. diisopropylethylamine, or pyridine), which. along with the 
exclusion of oxygen. tend to minimize the formation of undesired by-products 
observed with direct Cu(l) catalysis. One of the primary by-products of direct Cu(l) 
catalysis are the diacetylenes. resulting from the Cu(l)-catalyzed oxidative 
homocoupling of terminal acetylenes via their corresponding Cu(l)-acetylides. a 
reaction discovered by Carl Glaser in 1869, and termed the Glaser reaction [21]. In 
addition to generating the catalyst from a Cu(lI) source, a slight excess of ascorbic 
acid/ascorbate prevents formation of these oxidative coupling by-products [15]. 
As alluded to earlier. the reaction tolerates a wide range of solvents. Typically. water is 
used along with a variety of co-solvents ranging from the water-miscible tett-butanol 
[7.12]. ethanol [7.22], OMSO and OMF [17]. to the water-immiscible THF [7]. and 
OCM [23.24]. Microwave conditions have also been applied successfully for the 
generation of 1.2.3-triazoles [20.25]. In an attempt to simplify the experimental 
conditions even further, the one-pot synthesis of 1.2.3-triazoles from alkyl halides. 
sodium azide and alkynes has been successfully carried out [17]. 
The proposed catalytic cycle for the cycloadditon reaction is shown in Figure 3.4 The 
sequence begins with the coordination of the alkyne to the Cu(i) species. displacing 
one of the solvent ligands (e.g. water) and forming the copper acetylide I. This would 
explain why this reaction is not observed with internal alkynes. The azide then 
displaces a second solvent ligand. binding to the copper via the nitrogen proximal to 
the carbon as in II. After this. the terminal azide nitrogen then attacks the C-2 carbon 
of the acetylide. forming the six-membered Cu(lII) metaUacyde III. An energy favoured 
ring contraction then ocrurs to generate \V. and finally the release of the formed 
triazole and regeneration of the Cu(l) catalyst completes the catalytic cycle. This 
proposed mechanism explains the experimentally observed regioselectivity of the 
reaction, and is supported by extensive density functional theory (OFT) calrulations 
which strongly disfavour the concerted cydoaddition (B-direct) under conditions of 
Cu(l) catalysis [12.15]. 
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: B-dired: 
IV 
- H 
Figure 3.4: Proposed mechanism of the Cu(l)-catalyzed 1.3-dipolar cydoaddition reaction of 
azides and terminal alkynes [12]. 
The robust nature and experimental simplicity of this Cu(l)-catalyzed reaction has 
allowed for its wide application not just in mainstream organic chemistry. but also in 
medicinal chemistry/drug discovery for the synthesis of bioactive molecules and 
generation of libraries of drug-like scaffolds possessing the triazole ring [26.27]. It has 
also found application in biomedical research for such functions as cell-surface labeling 
[28]. activity-based protein profiling (ABPP) en] and DNA labeling [8J. Its application 
in drug discovery has led to the identification of triazole-containing compounds with 
interesting biological activities such as protozoal cysteine protease inhibition [26] and 
HIV-l protease inhibition [27] activity. 
Based on these positive reports. the current study therefore applied the Cu(l)-catalyzed 
cydoaddition of azides and terminal alkynes in the synthesis of selected hybrid 
compounds. 
3.4 Selection of the entities for hybridization 
3.4.1 Chalcones as curcumin-related compounds 
Chalcones are structurally related to curcumin (Figure 2.12). both having two aryl rings 
linked by a chain that contains an a..I3-unsaturated carbonyl system (in the form of a 
heptadienone chain for curcumin and a propenone chain for chalcones). Also. 
chalcones can be readily synthesized and have been shown to exhibit notable in vivo 
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and in vitro antimalarial activity [29.30]. Based on this. chalcones were chosen as the 
first class of curcumin-related compounds for this study. 
3.4.2 Dienones as curcumin-related compounds 
Dienones are also structurally related to curcumin (Figure 2.12), both having two aryl 
rings joined by an a..I3-unsaturated carbonyl system (in the form of a pentadienone 
chain for dienones). However, no reports on the investigation of the potential 
antimalarial activity of this class of compounds could be found in available literature. 
In an attempt to fill this gap. and considering their structural likeness to curcumin, 
dienones were selected as the second class of curcumin-related compounds for 
synthesis in this study. 
3.4.3 3' -azido-2' .3' -dideoxythymidine. AZT (Zidovudine®) 
AZT (Figure 3.5) is a nucleoside reverse-transcriptase inhibitor (NRTI). and was the first 
antiretroviral agent to be approved for use in HIV infection [31]. The rationale for the 
selection of AZT as an entity for hybridization was that it is relatively hydrophilic [32], 
and hybridization to chalcones or dienones could yield hybrid compounds with 
enhanced hydrophilicity (relative to the chalcone or dienone parent compounds), a 
factor that could enhance their in vitro and in vivo antimalarial activity. as well as their 
oral bioavailability. In add tion. AZT is a nucleoside (deoxythymidine) analogue; 
nucleosides are biological molecules that are known to be actively transported into 
mammalian cells [33]. and therefore linking AZT to the chalcones or die nones could 
potentially take advantage of this trans-membrane transport mechanism to further 
improve the oral bioavailability of the target molecules. as well as facilitate their 
delivery to their intracellular site of action. 
It is acknowledged that AZT too has its oral bioavailability challenges arising from poor 
absorption, enzymatic transformation within the intestinal cells and significant first-pass 
effect. However. hybridization to chalcones/dienones (which may be considered to be 
at the other end of the physicochemical spectrum) could yield more balanced hybrid 
compounds that could potentially exhibit improved bioavai\ability profiles. 
Furthermore. hybridization of the potentially antimalarial chalcones and dienones to a 
molecule with intrinsic anti-HIV activity could very well lead to the identification of 
molecules that exhibit both antimalarial and anti-HIV activity. This is particularly 
interesting considering that in sub- Saharan Africa, the high burden of both malaria and 
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HIV translates into high inddences of co-infection in many regions [34]. This overlap in 
the distribution of HIV and malaria also occurs in other regions of the world. such as 
Southeast Asia. latin America and the Caribbean [35]. 
Finally. AZT bears an azide functionality that could be conveniently exploited in its 
hybridization to other entities via click chemistry. 
3.4.4 7 -Chloroquinoline 
Several potent. quinoline-based antimalarial drugs have been used clinically for decades 
e.g. chloroquine and amodiaquine. The 7-chloroquinoline moiety. a main antimalarial 
pharmacophore present in this class of antimalarials. is thought to confer antimalarial 
potenc.y to these compounds by fadlitating binding to heme and consequently 
inhibiting hemozoin formation [36]. This study therefore aimed at exploiting this 
feature by incorporating the 7 -chloroquinoline moiety into hybrid molecules with 
chalcones and dienones. 
AZT()-4) 7<hloro-quinoline (4-substituted) 
Figure 3.5: Structures of AZT (3.4) and 4-substituted-7-chloro-quinoline. 
3.5 Chalcones 
3.5.1 Selection of Chalcones for synthesis and hybridization 
There were two main considerations in the selection of the chalcones to be 
synthesized: 
II The rational selection of the substitution patterns for the two phenyl rings of the 
chalcones; 
II The convenient introduction of the terminal alkyne in readiness for subsequent 
hybridization. 
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The selection of the chalcones for synthesis was guided by. firstly. the substitution 
pattern on curcumin (which bears the 4-hydroxy-3-methoxy substitution pattern on 
both phenyl rings, Figure 2.11) and. secondly, by the reported SAR results of two 
extensive studies on hydroxylated and alkoxylated chalcones by Glutteridge et at. 
2006 [29] and Uu et at. 2001 [30] (section 2.9.1.2), 
Based on these, and coupled with the range of starting materials (acetophenones and 
benzaldehydes) readily available to us, a small series of alkoxylated and halogenated 
chakones was selected for synthesis. The approach used was to vary the substitutions 
on one of the rings (as shown in Table 3.1) while maintaining the 4-hydroxy-3-
methoxy substitution pattern (derived from curcumin) on the opposite ring. i.e. 
varying the substituents on ring A while retaining the 4-hydroxy-3-methoxy 
substitution on ring B, and vice versa. The hydroxy group would then allow for the 
convenient introduction of the terminal acetylene group via a simple alkylation 
reaction as shown in Scheme 3.2, thereby yielding acetylenic chalcones ready for the 
anticipated hybridization to the appropriate azide-bearing entities. 
Table 3.1: Table showing the selected substitutions to be applied in chalcone synthesis 
Ring A substitutions Ring B substitutions 
2,4-dimethoxy 4'-methoxy 
2,3,4-trimethoxy 2',4' -dimethoxy 
2.4-dichloro 2' ,3',4' -trimethoxy 
4-f1ouro 
2,4-difluoro 
In order to maintain the 4-hydroxy-3-methoxy substitutions on ring A. 4-hydroxy-3-
methoxy benzaldehyde (vanillin. 3.5) was condensed with the appropriate 
acetophenones; for similar SUbstitution on ring B, 1-(4-Hydroxy-3-methoxy-phenyl)-
ethanone (acetovanillone. 3.6) was condensed with the selected benzaldehydes. 
o MeOff I H 
HO ~ 
o 
~OMe 
~OH 
Vanillin 3.5 Acetovanillone 3.6 
Figure 3.6: Structures of vanillin 3.5 and acetovanillone 3.6. 
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The selection of the chalcones for synthesis was guided by. firstly. the sUbstitution 
pattern on curcumin (which bears the 4-hydroxy-3-methoxy substitution pattern on 
both phenyl rings. Figure 2.11) and. secondly. by the reported SAR results of two 
extensive studies on hydroxylated and alkoxylated chalcones by Glutteridge et al. 
2006 [29] and Uu et al. 2001 [30] (section 2.9.1.2), 
Based on these. and coupled with the range of starting materials (acetophenones and 
benzaldehydes) readily available to us, a small series of alkoxylated and halogenated 
chakones was selected for synthesis. The approach used was to vary the substitutions 
on one of the rings (as shown in Table 3.1) while maintaining the 4-hydroxy-3-
methoxy substitution pattern (derived from curcumin) on the opposite ring. Le. 
varying the sUbstituents on ring A while retaining the 4-hydroxy-3-methoxy 
substitution on ring B. and vice versa. The hydroxy group would then allow for the 
convenient introduction of the terminal acetylene group via a simple alkylation 
reaction as shown in Scheme 3.2, thereby yielding acetyienic chalcones ready for the 
anticipated hybridization to the appropriate azide-bearing entities. 
Table 3.1: Table showing the selected substitutions to be applied in chalcone synthesis 
Ring A substitutions Ring B substitutions 
2,4-dimethoxy 4'-methoxy 
2,3,4-trimethoxy 2' .4' -dimethoxy 
2.4-dichloro 2',3',4' -trimethoxy 
4-f1ouro 
2,4-difluoro 
In order to maintain the 4-hydroxy-3-methoxy substitutions on ring A. 4-hydroxy-3-
methoxy benzaldehyde (vanillin. 3.5) was condensed with the appropriate 
acetophenones; for similar substitution on ring B, 1-(4-HydroXY-3-methoxy-phenyl)-
ethanone (acetovanillone. 3.6) was condensed with the selected benzaldehydes. 
o Me0d' I H 
HO ~ 
o 
~oMe 
~OH 
Vanillin 3.5 Acetovanillone 3.6 
Figure 3.6: Strudures of vanillin 3.5 and acetovanillone 3.6. 
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3.5.2 Synthesis of Chalcones 
Chalcones are typically synthesized by the Claisen-Schmidt condensation of 
appropriately substituted benzaldehydes and acetophenones [9.29.30.37]. In general. 
this reaction involves the acid or base-catalyzed condensation of two different 
carbonyl compounds, one acting as the nucleophile in its enol or enolate form. and the 
other acting as the electrophile. It therefore requires that one of the carbonyl 
compounds be capable of enolization. while the other carbonyl compound be 
incapable of enoiizing and be more electrophilic than the enolizable partner [9]. 
o 
~H+ ~~ R 
o 
~ Add or base catalysis I -R' .. .0 
RfngA Rings 
Scheme 3.1: General scheme showing the synthesis of chalcones 
In the case of the synthesis of chalcones. the acetophenone is the enolizable carbonyl 
compound, while the benzaldehyde is the more electrophilic. non-enolizable carbonyl 
compound. The mechanism for this reaction is outlined in figure 3.7. 
In acidic conditions, the reaction begins with the acid-mediated keto-enol 
tautomerization of the enolizable acetophenone. resulting in the formation of the 
neutral enol I. The enol then attacks the electrophilic carbonyl carbon of the 
benzaldehyde (made more electrophilic by the protonation of the adjacent oxygen) to 
form the aldol intermediate II. Due to steric and electronic factors, ketones are less 
reactive than aldehydes, and the enol attacks the benzaldehyde preferentially to any 
un-enolized acetophenone that may be present. The aldol intermediate then 
dehydrates via the E2 mechanism to yield the more stable (l,p-unsaturated system of 
the final chalcone III. while regenerating the add catalyst [9]. 
In basic conditions, the reaction begins with the base abstracting the acidic a-proton of 
the acetophenone, forming the enolate IV; the benzaldehyde lacks any a-protons. and 
hence lacks the ability to enolize. The resulting enolate then preferentially attacks the 
benzaldehyde to form the aldol intermediate V. The resulting aldol then dehydrates 
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via the ElcB mechanism to yield the a..j3-unsaturated system of the final chalcone 
product VI. while regenerating the base catalyst [9]. 
a) Addie conditions." C HO 
'0: 
~H_ ~~ ~ R' _ .. _:t_ff> __ :JU R' R I R 
(
HG 
:OH 0 
-~R;--~.) ._ V 
R II 
cfl) 
<±> 
~OH OH ~ I I -R' /0 0 
R 
b) Sasic conditioos_. 
... 
IV 
Figure 3.7: Schematic diagram showing the mechanism for the synthesis of chalcones under a) 
acid. and b) base-cataJyzed. conditions [9]. 
By far the most popular method of chalcone synthesis is the base-catalyzed 
condensation [37], probably because of the associated shorter reaction times and the 
relatively higher yields. However. it has been reported that. in the synthesis of 
hydroxylated chalcones. protection of any para-hydroxyl groups (such as the ones on 
3.5 and 3.6) prior to the base<atalyzed condensation is necessary for improved yields 
[30]. This is probably due to the dissociation of the acidic phenolic proton in the basic 
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reaction medium - the proton's inherent addic nature (being a phenolic proton) is 
further enhanced by the presence of the para carbonyl sUbstituent (aldehyde or 
ketone). which is electron withdrawing and attracts orrho and para electrons [38]. The 
resulting negative charge of the phenoxide would then be delocalised into the ring and 
the electron-withdrawing carbonyl system. as shown by the two extreme resonance 
structures below. 
.:~~/ 
,;~~~ 
R=H: benzaldehyde 
R=CH3:acetophenone 
Figure 3.8: Resonance structures of deprotonated 4-hydroxylated benzaldehyde and/or 
acetophenone. 
The result of this would be. for the benzaldehyde. decreased eledrophilidty of the 
carbonyl carbon and. for the acetophenone. decreased addity of the a-protons 
necessary for abstraction by the base during enolization. This~ coupled with the fact 
that some of the base required for the catalysis of the aldol reaction will have been 
consumed in deprotonating the phenolic hydroxyl group, probably explains the low 
yields observed during base-catalyzed chalcone synthesis from un-protected 
hydroxylated benzaldehydes and/or acetophenones. This problem is avoided either by 
the use of add catalysis [39]. or by protection of the para-hydroxy group prior to the 
base catalyzed condensation. This protection is generally as tetrahydropyranyl (THP), 
methoxymethyl (MOM). or methoxyethoxymethyl (MEM) ethers [30,40]. 
For this study. this potential problem was avoided by the a-alkylation of the phenolic 
hydroxyl groups of the vanillin 375 and acetovanillone 3.6 prior to the base-catalyzed 
Claisen-Schmidt condensation reaction (Scheme 3.2). As it was intended to further 
derivatize these chalcones by "ligation" of an azide and a terminal alkyne via dick 
chemistry, this a-alkylation involved repladng the phenolic proton with a 2-propynyl 
chain: this effectively eliminated the addie phenolic proton. and at the same time 
introduced the terminal alkyne necessary for the click chemistry to follow. 
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~~R ____ (_Q __ __ 
HoN 
3.5: vanillin, R"H 
3-6: acetovanillone, R=CH3 
MeOdO I R 
o ,-::::. 
~ 
3.7: R=H (82%) 
3.8: R=CH3 (82%) 
o 
(ii) 
.. 
o 
~ ::: 4'-methoxy, 2',4'-dimethoxy and 2',3',4'-trimetho 
Rl ::: 2,4-dimethoxy, 2,JA-trimethoxy. 2,4-dichloro, 
4-fluoro and 2,4-difluoro 
Scheme 3.2: Reagents and conditions: (i) propargyJ bromide. K2C03, DMF. 30 0(, 18hrs; (ii) 
appropriate acetophenones (for 3.7) or benzaJdehydes (for 3.8), 205M NaOH. MeOH. 70°C. 
3-6 hrs. 
The synthesis of the targeted acetylenic chakones 3.9 and 3.10 was therefore a two-
step procedure as shown in Scheme 3.2. The first step was the alkylation reaction, 
involving the reaction of 3.5 or 3.6 with 1.5 eq of propargyl bromide in anhydrous 
DMF and in the presence of 1.5 eq of anhydrous ~C03. This reaction yielded the 
respective acetylenes 3.7 and 3.8 in good yield after purification by recrystallization 
from DCM/Hexane mixtures. The second step was the Claisen-Schmidt condensation of 
3.7 and 3.8 with the appropriately substituted benzaJdehydes and acetophenones. The 
method reported by Uu et al. 2001 [30] was modified for this purpose, and involved 
the reaction of 3.7 and 3.8 with an equimolar amount of the appropriate 
benzaldehyde/acetophenone in methanol, in the presence of aqueous NaOH as 
catalyst. The products were then purified by silica gel column chromatography to 
furnish the pure target acetylenic chakones 3.9 and 3.10 in good yields, as shown in 
Table 3.2. 
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Table 3.2: Yields of acetylenic chakones 3.9 and 3.10. 
Compound code R Yield (%) 
3.9a 4'''()Me 76 
3.9b 2',4'-diOMe 90 
3.9c 2' ,3',4' -triOMe 84 
3.10a 2,4-diOMe 89 
3.10b 2,3.4-triOMe 78 
3.tOc 2.4-diCI 79 
3.10d 4-F 88 
3.1Oe 2.4-diF 85 
3.6 Dienones 
3.6.1 Selection of dienones for synthesis and hybridization 
The dienones selected for synthesis were to bear similar sUbstitution patterns to the 
acetylenic chalcones described previously. This would enable a direct SAR comparison 
of the in vitro (and possibly in vivo) activities of similarly substituted chalcones and 
dienones. where the only difference between the pairs of compounds compared would 
be the length of the chain linking the two aromatic rings. 
3.6.2 Synthesis of dienones 
The retrosynthetic analysis of the target acetylenic dienones. outlined in Scheme 3.3. 
shows that these compounds could be generally synthesized by sequential 
condensation. i.e. the condensation of 3.7 and acetone to yield the acetylenic enone 
3. n. which would then be condensed with various appropriately substituted 
benzaldehydes to yield the target acetylenic dienones 3.12. 
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o o H~R' 
H 
o 
MeO~H ~ 
oN 
~3'7 
H 
Scheme 3.3: Retrosynthetic analysis of dienones 
The condensation of acetone, itself an enolizable carbonyl compound, to 3.7 is quite 
similar to that carried out in the synthesis of chalcones, and was carried out using the 
(modified) method reported by Ramachandra and Subbaraju, 2006 [41J. Intermediate 
3.7 was stirred .in acetone (as reagent and solvent) in the presence of aqueous 2.5M 
NaOH at room temperature for 6 hours. The crude product of the reaction was 
purified by silica column chromatography to yield 3. n in 71% yield. 
o 0 o 
Meo~1 ~ H (i) Meo~ (ii) N -....:...:..--~ ~ -----~~7 ~ 
H H 
R = 4-methoxy, 2,4-dimethoxy, 2,3,4-trimethoxy, 
2,4-dichloro, 4-fluoro. 2,4-difluoro 
Scheme 3.4: Reagents and conditions: 0) acetone, 2.5M NaOH. r.t.. 6 hrs; (ii) appropriate 
benzaldehydes, BF3-Et20, dioxane, 50°(, 16 hrs. 
It had been envisaged that the second set of condensation reactions (of the enone 
intermediate 3.11 and the appropriately substituted benzaldehydes) would be carried 
out under similar conditions. However. when this was attempted. the reaction yielded 
an un-resolvable mixture of products. possibly due to competing side reactions such as 
the Cannizzaro reaction [9]. 
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However. this condensation was successfully carried out by applying a method 
reported for the synthesis of chalcones and which makes use of boron-trifluoride 
etherate (BF3-EbO) as a lewis-add catalyst [42]. The reaction conditions are shown in 
Scheme 3.4. and involved the reaction of 3.11 with 1.t eq of the appropriate 
benzaldehyde in the presence of 1.5 eq BF3-Etp; the reaction was carried out in 
anhydrous dioxane under a nitrogen atmosphere. The crude products were purified by 
silica gel column chromatography (EtOAc/Hexane) to yield the target acetylenic 
dienone products. The respective yields are given in Table 3.3. 
The reasons for the relatively low yields for this final step of the dienone synthesis are 
unclear. However. during the purification of these compounds by silica column 
chromatography (necessary to separate the target molecule from the residual 
benzaldehyde starting material that was used in a slight excess). a significant amount of 
baseline material was observed. suggesting the possibility of the formation of 
complexes and other decomposition products during the course of the reaction. 
The proposed mechanism for this reaction is outlined in Figure 3.9. The lewis add. 
boron trifluoride, coordinates to the carbonyl oxygen of the benzaldehyde to form I. 
thereby increasing the electron-withdrawing effect of this oxygen; this in tum increases 
the electrophilidty of the adjacent carbonyl carbon. making it even more susceptible to 
nucleophilic attack by the enol tautomeric form of 3.11. The result is the intermediate 
II. equivalent to the aldol intermediates described in Rg. 3.7 above. During the 
aqueous work-Up of this reaction. this intermediate undergoes the equivalent of a 
dehydration reaction to yield the target dienone 3.12. 
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• 
MeO 
• • 
, 
0 
~ " , 
'0 
I M'" 
I " '" 
MeO ",/,-/'",/,,~ 
I - F • 
0 
.& 
o .& 
~ ~ 
0 
/ H- QK 
M,O 
o 
~ 
Figure 3.9: Proposed mechanism of tile conden5ation of the en one intermediate and a 
benzaldehyde. 
Table 3.3: Yields of acetylenic dienones 3.12 
M,O 
o I .& 
~ 3.12 
Compound code R Yield (%) 
3.12a 4'-OMe 39 
3.12b T.4··diOMe 49 
3.12c 2·.3',4'-triOMe 47 
.. ........ -_ ... __ . 
3.12d 2A-diCl 65 
.. - +-- .. --_._---_. 
3.12e 
3.12f 
-
4·F 
2.4-diF 
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3.7 Synthesis of the 4-azido-7-chloro-quinoline 
Whereas AZT already bears the azide group and is. as it were. ready for "clicking", the 
4-azido-7-chloro-quinoline 3.13 was furnished by applying the method described by de 
Souza et al. 2009 [43]. whereby 4.7-dichloroquinoline was reacted with 2 eq of NaN3 
in anhydrous OMF at 65 "c for 6 hours. Crystallization of the product from 
OCM/hexane mixtures afforded 3.13 in 86% yield (Scheme 3.5). 
}.13 (86%) 
Scheme 3.5: Reagents and conditions: (i) NaN3• DMF. 65 0(. 6 hrs. 
3.8 Synthesis of the Triazoles 
As outlined in section 3.5 above. the primary synthetic aim was to apply the Cu(l)-
catalyzed cycloaddition reaction of azides (AZT 3.4 and 4-azido-7-chloroquinoline 
3.13) and alkynes (the acetylenic chalcones 3.9 and dienones 3.12) to yield the. target 
triazolyl chalcone/AZT. chaicone/chloroquinoline. dienone/AZT and 
dienone/chloroquinoline hybrid compounds. The Cu(l) required for catalysis would be 
generated by the in situ reduction of Cu(lI) to CuO) by sodium ascorbate. 
With the entities for hybridization already synthesized as described above (AZT was 
kindly provided by Cipla ltd.). the cydoaddition reaction was then carried out using 
the (modified) procedure reported by Feldman et al2004 [17]. Equimolar amounts of 
the relevant azide and acetylenic compound were dissolved in OMF. after which 1 M 
sodium ascorbate (0.4 eq) and 1 M CUS04 (20 mol%) were added sequentially. in that 
order. The reaction mixture was then stirred vigorously at 65" C for 24 hrs. Purification 
was by silica gel column chromatography. 
The chalcone hybrid compounds 3.14 - 3.17 were synthesized by the reaction of the 
acetylenic chalcones 3.9 and 3.tO with either 3.4 or 3.13 using the procedure described 
above. 
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MeoX)\)~ "-'::::: 
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(../N 
N 
I 
R, 
3.14: R1 = AZT; 
3.15: R1 = 7-ch1oroquinoline 
3.10 ) p-
H 
3.16: Rl = AZT; 
3.17: Rl = 7-chloroquinoline 
Scheme 3.6: Reagents and conditions: (i) 3.4 or 3.13. 1M Na ascorbate. 1M (uS04.5H20. DMF. 
65°C. 24hrs. 
However. the synthesis of the target dienone hybrid compounds was approached in a 
slightly different way (Scheme 3.7); these were synthesized by initially reading 
acetylenk enone intermediate 3.n with either 3.4 or 3.13 to generate the enone-
triazole derivatives 3.18 and 3.19. and then subsequently condensing these 
intermediates with the appropriate benzaldehydes using boron-trifluoride etherate as 
catalyst as already described above to yield the target hybrid dienone derivatives 3.20 
and 3.21. 
(i) 
.. 
o 
Meo~ 
o~ (ii) 
~~\ I(/N 
N 
I 
R, 
JotS: R1 = AZT (80%); 
3.19= Rl = 7-chloroquinoline (62%) 
.. ~~, ~../N 
N 
I 
R1 
3.20: R1 = AZT; 
3.21: R1 = 7-chloroquinoline 
Scheme 3.7: Reagents and conditions: (i) 3.4 or 3.13. 1M Na ascorbate. 1M (uS04-5H20. DMF. 
65 0(. 24hrs; (ii) appropriate benzaldehydes. BF3-Et20. dioxane. 50°(, 16 hrs. 
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CHAPTER THREE: DESIGN AND SYNTHESIS OF CHALCONE- AND DlENONE-BASED HYBRID COMPOUNDS 
The yields of the chalcones and dienone hybrid compounds are tabulated below. The 
relatively low yields observed for the chalcone dick reactions was probably the direct 
consequence of difficulties in isolating and purifying the target compounds. The crude 
product of the reaction (predpitated out of the reaction mixture by the gradual 
addition of cold water) was particularly difficult to manipulate. and showed a limited 
solubility in common organic solvents; this then led to product losses during 
purification by column chromatography. Attempts at purification by crystallization 
were unsuccessful. 
However. suffident amounts of the target compounds were isolated for in vitro 
antimalarial assays. and for this reason no attempts were made at this stage to optimize 
the reaction conditions and isolation methods. 
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Table 3.4: YieJd~ of c.halcones hybrid compounds 3.14 - 3,17 
o 
, 
M(,()~
~ ~R 
\-: '" A 
It" , 
"oN~" "",,0 
I ' 
"" 
o 
Compound c<XJe 
3.14a 
3, I4b 
3.14c 
3,15a 
3.15b 
3.ISc 
R Yield (% ) 
4'-OMe 50 
- --
2' ,4'-diOMe 47 
2',3' ,4'-lriOMe 46 
4' -OMe 58 
2'.4' -diOMe 51 
2'.3',4' -triOMe 54 
----1-------
3_16a 2A-diOMe 44 
3.1 6b 2,3 A·!riOMe 
3.16c 2A-diCI 
3.160 4-F 
3.16e 2.4-diF 
f- - ----/-
3.17a 2A·d iOMe 
2. 3.4-lriOMe 3.17b 
3J7c 
3,17d 
- - ----- ----
2,4-diC\ 
3,17e 2.4-diF 
51 
45 
-------
48 
44 
41 
54 
---------- ---
52 
52 
38 
o 
------------~--~~~~----------~.-- -rill(" M C.UANTA! Ph 1') 1 ~II ~I~ ~()J(I 
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Table 3.5: Yields of dienone hybrid compounds 3.20·3.21 
o o 
MeO 
3·20 
HO M 0 ~t 
o 
Compound cocle 
3.20a 
3.20b 
3.20c 
3.20d 
3.20e 
3.20f 
3. 21a 
" -R 
McO 
'" 
R 
4'·OMe 
2'A'-diOMe 
2',3'A'-triOMe 
2A-diCI 
4-' 
2A-diF 
4'·OMe 
3.21b 2·A'·diOMe 
3.2k 2',3'A'-triOMe 
3.21 
Yield (%) 
42 
52 
.. 
40 
58 
32 
31 
36 
33 
- 1-----------
33 
- --- ------ -------- ----- --
3. 21d 2A-diCI 42 
3. 21e 38 
- - -- -
3.21f 2A-diF 31 
3.9 Characterization of the Target Compounds 
All compounds were characterized by 'H-NMR, ' JC-NMR, Mass Spectrometry, !R 
Spectroscopy, Elemental analysis and melting point determination. 
However, in this section the focus will be on 'H-NMR, with particular attention being 
paid to signal peaks that were diagnostic for each set of target compounds, The full 
characterization data for each of the synthesized compounds is reported in the 
Experimental chapter (Chapter 8). 
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3.9.1 Acetylenic dlalcones 
Confirmation of the formation of the chalcones was by the presence of two distinct 
doublets in the lH-NMR spectra. each integrating for one proton. lying in the region 
between 0 7 - 8 ppm. and sharing a 3 J-trans coupling constant of between 15-16 Hz. 
These signals confirm the formation of the new carbon-carbon double bond (with a 
trans geometry) between the parent benzaldehyde and acetophenone. Also distinct on 
the spectra of the acetyienic chalcones are the signals from the terminal acetylene 
group: a triplet at approximately 0 2.5 and a doublet at approximately 0 4.8. both 
sharing an allylic 4 J coupling constant of 2 - 3 Hz (Figure 3.10). 
The aromatic signals from the different chalcones varied depending on the differing 
substitution patterns of the two aromatic rings. The full spectroscopic characterization 
of these compounds compared well with literature reports [30]. 
3.9.2 Acetylenic dienones 
Confirmation of the dienones was by the presence of two pairs of distinct doublets 
similar to those observed for the chalcones - they occur as two pairs simply because 
the dienones possess two a-~ unsaturated carbonyl systems (sharing the same carbonyl 
group). The signals from the terminal acetylene group - the triplet and the doublet-
were also present on the spectra of the acetylenic dienones. (Figure 3.11) 
3.9.3 Triazole hybrid compounds 
Empirical analysis of the lH-NMR to confirm presence of the triazole products was by 
noting: 
., The presence of signals attributable to the two parent entities; 
., The absence of the triplet at about l) 2.5 ppm and integrating for one proton that 
corresponded to the terminal acetylenic proton of the parent acetylenic entities; 
., The appearance of a singlet integrating for one proton appearing at about 0 8. t 
ppm. attributed to the single proton on the triazole ring; 
., The signal at approximately 0 5.5 ppm and integrating for two protons 
corresponding to the two methylene protons on the carbon adjacent to the 
triazole ring (and initially on the 2-propynyl side chain of the chalcone). The signal 
is now a singlet due to the absence of the terminal acetylenic proton that these 
protons were coupling with. (Figure 3.12) 
.ERIC M GUANT AI - Ph.D THESIS 2010 
90 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
-- .--~------ ----
CHAPTER THREE: DESIGN AND SYNTHESIS OF CHALCONE- AND DIENONE-BASED HYBRID COMPOUNDS 
3.10 Condusion 
The concepts of molecular hybridization and dick chemistry were introduced and 
discussed, after which is given a description of how they were applied in the design. 
synthesis and characterization of chalcone/AlT. chaicone/chloroquinoline. 
dienone/ AlT and dienone/chloroquinoline hybrid compounds as potential antimalarial 
agents. The target compounds. as well as selected intermediates, were then assayed for 
in vitro antimalarial activity - the results are reported and discussed in the chapter that 
follows. along with results from limited mechanistic studies. 
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I 6 (ppm) M ultiplidty J (Hz) H, 
1-
7.60 I d 15.7 H·, 
7.37 d 15.7 , H·b 
_. 
4.79 d 2.4 H·5 
, 
I 
-----
-
, 
I H·6 i 2.53 t 2.4 
--
.' 
• , 
'"" 1 1(H3 1-1 3(0 
"', '" " I , I» 
-" 
, 
" 
" 0 0(1-13 
.' 3 
" '~ 3·9b 
II 
• 
H·, Hb 
H·, I I , 
.fL I ' I H·' 
_AJL ! J l -- -- it I ' -,----.-,-~ 4.8 > 4.78 
_J' , .... , Ii ,.' " " 7·} I 
1 l 2.5/' 2_5 2 , 
"I tL T I , 
__ J , • II' . I 1ulLt' J. __ .~ .. )L_ 
-...... 
~-...,- . , , , 
" 
,.' 6·5 , .. 5-5 ,.' 
f' (ppm) 
4·5 
" 
'., ,. 2 _5 
Figure 3 .10: Example of iln H·NMR spectrum for an acetylenic cha lcone. 
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H-a' 
7·9 7·7 
H·b' 
• (ppmll Mul<'p"<ity I J(H'~I H. I l 7.~4 d I 16.1 I H·,' .1 7.68 I _ d --------i- ~ 5.9_~ 
7.07 I d 16.0 H·b· 
::: : ~: t ::: 
[ 2.55 2.4 , H·6 
--
H·b 
7.10 7.0~ 7·00 6 .9'> 
! I I i~ . 
.JUL ~ ~~LL _. _---' .. _ L ._ .. ~L,--.. _ 
' .0 ~.~ ~.Q ).', 
" ( ppm) 
Figure 3.11 : Ex<lm p1e of <In H -NMR spect rum for <In acely lenic d ienone. 
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Figure 3.12: Example of an H-NMR sp6:l rum for a quinoline triazole derivative of a chalcone. 
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CHAPTER FOUR 
IN VITRO ANTtMAlARIAl EVAlUAT10N AND MECHAN1ST1C STUDIES 
4.1 Preamble 
This chapter contains the work done to address the second specific aim of the study. 
which was: To pharmacologically evaluate the synthesized compounds in vitro for 
antimalarial activity and possible mechanisms of action. 
This chapter therefore focuses on the in vitro antimalarial assays applied in the current 
study. After a brief introduction. the assays of the synthesized compounds will be 
described. and the results reported and discussed. The chapter ends with a brief 
description of. and the results from. limited mechanistic studies on a selected number 
of the target compounds. 
4.2 Introduction 
Bioassays are quantitative procedures that determine the effect of a substance, or 
mixture of substances. on a biological system. They are performed either in vitro or in 
vivo. and as such may involve the use of animal models. isolated organs and tissues. 
whole cell cultures or sub-cellular systems/molecular targets. principally enzymes and 
receptors. Their main purpose is to quantify the relative 'activity' or • potency' of a 
substance. i.e. its capacity to elicit the intended biological effect, and which may be 
expressed relative to a standard substance of known potency. This is determined by 
observing or objectively evaluating a given measurable parameter at a set interval from 
the bioassay starting point. As expected, the biological effect of a substance generally 
increases with increasing concentration (within limits), and the determination of the 
biological effect of a substance over a suitable range of concentrations usually enables 
the generation of analyzable 'dose-response' data [1.2]. 
4.3 In Vitro Antimalarial assays 
Consistent with the specific aims of this study, the target compounds were evaluated 
for their in vitro antimalarial activity against both chloroquine sensitive (CQS) and 
chloroquine resistant (CQR) strains of P. falciparom. The strains used for the assays 
were the 010 (CQS) and Dd2 (CQR) strains. In addition. samples of the compounds 
eRIC M. GUANTAI - Ph.D THESIS 2010 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
were also tested against the (CQR) W2 strain of P. fa/ciparom in the laboratories of 
Prof. P. J. Rosenthal at the University of California. San Francisco (UCSF). 
4.3.1 In vitro antimalarial testing 
4.3.1.1 Culturing of the malaria parasite in vitro 
The asexual erythrocytic stages of the parasites were maintained in continuous in vitro 
culture by the (modified) method described by Trager and Jensen. 1976 [3]. Briefly. 
the parasites were maintained at between 2 - 10% parasitemia in type a-positive 
human erythrocytes (Groote Schuur Hospital. Cape Town. South Africa); these were 
suspended in complete culture medium composed of 10Agll RPMI 1640 culture 
medium (Biowhittaeker) supplemented with 4 gil glucose, 6 gil HEPES buffer. 0.088 
gil hypoxanthine. 5 gil albumax. 1% sodium bicarbonate and 0.05 gil gentamicin. 
The cultures were incubated at physiological temperature. 37°C, under an atmosphere 
of 3% O2• 4% CO2 and 93% N2• The culture medium was replaced daily. and 
parasitemia was determined from Giemsa stained blood smears of the cultures. 
The cultured parasites were. whenever necessary. synchronized (maintained in phase) 
by treatment with 5% O-sorbitol (Sigma) at the ring stage of their development. 
applying the (modified) method described by Lambros and Vanderberg. 1979 [4]. 
4.3.1.2 Assay procedure 
Chloroquine diphosphate (Sigma) was used as the positive control/reference 
compound in all experiments, with a stock solution of 2 mglml prepared in Millipore 
water. The test compounds were prepared as initial 20 mglml stock solutions in 
OMSO, sonicated to enhance solubility as required. These stock solutions were stored 
at -20°C. 
The assays were carried out in 96-well micro-titre plates (Greiner). Each plate could 
accommodate duplicate determinations of chloroquine and three test compounds 
(Figure 4.1). The stock solutions were aseptically diluted in complete medium to 
furnish working solutions of appropriate, pre-determined starting concentrations, i.e. 
for chloroquine. 200 nglml for 010 assays and 2000 nglml for Od2 assays; the 
solutions of test compounds were similarly diluted to a starting concentration of 200 
l1g1mL For those test compounds that exhibited relatively high activity in preliminary 
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assays. this starting concentration was lowered to 100 ~g/ml. 20 pg/mL and 2 ~g/ml. 
as appropriate. 
Figure 4.1: Figure showing the assay layout of the 96 well micro-titer plate for in vitro 
antimalarial testing. 
200 pL of these working solutions were then transferred into the wells in column 3 (in 
duplicate). after which two-fold serial dilutions were carried out in complete medium 
across the plates. The outcome was that the wells in columns 3 - 12 contained 100 pL 
of the compound solutions in serially redudng concentrations. 100 III of complete 
medium was added to each of the wells in columns 1 and 2. 
Synchronized parasites were harvested in the trophozoite stage of development. and 
the parasitemia and hematocrit adjusted to 2% by addition of appropriate amounts of 
unparasitized erythrocytes and complete medium, respectively. 100 pL of these 
parasitized erythrocytes (2% parasitemia. 2% hematocrit) was then added to each of 
the wells in columns 2 - 12. 100 pl of un parasitized erythrocytes (2% hematocrit) was 
added to each of the wells in column 1. The final volumes in each well were therefore 
200 pL In this way. the parasites in columns 3 - 12 were exposed to a serially 
decreasing concentration of chloroquine and the various test compounds in a manner 
that could be used to determine the concentration of each compound that would 
inhibit the growth/viability of the parasites by 50% (ICso). 
The plates were then incubated for 48 hours at 37 "c in airtight gas chambers under a 
gas environment of 3% 02. 4% CO2 and 93% N2. 
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The final layout of a typical 96-well assay plate is depicted in Figure 4.1: 
• Wells in column 1 contained un-parasitized erythrocytes (1% hematocrit); this 
was the blank: no parasites, no test compounds. 
• Wells in column 2 contained parasitized erythrocytes (2% parasitemia, 1% 
hematocrit); this was the negative control. essentially a row in which the 
parasites were not exposed to either chloroquine or any of the test 
compounds. 
• Wells in column 3 contained parasitized erythrocytes (2% parasitemia. 1% 
hematocrit) and either 100ng/ml chloroquine (1000ng/ml for Dd2 assays) or 
100 !J.g/ml (or lower) of the test compounds. in duplicate; 
• Wells in columns 4 to 12 contained parasitized erythrocytes (2% parasitemia. 
1% hematocrit) as well as the two-fold serial dilutions of chloroquine/test 
compounds starting from column 3. 
The concentration of DMSO that the parasites were exposed to during these assays did 
not exceed 0.5%v/v. thereby ensuring no solvent-induced adverse effects on parasite 
survival. and in so doing maintaining the validity of the assays. 
4.3.1.3 Quantitation and analysis based on plDH activity 
In vitro antimalarial assay protocols are generally based on either microscopic 
detection of Giemsa-stained lides. flow cytometry. 3H-hypoxanthine uptake inhibition, 
fluorescence (such as the SYBR Green I-based fluorescence assay) or, as for this study, 
determination of parasite lactate dehydrogenase (pIDH) activity for their assessment of 
compound efficacy against P. faldparom [5,6]. 
lactate dehydrogenase (lDH) catalyses the reduction of pyruvate to lactate with the 
concomitant oxidation of NADH to NAD+. This enzyme is particularly vital for the 
malaria parasite as the NAD+ that it regenerates is essential for the continuation of 
glycolysis. the biochemical pathway upon which the parasite is dependent for the 
generation of its energy in the form of ATP [7]. plDH has an intrinsically higher rate of 
catalySis than human lDH; in addition. when the NAD+ analog 3-acetylpyridine 
adenine dinudeotide (APAD) is used as co-factor, plDH exhibits a several hundred-fold 
higher catalytic conversion of lactate to pyruvate than human lDH. with the 
concomitant reduction of APAD to APADH [8]. Based on this, the activity of plDH can 
be selectively detected in the presence of human lDH [9], and this was applied in the 
development of an in vitro antimalarial assay protocol by Makler and co-workers. 
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CHAPTER FOUR: IN VITRO ANTIMAlARIAL EVALUATION AND MECHANISTIC STUDIES 
1993 [10]. This plDH assay was found to be rapid. robust, selective. easy to perform. 
cheaper than the 3H-hypoxanthine uptake protocols. yielded reproducible results and 
allowed for the freezing of the assay plates at -20°C until it was convenient to run the 
assays [10]. 
The rurrent study therefore applied this approach to indirectly determine the inhibition 
of growth of the parasites exposed to the various test compounds relative to the 
unexposed parasites (the negative control described above). This was done by 
colorimetrically quantifying plDH activity using the light sensitive reagent mixture of 
nitroblue tetrazolium (NBT)/phenazine ethosulphate (PES). which. in the presence of 
APADH. is reduced to a strongly colored blue formazan product. The intensity of the 
blue color was proportional to the amount of blue formazan product formed, which 
was directly proportional to the amount of APADH present, which in tum was 
proportional to the level of pLDH activity present. This level of plDH activity was 
dependent on the number of viable parasites still present at the end of the inrubation 
period. 
After the 48 hour inrubation period. the assay plates were retrieved from the gas 
chambers. and the contents of each well were re-ruspended. Maintaining the same 
layout as the assay plate. 15 pl of the re-suspended mixtures were then transferred to a 
separate 96-well plate containing 100 pl of Malstat reagent (1 mVl triton, 0.33 gil 
APAD and 3.3 gil TRIS buffer) in each well. 25 pl of NBSIPES solution was then 
added into each well. after which the plates were allowed to develop for 5 - 10 
minutes in the dark. The absorbance of the formazan products in each well was then 
measured at 620 nm on a 7520 Microplate reader from Cambridge Technology Inc. or 
on a Modulus microplate reader from Turner Biosystems. 
The absorbance data from the colorimetric assays was then transformed to represent 
percentage viability by adjusting for the absorbance in the blank and control wells; this 
data was then analyzed using GraphPad Prism® Version 4 software to yield semi-
logarithmic dose-response rurves and the corresponding 'Cso values for the 
compounds. 
For studies with the W2 strain, assays were conducted as previously reported (Shenai 
et al. 2003) [n] with parasites rultured in standard medium including 10010 human 
serum; parasite development was assessed with a FACS-based assay. as previously 
described (Sijwali and Rosenthal. 2004) [t2]. 
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ClIAPTER FOUR: IN VITRO ANTIMALARIAl EVAlUAllON AND MECHANISTIC qUOIES 
4.3.2 In vitro antimalar ial assay results 
4.3.2. 1 Acetylenic cha1cones 
Table 4.1: IC50 values of the acetylenic chalcones 3.9 and 3.10 against the 010. Od2 and W2 
strains o f P. faldparum 
0 
" I / / '" 
OMe 
, 
3.10 
Compound code R DlO IC~ Od2 lCw W2 IC~ (!-1M) (.M) (J.1M) 
3.9a 4"-OMe 9.7 13.5 8A 
.. _-_. 
--------
. -
._ .. 
3.9b 2' ,4'-diOMe 3A 4.3 3.8 
- ---
3.9c 2',3',4'-triOMe 7.7 2.8 7.0 
-----
- - -- ------ ---
. 
- ---
3. IOa 2,4-diOMe >20 14.5 9.7 
--- - -- ---- -- -- ------
-_._._----_._--
---------
- -
3.10b 2.3,4-triOMe 4.1 2A 6.7 
-
._-._ ,--- ---
- - - - --- - ---- f - ---------------
3.1Oc 2,4-diCI 3.3 2.8 5.0 1------- ---------- --- --- .... ,_ ... -,-'"- ._----- ----
_. 
3.tod 4-F 7.2 7.7 >20 
... 
-- ---------- ---- --" 
3.10e 2,4-diF >20 5.2 9A 
._-
- ------f- ------- - .. ---- -
(COl . 0.017 0.097 0 .069 
NB: (hese are average values from two independent determinations. each carried out in duplicate 
As pointed out earlier, the IC so values represent the concent ration of a compound that 
inhibits t il e growth/viability of the parasites by 50%, and thereby provide a means of 
comparing the activities of different compounds: tile lower t ile IC so v alue, tile more 
active the compound is. 
From Table 4.1. it can be seen til at the acetylenic chalcones exhibited moderate in vitro 
antimalarial activity relative to the reference com pound chloroquine, w ith IC50 val ues 
generally falling in the lower micro molar region. Compounds 3.lOa and 3.10e were 
inactive against tile OlD strain of P. faldparum, as was 3.1Od against t il e W2 strain. at 
the highest concentrations tested (IC 5O >20 pM). Excluding the se three results, it would 
appear that the activity of tllese series of compounds is conselVed across the three 
strains of parasites, with 1(50 values o f between 2.4 - 14.5 pM: this would suggest 
similar susceptibility of both tile chlo ro quine sensitive and chloroquine resistant strains 
of the parasite to tile antimalarial activity of these compounds, No particular trends 
could be delineated with respect to the different substitution patterns, 
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4.3.2.2 Chalcones hybrid compounds 
Table 4.2: ICo;() va lues of the chalcone hybrid compounds 3.14 ·3.17 against the DIO. Dd2 and 
W2 st rains of P. faldparum 
o 
Meo~" " 1.1 I - R 0;::::- / 
~I ~ 
" N,N 
o HO~::O 
o 
Compound code R OJO IC"" Dd2 IC,;o W2 IC,;o (f-1M) ("M) (f-1M) 
3.14a 4· ·O Me 2.9 6.1 8.0 
-- ----
3.14b 2·.4··d iOMe 1.5 4A SA 
- -
_ .. -
- ---
------_ .. _.- --_.- _._-
_ .. _. ... _ .. 
-
3.14c 2",3·.4"-triOMe 3.3 3.7 SA 
--
3. ISa 4··OMe 0.6 2.2 5.0 
-
3. ISb 2'.4' -<flOMe 0.04 0.07 0.09 
--
3.1 5c 2",3' .4"·triOMe OA OA 0.6 
._ .. 
--
. __ .. . _ .. ._ .. 
... -
--
3.16a 2,4·diOMe 10.2 11 .8 9.0 
3.16b 2.3,4·triOMe 5A 3.8 7.1 
--_. .. _--_ ... _ .. --_ ... _ ... 
_ ... __ ... _ .. _ .. _ .. 
-_._--
3J 6c 2,4-diCI 3.7 1.9 8A 
-
3.16d 4·F 73 6.1 6.6 
-
-_ .. 
-
. _ .... 
-
.. . .... . _ .. 
. 
3.16e 2,4·diF 3.9 4.8 7.1 
._--
-
3.17a 2,4·diOMe 5.2 11. 7 6.6 
3.17b 2.3,4·triOMe 0.3 0.3 0.5 
-_._- -_._-
-
_ ... 
-
3 .17c 2,4·diCl 6.0 1.9 11.5 
-- - ---- -
3.17d 4·F 7A 1.6 6.9 
3.17e 2,4·diF 4.1 2.1 10.6 
---
. _ ... ._-_ .. 
- -
(CQ) - 0.017 0.097 0.069 
N8: these are average values from two Independent determmatlOns, each earned out in duplicate 
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CHAPTER FOUR: IN VI7ROANfIMAIARIAl EVALUATION AND MECHANISTIC STUDIES 
From Table 4.2, it can be seen that the chalcone-AZT hybrid compounds 3.14 and 3.16 
exhibited moderate in vitro antimalarial activity. with I(so values within the lower 
micromolar region and ranging from 1.5 - 11.8 ~ for the three strains of P. 
fa/dparum. This is comparable to the activities seen previously for the acetylenic 
chalcones. suggesting that the linking of the chalcones to AZT does not improve the in 
vitro antimalarial activity of the acetylenic chalcones. The activity of these chalcone-
AZT hybrids was also generally conserved across both strains of the parasite used for 
testing. AZT was experimentally determined to have no antiplasmodial activity even at 
the highest concentration tested (2OpM). 
However. of the chalcone-chloroquinoline hybrid compounds (3.15 and 3.11). there 
were three compounds that showed notably high in vitro antimalarial activity. with 
sub-micromolar I(so values being observed for 3.15b. 3.15c and 3.11b (Figure 4.2). Of 
these three. compound 3.15b was the most active, having I(so values of 0.04 fJM. 0.01 
fJM and 0.09 ~ against the 010, Od2 and W2 strains of P. fa/dparum. respectively. 
Interestingly. these three compounds were either di- or tri-methoxylated chalcone-
chloroquinoline hybrids: none of the halogenated chalcone-chloroquinoline hybrid 
compounds exhibited sub-micromolar I(so values. 
P. falciparum 010 strain - Cpd 3.15b 
II1II IC50 :: 0.04 IJM 
·2 -1 0 1 2 
log cone (pglml) 
Figure 4.2: Example of a typical dose response curve - specifically for data from the assay of 
compound 3.1Sb against 010 P. faldparum. 
The presence of the chloroquinoline moiety on the three more active compounds is 
most likely responsible for the improved activity that these compounds exhibit; this 
would be no surprise since. as mentioned previously, this sub-structure is present in a 
variety of antimalarial drug classes, ranging from the aminoquinolines (e.g. 
chloroquine. amodiaquine) to the quinoline-methanols (e.g. quinine, mefloquine), and 
is thought to confer antimalarial potency to these compounds by fadlitating binding to 
intra-parasitic heme and consequently inhibiting hemozoin formation [13]. However. it 
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CHAPTER FOUR: IN VITRO ANTIMALARIAL EVALUATION AND MECHANISTIC STUDIES 
should be noted that this significant improvement in activity was not universal, as 
shown by the fact that the other hybrid compounds in this class had in vitro activities 
comparable with those of the acetylenic chalcones and the chalcone-AZT hybrid 
derivatives. 
o OMe 
MeO ~ 
1.0 
~~ ,.$ 
N 
~ ~~CI 
o OMe OMe o 
MeO ~ 
I~ 
OM. ~" .. '" 
~ ~~CI 
Figure 4.3: Figure showing the three chalcone derivatives that were most active in vitro 
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4.3.2.3Acetytenic die nones 
Table 4 .3: 1(',0 valuC?S o r the acetylenic ef10ne 3.11 ilnd Jcetylen ic d ienoncs 3.12 the 010 , Dd 2 
and W2 strains of P. fdldpurum 
0 0 
M~~ MeO '" '" h-
'0 I", ~ ,n 0 J.1l ~ 
" " 
Compound code R 010 !COlI Dd2 IC:,o W2 ICw ("M) (11M) ( JM) 
3.11 
- 9.7 7.5 >20 
.- - - -- - ,-----, 
-
-_. --
-
•..• 
-
3.12a 4'·OMe 11.8 10.7 >20 
-
3.12b 2" .4' ·diOMe 5.4 4.0 18.9 
.-.- ---
- -- --
-
-
.. _- -
------_. - ... - . _. -,. _ . -..•. .. _. __ ._._-
3.12c 2'.3'.4' -tdOMe 0.9 1.4 9.2 
-
. •....•. 
- - -
..... 
3.12d 2A·diel 9.2 9.0 >20 
f--- - --. - ~-.--- -------_.,---- --_.- - - --
3.12e 4-F 9.8 6.5 21.5 
-
-
-- -
- - -- ---
3.12f 2.4<lif 11 .9 9. 3 >20 
-- - -
(CQ) 
- 0.OJ7 0.097 0 .069 
NB: these are average values from two Independent determmatlons. cdch Ulrned oul In duphcale 
From Table 4.3 , it can be seen that the acetylenic dienones exhibi ted moderate in vitro 
antimalarial activity against the DID and Dd2 ~ train s, with ICso va lues generally falling 
in the lower micromolar range of 0.9 - 11.9 pM. However, these compo unds tend to 
be noticeably less active against the W2 main of P faldparom. with compounds 3. 12a. 
3.12d and 3.t2f showing no detectable antimalarial activity against thi s strain at the 
maximum concentratio n tested. 
The mort aCT ive compound of this series was 3.12c, the tri-methoxylated acetylenic 
dieno ne. which had an ICso of 0.9 pM aga imt P faldparum DIO. Interestingly. the 
acctylenic coone intermediate 3. 11 al so showed moderate anl imalarial activity 
comparable to that of the acetylenic chalcones, with IC:oos of 9.7 p M and 7.5 p M 
against P. falciparum DIO and Dd2. respectively. This would suggest that for (halcones 
and dienones. the mo st basic structure/ pharmacophore requited to exhibit antimalarial 
activity (auld be the phenyl-propenone mOiety. 
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n 1"1' _ I< fOIJIl- IN V 'RO ANI-IMAlAl<iAI. EVALUATION AND Mrn IANI" I( ,Wf': , 
4,3,2 ,4Dienones hybrid compound~ 
Table 4.4: [(so values of the dienone hybrid compounds 3.20 - 3.21 against the DIO. Dd2 and 
\:JJ2 strains of P fa!ciparum 
o o 
MeO,~-",,./ ",~,r''-'''~", M'" 
] .20 
Compound code 
3.18 
-
-
3.19 
-R 
"" o 
o 
M'O~'" ' 
1/ 
o 
~N 3·18 ! ' , N N 
HO Fo1 0 ~~ 
o 
R DID 1( 0;0 (.M) 
12.0 
Dd2 ICso 
<.M) 
16.4 
0.8 0.7 
W2 I(so 
(.M) 
ND 
ND 
- - - --------+ -- - - ---
_._.-
-
3.20a 
3.20b 
3.20c 
3.20d 
3.20e 
3. 20f 
3.21a 
., 
4' ·OMe 2.8 1.5 
2·.4'·diOMe U 1, 2 
2',3'.4' ·triOMe U 2A 
. - .,--_ .. . 
2 .4-di(1 1,4 1,7 
.... .... . -... -.-.--
4·' 1,7 2.6 
2,4·diF 1.4 1, 7 
4' -OMe 3.0 2,' 
-
lB.2 
14.5 
8,' 
9,1 
ND 
12.4 
5,3 
3, 21b 2·,4· ·c!iOM e 5,1 >20 
_+ ___ -"6"',4 __ 1 ____ -I 
3. 2 1c 2',3',4'-triOM e 2.5 2,' 
3.21d 2.441(1 f------t--------f __ 1.,9"'.0 __ ~1~---'1"'6,,,8--
3. 2 1e 4-F 
-
3.21f 2.4-diF 
(CO) 
9,4 
10.2 
0,017 
93 
6.5 
0 ,097 
18.5 
>20 
>20 
>20 
0 .069 
NB: these are average value. from two Independent determlnahoos. each carned out In duplicalc 
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CHAPTER FOUR: IN VITRO ANTIMALARIAL EVALUATION AND MECHANISTIC STUDIES 
The dienone-AZT triazole derivatives 3.20 had moderate in vitro antimalarial activity. 
with ICso values also within the lower micromolar region and ranging from 1.2 - 2.8 
~ for the DtO and Dd2 strains of P. faldparvm. As was previously observed for the 
acetylenic dienones. the dienone-AZT hybrids also tend to be noticeably less active 
against the W2 strain of P. faldparvm. 
The dienone-chloroquinoline triazole derivatives 3.21 also had moderate in vitro 
antimalarial activity. with ICso values also within the lower micromolar region and 
ranging from 2.07 - 18.96 ~ for 010 and Dd2 P. faldparvm; unlike the chalcone-
chloroquinoline hybrid counterparts. none of these similarly derivatized dienones had 
ICso values in the sub-micromolar region. Again. this set of compounds was also less 
active against the W2 strain of P. faldparvm. 
The AZT triazole intermediate 3.18 shows moderate in vitro activity against D10 and 
Dd2 P. faldparvm; interestingly. however. the chloroquinoline triazole intermediate 
3.19 shows notably high in vitro antimalarial activity, with sub-micromolar ICso values 
against these two strains of the parasite. It would therefore appear that the 
introduction of the chloroquinoline sub-structure is associated with a marked increase 
in in vitro antimi.darial activity of the acetylenic enone intermediate 3.n, which is not 
surprising for reasons already pointed out; this is not the case when AZT is introduced. 
4.3.3 Discussion 
The moderate in vitro antimalarial activity observed for the acetylenic chalcones 3.9 
and 3.10 is very much in line with the published results for alkoxylated chalcones, 
which have been reported as having ICso values in the high nanomolar to low 
micromolar ranges [14.15]; this activity does not seem to be compromised by the 
presence of the acetylene substitution. 
It is interesting to note that the acetylenic dienones exhibit comparable antimalarial 
activity to the acetylenic chalcones. As has been noted previously, this is probably 
attributable to the presence of the common phenyl propenone sub-structure in both 
these series of compounds, as the acetylenic enone intermediate 3.11 also exhibits 
comparable in vitro antimalarial activity. 
The AZT hybrid compounds of both the chalcones and dienones did not exhibit 
notably higher in vitro antimalarial activity relative to their acetylenic precursors, 
though the retention of activity in most cases is still noteworthy. It is therefore possible 
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that the envisaged benefits of the AZT hybridization strategy. which were primarily the 
increased solubility and possibly enhanced oral bioavailability of these compounds, 
may only become apparent through pharmacokinetic profiling or in vivo antimalarial 
efficacy assays. 
However, the chloroquinoline-hybridization strategy did lead to the identification of 
significantly active hybrid compounds, Le. 3.15b, 3.15c and 3.17b, as well as the 
enone-chloroquinoline intermediate 3.19. Compound 3.15b was the most active of 
these. with sub-micromolar ICso values for all three P. falciparum strains. Interestingly. 
both the chaicone-chloroquinoline hybrid compounds 3.15 and their dienone 
counterparts 3.21 can be considered as derivatives of intermediate 3.19 via 
modifications on its a-carbon. It is also intriguing to note that hybridization to 
chloroquinoline did not lead to a similarly remarkable activity in all these compounds; 
instead. only the three methoxylated chalcones mentioned previously had notably 
improved activity. This indicates that the group on the terminal a-carbon of 3.19 is 
crucial for the retention of activity. and some groups could actually negate any 
beneficial effects that the chloroquinoline moiety confers (as is the case with the 
halogenated chalcone-chloroquinoline and the dienone-chloroquinoline hybrid 
compounds). 
No obvious trends were observed as far as the influence of the different substitution 
patterns of the chalcones or die nones on antimalarial activity is concerned. The only 
valid comment that could be made in this regard is that, of all the compounds with 
notable antimalarial activity/sub-micromolar ICso values. none of them were 
halogenated compounds. 
In conclusion. the most promising candidate for further development based on in vitro 
antimalarial potency was 3.15b. and this compound was therefore prioritized for 
subsequent pharmacokinetic profil1ng and in vivo antimalarial efficacy assays. In 
anticipation of this. compound 3.15b was evaluated for its cytotoxicity against the 
Chinese Hamster Ovarian (mammalian) cell line. No cytotoxicity was observed at the 
highest concentration (100 11M) tested. 
It is acknowledged that pharmacokinetic and/or in vivo efficacy profiling of 
representative AZT-based hybrid compounds would have been useful for proof-of-
principle, i.e. to test the hypothesis on the potential beneficial effects in vivo of 
hybridization to the hydrophilic nudeoside AZT. However. due to mainly time 
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constraints. this was not carried out during the course of this study. but has been 
earmarked for future follow-up (see section 7.2). 
4.4 Mechanistic studies 
A limited mechanistic investigation was carried out" on some of the compounds so far 
synthesized and tested in an attempt to elucidate their possible mechanisms of action. 
The compounds for this investigation were selected from among the chalcone-
chloroquinoline hybrid compounds 3.15 and 3.17. as these were the hybrid 
compounds that had yielded the most active compounds, such as 3.15b. Compound 
3.9b, the acetylenic chalcone precursor of 3.15b. was also included for investigation. as 
was curcumin. 
The mechanisms of action considered for investigation were based on literature 
accounts of the possible mechanisms by which chalcones and quinoline-containing 
compounds exerted their antimalarial activities. 
4.4.1 Inhibition of hemozoin OJ-hematin) fonnation 
As mentioned in Chapter One. hemoglobin degradation is the principle way by which 
the malaria parasite secures its supply of iron [16] and amino adds [17] vital for its 
survival. Heme, one of the by-products of this metabolic process, is toxic to the 
parasite, and accumulation of heme within the parasite would be lethal. The parasite 
therefore detoxifies heme mainly via its conversion to hemozoin (malaria pigment), an 
inert, crystalline form of heme D8]. lnhibition of hemozoin formation therefore is an 
attractive target for antimalarial drugs, and quinoline-based antimalarials such as 
chloroquine and amodiaquine are proposed to exert their antimalarial activity via this 
mechanism [18-20]. On the strength of this. the chaicone-chloroquinoline hybrid 
compounds were investigated for their potential to inhibit hemozoin formation. 
Assays have been designed to estimate the ability of compounds to inhibit hemozoin 
formation [20]. The assay described by Ncokazi and Egan. 2004 [21] is one such assay, 
which colorimetrically quantifies the ability of a compound to inhibit the conversion of 
hematin to ~-hematin. the synthetic equivalent of hemozoin. The IC50 values from this 
assays represent the number of molar equivalents of the test compound, relative to 
hematin. that are required to inhibit its conversion to ~-hematin by 500/0 - the lower 
the \(50. the more potent the compound is at inhibiting ~hematin fonnation. 
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constraints. this was not carried out during the course of this study. but has been 
earmarked for future follow-up (see section 7.2). 
4.4 Mechanistic studies 
A limited mechanistic investigation was carried out on some of the compounds so far 
synthesized and tested in an attempt to elucidate their possible mechanisms of action. 
The compounds for this investigation were selected from among the chalcone-
chloroquinoline hybrid compounds 3.15 and 3.17. as these were the hybrid 
compounds that had yielded the most active compounds. such as 3.15b. Compound 
3.9b. the acetylenic chalcone precursor of 3.15b. was also included for investigation. as 
was curcumin. 
The mechanisms of action considered for investigation were based on literature 
accounts of the possible mechanisms by which chakones and quinoline-containing 
compounds exerted their antimalarial activities. 
4.4. i Inhibition of hemozoin OJ-hematin) formation 
As mentioned in Chapter One. hemoglobin degradation is the principle way by which 
the malaria parasite secures its supply of iron [16] and amino acids [17] vital for its 
survival. Heme. one of the by-products of this metabolic process, is toxic to the 
parasite. and accumulation of heme within the parasite would be lethal. The parasite 
therefore detoxifies heme mainly via its conversion to hemozoin (malaria pigment), an 
inert, crystalline form of heme [18]. lnhibition of hemozoin formation therefore is an 
attractive target for antimalarial drugs, and quinoline-based antimalarials such as 
chloroquine and amodiaquine are proposed to exert their antimalarial activity via this 
mechanism [18-20]. On the strength of this, the chalcone-chloroquinoline hybrid 
compounds were investigated for their potential to inhibit hemozoin formation. 
Assays have been designed to estimate the ability of compounds to inhibit hemozoin 
formation [20]. The assay described by Ncokazi and Egan. 2004 [21] is one such assay, 
which colorimetrically quantifies the abHity of a compound to inhibit the conversion of 
hematin to (3-hematin, the synthetic equivalent of hemozoin. The lCso values from this 
assays represent the number of molar equivalents of the test compound. relative to 
hematin. that are required to inhibit its conversion to (3-hematin by 500/0 - the lower 
the tCso, the more potent the compound is at inhibiting ~hematin formation. 
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The selected compounds were submitted for this assay, which was carried out by Dr. K. 
Ncokazi in the laboratories of Prof. Timothy J. Egan at the Dept. of Chemistry. UCT. 
The results are presented in Table 4.5. 
4.4.2 Inhibition of Faldpain-2. a plasmodial cysteine protease 
The subsequent breakdown of the globulin component of hemoglobin into smaller 
peptide fragments is known to involve the activity of cysteine proteases, principally 
Falcipain 2 and Falcipain 3 [22.23]. These enzymes therefore offer themselves as 
targets for potential antimalarial agents. Plasmodial cysteine proteases. and in 
particular Falcipain 2. have been proposed as such [24.25], and efforts have been 
made to develop cysteine protease inhibitors as novel antimalarial agents [26]. Several 
quinolinyl chalcones have been identified that actually inhibited plasmodial cysteine 
proteases (contained in soluble parasite extracts) at micromolar concentrations. though 
there was no correlation between this inhibition and the in vitro antimalarial activities 
of the compounds [27]. 
On this basis. the selected chalcone-chloroquinoline hybrid compounds were submitted 
for recombinant Falcipain-2 inhibition assays, which were carried out by Dr. J. Gut in 
the laboratories of Prof. P. J. Rosenthal at the University of California. San Francisco 
(UCSF), USA. The results are also presented in Table 4.5. 
4.4.3 Inhibition of sorbitol-induced hemolysis 
Infection of human erythrocytes with the malaria parasite induces the activation of 
channels. dubbed new permeability pathways (NPPs). hitherto absent in the 
erythrocyte membrane. These channels aUow for the influx of electrolytes and essential 
nutrients (such as amino-acids. nucleosides and sugars) required by the parasite while 
allowing the efflux of metabolic waste products extruded by the parasite [28.29]. The 
fact that these channels are absent in non-parasitized cells and are essential for the 
survival of the intracellular parasite make them an attractive target for novel 
antimalarial agents [30]. 
Inhibition of sorbitol-induced lysis of infected erythrocytes is an experimental 
technique used to assess compounds for their potential to inhibit these NPPs [31]. 
Briefly. when a parasitized erythrocyte is exposed to an isosmolar solution of sorbitol, 
the sorbitol (which is one of the solutes that can pass through the NPPs) is taken up via 
these NPPs and accumulates in the erythrocyte. What follows is a rise in intracellular 
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osmotic pressure, and the resultant osmosis of water into the erythrocyte causes it to 
swell and ultimately lyse. The assay is based on the obsetved fact that less lysis is 
obsetved in erythrocytes exposed to inhibitors of NPPs relative to erythrocytes not 
exposed to N PP inhibitors; the more potent the inhibitor, the less the obsetved lysis. 
A study of some of· the chalcones from a series of alkoxylated and hydroxylated 
chalcones (mentioned in Chapter Three, Section 3.5.1. [32.33]) for their inhibition of 
sorbitol-induced lysis of parasitized red blood cells found that most of the good 
inhibitors of sorbitol-induced lysis were also active antiplasmodial agents. However, 
not all active antiplasmodial agents inhibited sorbitol-induced lysis. This. along with the 
fact that the chalcones were not exceptionally potent inhibitors of the parasite induced 
channels relative to other known inhibitors. strongly suggested the presence of 
alternative antimalarial mechanisms of action. Some chalcones with poor in vitro 
antimalarial activity were good inhibitors of sorbitol-induced lysis [31]. 
The selected chalcone-chloroquinoline hybrid compounds were therefore evaluated for 
inhibition of sorbitol-induced lysis of infected erythrocytes. The method described by 
Go et al. 2004 [31] was applied for this assay, with modifications. in our UCT 
laboratories. 
Briefly, chloroquine-sensitive P. falciparum 010 was cultured as described in section 
4.3.1.1, and trophozoite-stage infected erythrocytes (10% parasitemia) were hatvested 
by centrifugation (750 r.p.m .• 3 min), washed twice with a solution of NaCi (150 mM) 
- HEPES (20 mM) (pH 7.4; 304 mosM), and suspended in the same solution to give a 
hematocrit of about 50%. 
Test compounds were dissolved in dimethylsulfoxide (DMSO) to give 10 mM stock 
solutions, which were diluted further with a solution comprising 300 mM sorbitol - 20 
mM HEPES (pH 7.4; 345 mosM) to give the test solutions of 100 jJM. 
In 10 ml sCTe'W-cap centrifuge tubes, 100 pl of the test solutions were separately 
combined with an additional 700 jJL of the sorbitol-HEPES buffer and 200 jJl of the 
parasitized cell suspension in NaCI-HEPES buffer. The final concentration of the test 
compounds was 10 jJM. For the negative control. 800 jJl of the sorbitol-HEPES buffer 
and 200 pi of the parasitized cen suspension in NaO-HEPES buffer were transferred 
into a 10 mL screw-cap centrifuge tube. For the blank, 800 pl of the sorbitol-HEPES 
buffer and 200 jJl of non-parasitized erythrocyte suspension (50'10 hematocrit) in 
NaCl-HEPES buffer were transferred into a 10 ml screw-cap centrifuge tube. The 
mixtures were inmOOted at 37°C for 15 min and centrifuged, and aliquots of the 
supernatant (l00 pL) were dispensed into 96-well plates. The absorbances at 560 nm 
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CHAPTER FOUR: IN VITRO ANTIMALARIAL EVALUATION AND MECHANISTIC STUDIES 
With the exception of 3.17a which was inactive at the highest concentration tested. the 
submitted compounds showed inhibition of (>-hematin formation to varying degrees. 
The most potent compound was 3.15c. with an ICso of 0.2 equivalents. Interestingly 
curcumin and the acetylenic chalcone 3.9b were also more potent inhibitors of p-
hematin formation than chloroquine. with ICso values of 0.3 and 0.5 equivalents. 
respectively. Compound 3.15b. the most potent compound in vitro. was only slightly 
more potent (lCso 1.6 equiv.) than chloroquine. as was 3.17e with a similar ICso. 3.17b 
and 3.17d were less potent inhibitors of ~-hematin formation than chloroquine. 
Though the chalcone component of the hybrid compounds could contribute to their 
potency as inhibitors of (>-hematin formation (the chalcone 3.9 was a potent ~-hematin 
inhibitor. for example). no obvious structural features could be identified that could 
account for why some of the hybrid compounds were significantly more potent ~­
hematin inhibitors than others. 
There was also no consistent correlation between ~-hematin inhibition and in vitro 
antimalarial potency. as the more potent inhibitors of ~-hematin formation were not 
necessarily the more potent compounds in vitro. This implies the possible influence of 
other factors; one such factor could be the degree of accumulation within the parasite 
digestive vacuole. which is the definitive site of hemoglobin catabolism and therefore 
the site of action of hemozoin inhibitors. Chloroquine accumulates considerably within 
the parasite digestive vacuole by both saturable [34.35] and non-saturable (pH-
dependent) [13.36.37] mechanisms. a factor that undoubtedly contributes to its 
antimalarial potency. The lower in vitro antimalarial activity (relative to chloroquine) 
of those target compounds showing comparable or superior p-hematin inhibition could 
therefore suggest the absence of equivalent accumulation mechanisms. resulting in 
lower concentrations at the site of action (digestive vacuole) and ultimately in 
relatively lower in vitro antimalarial efficades. The target compounds were notably 
not as basic as the dibasic chloroquine. which would rule out pH-dependent 
accumulation as a possible mechanism of accumulation for these compounds. 
However. the fact that some of the compounds were quite potent inhibitors of ~­
hematin formation (in several cases more active than chloroquine) would suggest that 
this is a primary mechanism by which these compounds exert their antimalarial activity. 
though the presence of other mechanisms of action is' also quite possible. 
The compounds showed only moderate inhibition of Faldpain 2. with ICso values in 
the lower micromolar region; this is relative to E64. a known potent inhibitor of 
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were then determined and U5ed' to e5timate the amount of hemoglobin re leased and . 
by extemion. the degree o f sorbitol- induced hemoly sis. The a b~orbances o f the control 
and blank wells were determined concu rrent ly , and corrections to the absorbances 
measured in the test wells w ere made as appropriate. The percentage inhibition of 
sorbito l-induced lysiS w as then calrulated for each l est compound. and the results are 
presenled in Table 4.5. 
4 .4.4 Results 
Table 4.5: Results from the mechanistic studies 
fJ·hemalin 
r a lcipain-2 %age Sorbitd - , Compound 
R DIO IC'IO Dd2 IC50 W2 IC'IO inhibition Inhibition induced 
",de ( fl M ) (flM) (flM ) (IC'IO in hemolysis , 
equiv,)' lC~o (,..M)l> inhibition. '· ... 
3.% 2'A'-diOMe 3.4 4.3 3.8 0.5 >50 58.8 
-
.. 
- -
• . . 
3.15b 2'.4' -diO /lAe 0.04 0.07 0.09 16 10.8 ISA 
3.1Sc 2'.3·.4·,trlO Me 0.4 0.4 0.6 0.2 15.7 7.1 
---
--·--·l 3.17a 2.4·diOM C! 5.2 11.7 6.6 Inactive 24.3 11 6 . 
3. 17b 2.3 A-triOMe 0.3 0.3 0.5 4 .1 11 .9 11 3 
f-- - --,- --.----- ------- - --- - . _ . . -- -.-.- -
3.17d 4-F 7.4 16 6.9 4.8 12.7 <1 
-
. 
3.l7e 2 A-diF 4.1 2.1 10 .6 16 13.1 10.0 
.. 
Curcumln · 5.6 4.1 . 0.3 5.2 25.3 
-
CQ · 0.017 0,097 0.069 1.91 . 
-
E64 
· 
. . . . 0 ,055 
. : The 1(-0$ an: JV;:r.lges of tnpltaat ... de1ermlr.:ltIOns and are reported In equlvalenB o f UIt: drug ~atlVe to 
h ... rTI/I[ in. 
b: The lew are awrnges o f dup;icale de[ermi na!ion~ and are reported in pM 
' : Avernge perc~nta~ inhibit ion (mm duplicate detf!rmirotion~ or sorbil ol·i ndlJC~>d lysi1 by IhI: test compound~ at a 
conc:~nlr.llion of 10 pM. 
0: Furo!emide, [~ [Vpical pC>Sfl iw control for th is assay. was unfortUnille[V Ur\llV3113b1e 3[ ,lit: time Ihe assay_~ 
being carried out , 
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Falcipain 2 with an ICso of 0.055 11M. Interestingly, curcumin was the most active of 
the selected compounds submitted for this assay. with a moderate ICso of 5.2 11M. 
Compound 3.9b, the acetylenic chalcone precursor of the highly active hybrid 
compound 3J5b. did not inhibit Falcipain 2 at the highest concentration tested (50 
11M). 
Again. there was no consistent correlation between Falcipain 2 inhibition and in vitro 
antimalarial potency as the more potent compounds in vitro were not necessarily the 
more potent inhibitors of Falcipain 2. For example compound 3.15b. which showed 
the highest antimalarial activity in vitro. was not the most potent inhibitor of Fakipain 
2. In addition. the relatively low potencies of the compounds as Falcipain 2 inhibitors 
suggests that this is not a primary mechanism of antimalarial action of these 
compounds, though inhibition of the enzyme may still contribute to their overall 
observed antimalarial activity. 
The most potent inhibitor of sorbitol-induced lysis was actually the acetylenic chalcone 
3.9, which inhibited hemolysis by 58%. The rest of the molecules tested were poor 
inhibitors of sorbitol-induced lysis; curcumin inhibited hemolysis by 25%. while the 
chalcone-chloroquinoline hybrid compounds inhibited hemolysis by ~ 15%. This 
probably discounts inhibition of N PPs as a mechanism of action for the hybrid 
compounds, though this mechanism of action could possibly contribute to the 
moderate in vitro potency observed for 3.9. 
4.4.5 Conclusion 
The results above suggest that inhibition of hemozoin formation is likely to contribute 
to the antimalarial activity of the target compounds. This is particularly so for the 
hybrid compounds 3.15b, 3.15c and 3.15e. which were all comparably or more potent 
than chloroquine in inhibiting J3-hematin formation. This would not be surprising as 
these hybrid compounds also contain the chloroquinoline moiety. Inhibition of 
Faldpain 2 could also contribute to the overall observed antima\aria\ activities of these 
compounds, albeit to a limited extent. Inhibition of parasite-induced transport channels 
does not appear to be a notable mechanism of action for these compounds. 
The lack of correlation between these proposed mechanisms of action and the 
observed in vitro antimalarial activities of these compounds suggests the possibility of 
either the existence of additional mechanisms of action. varying contributions of the 
various proposed mechanisms of action to the overall observed antimalarial activity, or 
of other factors that influence the in vitro antimalarial activities of these compounds 
such as varying degrees of lysosomal accumulation within the malaria parasite. 
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Also worth mentioning is that curcumin appears to be a potent inhibitor of j3-hematin 
formation (lCso 0.3 equiv.), as well as a moderate inhibitor of Falcipain 2 and parasite-
induced permeability pathways. This would suggest the likelihood that these 
mechanisms. possibly among others. contribute to the overall antimalarial activity of 
this natural product. 
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CHAPTER fiVE 
INTEGRATION OF IN SIUCOTOO15IN THE IDENTIFICATION OF IN VITRO HITS. WITH 
SUPERIOR PREDICTED PHYSICOCHEMICAL AND ADME PROPERTIES 
5.1 Preamble 
This chapter contains the work done to address the third spedfic aim of the study. 
which was: To apply in silico (computational) techniques to guide the design of 
derivatives of the more active compounds with potential", superior physicochemical 
and/or ADME properties for subsequent synthesis as well as in vitro and in vivo 
antimalarial testing and mechanistic studies. 
The chapter begins by briefly introducing in silieo (computationa\) prediction of 
physicochemical and ADME (Absorption. Distribution. Metabolism and Excretion). as 
well as the main determinants of oral bioavailability. It then goes on to describe the in 
silico-guided design of proposed analogs. as well as the subsequent synthesis. 
characterization and in vitro antimalarial testing of the selected analogs. The chapter 
then concludes with a brief description of. and the results from. limited mechanistic 
studies on selected analogs. 
5.2 In sillCD (romputational) prediction ofphysicod1emical and ADME properties 
It is widely acknowledged that challenging ADME properties significantly hamper the 
development of many promising compounds into leads and drug candidates £1.2]. This 
has led to an increased interest in the early' determination (and/or prediction) of 
ADME properties of compounds. and it is therefore becoming increasingly routine for 
compounds to be simultaneously filtered in vitro for potency and in silieo (and in 
vitro) for suitable ADME properties [1]. 
Of interest to the OJrrent study was the application of in silico tools in the prediction 
of ADME and physicochemical properties of compounds. In silieo ADME prediction 
models and tools complement in vitro and in vivo ADME efforts by facilitating the 
characterization of the ADME properties of rompounds prior to their synthesis. In 
other words. a reliable ADME predictive model can be applied on a set of proposed 
rompounds to identify those that are more likely to have favorable pharmacokinetic 
properties. thereby enabling their prioritization for synthesis and subsequent in vitro 
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and/or in vivo biological evaluation [2]. Such an approach would save time and 
resources by focusing synthetic and experimental evaluation efforts on a smaller 
number of more promising compounds. 
Any property of a particular molecule is encoded in its structure. A molecule's structure 
can be resolved into a complement of molecular descriptors, which are essentially 
measured or calculated properties of the molecule e.g. molecular weight, polar surface 
area, etc. It therefore fonows that the properties of a molecule can be deduced from 
molecular descriptors derived from its structure, and that for different properties, the 
sets of molecular descriptors that would be employed would be different [3J. Many in 
silica prediction tools, including the tools used in the current study. are based on this 
concept. and apply molecular descriptors (and the 3-D molecular interaction fields 
used to generate these molecular descriptors) as inputs in building the 
mathematical/statistical models that are then applied in the prediction of 
physicochemical and ADME properties of compounds. Properties that may be 
predicted in this way indude sotubUity. logP/logD. passive permeability. metabolic 
stability. plasma protein binding and volume of distribution. 
It is noted that this process is not as straight-forward as it would appear to be [3]. For 
example. a variety of models can be developed to predict the same property, and the 
predictive capacity of such models would be inherently different. This predictive 
capacity would vary depending on the molecular deScriptors used as inputs in the 
building of the individual models, the mathematical/statistical approach applied (and 
attendant assumptions made) in building the model. the chemical diversity/chemical 
space covered by the set of compounds used to train each model. and/or the quality of 
the data accompanying the training set of compounds. Furthermore. the prediction of 
ADME parameters is quite challenging because of the complicated nature of the actual 
in vivo ADME processes resulting from the complexities of participating organs and the 
simultaneous involvement of multiple mechanisms [1.2.4]. 
A recognition of these limitations implies that results from such predictions should not 
be over-interpreted. and has even led to proposals for the estimation of the 
applicability domain and prediction accuracy of models prior to their actual utilization 
for a given set of compounds [5]. 
However. despite these challenges. computational tools developed for the prediction 
of physicochemical and ADME properties have been successfully applied in the 
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characterization of compounds. with their results being corroborated by in vitro 
and/or in vivo AOME assays. For example. MetaSite®. which was one of the tools 
used in the rurrent study, was used to predict the sites of metabolism of several 
derivatives of the non-steroidal anti-inflammatory drug (NSAIO) indomethadn. 
MetaSite® ac:rurately predicted the sites of metabolism of the range of derivatives 
studied. with the predictions found to be in dose agreement with the results from in 
vitro and in vivo metabolism experiments carried out on the derivatives [6]. 
The rurrent study applied available in silica prediction tools in the characterization of 
compounds proposed for synthesis and which were based on promising compounds 
identified from the in vitro antimalarial assays described in the preceding Chapter. A 
deliberate attempt was made not to over-interpret the predictions. but rather use them 
only as a guide in determining whether or not the proposed compounds were likely to 
be improvements on the parent compounds. An attempt was also made to 
experimentally corroborate some of the predictions. 
5.3 The Tools 
Three software packages. with varying but complementary capabilities. were available 
for use in the in silico prediction of various physicochemical and AOME parameters. 
These were: 
• VoISurf+®: this software package computes 3D molerular interaction fields of 
molerules. and then compresses and converts these fields into a range of molerular 
descriptors that numerically characterize size, shape, polarity. and hydrophobidty 
of the molerules. Descriptors of this kind generated for extensive databases of 
diverse compounds are then utilized in the generation of mathematicaVstatistical 
models which can be applied for the prediction of various physicochemical and 
AOME parameters of compounds. such as aqueous solubility. logP (n-
odanol/water). logO (at various pHs), Caco2 permeability. metabolic stability. etc 
[7.81· 
e MetaSite®: this is an automated tool for the rapid prediction of the possible site(s) 
of metabolism of molerules by hepatic cytochromes (which constitute the bulk of 
the enzymes involved in drug metabolism in the liver) during phase I metabolism. 
MetaSite® also provides the structures of the predicted metabolites along with a 
probability ranking derived from the site of metabolism predictions. In addition to 
predicting the site of metabolism. this software package also highlights the atoms or 
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groups in the molecule that contribute to the prediction (i.e. that help direct the 
molerule into the cavity of the cytochrome's active site such that the predicted site 
of metabolism is in proximity to the catalytic centre) [6.9]. 
<III MoKa®: this is a software tool that enables the quick and acrurate prediction of 
the pKa of ionizable compounds; in addition. it also predicts (and graphically 
represents) the relative species abundance at various pHs [10]. 
5.4 The main detenninants of oral bioavailabiiity 
The main aim of the derivatization exerdse was to identify analogs with optimized 
oral bioavailability. This is because, for antimalarial drugs. oral administration is often 
the desired route for their delivery as it enhances patient compliance while reducing 
fonnulation and administration costs. This is important considering the financial 
challenges facing much of the population most affected by malaria En]. It was 
therefore necessary to first identify the main properties/parameters that would need to 
be addressed. 
The overall proportion of an orally administered drug that is delivered into systemic 
cirrulation (i.e. its oral bioavailability) is dependent on the outcome of several main 
factors. as shown in Figure 5.1. 
Figure 5.1: Figure showing the various processes between the oral administration of a drug and 
its delivery into systemic drculation [1:2] 
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5.4.1 Solubility 
The compound must be in solution before it can be absorbed; it could either be 
dissolved in an aqueous system prior to administration. or administered as a solid or 
suspension dosage form whereby it is expected to dissolve into the mainly aqueous 
contents of the gastro-intestinal (G.I.) tract after administration. The degree to which a 
compound dissolves (i.e. its intrinsic solubility) and which would directly impact on its 
oral bioavailability is dependent on. among other things. its chemical structure and (in 
the case of ionizable compounds) the pH of the aqueous environment that it is 
dissolving in [12.13]. 
5.4.2 Permeability 
Once in solution. the compound then diffuses to the wall of the G.I. tract, through 
which it permeates and enters the G.I. blood circulation. Biological membranes are 
essentially lipid bi-Iayers. and hence permeation through the G.I. wan involves the 
partitioning of the compound between aqueous phases (G.1. contents, intracellular 
cytosol and blood plasma) and lipid phases (biological membranes). The permeability 
of compounds through the G.i. tract wall is therefore dependent on their relative 
affinities for aqueous and lipophilic phases. a characteristic that is usually represented 
by the logarithm of the organic soivent/Water partition coefficient (i.e. logP). For 
ionizable compounds, this partition coefficient is pH dependent and usually expressed 
as the logO of the compound. which is essentially its logP at a specified pH [12]. 
It is no surprise. therefore. that logP/logO has been identified as a critical 
physicochemical property that influences oral bioavailability, and has been included in 
proposed guidelines for the design of compounds with favorable oral bioavailability 
such as the Upinski "rule of 5' [14]. 
The higher the lipophilicity of the compound. the higher it's logP/logO. and hence the 
faster ifs expected permeation through biological membranes; however. increased 
Jipophilicity is obviously at the expense of aqueous solubility. as depicted in figure 5.2 
below. Therefore. the aim is usually to strike a balance between the two antagonistic 
properties. with logP range of 0 - 3 being proposed as optimal [12]; this and other 
similar ranges are usually viewed more as guidelines rather than absolute cutoffs [15]. 
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figure 5.2: The relationship between aqueous solubility. logP and oral bioavailability [121 
5.4.3 Metabolic stability 
Once in the GJ. drrulation, the compound is then carried through to the liver via the 
hepatic portal vein. The liver is the primary metabolic and detoxification organ of the 
body. responsible for the chemical transformation and elimination of the majority of 
xenobiotics. This implies that any drug/compound must survive hepatic metabolism 
during this initial passage through the liver (referred to as first pa$$ metabolism) in 
order to enter systemic drrulation [12.16]. The metabolic stability of an orally 
administered compound is theref re crucial in determining the proportion of the 
compound that survives this first-pass metabolism. 
The above description is by no means exhaustive, and represents a very simplified 
version of the oral absorption process that does not take into account the effects of. 
for example. G.I. contents. active transport. efflux pumps. G.I. metabolism. etc [13]. 
Nevertheless. these three fundamental properties have a direct and apparent bearing 
on the oral bioavailability of compounds, and as such need to be addressed as early as 
possible in any drug discovery initiative. 
5.5 Strategies to improve oral bioavailability 
In general. strategies for improving the oral bioavailability of a compound involve 
either the use of formulations and/or the rational structural modification of the 
compound, i.e. the design and synthesis of related compounds predicted to have more 
favourable physicodiemical and ADME profiles relative to the parent compound. and 
which retain biological activity. 
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Both these approaches have been considered in the rurrent study. though this Chapter 
foruses on the latter of the two. Formulations as a strategy will be introduced and 
disrussed in Chapter Six. along with the findings from the actual PK and in vivo efficacy 
determinations. 
5.6 Design and characterization of proposed analogs 
5.6.1 Selection of compounds for derivatization 
As mentioned in Chapter Four above. compound 3.15b was the most promising of the 
target compounds so far synthesize based on in vitro antimalarial results. The next 
logical step would therefore have been to examine the PK and efficacy profiles of the 
compound under in vivo conditions. 
However. one of the main concerns about this compound (and which was a feature 
shared by all the tested compounds) was its poor aqueous solubility. This poor 
solubility necessitated the use of up to 100/0 DMSO as co-solvent (along with extended 
periods of sonication and agitation) during sample preparation prior to the in vitro 
antimalarial assays. As mentioned above. aqueous solubility. along with permeability 
and metabolic stability. is, a key determinant of oral bioavailability. and therefore the 
aqueous solubility challenges of the compound observed during the in vitro procedures 
could possibly have a detrimental effect on its oral bioavailability. 
In anticipation of such a situation. the primary forus was therefore to design and 
synthesize analogs of 3.15b with improved aqueous solubility. The other parameters 
outlined above that are also necessary for good oral bioavailability would be 
considered as well. Promising analog(s) would then be synthesized and evaluated in 
vivo alongside 3.l5b. 
However. it was apparent from the outset that this compound had notable constra!nts 
with respect to its chemical tractability. with the range of possible analogs somewhat 
limited (without deviating significantly from the parent structure or adding significantly 
to its molerular weight). With this in mind. the intermediate 3.19. which also showed 
notable in vitro antimalarial activity. was selected along with 3.15b (Figure 5.3). This 
was due to its potential for a more diverse range of analogs afforded by the open-
ended nature of the butenone side-chain. 
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Figure 5.3: Structures of compounds selected for structural modification (3.1Sb and 3.19) 
The evaluation of such potentially enhanced compounds based on the two selected 
compounds was to be guided by the in silicD (computational) tools, as described 
below. 
5.6.2 Selection of characterization parameters 
Considering the myriad of possible physicochemical and A.DME descriptors that could 
be predicted using the software to ls available, it was necessary to first identify a 
manageable but adequate complement of these parameters that would be considered 
in the characterization of the selected compounds as well as guide in the design and 
evaluation of any subsequently proposed analogs. 
The set of parameters to be derived was based on: 
• The overall objective of the derivatization process, which was to enhance oral 
bioavailability. 
• The range of physicochemical parameters that could be generated by the software 
packages available. and that can be directly and meaningfully interpreted. 
• The range of ADME parameters that could be generated by the software packages 
available: these are limited by the number of in-built predictive models. 
Critical for oral bioavailability and an obvious limitation of the two selected 
compounds, solubility (represented as the logarithm of the molar aqueous solubility at 
25°C and at a specified pH. 1..ogS) was therefore chosen as one of the parameters for 
characterization. 
ERIC M GUANTAI - Ph.D THESIS 2010 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
c: iX'!!:I, ,-;'.'1: i~rLC,R\ lIC:-'; Of 'V _liUCOTOOIS IN n I[ iDENTIFiCAIlON Ot' 1,\/ VITRO HITS \'l;lITH 5Upm:OR FRLDlC;;: 
PHYSICOCHEMICAL AND ADME PROPER n[, 
logO was also selected as another parameter for characterization. This represents the 
-' 
logarithm of the partition coeffident between an organic phase and water at a 
specified pH. and gives a measure of the lipophilicity/hydrophilidty balance of the 
compound. taking into account the presence of any ionizable groups. 
In addition. Cac02 permeation. which represents one of the in vitro methods available 
for assessing permeability (and which could be predicted by the software available). 
was also selected as a parameter for characterization. This parameter· describes the 
ability of a compound to traverse across a Cac02 epithelial cell monolayer (under the 
assumption of passive. transcellular permeation); the output of the prediction of this 
parameter is qua\ttative. indicating a good. intermediate or poor abmty to permeate 
through the epithelial cells. 
Metabolic stability is crucial in estimating the proportion of the compound that would 
survive first-pass hepatic metabolism and. for this reason. was selected as a 
characterization criterion of interest. This predicted metabolic stability provides an 
estimate of the metabolic stability of a compound when a predetermined 
concentration of the compound is incubated for 60 minutes with a fixed concentration 
of the enzymes at 37°C. The interpretation of the output of this predictive model is 
also qualitative. 
In addition. pKa predictions and site of metabolism predictions were also determined 
to provide support information. as appropriate. 
5.6.3 ~esign and characterization of proposed analogs 
In order to design analogs of 3.15b and 3.19. it was necessary to first identify the core 
structural feature(s) of the compounds that would be retained in the analogs with a 
view to maintaining the observed antimalarial activity. The choice of what sub-
structures would be retained based on the anticipated mechanisms of action of the 
compounds. 
Literature. along with the limited mechanistic studies so far carried out in this study 
(section 4.4) indicated that inhibition of hemozoin formation and. to a lesser extent. 
Falcipain 2 inhibition could be possible mechanisms of action of this type of 
compounds. For this reason. the core structural features identified for retention were 
the chloroquinoline moiety and either the phenyl-butenone moiety (for 3.19) or the 
chalcone moiety (for 3.15b) (Figure 5.4)- the chloroquinoline moiety for its potential 
role in hemozoin inhibition. and the chalcone and phenyl-ootenone moieties for their 
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possible dual roles in malarial cysteine-protease inhibition [17], and in fadlitating 
inhibition of hemozoin formation through 1C-1C stacking interactions. 
Chalcone 
~-------~-------~ r 0 OMe '\ 
MeO 
o OMe 
Tn"o~ link., { ~~N 
chloroquinoline { ~ ~NUCI 
Phenyl butenone 
o 
Meo~ 
ON 3.19 
~~N } Trnzol. II'*", 
~ } chloroquinoline ~NU(( 
Figure 5.4: Figure showing the core structural features of 3.15b and 3.19 
With these core features in mind. the sites on these two compounds that offer 
themselves for convenient modification/replacement were the triazole ring (here 
considered as a linker between the chloroquinoline and chalcone/phenyl-butenone 
groups). as well as the terminal carbon of the butenone side chain of 3.19. 
5.6.3.1 Replacement ofthe triazole ring: 
With the primary goal being to improve aqueous solubility, the types of structural 
modifications that would fadlitate this improvement were considered. such as the 
introduction of ionizable groups, the reduction of LogP, and the introduction of polar 
groups and groups capable of hydrogen bonding [t2]. Synthetic accessibility was an 
attendant consideration. 
Figure 5.5 shows the first set of proposed analogs. in which the triazole linker has been 
replaced with a variety of other linkers. 
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Figure 5.5: Figure showing the structures of the analogs of 3.19 and 3.15b derived from replacement of 
the triazole linker 
Compounds 5.8 and 5.10 were analogs of 3.19 in which the triazole linker has been 
replaced with the amino-ethoxy linker and the piperazinyl-ethoxy linker. respectively. 
Compounds 5.9 and 5.n are the equivalent analogs of 3.15b. 
The piperazinyl-methyl tinker was introduced for compounds 5.t2 and 5.13; however, 
rather than have the linker attaching at the 4-0 position of the chalcone/phenyl-
propenone sub-unit (as was the case with 5.8 - 5.11). the point of attachment was at 
the 5-position. leaving the 4-hydroxy-group untouched. This introduced a little more 
diver~ity into the analogs proposed. 
The proposed compounds 5.14 and 5.15 were analogs of 5.12 and 5.13, respectively. 
in which the 3-methoxy group has been omitted, again to introduce some diversity to 
the analogs as well as introduce the possibility for even further structural modifications 
at the 3-position (see Figure 5.13) 
In the proposed analogs. the amino-alkyl or piperazinyl-based linkers all introduce the 
4-amino-substitution on the chloroquinoline sub-unit. The introduction of a 4-amino 
group on the chloroquiooline ring enhances the pKa of the nitrogen on the quinoline 
ring. thereby increasing its basicity and enhancing ionization at this position; the 
resultant compounds are thus more polar and this in tum enhances their (pH-
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dependent) solubility. This feature has been successfully exploited in the formulation of 
chloroquine and amodiaquine. both of which are available as water-soluble salts. 
In addition, the piperazinyl-based linkers possess a second protonatable nitrogen. 
further enhancing the possible ionization of the analogs bearing this type of linkers. 
The incorporation of an ionizable centre. such as an amine or similar function, is a 
recognized strategy of improving water solubility of compounds [18]. Though this is 
the most common way of increasing solubility and ultimately bioavailability of poorly-
soluble compounds [19], this type of pH dependent solubility comes with its own set 
of limitations and concerns. A drastic change in pH would result in a loss of so\ubility. 
and the result could be the predpitation of such a compound out of solution. 
In addition. some molecules cannot traverse across the highly lipophilic biological 
membranes in the charged state. implying that complete ionization of such 
compounds, while being advantageous at improving solubility. could be detrimental to 
absorption and oral bioavailability - this is particularly so for addic compounds. 
However. the partitioning of basic compounds is reportedly highly favored and 
independent of the degree of ionization. This is believed to be due to electrostatic 
interactions with charged membrane phospholipids such as the addic phospholipid 
phosphatidylserine: this property is not shared with addic compounds [18]. 
However. most organic molerules are usually weak adds or bases, thereby ensuring the 
existence of an eqUilibrium between the ionized and non-ionized forms of the 
compound at intermediate pHs. This implies the continued presence of the non-
ionized species that can cross the biological membranes. and which is continually 
replenished from the reservoir of the ionized species by readjustment of the 
eqUilibrium as absorption progresses. Such equilibria would be favoured by the rather 
gradual pH transition of G.1. contents as they move along the G.1. tract. 
5.6.4 In sHiro characterization of 3.15b. 3.19 and the proposed analogs 
As the two compounds selected for derivatization 3.15b and 3.19 (as well as the 
proposed analogs) were chloroquinoline-based compounds, it was thought prudent to 
select the clinically approved chloroquinoline-based drugs amodiaquine and 
chloroquine (Figure 5.6) as benchmarks for the characterizations. In other words, 
chloroquine and amodiaquine would be characterized along with the study 
compounds to allow for comparison of the results. and in this way inferences could be 
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made on how these compounds compared with the two established drugs. A 
deliberate attempt was made not to over-interpret the prediction results. but rather use 
them only as a guide in determining whether or not the proposed compounds were 
likely to be improvements on the parent compounds 3.tSb and 3.t9. and to highlight 
any potential liabilities. 
Fig. 5.6: Chloroquine and amodiaquine. examples of chloroquinoline-based 
antimalarial drugs 
Characterization of the compounds and the two reference drugs yielded the following 
highlights: 
• ~~ •• ,.", .•• <.'~ •• " •• ~ ••• ~ •• ~~,., ... ~ •• ~~",.~ ••• . , , 
. , . 
, , . 
, , 
, . 
, ., . 
::'::' -~::t"'~::':::"::::::F:,':::::J::'-L:': 
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Fig. 5.7: Plots of predicted solubility (expressed as the logarithm. log 5) against the predicted n-
Octanol-water partition coefficient (also expressed as the logarithm. log D) at pH 5.0 and at pH 
7.5 
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• Chloroquine and amodiaquine show significantly superior predicted aqueous 
solubility both at approximately physiological pH (pH 7.5) and at pH 5.0 when 
compared to 3.15b. 3.19 and the proposed analogs (Figure 5.7). 
• At both pH 5.0 and 7.5. 3.15b showed the lowest predicted solubility; 3.19 was 
predicted to be more soluble than 3.15b. and this is most likely as a result of its 
lower molecular weight. Expectedly. a similar trend is seen for the proposed 
compounds. whereby analogs of 3.19 are predicted to be more soluble than the 
corresponding analogs of 3.15b. 
41 At pH 7.5. the predicted solubilities of the proposed analogs were only slightly 
higher than those of the parent compounds. However. and as anticipated. there is 
a significant influence of pH on the predicted solubilities of the proposed 
compounds - the predicted solubilities were significantly higher at pH 5.0 than at 
pH 7.5. This is attributable to the fact that these compounds. being basic. would 
exist predominantly in their ionised state at lower pH levels, rendering them more 
soluble. Analysis on MoKa® indicated that compounds 5.8 - 5.15 are predicted to 
be >90010 ionised at pH 5.0. 
• The number of protonable centres was also found to influence this pH dependent 
solubility. For example. among the analogs of 3.19, the piperazinyl analogs 5.10. 
5.12 and 5.14 (which have two protonable centres) were found to have higher 
predicted solubilities than the amino-ethoxy anatog 5.8. This was dE!spite the fact 
that these three piperazinyl derivatives have higher molecular weights than 5.8. A 
similar trend was observed for the analogs of 3.15b, and both can be attributed to 
the pOSitive influence on solubility of the higher charge to mass ratio afforded by 
the di-protonation of the piperazinyl analogs. 
• The predicted logD7.s values of the analogs were somewhat higher than those of 
the parent compounds 3.15b and 3.19, with the piperazinyl analogs having higher 
logD7.S values than their amino-ethoxy counterparts. Whereas the predicted 
logDs.o values for 3.15b and 3.19 remained unchanged, the logDs.o values for the 
proposed analogs were significantly lower. with values ~ 3.1. 
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Fig. 5.8: Plots showing the propmed analog5 proje<:ted onto tile PLS modeh used to predict 
( .. co2 permeability and metabolic stability - the black dots represent the compounds 
comprising the model~' tfaini{'lg datil sets while Ihe yellow dols represent the test compou!'.ds· 
Ihe blue regions indicale iJcceptable predicted permeabihly/meto t>olic SI.1bili ly while the red 
7.one~ ind.c.l lt' pOOl predicted properties. 
• Prediction and interpretation o f (aco2 permeabi liry was essenlially qualitative. 
When projected 0 1'110 the two-dimensiona l PL5 pia l o f Ihe database of compounds 
used to generate the in-built (aco2 permeation model. all the compounds (along 
with chloroquine and amodiaquine) ~how acceptable (ac02 permeation - they fall 
w ithin the blue zone o f the plot (Figure 5.8). 
• Amodiaquine and chloroquine are predicted to have intermediate metabolic 
stability. falling somewhat between the blue and red zones on the PLS plot (Fig. 
5.8). However. the two are predicted to be more stable to metabo li sm than Ihe 
test compound s. 
• 3.1sb is predicted to be less stable to hepatic metabolism than 3.19. The proposed 
analogs are also shown to have relatively low predicted metabolic stabilities. 
particularly compound~ S. Il . 5.15 and 5.10. 
Site of metabol ism analysis was carr ied out on MetaSite® in an attempt to shed 
light on t he~ findings (Figure 5.9). 
Tl IS 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
'-H'" nfi IIV'" .", -f, -V<TI')N OF IN ,lUee) . ,)Ol5 I~ • ,~t IOtNTlflCA"-ION IN rRe. H S \XII J H SlJPlRI PR! )!C no 
PIIY~I<OCII[MI'_.·-. ANr J.r>Iv" p", _ 
l(r'0 ~~~~b~~ 
AMQ 
Fig. 5.9: Output from Met<lSite® showing the predicted sites of metabolism on the various 
analogs. The blue ring indiciltes the predicted main site of melCibolism; red and pink rings 
indicate other predicted possible sites of metabolism (the more intense the color. the more 
likely the site). 
• N-dealkylation of the nitrogen-containing side-chain is the principle route of 
metabolism for chloroquine and amodiaquine as predicted by MetaSite®. This is in 
agreement with reported experimental findings, with their main metabolites 
identified as N-desethylchloroquine and N-desethylamodiaquine, respectively 
[20.21]. N-oxidation of the quinoline nitrogen (highlighted by MetaSite® as a 
possible site of metabolism) does not seem to be a favoured route of metabolism 
for this class of compounds. 
• The main route of metabolism for 3.15b is predicted as being O-demethylation of 
the para-methoxy group on ring B - this group is absent in 3.19. O-demethylation 
on ring A and N-oxidation of the quinoline ring are the main routes of metabolism 
predicted for 3. 19, but these may not be as efficient as O-demethylation on ring B, 
and this is probably why this compound is predicted to be more stable to 
metabolism than 3.15b. 
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a N-dealkylation of the nitrogen-containing linkers was predicted as a possible route 
of metabolism for the proposed analogs. The piperazinyl-based linkers (present in 
5.10 - 5.15) appeared to be predicted as being particularly susceptible to N-
dealkylation. and is possibly why these compounds were predicted as being 
relatively unstable to metabolism. A combination of this and the additional 
possibility of O-demethylation on ring B for 5. n is probably why this compound 
was predicted to be the least stable of them all. 
a The amino-ethoxy linker (present in 5.8 - 5.9) appears to be somewhat less 
susceptible to N-dealkylation. and was not predicted as the primary route of 
metabolism for these compounds. which are among the relatively more stable 
analogs. 
In summary. compounds 3.15b and 3.19 showed poor predicted solubility profiles. a 
factor that could be detrimental to their potential oral bioavailability as well as their 
distribution once absorbed. They had acceptable predicted Cac02 permeation when 
compared to the reference compounds chloroquine and amodiaquine, though their 
metabolic stability was predicted to be lower. 
The proposed analogs had improved predicted solubilities relative to their parent 
compounds, particularty at lower pH. and this was a feature that could possibly be 
utilized during their solubilization for PK studies. The analogs also maintained 
acceptably high predicted Caco2 permeability. The main alert was their possible 
metabolic instability. primarily due to N-dealkylation of the nitrogen-containing linkers 
or O-demethylation of the ring B of the chalcone derivatives. 
The analogs were nevertheless synthesized for in vitro antimalarial evaluation. to 
establish if they retained antimalarial activity. In addition. experimental solubility 
determination and in vitro metabolism studies were also carried. and the results 
compared to those from the in silica predictions 
5.7 Synthesis and characterization of the proposed analogs 
5.7.1 Synthesis 
The hydroxylated enones (5.1 and 5.3) and chalcones (5.2 and 5.4) were intermediates 
in the synthesis of these compounds; the synthesis of these intermediates is depicted in 
Scheme 5.1. and involved the add-catalyzed Claisen-Schmidt reaction. 
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5.1: R = OCH3 (84%) 
5.3: R = H (76%) 
.\'" 
o OMe 
5.2: R = OCH3 (68%) 
5.4: R = H (59%) 
OMe 
Scheme 5.1: Reagents and conditions: (0 acetone. 5M HCI, rt. 24 hrs: (ii) 2',4'-dimethoxy 
acetophenone. 5M HCI. MeOH. 50 °e. 24 hrs. 
Vanillin or 4-hydroxybenzaldehyde was stirred in acetone (as reagent and solvent) in 
the presence of aqueous 5M HCI at room temperature for 24 hours. The crude 
product of the reaction was purified by silica column chromatography to furnish the 
pure products 5.1 and 5.3 in good yields. The synthesis of the chalcones 5.2 and 5.4 
involved the reaction of vanillin or 4-hydroxybenzaldehyde with 1.1 equivalents of the 
2' 4' -dimethoxy-acetophenone in methanol. in the presence of aqueous HCI as catalyst. 
The crude products were then purified by silica gel column chromatography to furnish 
the pure chalcone intennediates in average yields. 
Scheme 5.2 shows the synthesis of the target analogs 5.8 - 5.11. The required 
hydroxylated quinoline intennediates 5.5 and 5.6 were afforded by typical aromatic 
substitution reactions using the (modified) methOO reported by Singh et at 1971 [22]. 
Briefly. 4,7-dichloroquinoline was heated with excess ethanolamine or with 1 
equivalent of 1-{2-hydroxyethyl)piperazine in the presence of potassium carbonate to 
yield the target intermediates in moderate to good yield after purification by 
crystallization. 
The intennediates 5.5 and 5.6 were then coupled to either 5.1 or 5.2 to yield the 
target compounds 5.8 - 5. n. This coupling was achieved by applying the Mitsunobu 
reaction. a convenient, one-step SN2 reaction using 1.2 equivalents of 
triphenylphosphine (PPh3) and 1.2 equivalents of diisopropyl azodicarboxylate (DIAD) 
(Scheme 5.2) as described by Debaene et at 2007 [23]. 
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(iii) 
5-5(89%) 
(iii) 
Scheme 5.2: Reagents and conditions: (i) ethanolamine. 130 "C. 5 hrs; (ii) 1-(2-
hydroxyethyl)piperazine. K2C03• DMF. 80 "C. 24 hrs; (iii) 5.1. 5.2. 5.3 or 5.4. PPh3• DIAD. 
DCM. 0 °C - rt. 6 hrs. 
Table 5.1: Yields of analogs 5.8 - 5.11 
Compound code R Yield (%) 
5.8 CH3 73 
5.9 2',4'-diMeOPhe 60 
5.10 CH3 68 
5.n 2',4'-diMeOPhe 74 
The application of the Mitsunobu reaction avoided the need to initially and separately 
convert the hydroxyl group of the aminoquinoline intermediates into a good leaving 
group (such as a toluenesulfonyl or methanesulfonyl ester) prior to the SN2 reaction 
with 5.1 or 5.2. As detailed in the mechanism below (Figure 5.10). the hydroxyl group 
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is converted in situ into a good leaving group bearing a (positively charged) 
phosphonium species. 
The reaction begins with the nucleophilic addition of PPh3 to the diisopropyl 
azodicarboxylate to yield the charged spedes I that bears a nitrogen anion stabilized by 
the adjacent carbonyl group. This anion then deprotonates the hydroxy\ated 
quinoline. and the resulting alkoxide immediately attacks the positively-charged 
phosphorous atom. yielding a phosphonium derivative of the alcohol (II) and 
displacing the charged species III that also bears a nitrogen anion stabilized in the same 
way as the first. This SN2 reaction at phosphorous is driven by ionk attraction and the 
strong affinity between oxygen and phosphorous. 
The displaced anion is basic enough to deprotonate the phenolic hydroxyl group (of 
5.1 or 5.2), and the resulting phenoxide then attacks the phosphonium derivative II to 
yie\d the target compound and tripheny\phosphine oxide as a by-product, with the 
formation of the highly stable P=O double bond being the driving force for this 
reaction [24]. 
Figure 5.10: Proposed mechanism for the Mitsunobu reaction [24] 
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The synthesis of the proposed analogs 5.12 - SolS began with the synthesis of the 
piperazinyl intermediate 5.7 via an aromatic substitution reaction of 4.7-
dichloroquinoline and 6 equivalents of piperazine. in the presence of potassium 
carbonate. using the (modified) method reported by Singh et al. 1971 [22]. Purification 
by silica gel column chromatography afforded 5.7 in good yield. 
, -- ,~~', 
, , , 
5.13: R = OCH3 (66%) 
5.15= R = H (49%) 
Scheme 5.3: Reagents and conditions: (i) piperazine. ~C~. NMP. 135 "C. 4 hrs: (ij) 5.1. 5.2. 
5.3 or 5.4. HCHO. EtOH. reflux at 110 "C. 12 hrs. 
The Mannich reaction was then applied to furnish the target analogs using the 
(modified) method described by Chipeleme et al. 2007 [25]. This involved the 
refluxing of the appropriate phenolic intermediate (5.1 - 5.4) and 1 equivalent of 5.7 
in ethanol in the presence of 10 equivalents of aqueous formaldehyde for 12 hours. 
The crude products were then purified by silica gel column chromatography to afford 
the pure target compounds in average yields. which could be partly attributed to the 
fact that these reactions did not proceed to completion even with the use of a large 
excess of formaldehyde or after extended refluxing. 
A typical Mannich reaction usually involves an enolizable aldehyde or ketone. a 
secondary amine. formaldehyde (either as paraformaldehyde or as its aqueous 
solution) and a catalytic amount of add [24]. For the Mannich reaction on phenolic 
compounds (such as t~e one described above). the enolizable carbonyl compound is 
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replaced by the phenolic compound, and no external add catalyst is added: the acidic 
phenolic proton provides the required add catalyst. 
The proposed mechanism for this reaction is described below (Fig. s.n): 
R'X{R" R'X{R" -7, :!: H+ -71 
HO ~ iii 0 .. 
. Nl (V 0 V ~N'R N'R 
R' R" W -O)~ III 
R~~~2 
'-.I 
II 
Figure S.H: Proposed mechanism for the Mannich reaction of phenolic compounds 
As with the typical Mannkh reaction. this proposed mechanism involves the 
preliminary formation of an iminium ion intermediate (II); the reaction begins with the 
nucleophilic secondary amine attacking the highly electrophilic formaldehyde. A 
proton transfer yields the neutral intermediate I. which then undergoes add-mediated 
dehydration facilitated by the acidic phenolic compound. The resulting iminium 
intermediate II then undergoes nucleophilic attack by the charged phenolic 
intermediate III (which can be seen to act as a nucleophilic enolate species) to yield the 
intermediate IV. The dehydration and subsequent nucleophilic addition are driven by 
the elevated temperatures of the reaction. which is carried out under reflux conditions. 
A proton transfer, driven by the restoration of the aromatidty of the phenyl ring. 
finally yields the target phenolic Mannich base V. 
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5.7.2 lH-NMR analysis 
The lH-NMR spectra of the target compounds bore distinct features of the different 
components of these hybrid compounds, i.e. the quinoline ring. the amino-ethoxy or 
piperazinyl linker. and the enone or chalcone components. 
The spectrum for compound 5.9 is used here as an example for discussion. Features of 
this spectrum (FIg. 5.12) indude: 
• A distinct pair of doublets - the first appearing at approximately 6 8.57 ppm. and 
the second at approximately 6 6.48 ppm - each integrating for one proton and 
sharing a coupling constant of 5.3 Hz. These are signature signals corresponding to 
the quinoline protons H-9 and H-8. respectively. 
• The presence of another set of two distinct doublets. each integrating for one 
proton. lying in the region between 6 7 - 8 ppm and sharing a 3 J..trans coupling 
constant of between 15 - 16 Hz. These corresponded to protons H-a and H-b. and 
were diagnostic of the Cl-~-unsaturated system present in the chalcone component 
of the compound. 
• A triplet at approximately 6 4.4 and a quartet at approximately 6 3.7. each 
integrating for two protons and corresponding to the methylene protons (H-5 and 
H-6. respectively) of the amino-ethoxy linker. 
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8.57 d 5.3 H-9 
7.61 I d 15.7 H., 
7.39 d 15.7 H·b 
6.48 d 5.3 H·8 
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4.39 t HH 3.72 ! q H·6 
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Figure 5.12: 'H_N MR analysts o f compound 5.9 
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5.8 Results from the experimental determination of in siliro-predided properties 
5.8.1 Solubility 
To corroborate the in silica solubility predictions described above. samples of some of 
the synthesized compounds were submitted for the experimental evaluation of this 
property. These determinations were carried out by Roslyn Thelingwani in the 
laboratories of Prof. Conen Masimirembwa at the African Institute of Biomedical 
Sdence & Technology (AiBST) in Harare. Zimbabwe. 
Solubility was determined using a turbidimetric assay, which is a plate-based assay for 
determining aqueous solubility. It is based on the fact that. for any given compound. a 
predpitate begins to form when maximum solubility is reached, and this formation of a 
predpitate can be detected using UV-Vis spectrophotometry. 
Experimentally. concentrations of 0, 1. 2. 4, 6, 10. 20. 30. 50. 70. 90 and loc:JfJM are 
prepared for each compound by dilutions in aqueous buffer of stock solutions 
prepared in DMSO. These dilutions are effected such that the final concentration of 
DMSO does not exceed 2%. In order to determine the pH-dependent solubilities of 
ionizable compounds. the assay may be performed at different pH simply by altering 
the buffer used. 
These solutions are inrubated at a given temperature, in this case 37°C. and their 
absorbances determined at 620 nm. Plots of absorbance versus concentration are then 
used to determine the concentration at maximum solubility. which is the solubility 
when predpitation begins to ocrur. This is read off at the point of inflection on the 
plot. i.e. the point at which absorbance begins to rise with increasing concentration 
rather than remain constant and relatively negligible, and which indicates that 
maximum concentration has been reached (and that surplus compound is predpitating 
out. leading to the observed rise in absorbance). 
The results for the solubility experiments at both pH 4.0 and physiological pH (pH 
7.4) are given in Table 5.2. The following guide was used in the ranking of the 
compounds: <10 = insoluble; >10 - 20 = mild; >20 - 50 = moderate; >50 -100 = 
soluble; >100 = highly soluble. Two controls were used: nidosamide (insoluble) and 
paracetamol (soluble). 
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Tabl(! 5.2: R(!sulH from the experimental 50Iubility de!(!rminllliOIH al pH 4 and pH 7 
Compound Solubility Solubility pH InlefJKelalion pH 4 (PM) 7.4 (PM) 
Parac(!lamol >100 >100 Highly Soluble 
-
- ---
_._-_. 
-
Nidosami(j(! 6 10 Insoluble 
.- ,------_.-
----
--_._------
-- -- -- --_. 
-
-
-
- - -
3. 1Sb 4 4 Insolubl(! 
-
- - - -
3.19 20 70 Mild at pH 4 and sotub~ at pH 7.4 
-
.-.. 
S.B 90 90 Soluble at both pH 7.4 lind pH4 
.-- _. 
----., 
--
-
5_9 >I(]() 20 Highly '>Oluble lit pH 4 ilrld mild al pH 7.4 
-- - ------
- --------
--
.5.10 >100 JO Highly soluble at pH 4 lind insoluble <II pH 7.4 
-
-
- -
. .. - .. _ .. _----
-- -
-
..... 
- - - - - ---
5. 11 >100 I Highly soluble at pH 4 lind in so luble al pH 7.4 
- I- ---- - - --_. 5.12 > 100 20 Highly soluble al pH 4 lind insoluble at pH 7.4 
-
- -- -
-
-
5.13 90 20 Soluble al pH 4 and in solubla II! pH 7.4 
- -
- - -
- -
5.14 90 20 Soluble- lit pH 4 and mild <II pH 7.4 
-
- - - - --- - - --.. --.. --
-
5.15 90 20 SoIubla at pH 4 and insoluble at pH 7.4 
The expenmental re~ult~ show ~imilar lrend~ 10 those observed from l he in silica 
predictions. 
• Compound 3. 15b was poorly ~Iuble in aqueous media, and this solubi lity was not 
enhanced al lower pH: 3. 19 was more mluble than 3.1Sb. though Ihis solubility 
appeared to be lower at pH 4.0 than at pH 7.4. Th€ possible reasons for thi5 are 
not clear. 
• With the exception of 5. 11 , the analogs showed slightly improv€d solubilities at pH 
7.4 relative to 3.1 9, though these solubiiities were still poor. However. al l the 
analogs ~Ilowed remarkably higher m lubilities at pH 4.0. which was to be expected 
as these compounds would be ionized at Ihis pH. Compound 5.8. which had the 
lowest molecular weight of all t he analogs. showed a similarly high solubility at pH 
7.4 as it did at pH 4.0. The other analogs .howed a significantly higher solubility at 
low pH than they did at pH 7.4. 
The tentative conclusions that were drawn from the in sllico solubility predictions were 
therefore supported by these experimental remits. 
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5.8.2 Metabolism and metabolic stability 
To corroborate the site-of-metabolism and metabolic stability predictions. samples of 
some of the synthesized compounds were submitted to the laboratories of Prof. Susan 
Charman at the Centre for Drug Candidate Optimization (COCO). Monash University. 
Australia, for in vitro metabolism studies. The aim of these studies was to determine 
the in vitro metabolic stability of 3.15b. 3.19, and 5.8 - 5.15 in both human and mouse 
liver microsomes as a preliminary indication of their lik.ely in vivo metabolic dearance. 
and to identify potential metabolic products for comparison with the predicted routes 
of metabolism of these compounds. 
The metabolic stability assays were performed by separately incubating the test 
compounds at 37°C (in duplicate. substrate concentrations 1 i-IM) with human or 
mouse liver microsomes (O.4 mg/ml protein concentration). The metabolic reaction 
was initiated by the addition of an NADPH-regenerating system (containing 1 mg/ml 
NADP, 1 mg/ml glucose 6-phosphate. 1 U/ml glucose 6-phosphate dehydrogenase) 
and quenched at various time points over the incubation period by the addition of 
acetonitrile. NADPH is the cofador required for CYP450-mediated metabolism. 
Additional samples with the dual cofadors NADPH and UDPGA (the latter being the 
cofactor for glucuronidation) were also induded in the incubations for the qualitative 
assessment of the potential for glucuronide formation. Control samples (containing 
neither NADPH nor UDPGA) were induded to monitor for potential degradation in 
the absence of cofactors. 
The concentrations of the substrates after the various periods of incubation were 
quantified by lC-MS against standard CUlVes prepared in blank. microsomal matrix. The 
MS scan data from the metabolic stability assay of each compound was screened for 
the presence of fragments corresponding to putative metabolites; data acquisition was 
conducted in MS scan mode (spectra acquired from 100 to t<XJO Oaltons). It should be 
noted that the identities of the putative metabolites were not confirmed by dedicated 
MS-MS experiments. 
The results for the in vitro metabolism studies are summarized in Table 5.3. Two peak.s 
were observed for 3.19. 5.10 and 5.n during chromatographic lC-MS analysis. most 
lik.ely indicating ds - trans isomerism occurring under assay conditions. The rates of 
degradation for each individual peak were therefore determined. 
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Table 5. 3: Results from the in vilrometabolism studies 
Compound 
3.15b 
-
Peak I 
3.19 
Peak 2 
5.8 
5.9 
Peak I 
5.10 
Peak 2 
Peak 1 
5. 11 
Peak 2 
5.12 
5.13 
5.14 
5 .15 
Chloroquine 
o OMe 
Meo~
;.J Vu ~N ", & M. 
N 
o 
Meo:cr"/'-I R 
o "-
~ 5· I O&S·ll ( ) 
N 
Jy--~JlJ-CI 
R 
Degrildation 
half-ti fe (min) 
Human Mouse 
. 51.1 56.S 
Microsome·Predicted 
Extraction ralio (EH) 
Human Moo .. 
0.65 0.57 
~- . 
. _ .
--
7.4 10.8 0.93 0.88 
. __ . 
9.1 6.2 0.91 0.92 
---- -
CH, 10.5 13.4 0.90 0.85 
.... -_ .•. -
_. ---- . .. _ ...... -
2' .4'. 
diOCHl- 17.5 12.7 0.B5 0,86 
.. ' 
-
14.2 6.7 0 .8'/ 0.92 
CH, -- --
9. 8 5.6 0.91 0.93 
-
-- - _._-_._-_.- . -
2' .4'- 11 .5 9. 8 0 .89 0.89 
diOMe- -~- . 
Ph. 93.2 149.8 0.51 0.]4 
OCH, 16.9 14.0 0.85 0,84 
_. 
OC H) ]7.0 11 .8 0.72 0.B7 
- - --
H 7.5 15.0 0_93 0.84 
. 
-
-
. . 
-
H 58.6 45.4 0.62 0.63 
-
f----
-
>250 177.0 <0.28 0. ]1 
,,', ' \_D 
Melaboliles detected 
P+16 
Not Dett'<:ted 
P-2 18 
P+16 (x2) . P+]2 (x2). 
P-14. P+16+176 
- P·14. P·2IB 
--
P+ I6 (x4) . P-14 (x2) 
P-340 
- --.. - ---_ ... _--
P+16. P·204. P+176 
-
-
P·14 (x2), P-326. P+176 
P+16. P_T74. P+176 
P+16 (x2). P-14 . P-296 
P+176 
.- -
No! Undertaken 
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With respect to metabolic stability. the compounds examined exhibited varying 
degradation half-lives in human and mouse microsomes. However. all of the 
compounds exhibited similar extraction ratios (EH values) in both human and mouse 
liver microsomes; EH values take into account the different liver masses (g liver/kg body 
mass) and hepatic flow rates (mL/min/kg) of both species. and therefore the similarities 
in these values suggested that there are no significant inter-species differences in the 
relative rates of metabolism of these compounds. 
Most of the compounds exhibited high EH values (>0.7). suggesting notable 
susceptibility to hepatic metabolism. This is particularly apparent when compared to 
the relatively low values for chloroquine (::;;0.31). and is in agreement with the 
predicted metabolic stability of this set of compounds. which were predicted to be less 
stable than chloroquine to hepatk metaboUsm. Notably. 3.l5b and 5.15 had 
intermediate EH values. as did the isomer of 5.11 corresponding to peak 2. indicating 
relatively better metabolic stability. 
The majority of the test compounds showed no measurable degradation in the 
microsomal matrix devoid of cofactors (Le. controls). suggesting that there was no 
major non-cofactor dependent metabolism contributing to their overall rate of 
metabolism in liver microsomes (i.e. metabolism by enzymes other than hepatic 
cytochromes and transferases). The only exceptions were 3.19 (peak 2) and 5.10 (peak 
2). both of which demonstrated apparent non<ornctor dependent degradation (which 
was not observed for the other isomer). potentially indicating a stereo-specific process. 
With respect to routes/sites of metabolism. the metabolite profiles of all the examined 
compounds were found to be similar across the two species tested. Oxygenation. 0-
demethylation and N..cfealkylation appeared to be the predominant pathways. This 
was remarkably consistent with the site-of-metabolism predictions derived from 
MetaSite® (Figure 5.9). where these three were the major routes of metabolism 
predicted for this set of compounds. However. there were some differences between 
the predicted routes of metabolism and detected metabolites for some of the 
compounds; for example. no predicted O..cfemethylation metabolites were detected 
for 3.15b and 5.8. and no N..cfealkylation metabolite was detected for 5.9. 
For compounds with the piperazine linkers (5.10 - 5.15) a common metabolite with 
m/z of 248 Daltons was found. consistent with N..cfealkylation of the side chain from 
the piperazine. For 5.8, N..cfealkylation of the amino-ethoxy linker was observed, 
resulting in the generation of a metabolite with m/z 179 Daltons; this was not 
observed for 5.9, which also bears an amino-ethoxy linker. The putative metabolites 
from these N..cfealkylation reactions are shown in Figure 5.13. 
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Figure 5.13: Figure showing the structures of the putative metabolites of 5.10 - 5.15 (A) and 5.8 
(8) 
The potential of the test compounds to undergo primary glucuronidation was assessed 
in the microsomal incubation by the addition of the cofactor UDPGA. There was no 
major increase in the rate of degradation of 3.15b. 5.8. 5.9 and 5.11 (or chloroquine) 
in microsomal samples containing NADPH and UDPGA relative to NADPH alone. 
suggesting that these compounds were not susceptible to primary glucuronidation in 
the microsomal test system. For 3.19 and S.lO. the impact of UDPGA on the overall 
rate of metabolism could not be assessed. as the rate of NADPH-dependent 
degradation alone was too rapid. For these two compounds. there were no putative 
metabolites detected having molecular weights consistent with glururonidation. 
However. there was evidence of primary glucuronidation for S.12 - 5.1S in the 
microsomal assay. where there was an increase in the relative rates of degradation of 
test compounds in the presence of UDPGA and/or the detection of a putative 
metabolite with a molecular weight consistent with glucuronide conjugation (P+176). 
All these compounds bear a free phenolic -OH group. and it therefore is somewhat 
expected that they are substrates for glucuronidation. This route of metabolism was 
not predicted by MetaSite®. which only predicts cytochrome-mediated phase I 
metabolism. 
In summary. there was no evidence of significant inter-species differences in the relative 
rates of metabolism of these compounds. However. most of the compounds exhibited 
high EH values (>0.7). suggesting notable susceptibility to hepatic metabolism. 
Oxygenation. O-demethylation and N-dealkylation appeared to be the predominant 
metabolic pathways. which was consistent with the site-of-metabolism predictions 
derived from MetaSite®. There was also evidence of primary glucuronidation for 5.12 
-5.15. 
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PHYSICOCHEMICAL AND ADME PROPERTIES 
5.9 In vitro antimalarial assays 
5.9.1 Results and disrussion 
Analogs 5.8 - 5.15, along with the phenolic intermediates 5.1 and 5.2 and the 
chloroquinoline intennediates 5.5 - 5.7 were tested for in vitro antimalarial activity as 
described in Chapter Four above. The results of these assays are presented in Table 5.4 
and discussed below. 
Table 5.4: ICso values of the analogs 5.8 - 5.15 as well as selected intermediates against the 
010. Dd2 and W2 strains of P. fa/dparum 
o 
Meo~ 
HO ~ 5.1 
o 
Meo~R 
A) L 5·8&5·9 
fr ~~I 
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DIO 1(-;0 Dd2 ICso w2 IC';I} Compound code R ("M) (~M) (~M) 
5.1 
-
>20 >20 >10 
---
-
-
5.2 
-
5.3 7.3 >10 
5.5 - 2.6 1.0 0.2 
--
-
-----
5.6 - 5.2 3.8 1.0 
-
5.7 - 0.7 0.9 0.3 
----
----
5.8 CH, 1.0 1.5 0.1 
-
-
- _._. 
5.9 2'.4' ·diOC H)·PIle 0.8 1.0 0.4 
5.10 CH, 1.2 1.1 0.5 
- -----
5. 11 2'.4' ·diOMe·Plle 1.2 0.5 0.6 
_.-
-
5.12 OCH j 1.0 1.7 0.5 
- -
5.13 OCH, 0.5 0.5 0.4 
5.14 H 1.7 3.1 0.7 
5.15 H 0.6 0.5 0.3 
(3.19) 
-
0.8 0.7 ND 
. 
-
(3.tSb) 
-
0.04 0.07 0.09 
-
(CQ) 
- 0.OJ7 0.097 0.069 
NB: the~ are <:lVerage valu~ from two independent determinations, each carried 01.11 in duplicate 
Tile hydroxylated €'none intermediate 5.1 showed negligible anti malarial adlvity in 
vitro across all three st rains at concentratiom ~IO IJM. However, the chalcone 
intermediate 5.2 showed moderate antimalarial adivity against DID and Dd2 P. 
faldparum, but showed negligible activity against W2 P. ialdparum even a t 10 pM 
concentration, 
The chlo roquinoline-based intermediates 5.5, 5,6 and 5.7 showed antimalarial activity 
in vitro. with 5.7 showing sub-micromolar ICso valUes against all thr~ strains of P. 
faldparum. 
All Ihe target analogs exhibited notable antimalarial activity, with ICso values in the 
lower micro-molar to mid nanD· molar range, Thi~ indicated that replacement of the 
triazole linker in 3.15b and 3.19 with the selected nitrogen·containing linkers was 
aS50ciated with retention of antimalarial activity, though none were as active as 3.15b. 
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CHAPTeR FIVE: INTEGRJ\TION OF IN :,-/LiCO rooLS IN THE IDENTIFICATION OF IN VITRO HITS WITH SUPERIOR PREDICTED 
PHYSICOCHEMICAL AND ADME PROPERTIES 
The related analogs 5.13 and 5.15 were the most active of the analogs: both were 
chalcone derivatives with piperazinyl linkers. and had lCso values between 0.3 - 0.6 
11M against all three strains of P. faldparom. 5.11 was also quite active. with mid-
nanomolar ICso values against the CQR Dd2 and W2 P. faldparom strains. 
These results demonstrated that these compounds were indeed viable candidates for 
preliminary PK profiling and in vivo antimalarial assays. However. due to time and 
resource constraints. only two compounds were selected for this: 
• Compound 3.15b. the most active of the compounds so far synthesized and tested. 
• Compound 5.13. an analog of 3.15b. and which was one of the more active 
analogs identified. 
In anticipation of this exercise. both compounds were evaluated for their cytotoxicity 
against the Chinese Hamster Ovarian (mammanan) (en nne. No cytotoxidty was 
observed at the highest concentration (100 11M) tested. 
Furthermore. there was the added possibility of tracking one of the predicted 
metabolites of 5.13 during the PK studies. Intermediate 5.7 was predicted by 
MetaSite® as. the main metabolite of 5.13. and was also identified during in vitro 
metabolism studies as a putative metabolite arising from N-dealkylation of the 
piperazinyl linker (see section 5.8.2). The fact that it exhibits notable in vitro 
antimalarial potency implies that this intermediate/metabolite could very well 
contribute to any observed in vivo antimalarial activity of 5.13. and thereby offset any 
potential liabilities of the compound arising from its susceptibility to metabolism via 
this route. Using the synthesized 5.7 as reference. it would be possible to follow its PK 
profile alongside that of 5.13 (following the administration of 5.13 only). and in this 
way provide an additional dimension to the PK profiling of 5.13. 
5.9.2 Summary and condusions 
3.15b and 3.19 were selected for structural modification with the aim of identifying 
analogs with improved solubility and which retained antimalarial potency. Eight 
analogs were proposed. and these were characterized in silico for selected 
physicochemical and ADME parameters. These analogs were predicted to have 
improved solubilities relative to the parent compounds, particularly at low pH: they 
retained acceptable predicted Cac02 permeabilities. but were identified as possible 
substrates for N-dealkylation by hepatic cytochromes. 
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These proposed analogs were then synthesized and tested. and were found to exhibit 
notable in vitro antimalarial activity. 5.13 and 5.15 were the most active of the 
analogs. 5.7. an intennediate in the synthesis (and a predicted metabolite) of some of 
the analogs was also found to exhibit notable antimalarial activity in vitro. 
Compounds 3.15b and 5.13 (Figure 5.14) were thereafter selected for preliminary PK 
profiling and in vivo antimalarial testing. The possible simultaneous PK profiling of 5.7 
alongside 5.13 was an additional reason for the selection of 5.13. This is reported and 
discussed in the following Chapter. 
o OMe OMe 
OMe 
Figure 5.14: Figure showing the structures of the two compounds selected for pharmacokinetic 
profiling and in vivo antimalarial efficac  studies 
The proposed analogs were by no means exhaustive. but represented analogs that did 
not represent significant deviations from the molecules known to be active. and were 
therefore more likely to retain activity. They represented a small range of compounds 
that could be conveniently synthesized. and which offered possible improvements on 
certain physicochemical and/or ADME properties of the parent compounds, 
particularly solubility. In addition. they opened up possibilities for even further 
derivatization in future, as highlighted in Figure 5.15. 
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Figure 5.15: Figure showing a few examples of possible further derivatization of some of the 
analogs already synthesized 
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5.10 Medlanistic studies 
5.10.1 Results 
Analogs 5.8 - 5.15. along with the chloroquinoline intermediates 5.5 and 5.7 were put 
through the same mechanistic studies as described in Chapter Four above. The results 
of these assays are presented in Table 5.4 and discussed below. 
Compounds 5.8 - 5.15 were all very potent inhibitors of J3-hematin formation, more 
potent than chloroquine. They all had comparable. sub-micromolar ICso values, with 
compounds 5.11 and 5.15 (which were some of the more active of these analogs in 
vitro) having the lowest values of 0.2 equivalents. This indicates the notable potential 
of these compounds to inhibit hemozoin formation. and suggests that this could be a 
primary mechanism of antimalarial action of these compounds. The intermediates 5.5 -
5.7 showed only moderate inhibition of J3-hematin formation. 
The analogs showed moderate to poor inhibition of Faldpain 2 relative to E64: 
analogs 5.9, 5.11. 5.13, 5.14 and 5.15 had lower micromolar IC50 values. while the 
other compounds tested did not show appredable Faldpain 2 inhibition even at a 
concentration of 50 f.LM. The relatively low potendes of these compounds as Faldpain 
2 inhibitors suggests that this is not the primary mechanism of antimalarial action of 
these compounds. though inhibition of the enzyme may still contribute to the overall 
observed antimalarial activity of some of them. 
These analogs tested were poor inhibitors of sorbitol-induced lysis. with 5.12 showing 
the highest % inhibition of only 17%. This would discount inhibition of N PPs as a 
mechanism of action for these analogs. 
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Table 5.5: Results from the mechanistic studies 
0 
ME'O~ 
HO 5.1 
0 OM, 
Meo~ 
I"", I"", 
HO ;'2 OMe 
o 
MeO~R 
oN 
l 5.10 &5.11 
c") 
N , 
~ ~~CI 
HO....., 
"'Nil 
en ~" h a 
,., 
OH 
" ( c") N C) N ro Co "",.. h (I N I (1 ,., 
, .6 
(ompound (I-hematin inhibit ion Falcipai n-2 Inhibition % age Sorbitol-
• induced hemolysis wd, ( [(0;0) ' 1(0;0 ( IJM)~ inhibition.' 
5.5 
· 
4.9 >50 0.9 
--- ~.- - --- -
5.6 
· 
3.9 >50 NO 
5.7 
· 
'.2 »0 5." 
-------
-_._-- -
5.S CH, 0 .6 >50 12.3 
5.9 diMeO·Phe 0.3 22.9 NO 
5.10 CH:; 0.5 >50 ND 
-
5.11 diMeO·Phe 0.2 11 .7 NO 
5.12 OCH, 0.5 >50 16.8 
5 .13 OCHi 0.3 9.1 3.9 
-.- . 
._. -
- - - ---- --
---..... -.• 
--- --
.- - --_._-_ .. -
5.14 H 0 .5 29.9 11 .6 
5.15 H 0 .2 10.0 NO 
-
.- --- ---
- -
CQ - 1.91 - . 
-- --- -
' 64 - . 0.055 -
"; The ICso1 are average~ 01 tnpitcale detenmnatlons and are n"ported In equlvalenl~ of tne drug relatIve 10 
hematin. 
b: fhe IC!(,S are avel'i)ges o f c!l.plicale determinatiom and are reported in 11M. 
~: Percelllage inhibition of sorbitol·induced Iy~is by the test compound~ at a coocenlr",ion of 10 /-1M. 
ND: Not delermif'l!d 
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PHYSICOCHEMICAl AND ADME PROPERTIES 
5.10.2 Summary and condusions 
The results above suggest that inhibition of hemozoin formation is likely to contribute 
substantially to the observed anti plasmodial activity of analogs 5.8 - 5.15. These 
analogs were all more potent than chloroquine at inhibiting i3-hematin formation. This 
would not be surprising as these analogs also contain the chloroquinoline moiety. 
Inhibition of Faldpain 2 could also contribute to a limited extent to the overall 
obsetved antimalarial activities of these compounds, while inhibition of parasite-
induced transport channels does not appear to be a notable mechanism of action for 
these compounds. 
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CHAPTER SIX 
PHARMACOKINETIC AND IN Vil-U ANTIMALARIAL EFFICACY SlUDIES 
6. t Preamble 
This chapter contains the work done to address the fourth and final spedfic aim of the 
study, which was: To elucidate the pharmacokinetic profiles and evaluate the in vivo 
antimalarial efficacy of the most promising compounds using the mouse model. 
This chapter therefore reports the pharmacokinetic profiling and in vivo antimalarial 
assays of the two compounds identified in Chapter Five. After brief introductions, the 
pharmacokinetic analysis and in vivo antimalarial assays of 3.15b and 5.13 are 
described. and the results discussed. 
6.2 The use of animal models for preliminary PK and efficacy investigations 
The use of laboratory animals for preliminary pharmacokinetic and efficacy 
experiments is generally carried out as part of the pre-clinicaI drug development 
process. Preliminary pharmacokinetic experiments are aimed at investigating the time 
course of the test compound in a living organism. In other words. such studies 
investigate the influence of physiological and anatomical factors on the disposition of 
the test compound after its administration to a living organism. In vivo efficacy studies 
aim to demonstrate the ability of the test compound to exert its anticipated 
pharmacological effect in an appropriate disease model under the influence of the 
physiological and anatomical factors alluded to above. Other effects of the test 
compound. such as toxicity and carcinogenicity. may also be investigated through such 
studies. 
The overall aim of these studies is to serve as an aid in assessing the potential of the 
test compound to exhibit acceptable pharmacokinetic. pharmacodynamic and toxicity 
profiles should they be administered to human beings. and is almost invariably a 
procedural and ethical requirement before any clinical testing may be allowed to 
proceed in humans. 
The murine malaria disease model has been extensively used for in vivo antimalarial 
efficacy testing. and this was the model applied in this study (section 6.6). Preliminary 
PK profiling of the two compounds was also carried out in mice. and was done prior 
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to the in vivo efficacy testing. In this way, the results from the PK studies were 
available to establish the ability of the compounds to access systemic circulation after 
administration and the best formulation to use for the in vivo efficacy studies, as well 
as to guide in the interpretation of the results from the various dosing regimens to be 
used during the in vivo efficacy studies. 
6.3 Formulations 
As mentioned in section 5.5 (Chapter Five), some of the general strategies for 
improving the oral bioavailability of a compound involve either the use of appropriate 
formulations and/or the rational structural modification of the compound. Structural 
modification as a strategy has been discussed in Chapter Five. The use of formulations 
is introduced below. 
In PK and in vivo experiments. the formulation of test compounds (Le. the way the 
compound is prepared for administration) is an important consideration. For example. 
a study of the in vivo efficacy of some endoperoxide antimalarials in murine and 
simian (monkey) models demonstrated significant differences in the efficacy of some of 
the test compounds (ranging from curative to negligible activity) arising from the 
different formulations used in the study. The compounds were administered either as 
simple water solutions, as water solutions with 10% DMSO as co-solvent. as oil 
solutions (e.g. in sesame oil). and as formulations incorporating gelatin or 
carboxymethylcellulose as a standard suspending vehicle (SSV). The differences in the in 
vivo efficacies observed were linked to the varying levels of bioavailability afforded by 
the different formulations [1]. 
Ideally, compounds are best administered as solutions in water/aqueous media. Highly 
water soluble compounds therefore pose no formulation challenges as they can be 
prepared as simple solutions in water or normal saline for parenteral and/or oral 
administration. 
Adjustment of pH can be used to render poorly soluble but ionizable compounds 
soluble in appropriately buffered aqueous systems. For example. basic compounds such 
as compound 5.13 can be prepared in appropriate buffer solutions of low pH in which 
they become protonated/charged, thereby rendering them more soluble in aqueous 
media. This is a recognized strategy for the formulation of hydrophobic but ionizable 
compounds. with the pH range of 4.0 - 9.0 being regarded as acceptable for routine 
discovery in vivo studies [2,3]. Compound 5.3 was therefore to be formulated in 
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isotonic sodium acetate buffer pH 4.0 for PK and in vivo studies; this buffer has been 
safely and successfully applied for in vivo experiments in mice. rats. dogs and monkeys 
[4]. For comparison. 5.13 would also be formulated in water with lO% DMSO as a 
water-miscible organic co-solvent. 
For poorly water-soluble compounds that are non-ionizable within the pH range 
appropriate for in vivo studies (such as compound 3.l5b). the use of mixed-phase 
formulations is an additional approach available for their formulation. These are lipid-
based formulations. which have long been recognized as' alternative strategies for the 
delivery of lipophilic drugs with aqueous solubility and oral bioavailability challenges 
[5]. Many lipid-based formulations. such as SMEDDS (self-micro-emulsifying drug 
delivery system) and Pheroid formulations. are essentially stable oil-in':water (o/w) 
micro-emulsions - micro-droplets of a lipid phase (into which the lipophilic compound 
is entrapped) dispersed within an aqueous phase [5-7]. 
The Pheroid formulation (developed by the Department of Pharmaceutics. North-West 
University. South Africa) is a stable sub-micron emulsion composed of mainly ethyl 
esters of plant and essential fatty acids such as linoleic acid. linolenic acid. and oleic 
acid. emulsified in water saturated with nitric oxide (NO); the lipid droplets into which 
the hydrophobic compound is entrapped tend to be within the nano- to micro-me.ter 
size range [7.8]. On the other hand. the SMEDDS formulations consist of an oil phase 
(e.g. sesame oil. linoleic acid or its ethyl ester) dispersed as a micro-emulsian in an 
aqueous phase; these emulsions are stabilized by the combination of a surfactant. 
principally Tween 80. and a co-surfactant such as a PEG 400 or short chain alcohol 
(e.g. ethanol) [6.9]. 
These formulations enhance the oral absorption of highly lipophilic compounds by 
presenting the compound in a dissolved form (within the lipid droplets). and. as a 
result of the small droplet size and large number of droplets. concurrently providing a 
large interfacial surface area for drug release and absorption [6.7]. In addition. the 
specific components of some of these formulations may promote the intestinal 
lymphatic transport of drugs possibly by increasing membrane fluidity. thereby 
fadlitating trans-cenular absorption; they may also open tight junctions to allow para-
cellular transport [7.10]. Some formulations may interact with the transport and 
metabolic processes of the intestinal cells. thereby influencing drug uptake. efflux. 
disposition and the formation of metabolites within these cells [lO]. Notably. the use 
of formulations also enables the parenteral (IV) administration of lipophilic compounds 
that could otherwise not be administered by this route. 
ERIC M. GUANT AI - Ph.D THESIS 2010 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
In this regard. the Pheroid formulation (kindly provided by the Department of 
Pharmaceutics. North-West University. South Africa) and the SMEDDS formulation 
were used in the preparation of the compound 3.15b for in vivo evaluation in this 
study. 
In summary, for the preliminary PK studies, compound 3.15b was separately 
formulated in Pheroid and SMEDDS formulation as well as in water with 10% DMSO 
as co-solvent. Compound 5.13 was formulated in isotonic sodium acetate buffer pH 
4.0 as well as in water with 10% DMSO as co-solvent. In this way, the bioavailability 
results obtained for each compound using the various formulation strategies could be 
compared, and the most appropriate formulation strategy (I.e. the one affording the 
best oral bioavailability) would then be applied for the dosing of the compounds 
during the in vivo efficacy studies. 
6.4 Pharmacokinetic studies 
Pharmacokinetics (PK) is the study of the time course of the disposition of a drug 
within the body. This is based on determinations of the drug concentration in 
blood/plasma at different time points after administration of a drug. In general. it is the 
total drug concentration of the drug in plasma that is considered. and this is a 
combination of the fraction of the drug that is bound to plasma proteins and other 
blood components. as well as the free (unbound) fraction [11]. 
When a drug enters the body, several processes begin to almost simultaneously act on 
the drug; specifically. these processes are absorption. distribution. metabolism 
(biotransformation). and elimination/excretion (ADME) [11.12]. Therefore, the time 
course of a drug (i.e. its pharmacokinetics) is a reflection of the outcome of these 
processes on the drug after its administration. 
Absorption is the movement of a drug from its site of administration into the central 
compartment (the blood). and the extent to which this occurs [12]. For example. a 
drug administered orally must traverse the GI mucosa to reach the blood; drugs 
administered topically must get past the skin barrier (epidermis and dermis). 
Absorption after parenteral administration is somewhat simpler: after intramuscular 
(1M) or sub-cutaneous eSC) administration. absorption involves simple diffusion along 
the concentration gradient from site of administration to the blood; intravenous (IV) 
administration circumvents any need for absorption as the drug is directly introduced 
into the blood [11.12]. 
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Once in the blood, the drug exists in equilibrium between the free (unbound) fraction 
and the fraction bound to blood components. principally' plasma proteins. The drug 
then distributes into the. interstitial/intercellular and intracellular compartments of 
tissues. The extent to which a drug distributes into the tissues is dependent on both 
physiological factors (e.g. tissue perfusion and capillary permeability) and the drug's 
physicochemical properties (mainly its lipophilicity). Initially, the liver. kidney and 
other well-perfused organs receive most of the drug. whereas delivery to musde, most 
other organs. the skin. and fat is slower and may take several hours. Only the free 
(unbound) fraction of the drug in plasma is available for distribution. and therefore 
one of the more important determinants of blood-tissue partitioning is the binding 
affinity of the drug to plasma proteins relative to tissue membranes and 
macromolecules [11.12]. 
Metabolism, by and large. generates more hydrophilic products (metabolites) of drugs 
and other xenobiotics. and in this way facilitates their more effident excretion from the 
system in urine. This may be by the introduction or revelation of polar groups on these 
molecules in what is traditionally termed as phase I metabolism, or by the covalent 
conjugation of these molecules (or their phase I metabolites) to highly hydrophilic 
endogenous entities in what is referred to as phase II metabolism. Phase I metabolism 
mainly involves oxidation. reduction and hydrolysis reactions mainly carried out by 
enzymes of the cytochrome P450 family. Phase II metabolism usually leads to the 
formation of glucuronide. sulfate, glutathione, acetate or amino-add conjugates by the 
action of the relevant transferase enzymes. The enzyme systems involved in the 
biotransformation of drugs are localized primarily in the liver. although every tissue 
examined has some metabolic activity, including the Gl tract. kidneys. and lungs. Phase 
I metabolism usually results in loss of pharmacological activity of a drug, though in 
some cases the resulting metabolites may acquire or retain pharmacological activity 
(e.g. in the case of pro-drugs and active metabolites). or even exhibit toxic or altered 
pharmacological activity [11.12]. 
Drugs are eliminated from the body either unchanged or after their conversion to 
metabolites. The kidney is the most important organ for excreting drugs and their 
metabolites. and eliminates polar compounds more efficiently than substances with 
high lipid solubility. Upophilic drugs tend to be reabsorbed quite effidently by the 
kidneys. and it is for this reason that they are not readily eliminated until they are 
metabolized to more polar compounds. It is also noted that only the unbound fraction 
of the drug in plasma is available for renal dearance, and hence drugs with high plasma 
protein binding tend to be excreted relatively slowly by the kidney [11.12]. 
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6.5 Preliminary PK profiling of compounds 3.15b and 5.13 
As described in Chapter Five. compounds 3.15b and 5.13 were selected for preliminary 
PK profiling and in vivo antimalarial testing. Compound 3.15b was the most active 
target compound so far identified; compound 5.13 was one of the more active analogs 
of 3.15b. had a significantly improved predicted (pH-dependent) solubility relative to 
3.15b, and was a potent inhibitor of hemozoin formation. The possible simultaneous 
PK profiling of 5.7. a predicted metabolite of 5.13. was an additional reason for the 
selection of 5.13 for these studies. 
Briefly, the intention was to formulate the selected compounds appropriately. dose 
them individually (orally and/or otherwise) to healthy mice and determine the 
circulating concentrations of the compounds at different time points over a sufficient 
duration of time. The concentration-time profiles thus attained would enable a 
qualitative analysis of the absorption and elimination patterns of the two compounds. 
as well as a quantitative estimation of such parameters as half life (tlh). maximum 
concentration (Cmax). and time to maximum concentration (Tmax). 
These results would also guide in the selection of appropriate formulation for each 
compound in the subsequent in vivo efficacy studies. and in the interpretation of the 
results from these assays. 
6.5.1 Analytical methodology 
The anticipated PK studies were envisaged to proceed via the following broad steps. 
• Dosing of the mice via the appropriate route(s); 
• Sampling of blood from the dosed mice at appropriate intervals; 
• Liquid-liquid extraction to extract the compound from the blood plasma (an 
aqueous medium) into a suitable organic solvent; 
• Determination of the concentration of the compound in the organic solvent; 
• Calculation of the initial concentration of the compound in the blood sample, 
which would correspond to the circulating concentration of the compound at the 
time of sampling. 
• Analysis of the resulting concentration - time profile. 
However, prior to the dosing of the mice, it was necessary to develop suitable sample 
preparation and analytical methods capable of detecting and quantifying the two test 
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compounds 3.t5b and 5.13 at low (nano-molar) concentrations from mouse whole-
blood samples. The~e analytical methods were kindly developed and validated by Dr. 
Tracy Kellerman in our laboratories at the Division of Pharmacology. University of 
CapeTown. 
The methods are summarized below. 
6.5.1.1 Chromatography and Mass spectrometric conditions 
An AB SCIEX API 3200 Triple Quadropole system (Applied Biosystems) was used for 
sample analysis. The instrument was equipped with a Turbo electro·spray ionization 
(ESI) sourc!:!. rhe system was operated in positive ion mode. The spray voltage and 
source temperature were 5500 V and 450"( respectively. Nitrogen was used as the 
nebulizer and curtain gas and set to 50 and 20 (arbitrary) unih. respectively. The argon 
collision gas pressure was set to 5 (arbitrary) unils. 
The MS-MS system was coupled to an Agi lent 1200 Series HlllC System (Agiient 
T echno logies). and both instrumenh were interfaced with a lenovo® Windowsill XP 
computer running Applied Biosystems Analyst Soth-vare venion 1.5. 
For the analYSis of 3.t5b (and 3.t5c. here used as an internal standa rd). Ihe system was 
fitted with a Supeko® Luna NX 100A (50 I( 2.00mm) column. maintained at a 
temperature o f 20°C. Gradient elution was applied using binary mixtures of 2.5 mM 
ammonium bicarbonate (solvent A) and AcN (solvent B). at a now rate of 0.6ml/min. 
rilble 6.1: l~ble showing Ihe gradient elution Jpplied for 3.15band 3.15c 
Time (min) Flow rilte (pVmin) A (%) • (%) 
0.00 600 70 30 
-~.----.---- -
1.00 600 70 30 
1.10 
~~-r--~~ .~ 
600 -----l- 5 95 
490 600 5 95 
5.00 600 70 30 
8.00 600 70 30 
The lC·MS-MS ~ystem was operaled at unit resolution in the muiliple reaction 
monilor'lng (MRMj mode, monitoring the transition 01 the molecular lor' mlz 557.08 
[l.Ie M ~UA!\'"TAI PI- D fll(1 '0 
'" 
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to the product ion m/z 161.90 (quantifier) and 215.00 (qualifier) for 3.15b, and 587.11 
to the product ion mlz 162.00 (quantifier) and 215.00 (qua lifier) fo r 3.1Sc. 
For the analysis of 5.13, iB proposed metabolite 5.7 and internal standard 5.8. Ihe 
system was tilted w il h a Phenomenex® lu na 5/J PFP 100A (SO x 2.00mm) column. 
maintained at a temperature of 20 "c. Gradient elution w as applied using binary 
mixlure~ o f 10 mM ammonium acetate (solvent A) and MeOH (solvent B), al a now 
rate of 0.5mVmin. 
T.lble 6.2 : T.lble >l1Owing the gradient elutiO!l applied for 5.13. 5.7 and 5.8 
Time (min) f low rale (pl/fnin) A (%) 13 (%) 
0.00 500 28 72 
1.00 500 28 72 
1.1 0 500 J 97 
5.00 500 3 97 
5.10 500 28 72 
8.50 500 28 72 
The LC -MS -MS system monitored the tramition o f the molecular ion mIl. 574.1 4 to the 
produd ion m/z 189.00 (quantifier) and 248.15 (qua lifier) fo r 5.13 . 248.10 to the 
product ion m/z 205.10 (quantifier) and 191.00 (qllalifierJ for 5.7 and 397.08 to the 
product ion mlz 205.20 (quantifier) and 178.10 (qualinL .... ) for 5.8. 
Exampl c~ of the chromatograms from the ana\y~is of the compound~ are shown be low 
(Figurf;! 6.1). 
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A 
... lOCoI_tllpoinI):5117.1I215.1) ____ '(S1)oI'--(T-~ 
-".206<110 
1.1_ 2.8$ 
1.D0006 3.15c (Internal standard) 
8_ 
Ii 
f8-
ii ];.-
2._ 
o.w 
0.5 1.1) 1.5 2J) 2.5 :1.0 3.li 4.1) 4.5 !i.iI U IS.O 8.5 7.0 7;5 _ ....
... lOCoI_ til poiro~551.1I21S.I)_-' __ ' (S1)oIll11l1_(T_~ 
-'1311.3 cpo, 
2.8$ 
700 I 
-
I 
3.15b 
500 
H-
i 400 
I 300 
li\ 200 
II 
100 \ I Ie, .,r, ~ 
0.5 1.0 1.5 2J) 2.5 :1.0 3.5 
.,.,!.o ... 4.5 !i.iI 5.5 8.0 8.11 7.0 7.5 
B: 
A.cq. Fil1!!: 1I3fi.tlliff Page 1 of 1 
5.8 (Internal standard) 
5.13 
5.7 
Project: Brie 
figure 6.1: Sample chromatograms from the analysis: A: 3.15b and 3.15c (as internal standard): 
B: 5.13. 5.7 (putative metabolite) and 5.8 (as internal standard). 
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6.5.1.2 Preparation of Calibration Standard Solutions 
Combined calibration standard mlutions o f 3.15b, 5.7 and 5. 13 in whole mouse blood 
were prepared as follows. 
Three 1.0 mg/ml stock ~Iutions (551) were prepared by separately d issolving 1 mg of 
3. 15b, 5.7 o r 5.13 in 1.0 m l DMSO. The solutions were vort cxcd fo r 1 m in 10 
comp lete di ssolution, A 1:10 dilution in DMSO was carr ied out fo r each 551 to yield SS2 
so lu tions of 100 J..iglm l. All stock solutiom were kept frozen (·80 °C) when not in use, 
20 ,U L of each o f the three SS2 was added into the same 1940 J..il mouse whole blood 
to yield 2 mL o f the standard solution S9 containing 1000 nglm l of each analyte, and 
Wllicfl represe nted the upper limit of quantitation (ULOQ). The solutio n was vortexed 
fo r 1 min. aner which 1 mL of this S9 was transferred to 1 mL o f w ho le mouse blood to 
y ield the 500 ng/mL 58. Sim ilar 1:1 di lutions were continued down to the 3.9 ng/mL 
SI (Table 6.3). 
Fresh standard solutions were p repared for every batch run. 
Table 6.3: Concentrations of calibration standard .. 
Standard SI· LLOQ 52 53 54 55 56 57 I 5. 59· ULOQ 
Cone. 3.9 7 .• 15.6 31.31 62.5 125 250 ~ 500 1000 {ng/mlj , I 'j , 
6.5.2 Dosing and sample collection 
M ale C578LACK6 mice weighing 18 - 22g were sourced from the animal breeding 
facili t ies at the University of Cape Town (UCT), South Africa. The animals were housed 
in an accredited fadlity run on a 12-h light and dark cycle. and were allowed 
unrestricted access to food and water. A ll protocols fo r the anima l studies conformed 
to the highest standards for the hum ane handling, ca re. and treatment o f research 
anima ls and were approved by the ucr Animal Ethics Committee. 
3.15b was admini stered to 5 m ice per group a~ follows: 
.. 10% DMSO·water formulation at 20mg/kg by o ral gavage: 
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• Pheroid formulation (3.S% Pheroid + 96.2% gassed water) at 20mg/kg by oral 
gavage; 
• SMEOOS formulation (50% sesame oil. 15% water: 7% PEG400: 7% ethanol; 21% 
Tween SO) at 20mg/kg by oral gavage. 
• 3.t5b was also administered to 3 mice intravenously at 2mg/kg in 10% OMSO-
water: injected into dorsal penis vein. 
5.13 was administered to 5 mice per group as follows: 
• 10% OM SO-water formulation at 20mg/kg by oral gavage; 
• pH4 acetate buffer at 20mg/kg by oral gavage; 
• 5.13 was also administered to 3 mice intravenously at 2mg/kg in 10% OMSO-
water: injected into dorsal penis vein. 
At the low concentration used for IV administration. the compounds remained in 
solution in 10% OMSO-water. and were therefore suitable for intravenous use. The 
volume administered for both oral and IV dosing was 200 fJL 
Immediately before dosing (0 hrs). 15fJI of whole blood was collected by making a 
small incision in the upper tail and collecting the blood in hepanarized tubes. The 
blood was immediately transferred to polypropylene vials on ice containing 50JJI of 
pH9 Britton Robinson universal buffer after which they were vortexed and frozen at -
SOOC until analysis. 
Each mouse then received an oral or IV dose as outlined above. Subsequently, 15 IJL 
samples of blood were drawn as described above from each mouse at 0.5. 1. 2. 5. S 
and 24 hours after dosing. However. for the IV experiments. the first samples were 
drawn 5min after dosing: the remaining samples were then drawn at the same time 
points as indicated above. 
All samples were immediately frozen at -Sooc. 
6.5.3 Extraction procedure 
The same method was developed for the extraction of all the mouse blood samples 
(I.e. the calibration standards Sl-S9 and the actual mouse blood samples from the PK 
experiments). with the only variation being the internal standard solution used for 
extraction. The general extraction procedure is described below. 
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The frozen samples were thawed in a water bath at 37"C. 15 jJL of the calibration 
standards in mouse whole blood were transferred in duplicate to 1.5 ml 
polypropylene centrifuge vials containing 50 jJl of universal buffer pH 9.0. The actual 
mouse blood samples from the PK experiments were already in the buffer pH 9.0. and 
were thus ready for extraction after thawing. 
To each of these mixtures. 250 jJl of ethyl acetate containing the appropriate internal 
standard was added - for the extraction of samples of 3.15b, a 50 ng/ml solution of 
3J5c in ethyl acetate was used as the extraction solvent: for the extraction of samples 
of 5.7 and 5.13. a 25 ng/ml solution of 5.8 in ethyl acetate was used as the extraction 
solvent. 
The vials were capped. vortexed for 1 min. and the mixtures clarified by centrifugation 
at 13000 rpm for 5 minutes. 210 jJl of the dear ethyl acetate supernatant was then 
carefully transferred from each vial into clean vials and dried under a steady stream of 
nitrogen. The residues were then re-dissolved in an AcN/water (75:25) mixture. These 
were then vortexed for 30 sec. transferred to low-volume glass inserts and placed into 
glass chromatography vials. ready for lC-MS-MS analysis (10 jJl injection volume) using 
the method described above. 
A pair of blank samples was prepared by transferring plain mouse whole blood (15 Ill) 
into 50 jJl of universal buffer pH 9.0 and extracting with ethyl acetate solution of the 
appropriate internal standard. A pair of double blanks was also prepared by 
transferring plain mous  whole blood (15 IJl) into 50 jJL of universal buffer pH 9.0 
and extracting with plain ethyl acetate. 
For both 3.15b and 5.13, the samples were extracted, prepared and analyzed as single 
batches. 
6.5.4 Results 
6.5.4.1 Calibration curves 
For compound 3.15b, the calibration standards were analyzed (in duplicate) along 
with the unknown blood samples (from the PK experiments) as a single batch. The 
results from the lC-MS-MS analysis of the calibration standards were used in the 
generation of standard calibration curves which were then be applied in the 
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quantification of 3.15b in the unknowns. A similar approach was used for the 
simultaneous quantitatlon of 5.13 and 5.7. 
Examples of the calibration curves are given below (Figure 6.2): 
I"~-"'·"---""-'·"""'''·-··-··'-' 
... 
-~.~.~---~-~-~~~-~-~-~-~-~-~-~~--~-~-~-~­,..,c __ t.c:-.. 
3.15b 5.13 
5.1 
figure 6.2: Examples of calibration curves for 3.15b. 5.13 and 5.1 
An the caUbration curves showed good fit. with r-squared values an > 0.9. 
The quantitation of the unknown samples was done automatically by the Analyst 
Software version 1.5. using the generated calibration rurves as reference. 
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6.5.4.2 Pharmacokinetic re~ult~ for 3.1Sb 
o OMe 
OM. 
Compound 3.15b 
The determined concentrations of 3.1Sb are 5nown in Table Al (Appendix AJ. The 
average concentrations were then plotted agaimt time o f sampling to yield the 
concentration-time profiles shown in Figure 6.3 below. 
800 
E 700 
1 600 
;- 500 
.g 400 
• !:. 300 
c 
~ 200 
~ 100 
3.1Sb oral 
(n = 5) 
" 0 ....... '-'-'....,h--A-______ -~_-~ ..... 
o 2 4 
_ DMSOIwater 2()mgf)l;g 
6 8 10 12 14 16 18 20 22 24 
Time (hours) 
"." SMEUOS 10mg/kg _ Pherod A 20mgikg 
lRJCM.",U/" ,1 ,·ID~l:;: 
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Figure 6.3: Graphs showing how circulafing concentrations of 3.1Sb vary with time. A: after 
oral administration: B: after IV administration. (Error bars represent standard deviations.) 
The lO%DMSO-water formulation yielded the highest exposure after oral dosing, with 
circulating concentrations reaching a maximum of 520 ng/mL. With this formulation. 
the compound exhibited a ponible bi-phasic concentration-time profile. with two peak 
concentrations. Maximum circulating concentrations were achieved approximately 1 
hour after dosing; these levels then fell gradually over 4 hours, reaching lows of just 
over 80 ng/mL about 5 hours post-dosing, before rising again to give a second peak 
concentration of approximately 240 ng/mL approximately 8 hours after dosing 
(however, the large error bar a sociated with this second peak introduces a degree of 
uncertainty around the obs rved bi-phasic profile). Concentration levels fell to below 
quantifiable levels within 24 hours after dosing. This bi-phasic profile did not allow for 
the modelling of the data and the estimation of descriptive PK statistics (e.g. half-life). 
Exposure from the alternative formulations (SMEDDS and Pheroid) was, by 
comparison, very poor, with circulating concentrations never exceeding 50 ng/mL. No 
evidence of a bi-phasic PK profile with these formulations was observed. 
As expected after IV administration, peak circulating concentrations of 3, 15b were seen 
immediately after dosing - a maximum concentration of almost 3000ng/mL was 
observed. However, this concentration fell rapidly to just over 400 ng/mL after 1 hour. 
Basic PK analysis using WinNonLin version 4.1 estimated the half life of 3.tSb as 1.1 hrs. 
This rapid decline then tapered off. and circulating concentrations feU more gradually, 
reaching approximately 40 ng/mL after 5 houn and falling to below quantifiable levels 
after 8 hours. 
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NB: the results from one of the mice used for the IV PK experiment were unusually 
lower than Those from the other two mice (see Table AI , Appendix A). and were 
therefore omitted from the analysis. 
6.5.4.3 Pharmacokinetic results for 5.13 
OM. 
HO OM. 
o OM .. 
~ ~N~CI 
Compound 5.13 
The determined concentrations o f S.l3 are shown in Table A2 (Appendix A), Table A3 
show~ Ihe conc('ntraliom of 5.7. the predicted metaboli te. in Ihe same samples. The 
averag~ concentratio ns o f both compounds are plo lted against lime o f .. ampli ng to 
yield the concentration-rime profiles shown in Figure 6. 4 below. 
200 
-~ 150 
~ 
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0 
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0 
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Figure 6.4: Cr:lphs showing now circulating concentrations of 5.13 and 5.7 vary witn time. A: 
after oral administration: 8: after IV admini st ration. (Error bars represent sl<mdard deviations.) 
As was the case for 3.15b. the l O%DMSO-w ater formulation also yielded the highest 
exposure after oral do~ing of 5.13 . with d rculaling concent (at jo fl~ reaching a maximum 
of just over 250 nglml within 30 min of dosing. These levels then dedined rapidly. 
down to approximately 60 ng/mL after I hour. and then more gradually to below 
detectable levels after 5 hours. 
N8: the resulh from one of Ihe mice used for the 5.13 DMSO-water oral experiment 
were unusually higher than those from the other four mice (see Table A2 . Appendix 
A), and were therefore omit ted from the ana ly~i~. 
Exposure from the alternative formulation (acetate buffer pH 4.0) foll owed a simila r 
trend but h. by comparison, relatively poor. The maximum Circulating concentrations 
w ere just over 50 ngimL. 
As expected after IV administration. peak circulating concentrations of 5.1 3 were 5een 
immediately after dosing. However. the maximum concentrations obseNed of 
approximately 11 40 ng/ml were not as high as Chow observed for 3.1 5b. Th~e leve l ~ 
also fel l quite rapidly. down to just under 60 ng/ml w i thin 1 hour. approJo:imalely 25 
nglmL after 2 hours and fell to below quanti fiable levels after 5 hours, Bask PK analysis 
using W inNonlin version 4.1 estimated the half li fe o f 5.13 as 0.6 hrs. 
Inferestingly. the predicted metabolite 5.7 was detected in circulation after both ora l 
(!O%DMSO-water formulation) and lV administration of 5.13. HOVJ€Ver. the detected 
levels o f this metabolite were very low. and never exceeded 20 nglmL 
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6.5.5 Discussion of results 
6.5.5.1 Compound 3.1Sb 
3.1Sb shows very rapid absorption after oral administration. reaching maximum 
concentration within 1 hour after dosing. The remarkably higher oral bioavailability of 
3.1Sb when administered as a DMSO-water formulation as opposed to the SMEDDS 
and Pheroid formulations indicates that these alternative formulations are not optimal 
for the oral delivery of this compound. This was rather unexpected, and couid point to 
a somewhat irreversible entrapment of the lipophilic compound in the lipid 
component(s) of these formulations. thereby hampering the release of the compound 
for absorption in the GIT. The result of such a situation would be the almost complete 
elimination of the administered compound in feces. A possible condusion from this is 
that perhaps the improvement or otherwise of the oral bioavailability of a compound 
by the use of formulations is compound-spedfic. dependent on the compound's unique 
properties and its interaction with the formulation. 
A possible bi-phasic PK profile was also a notable feature of 3.1Sb after oral 
administration as a DMSO-water formulation. Multi-peak PK profiles usually result 
from either: 
• entero-hepatic drculation. whereby the compound is excreted into the GIT in bile 
and thereafter gets reabsorbed; 
• redistribution of the compound into body tissues. where it subsequently undergoes 
a concerted release from these reservoirs back into drculation; or 
• staggered absorption. i.e. absorption in two separate sections of the GIT [3]. 
It would be expected that a compound that undergoes entero-hepatic drculation 
would still show features of biliary excretion and GI reabsorption even after IV 
administration. However. the PK profile of 3.1Sb after IV administration (Figure 6.38) 
does not show evidence of a second wave of absorption. thereby suggesting that 
entero-hepatic drculation does not explain the bi-phasic PK profile observed after oral 
administration of 3.1Sb. 
The appearance of the second peak in the PK profile of 3.1Sb after oral administration 
occurs approximately 8 hours after dosing. a period that is much too short to account 
for redistribution into bodily tissues and subsequent release. Furthermore. tissue 
redistribution would also occur after IV administration. and the absence of the bi-
phasic PK profile after IV administration of 3.1Sb discounts tissue distribution and 
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subsequent release as the mechanism behind the PK profile observed after oral 
administration. 
Therefore. the likely explanation for this PK profile would be the staggered absorption 
of 3.15b in two different sections of the GIT. For example. the first wave of absorption 
could occur in the more proximal portions of the GIT (the stomach or early parts of 
the small intestine). while the next phase could occur in more distal portions of the GIT 
(late small intestine or large intestine). The duration between the two peaks would 
also be consistent with GI motility and the movement of GI contents along the tract 
[3]. Such a phenomenon could also be facilitated by possible compound precipitation. 
followed by slower re-dissolution and delayed absorption: this is quite possible 
considering the poorly solubility of the compound. 
The rapid decline in the circulating concentrations of 3.15b after IV administration. 
approximately six-fold within the first hour. indicates an extremely efficient clearance 
of the compound. possibly a combination of both hepatic and renal clearance. As 
discussed in Chapter 5 (Section 5.8.2), compound 3.15b was shown during in vitro 
metabolism studies to exhibit intermediate extraction ratios in both human and mouse 
microsomes. The main route of metabolism of this compound appeared to be 
oxygenation, most likely resulting in the N-oxide metabolite (putative metabolite P + 
16). It is therefore quite possible that this biotransformation. and the subsequent renal 
excretion of the more polar oxygenated metabolite. could explain the rapid clearance 
of 3.15b from systemic circulation. 
6.5.5.2 Compound 5.13 
Compound 5.13 shows very rapid absorption after oral administration. reaching 
maximum concentration within 30 min after dosing. The DMSO-water formulation 
yielded the better exposure following oral administration of 5.13. affording maximum 
circulating concentrations over two times higher than those afforded after 
administration of the compound as a solution in acetate buffer pH 4.0. 5J3b was 
more soluble in buffer pH 4.0, forming a clear solution as opposed to a milky but 
stable suspension in DMSO-water; however, this improved solubility did not translate 
into the expected improved oral bioavailability. A possible explanation for this is based 
on the degree of ionization of the compound, as described below. 
The rationale behind formulation of insoluble but ionizable compounds in appropriate 
buffers is to allow for their ionization and the improved solubility that this affords. 
However, many compounds cannot traverse the GIT membrane in their ionized state. 
particularly weakly acidic compounds. Therefore. and as discussed in section 5.6.3.1. 
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the presence of an equilibrium between the ionized and non-ionized states is crucial for 
absorption. 
Compound 5.13 is predicted to be >90% ionized at pH 5.0, possibly higher at pH 
4.0. It would be expected that this degree of ionization would fall gradually as the 
administered formulation moves along the GIT into the more alkaline small and large 
intestines: the increasing portion of the non-ionized compound would then be 
available for absorption. It is quite possible. however. that the volume of administered 
buffer was sufficiently large to actually modify the pH of the intestines, lowering the 
otherwise alkaline pH and keeping most of the compound in the ionized state. This is 
particularly probable considering the rather small size of mice. and even smaller 
volume of their GI tract. and could perhaps explain the lower oral bioavailability 
despite the observed improved solubility with this formulation. 
Also noteworthy was that significantly higher exposure and circulating concentrations 
were observed for 3.15b compared to 5.13: the maximum circulating concentrations 
for 3.15b were approximately three times those observed for 5.13 when administered 
orally in similar formulations (DMSO-water). In this regard, 5.13 did not offer any of 
the anticipated improvement on the oral bioavailability of 3.15b. This is probably the 
result of the higher metabolic instability of 5.13 relative to 3.15b; based on the in vitro 
metabolism studies (section 5.8.2), 5.13 had a higher extraction ratio in both mouse 
and human microsomes. and was also susceptible to several routes of metabolism. 
including O-demethylation. N-dealkylation and glucuronide conjugation 
The bi-phasic PK profile observed after the oral administration of 3.15b was not 
replicated for 5.13, possibly due to the distinctly different physicochemical properties 
of the two related compounds. 
The rapid decline in the circulating concentrations of 5.13 after IV administration, 
approximately five-fold within the first hour. also indicates an extremely effident 
dearance of the compound. As discussed in Chapter 5 (Section 5.8.2). compound 5.13 
was shown during in vitro metabolism studies to exhibit relatively high extraction 
ratios in both human and mouse microsomes (EH > 0.7). The main routes of 
metabolism of this compound appeared to be O-demethylation. N-dealkylation and 
glucuronide conjugation. It is therefore quite possible that this susceptibility to several 
routes of metabolism. could explain the rapid clearance of 5.13 from systemic 
circulation. 
However, the detected levels of the predicted N-dealkylation metabolite 5.7 in 
drculation were very low, which could suggest that either this was not the primary 
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route of metabolism in mice. or that this particular metabolite was polar enough to be 
efficiently eliminated by the kidneys in urine before significantly accumulating in 
circulation. 
No detailed statistical analysis of the PK results of these compounds was carried out. As 
described above. only qualitative analysis of the data was carried out. as this was 
sufficient to allow for a general comparison of the bioavailability of the two 
compounds and enable preliminary conclusions to be reached. 
Of the various formulations used for the oral administration of 3.15b and 5.13. the 
10%DMSO-water formulation afforded the best oral bioavailability for both 
compounds. This formulation was therefore selected for oral dosing of the compounds 
for the subsequent in vivo antimalarial efficacy studies. reported in the ext section. 
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overall clearance: notably however. murine models with human hepatocytes (and 
which would ideally exhibit similar metabolic profiles) are under development [18]. 
In spite of these challenges. the murine malaria disease model continues to be 
extensively used for in vivo antimalarial efficacy testing. In this study. the P. yoelii 
murine malaria model was used for the in vivo efficacy studies of compounds 3.l5b 
and 5.13. 
6.6.2 In vivo antimalarial assays of compounds 3.l5b and 5.13 
Male C57BlACK6 mice weighing 18 - 22g were sourced from the animal breeding 
facilities at the University of Cape Town (UeT). South Africa. The animals were housed 
in an accredited facility run on a 12 hour light-dark cyde, and were allowed 
unrestricted access to food and water. All protocols for the animal studies conformed 
to the highest standards for the humane handling. care, and treatment of research 
animals and were approved by the UeT Animal Ethics Committee. 
The chloroquine sensitive Plasmodium yoelii N. strain used in the study was sourced 
from WHO repository, University of Edinburgh. Scotland. The parasite strain was 
propagated in mice and maintained by serial passage of infected erythrocytes. 
J 
The antimalarial activity of the two compounds 3.15b and 5.13 was evaluated using 
the modified Peter's 4-day suppressive test [19]. Each mouse was inoculated 
intraperitoneally with 1 x 107 P. yoelij.infected erythrocytes suspended in 200 Jll of 
phosphate-buffered saline. The mice were randomly divided into groups of five 
animals per cage and treated for 4 consecutive days (beginning on the day of infection, 
day zero) with daily oral doses of 20, 10 or 5 mg/kg/day of either 3.t5b or 5.13 
(10%DMSO/water formulation). Two control groups were used in each experiment; 
one was treated with chloroquine at a low non<urative dose (lOmg/kg/day, orally) 
and the other group was left untreated. Coded blood smears were prepared from 
blood samples from all the mice on day 2 (second day post-infection) and examined to 
confirm if the infection had taken. 
Thin blood smears were prepared from the tail blood obtained from each of the 
surviving mice on days 4. 7. and 10 after infection from the untreated controls and 
from treated animals. The levels of parasitemia were determined from the Giemsa-
stained smears by counting the percentage of infected erythrocytes in 500 - 600 
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6.6 In vivo antimalarial efficacy studies 
6.6.1 Introduction 
As previously mentioned in section 6.2. the purpose of in vivo antimalarial efficacy 
studies is to investigate the ability of a test compound to exert its antimalarial activity 
within a living organism. where anatomical. physiological. immunological and other 
biological factors present in such a system also come into play. 
Animal malaria models are usually applied for these studies. with the murine malaria 
model being the most widely used model [13]. Plasmodium berghei. P. yaelii. P. 
vinckei and P. chabaudi are four malaria species that infect African murine rodents that 
have been extensively used as malaria models for drug testing. malaria vaccine 
development and the study of immunopathological reactions and mosquito 
transmission [14,15]. Though phylogenetically distant. these species closely resemble 
human malaria parasites in terms of their basic biology. Biochemical and genetic 
processes. and hence similarities in drug susceptibility and mechanisms of drug 
resistance. appear to be relatively conserved between the different species [14]. 
The laboratory mice used for these studies are cheap. easily maintained and are usually 
well characterized through careful breeding. The murine malaria parasites used are 
usually well characterized clones. and the mouse model allows for experimentation 
with a range of different inoculation and treatment protocols. 
The main disadvantage of using these models (and indeed any animal model) is the 
difficulty in extrapolating results from these models to actual humans [15]. In the 
application of these murine malaria models, two important considerations must be 
made. 
First. the parasite species has been changed, and the test compound may be more or 
less potent against the murine parasite than the human parasite; it should be noted 
that, in an attempt to address this challenge, immune-compromised mice have been 
used to develop mouse <humanized' murine malaria models (mice inoculated with 
human malaria parasites) [t6.t7]; these are yet to become widely available for routine 
drug discovery studies, possibly due to cost implications associated with the need to 
use immune-suppressed and/or genetically manipulated mice for this model - rodents 
are not normally susceptible to infection by human malaria parasites [15]. 
Second. host pharmacokinetics and metabolism may differ between mice and humans 
in terms of the extent and nature of the metabolism of a compound. as well as its 
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overall clearance; notably however. murine models with human hepatocytes (and 
which would ideally exhibit similar metabolic profiles) are under development [18]. 
In spite of these challenges. the murine malaria disease model continues to be 
extensively used for in vivo antimalarial efficacy testing. In this study, the P. yoelii 
murine malaria model was used for the in vivo efficacy studies of compounds 3J5b 
and 5.13. 
6.6.2 In vivo antimalarial assays of compounds 3.15b and 5.13 
J 
Male C57BLACK6 mice weighing 18 - 22g were sourced from the animal breeding 
facilities at the University of Cape Town (UCT), South Africa. The animals were housed 
in an accredited facility run on a 12 hour light-dark cycle. and were aU owed 
unrestricted access to food and water. All protocols for the animal studies conformed 
to the highest standards for the humane handling. care. and treatment of research 
animals and were approved by the UCT Animal Ethics Committee. 
The chloroquine sensitive Plasmodium yaelii N. strain used in the study was sourced 
from WHO repository. University of Edinburgh. Scotland. The parasite strain was 
propagated in mice and maintained by serial passage of infected erythrocytes. 
The antimalarial activity of the two compounds 3.15b and 5.13 was evaluated using 
the modified Peter's 4-day suppressive test [19]. Each mouse was inoculated 
intraperitoneally with 1 x 107 P. yoelij:.infected erythrocytes suspended in 200 J.ll of 
phosphate-buffered saline. The mice were randomly divided into groups of five 
animals per cage and treated for 4 consecutive days (beginning on the day of infection, 
day zero) with daily oral doses of 20, 10 or 5 mg/kg/day of either 3.15b or 5.13 
(10%DMSO/water formulation). Two control groups were used in each experiment; 
one was treated with chloroquine at a low non-curative dose (lOmg/kg/day. orally) 
and the other group was left untreated. Coded blood smears were prepared from 
blood samples from all the mice on day 2 (second day post-infection) and examined to 
confirm if the infection had taken. 
Thin blood smears were prepared from the tail blood obtained from each of the 
sUiviving mice on days 4. 7. and 10 after infection from the untreated controls and 
from treated animals. The levels of parasitemia were determined from the Giemsa-
stained smears by counting the percentage of infected erythrocytes in 500 - 600 
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randomly counted erythrocytes. Weights. stress/discomfort and mortality were 
monitored daily in all groups during the post-inoculation period. 
The antimalarial activity of the compounds was then evaluated based on the degree 
and duration of suppression of parasitemia. the rate of decline of the mouse body 
weights and duration of mouse survival after infection. compared to that of 
chloroquine. an established antimalarial. 
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6.6.3 Results 
6.6.3. 1 Compound 3.T5b 
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The re wa, no notable difference between the three dosing level~ of 3.15b with respect 
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CHAPTER SIX; PHARMACOKI NETIC AND IN VIM? ANTIMAlARIAL EFFICACY STUDIES 
The rate at which parasitemias rose was somewhat lower for the mice treated with 
3.15b relative to the untreated controls, quite obvious after day 4. This suggested a 
present but limited level of suppression of parasitemia by 3.15b. However. this 
suppression was not comparable to that afforded by chloroquine; the group of mice 
treated with the non-curative dose of 10 mgIkgIday of chloroquine still had 
parasitemias lower than 5% even 10 days after infection. 
The mice in the three groups treated with 3.15b, as wen as the untreated controls, 
showed similar rates of dedine in average mouse weights. which was used as a proxy 
indicator of the health and well-being of the mice. However. the weights of the 
chloroquine-treated mice did not change notably over the course of the study. 
In terms of mouse survival. 2 mice from each of the three groups survived for n days 
after infection; no mice among the untreated controls survived beyond day 9. All the 
mice in the chloroquine group survived the course of the study. which was terminated 
after 13 days. 
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6.6.3 .2 Compound 5.13 
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There wa~ a similar trend amo ng the three d0 5ing levels of 5 .13 with respect to 
suppressio n o f para sit emia: intere5tingly. the rise in parasitemia is re la tively higher in 
the 20 mglkg/day and 10 mg/kg/day groups than in the 5 mglkg/day groups. No 
improvement over the untreated controls was observed. The group of mice treated 
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CHAPTER SIX: PHARMACOKINETIC AND IN VlliOANTIMAlARIAl EFRCACY STUDIES 
with the non-curative dose of 10 mg/kg/day of chloroquine maintained parasitemias 
lower than 5% throughout the duration of the study. 
The mice in the three groups treated with 5.13. as well as the untreated controls. 
showed similar rates of dedine in average mouse weights. a trend similar to that 
observed for 3.15b. However. the weights of the chloroquine-treated mice did not 
change considerably over the course of the study. although there was a notable dip in 
mouse weights 1 - 3 days after infection. 
In terms of mouse survival. no mice among the untreated controls survived beyond 
day 10; 2 mice from the 5 mg/kg/day group and 1 mouse from the 20 mg/kg/day 
group survived to day 12. whereas 00 mice survived beyond day n in the 10 
mg/kg/day group. As expected. all the mice in the chloroquine group survived the 
course of the study. which was terminated after 13 days. 
6.6.4 Disrussion and condusions 
The two compounds did not exhibit significant in vivo antimalarial activity. showing 
only marginal improvement to the untreated controls in terms of suppression of 
parasitemia. dedine in average mouse weights and overall mouse survival This activity 
was considerably inferior to that observed for chloroquine. 
Compound 3.15b showed slightly better efflcac::y than 5.13. with a notably slower rise 
in parasitemia in the middle and later stages of the study as well as more mice 
surviving for longer (relative to their respective untreated controls). This is probably 
explained by two facts: 
• its relatively more potent antiplasmodial activity of 3.15b (exhibited during the in 
vitro tests. Chapters 3 and 5). and 
• the better exposure achieved after oral administration of 3.15b relative to 5.13, 
both formulated in DMSO-water. 
The fact that 5.13 did not show notably inferior in vivo efficac::y to 3.1Sb despite its 
notably poorer anti plasmodial activity and oral bioavailability points to either a 
relatively higher susceptibility of the P. yael;; strain to 5.13. or perhaps a mechanism 
that enhances its antimalarial activity. such as accumulation into the addic food 
vacuole of the parasite. the putative site of action of this compound. This could be 
ERIC M GUANTAI - Ph.D THESIS 2010 
190 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Ci ,,\PI U, \IX: PIj,\l~M;\CC)KI1'-:nK ,'!\if) /,\/ l'!l '0 A!\ilIM,\L/\RL\L UTIC\CY Sl UC'I!:5 
facilitated by its more basic characteristics conferred by the piperazine linker. which 
would allow for protonation and acid trapping within the acidic food vacuole. 
In conclusion. though compound 5.13 offered the advantage of improved (pH 
dependent) solubility relative to 3.15b. this compound had the poorer oral 
bioavailability of the two compounds, and did not offer any improvement on its 
antimalarial activity either in vitro or in vivo. 
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CHAPTER SEVEN 
SUMMARY. CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE WORK 
7.1 Summary and condusions 
This study set out to identify novel hybrid compounds containing scaffolds that are 
structurally related to the natural product curcumin. and which possess in vitro and in 
vivo antimalarial potency. 
The initial objective of the study was to design and synthesize novel hybrid 
compounds as potential antimalarial agents which contain scaffolds that are structurally 
related to the natural product curcumin. Targeted series of chalcone/AlT. 
chaJcone/chloroquinoline. dienonelAlT and dienone/chloroquinoline hybrid 
compounds were therefore designed and synthesized. applying simple and robust click 
chemistry as the hybridization strategy. 
The second objective of the study was to pharmacologically evaluate the synthesized 
compounds in vitro for antimalarial activity and possible mechanisms of action. The 
synthesized hybrid compounds. as well as selected intermediates. were therefore 
assayed for in vitro antimalarial activity. The acetylenic chalcones 3.9 and 3.10 
exhibited moderate in vitro antimalarial activity consistent with published results for 
alkoxylated chalcones. The acetylenic dienones. as well as the acetylenic enone 
intermediate 3.n. exhibited comparable antimalarial activity to the acetylenic 
chalcones. The AZT hybrid compounds of both the chalcones and dienones did not 
exhibit notably higher in vitro antimalarial activity relative to their acetylenic 
precursors. though the retention of activity in most cases was still noteworthy. 
However. the chloroquinoiine-hybridization strategy did lead to the identification of 
significantly active hybrid compounds. i.e. 3.15b. 3.15c and 3J7b. as well as the 
enone-chloroquinoline intermediate 3.19. Compound 3.15b was the most active of 
these, with sub-micromolar ICso values for all three P. fa/dparum strains. No obvious 
trends were observed as far as the influence of the different substitution patterns of the 
chalcones or dienones on antimalarial activity was concerned. Results from mechanistic 
studies suggested that inhibition of hemozoin formation was likely to contribute 
substantially to the antimalarial activity of most of these compounds. This was 
particularly so for the hybrid compounds 3.15b. 3.15<: and 3.15e. which were all 
comparably or more potent than chloroquine in inhibiting ~-hematin formation. 
However, the lack of correlation between these proposed mechanisms of action and 
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the observed in vitro antimalarial activities of these compounds suggested the 
possibility of either the existence of additional mechanisms of action or of other factors 
that influence the in vitro antimalarial activities of these compounds such as varying 
degrees of lysosomal accumulation within the malaria parasite. 
An additional objective of the study was to apply in silica (computational) techniques 
to guide the design of derivatives of the more active compounds with potentially 
superior physicochemical and/or ADMET properties for subsequent synthesis. in vitro 
antimalarial testing and mechanistic studies. 3.15b and 3.19 were selected for structural 
modification with the aim of identifying analogs with improved solubility and which 
retained antimalarial potency. Eight analogs 5.8 - 5.15 were proposed, and these were 
characterized in silico for selected physicochemical and ADME parameters. These 
analogs were predicted to have improved solubilities relative to the parent 
compounds, particularly at low pH: they retained acceptable predicted Caco2 
permeability. but were identified as possible substrates for N-dealkylation by hepatic 
cytochromes. The tentative conclusions that were drawn from the in silica solubility 
predictions and metabolism predictions were supported by experimental solubility 
determinations and in vitro metabolism studies. These proposed analogs were then 
synthesized and tested. and were found to exhibit notable in vitro antimalarial activity. 
5.13 and 5.15 were the most active of the analogs. 5.7. an intermediate in the synthesis 
(and a putative metabolite) of some of the analogs was also found to exhibit notable 
antimalarial activity in vitro. Results from mechanistic studies suggested that inhibition 
of hemozoin formation was likely to contribute substantially to the anti plasmodial 
activity of analogs 5.8 - 5.15. These analogs were all more potent than chloroquine at 
inhibiting ~-hematin formation. 
The final objective of the study was to eluddate the pharmacokinetic profiles and 
evaluate the in vivo antimalarial activities of the most promising compounds using the 
mouse mode\. Compounds 3.15b and 5.13 were therefore selected for preliminary PK 
profiling and in vivo antimalarial testing. The remarkably higher oral bioavailability of 
3.15b when administered as a DMSO-water formulation as opposed to the SMEDDS 
and Pheroid formulations indicated that these alternative formulations are not optimal 
for the oral delivery of this compound. Compound 3.15b also exhibited a bi-phasic PK 
profile after oral administration as a DMSO-water formulation; this was most likely 
due to staggered absorption. i.e. absorption in two separate sections of the GI tract. 
The rapid decline in the circulating concentrations of 3.15b after IV administration 
indicated an extremely effident clearance of the compound. possibly arising from 
susceptibility to several routes of metabolism. The DMSO-water formulation also 
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yielded the better oral exposure than the buffer pH 4.0 formulation. Also noteworthy 
was that significantly higher exposure and cirrulating concentrations were observed for 
3.15b compared to 5.13 after oral administration. The rapid decline in the cirrulating 
concentrations of 5.13 after IV administration also indicated an extremely efficient 
clearance of the compound. The drrulating levels of the predicted N-dealkylation 
metabolite 5.7 after administration of 5.13 were very low. which suggested that either 
this was not the primary route of metabolism in mice. or that this partirular metabolite 
was polar enough to be efficiently eliminated by the kidneys in urine before 
significantly acrumulating in cirrulation. 
The two compounds did not exhibit significant in vivo antimalarial activity. showing 
only marginal improvement to the untreated controls in terms of suppression of 
parasitemia. decline in average mouse weights and overall mouse survival. This activity 
was significantly inferior to that observed for chloroquine. Compound 3.15b showed 
slightly better efficacy than 5.13. with a notably slower rise in parasitemia in the 
middle and latter stages of the study as well as more mice surviving for longer (relative 
to their respective untreated controls). 
Though compound 5.13 offered the advantage of improved (pH dependent) solubility 
relative to 3.15b. this compound had poorer oral bioavailability. and did not offer any 
improvement on its antimalarial activity either in vitro or in vivo. 
7.2 Recommendations for future work 
This study identified the existing potential in enone-chloroquinoline hybrid 
compounds. Guided by in silico ADME predictions. the design and synthesis of further 
analogs. such as those shown in Rgure 5.15. presents a viable approach to investigating 
this potential. 
Furthermore. structural modifications could be made in an attempt to address the 
metabolic instability observed with the first generation of analogs presented in this 
study. For example. new series of analogs could be designed by applying other 
hybridization strategies that yield linkers that are not very susceptible to N-dealkylation 
or other routes of metabolism. In addition. replacement of the methoxy groups with 
more metabolically stable substituents (e.g. trifluoromethyl groups) may afford more 
stable analogs. 
PK studies on a somewhat larger scale could also be quite informative. For example. 
the investigation of other formulation strategies including. but not limited to. the 
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varying of the different components of the SMEDDS formulation could facilitate the 
identification of optimal formulations suitable for this type of compounds. 
Also, pharmacokinetic and/or in vivo efficacy profiling of representative AZT-based 
hybrid compounds could also be useful as proof-of-principle, i.e. to test the hypothesis 
on the potential beneficial effects in vivo of hybridization to the hydrophilic nucleoside 
AZT. 
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8.1 Chemistry 
8.1.1 Reagents and Solvents 
CHAPTER EIGHT: EXPERll\IENT AL 
CHAPTER EIGI-IT 
EXPERIMENTAL 
All commercially available chemicals and reagents were purchased from either Sigma-
Aldrich or Merck. South Africa. 
Anhydrous DMF. anhydrous l.4-dioxane and anhydrous NMP were purchased as such 
from Sigma-Aldrich. South Africa. Other solvents were purchased from Kimix Chemicals 
or Protea Chemicals. South Africa. Chromatography solvents (EtOAc. CH2Cb and 
Hexane) were purchased as Chemically Pure (CP grade) solvents and distilled before use; 
the rest were purchased as Analytical Reagent (AR grade) solvents and used directly. 
8.1.2 Chromatography 
Reactions were monitored by thin layer chromatography [flC) using Merck F254 
aluminium-backed pre-coated silica gel plates. and were visualized under 254 nm 
ultraviolet light. 
Product purification by silica gel column chromatography was performed using Merck 
kieselgel 60: 70-230 mesh by gravity column chromatography. 
8.1.3 Physical and Spectroscopic characterization 
Melting points were determined on a Reichert-Jung Thermovar hot-stage microscope. 
and are uncorrected. 
Purity was determined by combustion analysis. and all compounds were confirmed to 
have >95% purity. This analysis was carried out on a Fisons EA n08 CHNO-S 
microanalysis instrument. 
All NMR spectra were recorded on a Varian Mercury rH - 300 MHz; BC - 75 MHz). 
Varian Unity rH - 400 MHz; 13C -100 MHz), or a Bruker Ultrashield-Plus Spectrometer 
rH - 400 MHz; 13C - 100 MHz) Spectrometer. All spectra were recorded in deuterated 
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8.1 Chemistry 
8.1.1 Reagents and Solvents 
CHAPTER EIGHT: EXPERIMENTAL 
CHAPTER EIGHT 
EXPERIMENTAL 
All commercially available chemicals and reagents were purchased from either Sigma-
Aldrich or Merck. South Africa. 
Anhydrous DMF, anhydrous lA-dioxane and anhydrous NMP were purchased as such 
from Sigma-Aldrich. South Africa. Other solvents were purchased from Kimix Chemicals 
or Protea Chemicals, South Africa. Chromatography solvents (EtOAc. CH2Cb and 
Hexane) were purchased as Chemically Pure (CP grade) solvents and distilled before use; 
the rest were purchased as Analytical Reagent (AR grade) solvents and used directly. 
8.1.2 Chromatography 
Reactions were monitored by thin layer chromatography (TlC) using Merck F254 
aluminium-backed pre-coated silica gel plates, and were visualized under 254 nm 
ultraviolet light. 
Product purification by silica gel column chromatography was performed using Merck 
kieselgel 60: 70-230 mesh by gravity column chromatography. 
8.t.3 Physical and Spectroscopic characterization 
Melting points were determined on a Reichert-Jung Thermovar hot-stage microscope, 
and are uncorrected. 
Purity was determined by combustion analysis, and all compounds were confirmed to 
have >95% purity. This analysis was carried out on a Fisons EA n08 CHNO-S 
microanalysis instrument. 
All NMR spectra were recorded on a Varian Mercury rH - 300 MHz; 13C - 75 MHz). 
Varian Unity ~H - 400 MHz; 13C - 100 MHz). or a Bruker Ultrashield-Plus Spectrometer 
rH - 400 MHz; BC - 100 MHz) Spectrometer. All spectra were recorded in deuterated 
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chloroform (CDCh) or deuterated dimethylsulfoxide (DMSO-d6) using tetramethylsilane 
(fMS) as an internal standard. All chemical shifts (6) are recorded in ppm and are 
rounded off to two decimal places; coupling constants (.-? are recorded in hertz (Hz) and 
rounded off to one decimal place. Abbreviations used in the assigning of lH-NMR signals 
are: br (broad), d (doublet), dd (doublet of doublets), m (multiplet). s (singlet) and t 
(triplet). 13C-NMR chemical shift values are listed without assignment to specific carbon 
atoms, a format accepted by most international journals. 
Infrared (IR) spectra were recorded on a Thermo Nicolete FTIR instrument in the 4000-
1000 cm-I range, with samples prepared either as chloroform solutions or as KBr discs. 
Low resolution Mass spectra (lRMS) were recorded on an API 4000 Triple Quadropole 
from Applied Biosystems. fitted with a Turbo Ion Spray source. or on a JEOl GC Mate II 
single magnetic sector mass spectrometer. 
8.1.4 Experimental 
8.1.4.1 Curcumin 
1.7-Bir(4-hydroxy-3-methoxy-phenyl)-hepta-t.6-diene-3.5-dione;Curcumin. 
d 
4 0 OH 
H3CO 
b c 
5 
HO 3 
l' 
3' 
Technical grade curcumin. (Aldrich) was 
adsorbed onto silica and purified by 
4' conventional OCH3 
silica column 
5' chromatography (tOO% CH2Cb). The 
OH 
residual solid after evacuation of the 
solvent was re-crystallized from a 
CH2CI;z/Hexane mixture to yield the pure 
target compound as a crystalline yellow solid; mp 174 - 176"C (from CH2CI2IHex): Rt 
(EtOAc:Hex 8:2) 0.69; IR Vmax (KBr)/cm-1 3506 (Ar O-H), 30n (Ar C-H), 1628 (C=O). 
1600 (Ar C=C); OH (400 MHz, CDeb) 7.61 (2H. d. J 15.8. H-a, a'). 7.14 (2H. dd. J 1.9 
and 8.2, H-2. 2'). 7.07 (2H. d. J 1.9. H-1. 1'). 6.95 (2H. d. ) 8.2. H-3, 3'). 6.49 (2H. d, J 
15.8. H-b. b'). 5.86 (1H. s, H-d), 5.82 (tH, s, H-c), 3.97 (6H, s, H4, 4'); Oc (tOO MHz, 
CDCl l ) 168.6 (2C), 148.8 (2C). 147.9 (2C), 140.5 (2C), 127.8 (2C). 122.9 (2C), 121.9 (2C). 
114.9 (2C), t09.7 (2C). 101.1. 56.0 (2C); lRMS (EI) mlz 366.9 (M + H) M+ C21 H2006 
requires 368.1; Anal. Caled. for C21 H:zo06 - C 68.5%. H 5.5%; found C 68.5%, H 5.7%. 
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CHAPTER EIGHT: EXPERIMENTAL 
8.1.4.2:Experimental details pertaining to Chapter 3 
General method I: synthesis of the acetylenic intermediates 3.7 and 3.8: 
Vanillin (4-hydroxy-3-methoxybenzaldehyde) or acetovanillone (4-hydroxy-3-
methoxyacetophenone) (13 mmol) was dissolved in 10 ml of anhydrous DMF. 
Anhydrous I<2C03 (2.7 g. 19.5 mmol) was then added to the solution. and the mixture 
stirred at 30"C for 30 minutes. Propargyl bromide (3-bromopropyne. 2.2 mL 19.5 rnmol). 
was then added slowly to the reaction mixture. which was subsequently stirred at 30"C 
for 6 hours upon which TlC indicated completion of the reaction. 
The reaction mixture was then diluted with 50 ml water and extracted with EtOAc (3 x 
50 ml). These extracts were then combined. washed with water (2 x 50 mL). dried over 
anhydrous N~S04 and evaporated in vacuo to yield the product residue that was then 
purified by crystallization from CH2Cb/Hexane mixtures. 
3 -Methoxy4-prop-2 -ynyloxy-benzaldehyde. 3.7 
White crystalline solid (2.0 g. 82°/0); mp 86°C (from 
CH2Ch/Hex); Rr (EtOAc: CH2Cb:Hex) 0.43; IR Vmax 
(CHCb)/cm-1 3307 (Alkynyl C-H). 3021 (Ar C-H).' 2127 
(C=C), 1683 (C=O). 1590 (Ar C=C); OH (300 MHz. 
CDCh) 9.87 (1H. s. H-7), 7.45 (1H, dd. J1.9 and 7.8. H-
2), 7.43 (1H. d. Jt9, H-U. 7.14 (1H. d, J7.8, H-3), 4.85 (2H. d. J2.4. H-5). 3.94 (3H. s. 
H-4). 2.55 (1H. t. J2.4. H-6); & (75 MHz, CDCb) 190.8. 152.1. 150.1. 131.0. 126.1. 112.7. 
109.6. 77.4. 76.6. 56.6. 56.0; lRMS (EI) mlz 191.3 (M + H) M+ CnHlO0 3 requires 190.1; 
Anal. Caled. for CnHo03 - C 69.5%. H 5.3%; found C 69.5%. H 5.2%. 
1-(3 -Methoxy4-prop-2 -ynyloxy-phenyl}-ethanone. 3.8 
Off-white crystalline solid (2.2 g. 82%); mp 90 - 91°C 
(from CH2Cb/Hex): Rr (EtOAc: CH2Cb:Hex 1 :4:5) 0.39; 
IR Vmax (CHCb)/cm-1 3308 (Alkynyl C-H), 3017 (Ar C-H). 
2127 (CsC). 1675 (C=O). 1591 (Ar C=C); OH (400 MHz, 
CDCh) 7.56 (TH. dd. J 2.0 and 8.2. H-2), 7.54 (tH. d. J 
2.0. H-i). 7.05 (tH. d. J 8.2. H-3). 4.83 (2H. d. J 2.4. H-5). 3.93 (3H. s. H-4) 2.56 (3H. 
s, H-7). 2.54 (tH. t. J 2.4. H-6); oc (100 MHz. CDCI3) 196.8. 151.3. 149.6. 131.5. 122.8. 
112.5. 110.7, 77.3. 76.4. 56.6. 56.0. 26.2; lRMS (El) mlz 204.9 (M + H) M+ C12H203 
requires 204.1; Anal. Calcd. for C12H203 - C 70.6%. H 5.9%; found C 70.3%. H 6.0%. 
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General methoo II: synthesis of the acetylenic chakones 3.9 - 3.10: 
The appropriately substituted acetophenone (3 mmol) was dissolved in 10 ml methanol, 
after which 2.5M aqueous NaOH (4 mL) was added and the mixture stirred at 70°C for 
15 minutes. The appropriately substituted benzaldehyde (3 mmol) was then added in one 
portion, and the mixture stirred at 700 C for a further 3 hours. 
This series of products precipitated out of solution, and, after allowing the reaction 
mixture to c.ool to ambient temperature. the chalcone products were filtered. washed 
with water, air dried and purified by silica column chromatography (EtOAc/Hex). 
1-( 4-Methoxy-phenyl)-3-(3 -methoxy4-prop-2-y nyloxy-phenyl)-propenone. 3.9a 
o 
5~ ~6 
o 
3' 
Yellow solid (980.4 mg, 76%); mp 128 - 1300C 
(from EtOAc/Hex); R, (EtOAc: CH2Cb:Hex) 
0.30; IR Vmax (CHCh)/cm-1 3301 (Alkynyl C-H). 
3015 (Ar C-H). 1655 (C=O). 1601 (Ar C=C); OH 
(400 MHz. CDCb) 8.03 (2H, d. J 8.8, H-l' ,4'), 
7.75 (1H. d. 115.6, H-a), 7.41 (lH, d, 115.6, H-
b), 7.24 (1H. dd, J 2.0 and 8.4. H-2). 7.17 (tH, d, J 2.0. H-t), 7.06 (lH, d, J 8.2, H-3), 
6.98 (2H. d, J 8.9. H-2',3'), 4.81 (2H, d. J 2.6, H-5), 3.95 (3H, s. H-5'). 3.89 (3H, s, H-
4).2.54 (1H. t. J2.6. H-6); oc (100 MHZ, CDCh) 188.7. 163.3.149.8. 148.9, 143.8, 131.3, 
130.7. 129.3. 122.3. 120.4. 113.9, 113.8, 110.9, 78.0. 77.4, 76.6, 76.2. 56.7, 56.0. 55.5; 
LRMS (EI) mlz 323.4 (M + H) M+ C2oH604 requires 322.1: Anal. Caled. for 
C2oH1S04.1hH20 - C 72.4%. H 5.4%; found C 72.5%. H 5.8%. 
1-(2.4-Dimethoxy-phenylj-3-(3 -methoxy-4-prop-2-ynyloxy-pheny/J-propenone. 3.9b 
z' 
Yellow solid (948.9 mg, 90%); mp: 900 - 91°C 
(from EtOAc/Hex); Rr (EtOAc: CH2Cb:Hex 1:4:5) 
0.30; IR v""", (CHCh)/cm-1 3303 (Alkynyl C-H), 
3015 (Ar C-H), 1651 (C=O). 1604 (Ar C=C); 01-1 
(400 MHz. CDCh) 7.72 (1H. d, J8.6, H-3'), 7.60 
(tH, d, J 15.7, H-a), 7.36 (lH. d, J 15.7. H-b). 
7.18 (1H. dd, J 2.0 and 8.2, H-2), 7.12 (tH. d. J 2.0, H-t), 7.03 (lH, d, J 8.2. H-3), 6.56 
(1H, dd, J2.2 and 8.6. H-2'), 6.50 (1H, d, J2.2, H-l'). 4.79 (2H. d, J2.4. H-5). 3.91 (3H. 
s, H-4') , 3.89 (3H. s. H-5'). 3.87 (3H. s. H-4), 2.53 (1 H. t, J 2.4, H-6); oc 100 (MHz. 
CDCb) 190.7. 163.9. 160.3. 149.8. 142.1. 132.7. 129.8. 125.9. 122.4. 122.0. 114.0. 111.1. 
105.2, 98.9, 77.3, 76.7, 76.1. 56.7. 56.0, 55.5; LRMS (EI) mil 353.3 (M + H) M+ 
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General method II: synthesis of the acetylenic chalcones 3.9 - 3.10: 
The appropriately substituted acetophenone (3 mmol) was dissolved in 10 ml methanol. 
after which 2.5M aqueous NaOH (4 ml) was added and the mixture stirred at 7(J'C for 
15 minutes. The appropriately substituted benzaldehyde (3 mmol) was then added in one 
portion. and the mixture stirred at 7(J' C for a further 3 hours. 
This series of products precipitated out of solution. and, after allowing the reaction 
mixture to cool to ambient temperature, the chalcone products were filtered. washed 
with water, air dried and purified by silica column chromatography (EtOAc/Hex). 
1-( 4-Methoxy-phenyl)-3-(3 -methoxy4-prop-2-y ny/oxy-phenyl)-propenone. 3.9a 
o 
CI 
3' 
Yellow solid (980.4 mg, 76%): mp 128 - 13(J'C 
(from BOAc/Hex): Rt (EtOAc: CH2Cb:Hex) 
0.30; IR V max (CHCb)/cm-1 3301 (A I kynyl C-H), 
3015 (Ar C-H). 1655 (C=O). 1601 (Ar C=C); OH 
(400 MHz. CDCb) 8.03 (2H. d, J 8.8, H-1',4'), 
7.75 (lH, d. 115.6, H-a), 7.41 (tH, d, 115.6, H-
b), 7.24 (lH, dd, J 2.0 and 8.4, H-2). 7.17 (1H, d, J 2.0. H-1). 7.06 (1H. d. J 8.2. H-3). 
6.98 (2H, d, J 8.9, H-2',3'). 4.81 (2H, d, J 2.6, H-5), 3.95 (3H. s. H-5'), 3.89 (3H, s, H-
4).2.54 (tH. t. J2.6. H-6); Oe (100 MHZ, CDCh) 188.7. 163.3.149.8. 148.9. 143.8, 131.3, 
130.7, 129.3. 122.3, 120.4, 113.9. 113.8. 110.9. 78.0. 77.4. 76.6, 76.2, 56.7, 56.0. 55.5; 
lRMS (EI) mlz 323.4 (M + H) M+ C:!OH604 requires 322.1; Anal. Caled. for 
C2oH804.~H20 - C 72.4%, H 5.4%; found C 72.5%. H 5.8%. 
1-(2,4-Dimethoxy-phenyl)-3-(3 -methoxy4-prop-2-ynyloxy-phenyl)-propenone. 3.9b 
4' Yellow solid (948.9 mg. 90%); mp: 9(J' - 91°C 
o OCH3 (from EtOAc/Hex); Rt (EtOAc: CH2Cb:Hex 1:4:5) 
0.30; IR Vmax (CHCh)/cm-1 3303 (Alkynyl C-H), 
2' 3015 CAr C-H), 1651 (C=O), 1604 (Ar C=C); OH 
(400 MHz. CDCh) 7.72 (1H, d, J8.6, H-3'). 7.60 
(tH. d. J 15.7. H-a). 7.36 (1H. d, J 15.7, H-b). 
7.18 (1H, dd, J 2.0 and 8.2, H-2), 7.12 (lH, d, J 2.0. H-l). 7.03 (lH. d. J 8.2, H-3), 6.56 
(lH, dd, J2.2 and 8.6, H-2'), 6.50 (tH. d. J2.2, H-t'), 4.79 (2H. d. J2.4, H-5). 3.91 (3H, 
s, H-4'). 3.89 (3 H. s, H-5'), 3.87 (3 H, s, H-4). 2.53 (1 H, t. J 2.4, H-6); Oe 100 (MHz. 
CDCb) 190.7. 163.9, 160.3, 149.8, 142.1. 132.7, 129.8. 125.9. 122.4. 122.0, 114.0, 111.1, 
105.2. 98.9. 77.3. 76.7. 76.1, 56.7, 56.0. 55.5; lRMS (EI) m/z 353.3 (M + H) M+ 
202 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
CHAPTER EIGHT: EXPERIMENTAL 
C:nH200S requires 352.1; Anal. Caled. for C21HwOs - C 71.6%. H 5.7%; found C 71.2%. H 
5.8%. 
3-(3 -Meth0xy4-prop2-ynyloxy-phenyl)-1-(2.3 .4-trimethoxy-phenyl)-propenone. 3.9c 
o 
f' 
OCH s· 3 
Yellow solid (t.1 g. 84%): mp: 85 - 86°C (from 
EtOAc/Hex); R, (EtOAc:Hex 4:6) 0.30; IR Vmax 
(CHCh)/cm-' 3308 (Alkynyl C-H). 3018 (Ar C-H), 
1652 (C=O), 1594 CAr C=C): oH (400 MHz. 
CDCb) 7.61 (tH. d. ) 15.7. H-al, 7.45 (tH. d, ) 
8.6. H-2'), 7.34 (tH. d. )15.7, H-b), 7.19 (1H, dd, 
)2.0 and 8.4, H-2). 7.13 (tH. d. )2.0. H-t). 7.03 (tH, d.) 8.4, H-3), 6.74 (tH. d. J8.8, 
H-r), 4.79 (2H, d, )2.4, H-5). 3.92 - 3.91 (t2H, m, H-3'. 5', 4', 4), 2.53 (tH, t, )2.4, H-
6); oc (tOO MHz. CDCh) 190.9, 156.9. 153.6, 149.7. 148.9. 143.0, 142.0. 129.4. 126.9. 
125.7, 125.2, 122.3. 114.0, no.o, 107.4, 77.3, 76.7, 16.1, 62.1, 61.1, 56.7, 56.1: LRMS (EI) 
mlz 383.4 (M + H) M+ C22Ha 06 requires 382.1; Anal. Caled. for C22H220 6 C 69.1%, H 
5.8%; found C 68.6%, H 5J~o/o. 
3-(2.4-Dimethoxy-phenyl)-1-(3-methoxy-4-prop2-ynyloxy-phenyl)-propenone. 3.10a 
o 
2' 
Yellow solid (946.1 mg. 89%); mp: 136 - 13rC 
(from EtOAc/Hex); R, (EtOAc:Hex 3:7) 0.17; IR 
V max (CHCh)/cm-1 3308 (Alkynyl C-H), 3019 (Ar C-
H), 1651 (C=O), 1598 (Ar C=C): OH (300 MHz. 
CDCh) 8.04 (tH, d, )15.6. H-a), 7.67 - 7.63 (2H. 
m, H-1, 3). 7.57 (tH. d, ) 8.8. H-2). 7.55 (tH. d. ) 
15.6. H-b), 7.08 (tH. d, )8.3, H-3'), 6.53 (tH. dd, )2.4, 8.3, H-2'). 6.48 (tH, d, )2.4, H-
1'). 4.84 (2H. d, ) 2.4, H-5). 3.96 (3H. s, H-4'). 3.85 (3H, s, H-5'), 3.85 (3H. s. H-4), 
2.54 (tH, t, ) 2.4, H-6); Oc (75 MHz, CDCh) 189.4, 162.9, 160.4. 150,5, 149.6, 139.9. 
133.0. 130.9. 122.3. 120.2. 117.3, 112.5. In.5. 105.4. 98.5. 77.4. 76.6. 76.3. 56.6. 56.0. 
55.5; lRMS (EI) m/z 353.0 eM + H) M+ C21 HwOs requires 352.1; Anal. Caled. for 
C21H200S.Y.zH20 - C 69.7%. H 5.5%: found C 69.6%*, H 5.7%. 
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1-(3-Methoxy4-prop-2-ynyloxy.phenylj-3-(2.3.4-trimethoxy.phenylj-propenone,3.10b 
4' o 
2' 
Yellow solid (1.5 g. 78%); mp 134 - 135"C (from 
EtOAc/Hex); Rt (EtOAc:Hex 3:7) 0.21: IR V max 
(CHCh)/cm-1 3308 (Alkynyl C-H), 3017 CAr C-H), 
1654 (C=O). 1594 (Ar C=C): OH (400 MHz. 
CDCh) 7.97 (1H. d. J 15.7. H-a). 7.65 (1H. dd. J 
2.0 and 8.2. H-3), 7.64 (lH. d. J 2.0. H-l). 7.56 
(lH, d, 115.7, H-b), 7.36 (1H, d. J 8.8, H-1'), 7.09 (1H, d. J 8.2. H-2). 6.72 (1H. d. J 8.8. 
H-2'). 4.85 (2H, d. J 2.4, H-S), 3.96 (3H. s, H-S'). 3.95 (3H. s. H-3'). 3.90 (3H. s, H-4), 
3.89 (3H. s. H-4'). 2.55 (1H. t. J 2.4. H-6); ; oc (100 MHz. CDCh) 189.1. 155.7, 153.8, 
150.7, 149.7. 142.6. 139.6, 132.8, 123.9. 122.4, 121.1, 112.6. 111.5. 107.7. 77.3, 76.7, 76.3. 
61.4. 60.9. 56.6. 56.1; lRMS (EI) mlz 383.4 (M + H) M+ C:nHn 06 requires 382.1; Anal. 
Calcd. for C:nH:n06 - C 69.1%. H 5.8%; found C 68.7%. H 5.2%. 
3-(2.4-Dichlorr:rphenylj-l-(3-methoxy.4-prop-2-ynyloxy-phenylj-propenone. 3.10:: 
Yellow solid (1.4 g. 79%); mp: 115 - 117°C (from 
EtOAc/Hex); Rt (EtOAc:Hex 4:6) 0.52; IR V max 
(CH h)/cm-1 3308 (Alkynyl C-H). 3017 (Ar C-H). 
1661 (C:::::O), 1584 (Ar C=C): OH (300 MHz. 
CDCh) 8.08 (1 H. d. J 15.6. H-a). 7.67 (1 H, d. J 
8.2. H-3 '), 7.64 (1 H, dd, J 1. 9 and 8.3. H-3). 7.63 
WH, d. J 1.9, H-U, 7.47 (1H, d, J 15.6. H-b), 7.46 (1H, d. J 1.9. H-r). 7.29 (lH. dd. J 1.9 
and 8.3. H-2'), 7.09 (1H, d. J 8.3, H-2). 4.86 (2H. d, J2.4. H-5), 3.96 (3H. s. H-4). 2.55 
(tH. t, J 2.4, H-6); oc (75 MHz. CDCh) 188.3. 151.2. 149.8. 138.7. 136.3. 135.9. 132.1. 
131.9. 130.1. 128.5. 127.5. 124.9, 122.7. 112.5. 111.4. 77.4. 76.6. 56.6. 56.1; lRMS (EI) 
mlz 362.4 (M + H) M+ C19H 4Cb03 requires 361.2; Anal. Calcd. for C19H 4Cb03 - C 
63.2%. H 3.9%; found C 63.4%. H 3.8%. 
3-(4-Fluoro-phenylj-l-(3-methoxy.4-prop-2-ynyloxy.phenylj-propenone. 3.1 Od 
F J' 
Yellow solid (1.4 g. 88%); mp 151 - 152"C (from 
EtOAc/Hex): Rt (EtOAc: CH2Cb:Hex 1:4:5) 0.43; 
lR Vmax (CHCb)/cm-1 3304 (Alkynyl C-H), 3018 CAr 
C-H), 1656 (C=O), 1597 (Ar C=C); OH (400 MHz, 
CDCh) 7.78 (tH. d, J 15.6. H-a). 7.65 (1H. dd, J 
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2.0 and 8.2. H-3), 7.63 (1H. d. J 2.0. H-O, 7.59 (2H, d, J 8.8, H-r. 4'). 7.42 (1H, d, J 
15.6, H-b), 7.09 (1 H. d, J 8.2. H-2), 6.94 (2H. d. J 8.8. H-2'. 3'), 4.85 (2H. d. J 2.4. H-
5),3.86 (3H. s, H-4). 2.55 (1H. t, J2.4. H-6); Sc (100 MHz, CDCh) 188.7. 150.6, 149.7, 
144.0, 142.8, 132.7, 130.1. 127.8. 122.3. 121.4. 119.4, 116.2, 114.4. 112.5. 1n.4. 77.3, 76.6. 
56.7. 56.1; lRMS (El) mlz 311.3 (M + H) M+ C19H sF03 requires 310.0; Anal. Caled. for 
C19H sF03 - C 73.5%. H 4.9%; found C 73.4%. H 5.4%. 
3-(2.4-Difluoro-phenyl)-1-(3-methoxy-4-prop-2-ynyloxy-phenylj-propenone. 3.1Oe 
F 
F 2' 
o Yellow solid (1.4 g. 85%); mp 98 - 99"C (from 
EtOAc/Hex); R, (EtOAc:Hex 3:7) 0.19; IR V max 
(CHCh)/cm,l 3295 (Alkynyl C-H), 2954 (Ar C-H), 
1654 (C=O). 1595 (Ar C=C); SH (300 MHz. 
CDC!;) 7.85 (tH. d. J 15.6. H-a), 7.66 (tH. dd. J 
1.9 and 8.3, H-2), 7.63 (1H. d, J 1.9, H-1). 7.57 
(1H. d. J8.8. H-3'), 7.54 (1H, d. 115.6, H-b). 7.09 (tH, d. J8.3. H-3). 6.73 (tH. dd, J2.4 
and 8.8, H-2'), 6.69 (1H. d, J2.4. H-r). 4.85 (2H. d, J2.4, H-5), 3.96 (3H. s. H-4). 2.55 
(tH, t, J 2.4. H-6); Sc (75 MHz, CDCb) 188.8. 150.9, 149.7. 139.9. 137.1. 132.5. 130.9, 
122.5. 120.2, 117.3. 112.5. 111.4. 105.4. 101.9. 98.5. 77.4. 76.6, 56.6, 56.1; lRMS (EI) mlz 
329.2 (M + H) M+ C'9H4F20 3 requires 328.1; Anal. Caled. for C19H4F203 - C 69.5%, H 
4.3% found C 69.1%. H 4.2% 
4-(3-Methoxy4-prop-2-ynyloxy-phenyl)-oot-3-en-2-one. 3.11 
of the benzaldehyde starting material. 
6.2 g (32 mmol) of the O-alkylated 
benzaldehyde (3.7) was dissolved in 30 ml 
acetone, after which 2.5M aqueous NaOH (t9 
mL. 48 mmol) was added. The mixture was 
then stirred at room temperature for 6 hours. 
after which TlC showed complete consumption 
The reaction mixture was then gradually neutralized with 2.5M HCl. during which the 
crude product precipitated out as an amorphous yellow solid. This crude product was 
then filtered. washed with water. air dried and purified by silica column chromatography 
(EtOAclHex) to yield a pale yellow, crystalline solid (5.3 g. 71%); mp 103 - 105°C (from 
EtOAc/Hex); R, (EtOAe:Hex 4:6) 0.33; IR Vmax (KBr)/em' 3253 (Alkynyl C-H). 2985 (Ar 
C-H). 1671 (C=O), 1595 (Ar C=C); SH (400 MHz, CDCb) 7.49 (1H, d, 116.2, H-a), 7.14 
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(1H, dd, J 2.0 and 8.3, H-2), 7.10 (1H, d, J 2.0. H-t), 7.05 (tH. d, J 8.3, H-3), 6.63 (1H. 
d. 116.2, H-b), 4.81 (2H, d, J 2.4, H-5). 3.93 (3H. s. H-4). 2.43 (1H. t. J 2.4, H-6), 2.38 
(3H, 5, H-b'); Oc (100 MHZ. CDCh) 198.1. 149.9. 143.2, 128.6. 125.8. 122.4 (2C). 113.9, 
110.4, 77.9. 76.2. 56.6. 55.9. 27.4: lRMS (EI) mlz 231.3 (M + H) M+ C14H403 requires 
230.1; Anal. Caled. for C14H403 - C 73.0%. H 6.1%: found C 72.8%. H 6.2 %; 
General method IV: synthesis of the acetylenic dienones (3.12a - 3.12f): 
A mixture of 230 mg (t mmol) of the acetylenk enone (3.11) and the appropriately 
substituted benzaldehyde (t.1 mmol) were dissolved in 10 ml anhydrous l,4-dioxane 
under a nitrogen atmosphere. To the stirring mixture. BF3-Et20 (0.2ml. 1.5 mmol) was 
added. and the mixture stirred overnight at 50"C. 
The reaction mixture was then allowed to cool to ambient temperature. diluted with 
CH2Cb and washed twice with water. The organic layer was then collected, dried over 
anhydrous Na2S04. concentrated in vacuo and the product residue purified by silica 
column chromatography (EtOAc/Hex). 
1-(4-Methoxy-phenyl)-5-(3-methoxy-4-prop-2-ynyloxy-phenyl)-penta-l. 4-dien-3-one. 
3.t2a 
o 
b b' 
o 
sl ~ ~6 
3' 
Yellow solid (135 mg, 39%): mp 124 - 125°C 
(from EtOAc/Hex): Rt (EtOAc:Hex 4:6) 0.30; IR 
5' V max (KBr)/cm-l 3289 (Alkynyl C-H), 3035 CAr C-
OCH 
H), 1643 (C=O). 1599 (Ar C=C): OH (300 MHz. 
CDCI;) 7.70 (t H. d, J 16.0, H-a). 7.68 (t H, d, ) 
16.0. H-a'). 7.56 (2H. d, J 8.8. H-r. 4'). 7.19 
(tH. dd. J 2.0 and 8.3, H-2), 7.15 (tH, d. J 2.0. H-l). 7.05 (tH. d. ) 8.3. H-3), 6.97 (lH, 
d. J16.0, H-b), 6.94 (tH. d, 116.0, H-b'). 6.92 (2H. d. J8.8. H-2', 3'). 4.81 (2H, d, J2.4, 
H-5). 3.94 (3H. s. H-4). 3.85 (3H. s. H-4'). 2.54 (tH. t. J 2.4. H-6); Oe (75 MHZ. CDCh) 
188.7, 161.6. 149.9, 148.9, 142.8, 142.6, 130.1 (2C), 129.1. 127.6. 124.4, 123.3. 122.4, 
114.4 (2C). 113.9, 110.7, 78.0. 76.2. 56.7, 55.9. 55.4; lRMS (EI) mlz 348.9 (M + H) M+ 
C22H2004 requires 348.1; Anal. Caled. for C22 H2004 - C 75.8% , H 5.8%; found C 75.7%, 
H 5.7%. 
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1-{2.4-Dimethoxy-phenyI)-S-(3-methoxy-4-prop-2-yny/oxy-pheny/)-penta-I.4-dien-3-one, 
3.12b 
o 
5~ ~6 
o 
b b' 
2' 
Yellow solid (185 mg. 49%); mp 57 - 59"C 
(from EtOAc/Hex): R, (EtOAc:Hex 4:6) 0.30; 
IR Y rnax (KBr)/em-1 3260 (AI ky nyl C-H), 2927 
(Ar C-H). 1642 (C=O). 1595 (Ar C=C): OH (300 
MHz. CDCb) 8.01 (1H. d. J 16.1. H-a'). 7.67 
(1H. d. J 15.9. H-a). 7.55 (1H. d. J 8.6, H-3'), 
7.19 (lH. dd. 11.9 and 8.3, H-2), 7.15 (1H. d, 11.9. H-l), 7.07 (1H, d, 116.0, H-b'), 7.05 
(1H, d. J 8.3. H-3). 6.98 (1 H. d. J 15.8. H-b), 6.53 (1H. dd, J 2.3 and 8.6. H-2'). 6.46 
(1H. d, J 2.2. H-t'). 4.81 (2H. d, J 2.4 H-5). 3.94 (3 H. s. H-4'). 3.90 (3H. s, H-5'), 3.85 
(3H, s, H-4). 2.54 (1H, t. J 2.4, H-6); oc (75 MHZ. CDCh) 189.3. 163.0. 160.1. 149.8, 
142.2. 138.5. 137.8. 130.4. 130.2. 129.4. 124.0. 122.2. 117.1. 113.9, 110.8, 105.5, 98.5, 
77.4. 76.2, 56.7. 55.9, 55.5, 55.4; LRMS (EI) mlz 378.9 (M + H) M+ C23H220 S requires 
378.2: Anal. Caled. for C23H220 S .lhH20- C 71.2%. H 5.9%; found C 71.5%, H 5.9%. 
1-(3-Methoxy-4-plOp-2-ynyloxy-phenyl)-S-{2.3.4-trimethoxy-phenyl)-penta-l,4-dien-3-
one.3.12c 
o 
b b' 
Yellow solid (191 mg, 47%); mp -67 - 69°C 
(from EtOAc/Hex); Rr (EtOAc:Hex 4:6) 0.33; 
IR Y max (KBr)/cm-1 3260 (Alkynyl C-H). 2934 
(Ar C-H). 1645 (C=O), 1588 (Ar C=C): OH 
(300 MHz. CDCh) 7.94 (1H. d. J 16.1, H-a'), 
7.67 (1H, d, 115.9, H-a), 7.36 (lH. d. J 8.8. H-
2'). 7.20 (lH. dd. J1.9 and 8.4. H-2). 7.15 (1H. d, J1.9, H-t), 7.06 (lH, d, 116.1. H-b'), 
7.04 (1H, d, J8.3. H-3). 6.97 (1H. d, 115.8. H-b). 6.71 (1H, d. J8.8. H-l'). 4.81 (2H. d. J 
2.4 H-5). 3.95 (3H. s, H-3'), 3.94 (3H, s, H-5'), 3.91 (3H. s, H-4'). 3.89 (3H. s. H-4), 
2.54 (1H, t, J 2.4. H-6); oc (100 MHZ. CDCb) 189.1, 155.7. 149.8. 148.9. 142.6. 138.1 
(2C), 129.2, 124.9, 124.3, 123.5, 122.3. 121.9. 113.9, 110.7 (2C). 107.7. 78.0. 76.2. 61.5, 
60.9,56.7.56.1.55.9: LRMS (EI) m/z 409.4 eM + H) M+ C24H2406 requires 408.2; Anal. 
Caled. for C24H240 6 .lhH20- C 69.00/0, H 6.00/0; found C 69.5%, H 6.1%. 
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1-(2.4-Dichloro-phenyl)-5-(3-methoxy-4-prop-2-ynyloxy-p/1enyl)-penta-l.4-dien-3-one. 
3.12d 
o 
b &' 
(I 
2' 
Yellow solid (251 mg. 65%): mp 74 - 76"C 
(from EtOAc/Hex): R, (EtOAe:Hex 4:6) 0.59; IR 
V max (KBr)/eml 3239 (Alkynyl C-H). 2949 (Ar C-
H), 1653 (C=O), 1588 (Ar C=C): ()H (300 MHz, 
CDCb) 8.03 (tH, d, )16.0, H-a'), 7.67 (tH, d, ) 
15.9, H-a), 7.64 (tH, d, J 8.5, H-3'), 7.46 (tH, 
d. J2.1. H-l'). 7.29 (lH. dd. )2.1 and 8.5, H-2'), 7.21 (tH. dd. J2.0 and 8.4 •• H-2). 7.14 
(lH. d, J2.0. H-l). 7.06 (tH. d. J8.3. H-3). 7.04 (tH. d. 116.0. H-b'). 6.96 (tH. d. 115.9, 
H-b). 4.82 (2H, d. ) 2.4 H-5). 3.94 (3H. s. H-4), 2.54 (tH. t, ) 2.4. H-6); oc (75 MHZ, 
CDCh) 188.5. 150.2, 149.2. 143.8. 137.4. 136.3. 135.9. 131.9. 130.1. 128.8. 128.4. 128.2. 
127.6. 123.7. 122.6. 113.9. 110.8. 77.9. 76.3.56.7.56.0; lRMS (EI) m/z 387.2 (M + H) 
M+ C21HI6Cb03 requires 386.1; Anal. Caled. for C21 H 6Cb03 - C 65.1%. H 4.2%; found C 
64.8%. H 4.2%. 
1-(4-Fluoro-phenyl)-5-(3-metooxy-4-prop-2-ynyloxy-phenyl)-penta-l.4-dien-3-one. 3.12e 
o 
b b' 
F 
3' 
Yellow solid (151 mg. 45%); mp 106 - 108G C 
(from EtOAc/Hex): R, (EtOAe:Hex 4:6) 0.50; IR 
Vmax (KBr)/eml 3231 (Alkynyl C-H), 2920 CAr C-
H). 1667 (C=O). 1591 (Ar C=C); OH (300 MHz. 
CDCh) 7.69 (1H, d, 115.9. H-a'). 7.67 (tH, d, J 
15.9, H-a), 7.61 (tH. d, J 8.7. H-4'). 7.60 (tH. 
d, J 8.7, H-1'), 7.20 (tH, dd. ) 1.9 ad 8.3. H-2), 7.15 (tH. d, J 2.0. H-l). 7.13-7.04 (3H, 
m. H-2', 3'. 3). 7.01 (tH. d, 116.3, H-b'). 6.93 (tH. d. 115.9. H-b). 4.81 (2H. d. J2.4 H-
5), 3.93 (3H, s, H-4), 2.54 (tH, t. ) 2.4. H-6); ()c (75 MHZ. CDCt 3) 188.5. 165.7. 149.9, 
149.1, 143.2, 141.7, 130.3, 130.1, 128.9. 125.0, 124.2. 122.6 (2 C). 116.2, 115.9. 113.9, 
110.7. 77.9. 76.2. 56.7, 55.9; lRMS (EI) m/z 336.9 eM + H) M+ C21 H 7F03 requires 336.1: 
Anal. Caled. for C21 H7F03 - C 74.9%. H 5.1%; found C 74.5%, H 5.1%. 
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1-(2. 4-Difluoro-phenyl)-5-(3-methoxy-4-prop-2-ynyloxy-phenyl)-penta-l.4-dien-3-one. 
3.12f 
o 
b 
o 
S~ ~6 
F 
2' F 
Yellow solid (153 mg. 43%): mp 99 - 101°C 
(from EtOAc/Hex); R, (EtOAc:Hex 4:6) 0.55; IR 
Vmax (KBr)/cm-l 3224 (Alkynyl C-H). 2992 (Ar C-
H), 1645 (C=O), 1584 CAr C=C): ()H (300 MHz. 
CDCb) 7.78 (1H. d, 116.1. H-a'), 7.70 (1H. d. 1 
15.9, H-a), 7.62 (1H, d. 18.5, H-3'), 7.21 (1H. 
dd. 12.0 ad 8.3. H-2). 7.16-7.12 (2H, m, H-b', l). 7.07 (1H. d. 18.3. H-3). 6.95 OH. d. J 
15.9. H-b). 6.90 (tH. dd. 12.4 and 8.6. H-2'). 6.87 (1H, d. 12.4. H-l'), 4.83 (2H. d. 1 
2.4 H-5). 3.94 (3 H. s. H4). 2.55 (t H. t. 12.4, H-6); oc (75 MHZ. CDCh) 188.5. 165.3. 
160.7. 149.9, 149.0. 143.5. 134.5. 130.6. 128.9, 127.3. 124.1. 122.7. 113.9. n2.3. 112.0. 
nO.7. 104.9. 78.0. 76.3. 56.7. 56.0: lRMS (EI) mlz 355.0 (M + H) M+ C2,H16F203 
requires 354.1: Anal. Caled. for C21H6F203- C 71.2%. H 4.6%; found C 70.8%.H 5.0%. 
4-Azido-l-chloro-quinoline. 3.13 
4.7-dichloroquinoline (2.0 g. 10 mmol) was dissolved in 5 mL 
anhydrous DMF. NaN3 (t.3 g. 20 mmol) was then added in one 
portion. and the resulting mixture stirred at 65" C for 6 hours. 
whereupon TlC incUcated reaction completion. 
The reaction mixture was then allowed to cool to ambient temperature. after which it 
was diluted with 100 ml CH2Cb. washed with water (3 x 30 mL). dried over anhydrous 
Na2S04. and evaporated to dryness. The resulting product residue was crystallised from a 
CH2Cb/Hexane mixture to yield the final pure product as colourless. needle-like crystals 
(t.7 g. 86%); mp 115"C (from CH2CI2iHex); R, (EtOAc:Hex 3:7) 0.29; IR Vmax (CHCh)/cm-
1 3021 CAr C-H), 2123 (azide), 1609 CAr C=CJ; ()H (300 MHz. CDCh) 8.83 (tH, d, 14.9, 
H-2). 8.09 (tH. d, 12.4, H-8), 8.01 (tH, d, 19.3, H-5), 7.49 (1H, dd, 12.4 and 9.3. H-6) 
7.13 (1H, d. 14.9, H-3); oc (100 MHz. CDCh) 150.9, 149.1, 146.8, 136.9, 127.9, 123.8, 
119.9. 108.7; LRMS (El) mlz 204.9 (M + H) M+ C9HsC1N4 requires 204.0: Anal. Caled. for 
C9 HsCIN4 C 52.8%. H 2.5%. N 27.4%: found C 52.8%. H 2.4%. N 27.5%. 
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General method III: synthesis of the chalcone--triazole derivatives 3.14 - 3.17: 
The appropriate acetylenic chalcone (1 mmol) and the appropriate azide (AZT or 10. 1 
mmol) were dissolved in 5 mL DMF and. while stirring at 65° C, 1 M sodium ascorbate 
(0.4 mL. 0.4 mmol) and 1 M CUS04 (0.2 mL. 20 mol%) were added sequentially. in that 
order. The reaction mixture was then stirred at 6S" C for 24 hrs. 
The crude product was then precipitated out by slowly adding cold water to the reaction 
mixture. after which it was filtered. washed with water. air dried and purified by silica 
column chromatography (eluents ranging in polarity from EtOAc:Hex 3:7 to 5%MeOH 
in EtOAc). 
1-[S-HydroxymethyJ..4..(4-{2-methoxy-4-[3-(4-methoxy-phenylJ-3-oxo-propeny~­
phenoxymethyJ}-[l,2.3]triazol-l-ylJ-tetrahydro-furan-2-ylj-S-methyJ.1H-pyrimidine-2'4-
dione, 3.14a 
o 
3' 
Yellow solid (294.4 mg, SOC/a); mp 121 - 122°C 
(from MeOH/EtOAc); R, (EtOAc:Hex 9:1) 0.11; IR 
Vmax (CHCI3)/cm-1 3385 (O-H) , 3015 (Ar C-H), 
1691 (C=O). 1599 (Ar C=C); ()H (300 MHz. 
DMSO-dt,) n.30 (1H, s, H-14), 8.41 (lH. s, H-6), 
8.14 (2H, d, )8.8. H-1', 4'), 7.81 (1H, d, 115.6, H-
a), 7.80 (1H, s. H-12), 7.65 (1H. d, ) 15.6, H-b), 
7.52 (1H, d. ) 1.7, H-l). 7.38 (tH, dd, ) 1.7 and 
8.3, H-2), 7.22 (1H, d, ) 8.3, H-3), 7.07 (2H. d, ) 
8.9, H-2'. 3'). 6.42 (1 H, t, ) 6.6, H-9), 5.42 - 5.3 7 
(1H, m. H-7). 5.20 (2H, s, H-5), 4.25 - 4.22 (1H, 
m, H-I0), 3.86 (3H, s, H-5'), 3.84 (3H, s, H-4), 3.72 - 3.60 (2H, m, H-ll), 2.78 - 2.62 
(2H. m, H-8), 1.8(3H, s, H-13); Oe (100 MHz, DMSO-d6) 187.9, 164.4, 163.8. 151.1. 150.5. 
149.9. 144.2. 143.3, 136.9. 131.5. 130.9, 128.9, 125.2, 124.1. 120.6, 114.6, 113.9, 111.8, 
110.3. 85.1. 84.6, 62.4. 61.5. 60.0. 56.4, 56.2. 37.9, 12.9; LRMS (EI) mlz 590.5 eM + H) 
M+ C30H31NsOa requires 589.2; Anal.Calcd. for C30H31NsOS.H20 - C 59.2%, H 5.4%, N 
n.5%; found C 59.3%. H 5.4%, N 11.6%. 
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1-[4-(4-{4-[3-(2.4-Dimethoxy-pheny/J-3-oxo-propenylJ-2-methoxy-phenoxymethyl}-
[1.2.3] triazol-l-y~-5-hydroxymethyl- tetrahydro-furan-2-ylJ-5-methyI-1 H-pyrimidine-2,4-
dione. 3.14b 
o OCH 4' 3 
2' 
Yellow solid (289.6 mg. 47%); mp: 133 - 134°C 
(from MeOH/EtOAc): Rt (EtOAc:Hex 9:1) 0.11: 
IR V max (CHCb)/cm-' 3385 (O-H), 3015 (Ar C-H), 
1694 (C=O). 1602(Ar C=C); OH (400 MHz. 
DMSO-d6) 11.30 (tH, s, H-14), 8.41 (1H, s, H-6), 
7.79 (1H. s. H-12), 7.56 (tH, d, J .5. H-3'). 7.47 
(tH. d, J 15.8. H-a). 7.39 (tH. d, J 15.8. H-b). 
7.31 (tH. d. J t.9, H-l). 7.26 (tH. dd, J 1.9 and 
8.3. H-2). 7.20 (tH. d, J 8.3 H-3), 6.66 (1H, d, J 
2.4. H-r), 6.62 (1H. dd, J 2.4 and 8.4. H-2'), 
6.42 (1 H. t. J 6.6. H-9), 5.41 - 5.36 (1H. m, H-7), 
5.25 (1H. s, H-15), 5.19 (2H, s. H-5), 4.24 - 4.21 (1H. m. H-I0). 3.87 (3H, s. H-4'). 3.83 
(3H, s, H-5'), 3.79 (3H. s. H-4), 3.71 - 3.60 (2H. m, H-ll), 2.77 - 2.61 (2H. m, H-8), 
1.80 (3H. s, H-13); Oc (100 MHz. DMSO-d6) 190.3, 164.3, 160.6, 151.1. 150.2. 149.9. 
143.3. 142.5. 136.9. 132.4. 128.9. 126.0. 125.2, 123.0, 122.4. 114.1. 1n.8. nO.3. 106.6. 
99.4. 92.2. 85.0. 84.6. 65.5. 62.4, 61.5. 60.0, 56.6. 56.1, 37.9. 12.9; lRMS (EI) mlz 
620.5 eM + H) M+ C31 H33Ns09 requires 619.2; Anal. Caled. for C31H33Ns09.V:zH20 C 
59.2%. H 5.4%. N 11.1%; found C 59.00/0, H 5.1%. N 10.6%. 
1-[5-Hydroxymethyl-4-(4-{2-methoxy-4-[3-oxo-3-(2.3.4-trimethoxy-pheny~-propenylJ­
phenoxymethyf}-[t.2.31triazol-l-y~-tetrahydro-furan-2-ylJ-5-methyI-1H-pyrimidine-2~4-
dione. 3.14c 
Yellow solid (299.1 mg, 46%); mp 103 - 105°C 
(from MeOH/EtOAc); Rt (EtOAc:Hex 9:1} 0.10; IR 
Vmax (CHCh)/cm-1 3385 (O-H), 3015 (Ar C-H), 
1694 (C=O), 1593 (Ar C=C); OH (400 MHz, 
DMSO-d6) 11.29 (1H. s. H-14), 8.42 (1H. s. H-6). 
7.80 (tH, s. H-12). 7.48 (1H, d. J 16.1, H-a), 7.32 
(lH, d, J 16.1. H-b). 7.36 - 7.28 (3H. m. H-2', 1. 
2). 7.22 (1H. d, J8.3, H-3), 6.93 (1H. d. J8.8, H-
n. 6.43 (1H, t, J 6.3, H-9), 5.43 - 5.37 (1H, m. 
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H-7), 5.24 (tH, s, H-15), 5.21 (2H, s. H-5). 4.27 - 4.23. (tH, m, H-lO), 3.88 (3H. s, H-3'), 
3.84 (3H, s, H-5'), 3.81 (3H, s. H-4'), 3.80 (3H, s. H-4), 3.75 - 3.63 (2H, m, H-ll), 2.81 -
2.62 (2H. m. H-8). 1.82 (3H. s. H-B); OC (100 MHz. DMSO-d6) 191.3. 164.4. 157.0. 
153.3. 151.1. 150.4. 149.9. 143.8. 143.3. 142.4. 136.9. 128.6. 127.3, 125.5, 125.2, 123.3. 
114.1. n1.8. nO.2. 108.5. 92.1. 85.1. 84.6.62.3.61.5.61.2.60.4.60.0.56.8.56.3. 37.9, 
12.9; LRMS (Ell m/z 650.7 (M + H) M+ C32H3SNsOlO requires 649.2: Anal. Calcd. for 
C32H3SNsOlO. Y.!H20 - C 58.3%. H 5.3%. N 10.6%: found C 58.2%. H 5.4%" N 10.8%. 
3-{4-[1-(7-Chloro-quinolin4-yl)-lH-[1.2.3]triazo/-4-ylmethoxyj-3-methoxy-phenyf}-l-(4-
methoxy.phenyl)-propenone. 3.15a 
o 
9 a 
3' 
Yellow solid (303.4 mg, 58%); mp 178 - 180"C 
(from EtOAc): R, (EtOAc:Hex 6;4) 0.25; IR VmilO< 
(CHCh)/cm-1 3021 CAr C-H). 1657 (C=O), 1599 (Ar 
C=C): OH (400 MHz. CDCh) 9.06 (tH. d, J4.8, H-
8). 8.27 (tH. d. J 2.0. H-9). 8.15 (tH, s, H-6). 8.01 
(2H. d, J 9.0. H-r. 4'). 7.98 (tH. d, J 9.0. H-ll). 
7.74 (tH, d. J 15.6. H-a). 7.59 (tH. dd. J 2.0 and 
8.9. H-lO). 7.51 (tH. d, J 4.8. H-7), 7.42 (tH. d. J 
15.6, H-b). 7.23 (tH, d. Jt8. H-l), 7.18 - 7.14 (2H. 
m. H-2, 3), 6.97 (2H, d, J9.0. H-2', 3'), 5.43 (2H, 
s, H-5), 3.94 (3H, s, H-5'), 3.88 (3H, s, H-4); oc (tOO MHz, CDCh) 188.7. 163.3. 151.1. 
149.8. 149.5. 144.8. 143.7. 141.1. 137.2. 131.2. 130.7. 129.6, 129.4, 128.8. 124.8. 124.5, 
122.5. 120.6. 116.0. 114.1. 113.9, 111.1. 62.9, 56.1, 55.5; lRMS (EI) m/z 527.6 (M + H) M+ 
C29H23C1N404 requires 526.1; Anal. Calcd. for C29H23CIN404.Y.!H20 C 64.9%, H 4.5%. N 
10.4%; found C 65.1%. H 4.5%. N 10.7. 
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3-{4-[1-fl-Chloro-quinolin4-y"-lH-[1.2.3]triazo/4-ylmethoxYJ-3-methoxy-phenylj-t-(2.4-
dimethoxy-pheny,,-propenone. 3.15b 
o 
9 a 
Yellow solid (282.7 mg. 51%): mp: 122 - 124"C 
(from EtOAc): R, (EtOAc:Hex 6:4) 0.12; IR V max 
(CHCh)/an-l 3020 CAr C-H). 1653 (C=O). 1604 CAr 
C=C): OH (400 MHz. CDCl3) 9.05 (t H, d, J 4.8. H-
8),8.26 (tH. d. J2.0. H-9). 8.13 (1H. s. H-6). 7.96 
(tH. d. J9.2. H-11). 7.74 (tH. d, J 8.6. H-3'), 7.60 
(tH, d. J 15.6, H-a). 7.58 (tH. dd, J 2.0 and 9.2, 
H-I0). 7.49 (tH, d. J4.6. H-7). 7.38 (tH. d, 115.6, 
H-b), 7.20 (1H. dd. J 2.0 and 8.4. H-2). 7.14 -
7.12 (2H. m. H-t, 3). 6.57 (tH. dd. J 2.2 and 8.6, 
H-2'). 6.50 (tH. d. J 2.2. H-t'). 5.48 (2H. s. H-5), 3.92 (3H. s, H-4'), 3.90 (3H. S, H-5'). 
3.87 (3H. s. H-4); oc (too MHz. CDCb) 190.5, 164.1. 160.2. 151.3. 150.2. 149.8. 149.2. 
144.9, 141.9. 140.9. 137.0, 132.7. 129.8, 129.5, 129.0, 126.0, 124.8. 124.5. 122.4, 122.1, 
120.6. 116.0. 114.2. 111.3, 105.2. 98.7, 63.0, 55.9, 55.9, 55.5; lRMS (EI) mlz 557.5 (M + 
H) M+ C30H2sCIN40s requires 556.2; Anal. Caled. for C30H2SClN40s C 64.7%, H 4.5%, N 
10.1%; found C 64.9%. H 4.4%. N 10.0%. 
3-{4-[1-fl-Chloro-quinolin4-y"-1 H-[1.2.3] triazo/4-ylmethoxYJ-3-methoxy-phen ylj-l-
(2.3.4-trimethoxy-pheny,,-propenone. 3.15c 
o 
I' 
CI 
9 
Yellow solid (318.3 mg. 54%); mp: 124°C (from 
EtOAc); R, (EtOAc:Hex 6:4) 0.20; IR Vmax 
(CHCb)/cm-1 3015 (Ar C-H), 1649 (C=O). 1593 (Ar 
ocrr; C=C): OH (300 MHz. CDCb) 9.05 (tH. d. J 4.4, H-
8), 8.27 (tH. d, Jt9. H-9), 8.14 (tH. s. H-6), 7.99 
(lH, d. J 9.3. H-ll), 7.61 (t H, d. J 16.1. H-a). 7.59 
(lH, dd. J1.9 and 9.3, H-1O), 7.50 (tH. d, J4.4, H-
7), 7.45 (tH. d. J8.8. H-2'). 7.31 (tH. d. 116.1. H-
b). 1.21 (tH, dd. J 1.9, 8.3, H-2), 1.16 - 1.12 (2H. 
m. H-l, 3), 6.15 (tH. d, J 8.8. H-r), 5.48 (2H. s. 
H-5), 3.92 - 3.90 (12H. m, H-3'. 5',4'. 4);oc (15 MHz. CDCh) 190.8. 156.9. 151.1. 149.8. 
149.4. 144.9. 142.9. 142.2. 131.2. 129.6. 129.5. 128.8. 126.9. 125.6. 125.3. 124.8, 124.6, 
122.5, 116.0, l14.0, In.O, t07.4. 62.9. 62.1. 61.1. 56.1. 56.0; lRMS (EI) mlz 581.4 {M + 
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H) M+ C31H27ClN406 requires 586.2; Anal. Caled. for C31H27CIN406 C 63.4%, H 4.6%, N 
9.6%; found C 63.2%, H 4.5%, N 9.5%. 
t-[4-(4-{4-[3-(2.4-Dimethoxy..phenyIJ-acryloy/j-2-methoxy-phenoxymethy/r£1.2.3]triazoJ. 
t-ylj-5-hydroxymethyJ.tetrahydro-tiJran-2-y/j-5-methyJ.1H-pyrimidine-2.4-dione, 3.16a 
o 
Yellow solid (272.6 mg, 44%); mp 135 - 136°C 
(from MeOH/EtOAc); Rt (EtOAc:Hex 9:1) 0.15; IR 
Vmao< (CHCI3)/cm-1 3021 (Ar C-H), 1691 (C=O), 
1599 (Ar C=C): OH (400 MHz. DMSO-d6) 8.43 
(1H, s, H-6), 7.95 (lH, d, J 15.7, H-a), 7.90 (lH, 
d, J 8.6, H-2'), 7.81 (lH. dd, n.8 and 8.6, H-3), 
7.78 (2H. m. H-1, 12), 7.74 (1H, d, J 15.6. H-b), 
7.57 (1H. d. J 2.0. H-r), 7.31 (tH, d, J 8.6, H-2), 
6.61 (1H. dd, J 2.0 and 8.6, H-3'), 6.61 (lH, t. J 
6.6, H-9), 5.42 - 5.37 (lH, m, H-7), 5.26 (2H. s, 
H-5), 4.24 - 4.21 (lH, m, H-10), 3.89 (3H, s, H-
5').3.83 (6H. s, H4, 4').3.74 - 3.63 (2H, m, H-lt). 2.77 - 2.61 (2H, m, H-8), 1.79 (3H. 
s. H-13); oc (75 MHz. DMSO-d6) 187.4, 163.6, 162.9, 159.8, 151.5. 150.3. 148.9. 142.4. 
137.8, 136.1. 131.3, 129.9. 124.5, 122.6, 119.0, 116.0, 112.4, nO.9, 109.5, 106.3, 98.2. 
84.4, 83.9, 61.7, 60.7. 59.3. 55.8. 55.5, 55.4. 37.1. 12.1; lRMS eEl) mlz 620.6 (M + H) 
M+ C31HnNs09 requires 619.2; Anal. Caled. for C31 H33Ns09.1hH20 C 59.2%, H 5.3%, N 
11.1%; found C 59.0%, H 5.5%, N 11.0%. 
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D M S O - d
6
)  1 1 . 3 0  ( t H .  s .  H - 1 4 ) .  8 . 4 3  ( t H .  s ,  H - 6 ) ,  
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5.37 (tH, m, H-7), 5.28 (2H, s, H-5), 4.25 - 4.22 (lH, m, H-l0), 3.83 (3H, s, H-4). 3.73 
- 3.60 (2H. m. H-ll). 2.77 - 2.61 (2H. m, H-8), 1.80 (3H, s, H-13); OC (75 MHz. DMSO) 
187.0. 163.6, 152.2, 150.4, 149.0, 142.3. 136.5. 136.1, 135.3. 134.9, 131.5, 130.5. 129.8. 
129.4. 127.8, 125.3, 124.5, 123.4. 112.4, 111.1. 109.6, 84.4, 83.9, 61.7. 60.7, 59.3. 55.6. 
37.1, 12.1; LRMS (EI) mlz 628.6 (M + H) M+ C29H2;,CbNs07 requires 627.1; Anal. Caled. 
for C29H2;,CbNs07.1hH20 - C 54.7%. H 4.2%, N n.O%; found C 54.4%, H 4.8%. N 
10.8%. 
1-[4-(4-{4-[3-( 4-Fluoro-phenyl)-acry/oylj-2-methoxy-phenoxymethyl}-[1 .2.3] triazol-l-yl)-5-
hydroxymethyl-tetrahydro-furan-2-ylj-5-methyl-l H-pyrimidine-2.4-dione. 3.16d 
o 
oc~ 
9 '0 
o '5 oy~N f~ H 
'4 HN I 
3 
o 
Yellow solid (278.1 mg. 48%); mp 130 - 132°C 
(from MeOH/EtOAe): R, (EfOAe:Hex 9:1) 0.18; IR 
Vmax (CHCh)/cm-1 3386 (O-H). 3018 (Ar C-H), 
1689 ((=0). 1597 (Ar (=C): OH (300 MHz, 
DMSO-d6) n.28 (lH. s, H-14). 8.43 (lH, s. H-6). 
7.85 (tH. d. j 15.6, H-a). 7.81 (lH. dd, J 1.9 and 
8.8. H-3), 7.79 (tH. s. H-12). 7.78 (lH. d, J 15.6. 
H-b), 7.76 (2H. d. J 8.8, H-l'. 4'). 7.58 (1H. d, J 
1.9. H-O. 7.31 (2H. d. J 8.8. H-2', 3'), 6.89 (tH, 
d, J 8.8. H-2). 6.42 (tH, t, J 6.8. H-9), 5.43 -
5.36 (1H, m, H-7). 5.27 (2H, s, H-5), 4.26 - 4.22 
(1H. m, H-lO), 3.85 (3H. s, H-4), 3.70 - 3.59 (2H, m, H-ll), 2.80 - 2.61 (2H, m. H-8), 
1.80 (3H, s, H-13); oc(75 MHz. DMSO-d.?) 187.4. 163.6, 155.5, 152.9, 151.6, 150.3. 148.9. 
142.4. 137.5, 136.1. 131.2. 124.5. 123.3, 122.8. 121.1. 120.4, 112.4. 111.0, 109.5, 108.4, 
84.4. 83.9, 61.7, 60.7. 59.3, 55.5. 37.1. 12.1; LRMS (EI) m/z 578.6 (M + H) M+ 
(29H2SFNs07 requires 577.2; Anal. (a led. for (29H2SFNs07 ( 60.3%, H 4.9%, N 12.1%; 
found C 60.1%, H 5.5%, N 11.9%. 
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1-[4-(4-{4-[3-(2.4-Difluoro-phenyl)-acryloyfj-2-methoxy-phenoxymethyIHl.2.3]triazol-l-
yl)-5-hydroxymethyl-tetrahydro-fiJran-2-yfj-5-methyI-1H-pyrimidine-2.4-dione.3.16e 
F 
F 3' 
o 
Yellow solid (248.9 mg, 44%); mp 128 - 13O"C 
(from MeOH/EtOAc); Rr (EtOAc:Hex 9:1) 0.18; JR 
Vmax . (CHCh)/cm-1 3386 (O-H), 3018 (Ar C-H), 
1692 (C=O). 1600 (Ar C=C): OH (300 MHz. 
DMSO-d6) 11.30 (1H. s. H-14). 8.44 (1H, s, H-6). 
7.97 (1H. d. 115.6. H-a), 7.90 (1H. d. J 8.3, H-2·). 
7.83 - 7.79 (2H. m. H-t, 3). 7.76 (1H. d. J 15.6. 
H-b). 7.59 (1H. d, J 1.9, H-r), 7.34 (tH, dd, J 1.9 
and 8.3. H-3'). 6.64 (1H, d, J 8.8. H-2). 6.44 (tH. 
t, J6.3, H-9). 5.44 - 5.38 (1H. m. H-7). 5.28 (2H. 
s. H-5). 5.25 (tH. IA. H-t5). 4.28 - 4.24 (1H. m. 
H-l0), 3.85 (3H. s, H-4). 3.76 - 3.63 (2H. m, H-ll). 2.81 - 2.62 (2H. m. H-8). 1.82 (3H. 
s, H-13); Oe (75 MHz, DMSO~) 187.4. 163.6. 162.9. 159.8. 151.5, 150.3. 148.9, 142.4, 
137.8. 136.1. 131.4. 129.9. 124.5, 122.6. 119.0. 116.0. 112.4. 110.9, 109.5, 106.3, 84.4. 
83.9, 61.7. 60.7. 59.3.55.4. 37.1. 12.1; lRMS (EI) mlz 596.4 (M + H) M+ C29H27F2Ns07 
requires 595.2: Anal. Caled. for C29H27F2Ns07.1hH20 _ C 57.6%. H 4.6%. N 11.5%; 
found C 57.8%. H 4.6°/0. N 10.9%. 
1-{4-[1-(7-Chloro-quinolin-4-yl)-tH-[1.2.3]triazoJ..4-ylmethoxYj-3-methoxy-phenyIt-3-C2.4-
dimethoxy-p/lenyl)-propenone. 3.17 a 
o 
3' 
9 
Yellow solid (228.3 mg, 41%); mp 157 - 158"C 
(from EtOAc); Rr (EtOAc:Hex 7:3) 0.25; IR V max 
(CHCb)/cm-1 3020 (Ar C-H). 1649 (C=O). 1599 
(Ar C=C): OH (400 MHz. CDCb) 9.09 (1H. lA, H-
8), 8.26 (1H. s. H-9). 8.15 (1H, s, H-6), 8.04 (1H, 
d, J 15.7, H-a), 7.98 (tH. d, J 9.2, H-ll), 7.68 -
7.65 (2H, m, H-1. 3), 7.59 (1H, d, J 9.2. H-lO), 
Cl 7.57 (tH. d. J 8.4. H-2'), 7.55 (tH. d. J15.7, H-b), 
7.51 (tH. lA, H-7), 7.18 (tH, d, J 8.6. H-2), 6,53 
(tH, dd. J 2.2 and 8.4. H-3'), 6.48 (tH, d, J 2.2, 
H-t'), 5.53 (2H. s. H-5). 3.96 (3H, s, H-5'), 3.91 (3H. s, H-4'), 3.86 (3H. s, H4); Be (75 
MHz, CDeh) 189.3, 163.0, 160.4, 151.1, 149.6. 140.1. 137.2. 133.0, 131.0. 129.7, 124.6, 
122.5, 119.9, 117.2. 112.6, 111.5, 105.4. 98.5, 62.8. 56.1, 55.6, 55.5; lRMS (EI) m/z 557.5 
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(M + H) M+ C30H2SClN40S requires 556.2; Anal. Cakd. for C30H2SCIN40S.H20 C 62.6%, 
H 4.4%. N 9.7%; found C 62.7%, H 4.3%, N 9.4%. 
1-{4-[1-(7 -Chloro-quinolin4-y.1-t H-[1.2.3] triazoJ..4-ylmethoxyj-3-methoxy.phenyI}-3-
(2,3 ,4-trimethoxy.pheny~-propenone. 3.17b 
o 
9 
Yellow solid (318.9 mg. 54%); mp 82 - 83°C 
(from EtOAc); R, (EtOAc:Hex 6:4) 0.33; IR Vmax 
(CHCI 3)lcm1 3015 (Ar C-H). 1670 (C=O), 1596 
(Ar C=C); OH (400 MHz. CDCh) 9,07 (tH, d. 1 
4.8, H-8), 8.27 (tH. d, 12.0, H-9), 8.16 (tH, s, H-
6). 7.98 (tH. d, 19.2; H-l1>, 7.98 (tH, d, 1 is.7, 
H-a), 7.68 - 7.66 (2H, m, H-t, 3), 7.60 (tH, dd, 1 
CI 2.0 and 9.2. H-W), 7.57 (1H. d, 115.7, H-b), 7.51 
(tH. d, 14.8. H-7). 7.36 (lH. d, 18.8. H-i'). 7.20 
(tH, d. 18.6, H-2), 6.72 (1H. d. 18.8. H-2'), 5.53 
(2H, s, H-5), 3.96 (3H, S, H-5'). 3.95 (3H. S, H-3'), 3.91 (3H. s, H-4), 3.89 (3H. s, H-4'); 
Oc (tOO MHz. CDCh) 189.1. 155.8. 153.7. 151.1. 149.7, 144.7. 142.6. 141.1. 139.7, 137.3. 
132.8. 129.7. 128.8. 124.9. 124.6, 123.9. 122.6. 122.1. 121.0. 116.0. 112.6, 111.5, 107.5, 
62.9, 61.4. 60.9, 56.1; lRMS (EI) mlz 587.5 (M + H) M+ C31H2;oClN406 requires 586.2; 
Anal. Calcd. for C31H27CIN406.Y2H20 - C 62.5%, H 4.5%, N 9.4%; found C 62.1%. H 
4.5%. N 9.2%. 
1-{4-[1-(7-Chloro-quinolin4-y.1-1H-[1.2.3]triazoJ..4-ylmethoxyj-3-methoxy.phenyI}-3-(2.4-
dichloro-phenY.1-propenone.3.17c 
(I o 
(I 3' 
9 
(I 
Yellow solid (295.7 mg. 52%); mp 85 - 87°C 
(from EtOAc); R, (EtOAc:Hex 1:1) 0.2; IR Vmax 
(CHCh)/cm1 3018 (Ar C-H), 1651 (C=O), 1595 
(Ar C=C); OH (400 MHz, CDCh) 9.05 (1H, d. 1 
4.8, H-8), 8.27 (tH, d, 12.2, H-9), 8.16 (tH, s, H-
6), 8.01 OH, d, 115.6, H-a), 7.96 (1H, d, 19.2, H-
11), 7.67 - 7.65 (2H, m. H-l. 3). 7.59 (1H. dd. 1 
2.2 and 9.2. H-10). 7.56 (lH. d. Ja.4. H-2'). 7.55 
(lH. d. 115.7. H-b), 7.51 (tH, d. 14.8. H-7). 7.19 
(tH, d, 18.6, H-2). 6.53 (tH, dd. 12.4 and 8.4. 
H-3'), 6.48 (tH, d. 12.4, H-1'), 5.53 (2H. s, H-5), 3.96 (3H. s, H-4); eSc (tOO MHz, CDCI 3) 
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189.3. 163.0. 160.3. 151.0. 149.6. 144.5. 141.0. 140.1. 137.1, 133.0. 131.1. 129.6. 128.8. 
125.0. 124.5. 122.5. 120.1. 117.2. 115.9. 112.8. 111.6. 105.5. 98.6. 62.8. 55.5; lRMS (EI) 
m/z 565.3 eM + H) M+ C2sH9CbN403 requires 564.1); Anal. Caled. for C2sH9ChN403 C 
59.4%. H 3.4%. N 9.9%: found C 59.7%. H 3.1%, N 9.5%. 
1-{4-[1-[l-Chloro-quinolin-4-yl)-1H-[1.2.3]triazo/-4-ylmethox;1-3-methoxy-phenyIJ-3-(4-
fluoro-phenyl)-propenone.3.17d 
" 
3' 
o 
Yellow solid (266.9 mg, 52%); mp 164 - 166°C 
(from BOAc); Rr (EtOAc:Hex 6:4) 0.3; IR Vmax 
(CHCb)/cm-1 3018 (Ar C-H), 1656 (C=O). 1595 
CAr C=C); OH (400 MHz. CDCh) 9.05 (1H, d, 4.6, 
H-8). 8.25 (1H. d. 12.2. H-9). 8.16 (1H. s. H-6). 
7.96 (lH. d. 19.2. H-ll), 7.80 (1H, d. 115.6. H-
a), 7.67 (1H, dd, 11.8 and 8.4. H-3)~ 7.65 (1H. d. 
11.8. H-1), 7.61 - 7.58 (3H, m, H-t'. 2'. 10). 7.49 
(1H. d. 14.6, H-7), 7.42 (1H. d, 115.6, H-b). 7.21 
(1H. d. H 8.4. H-2). 6.94 (2H. d. 18.9. H-3'. 4'). 
5.53 (2H. s, H-5), 3.97 (3H. s. H-4): oc (100 MHz. CDCh) 188.6. 161.7. 151.3. 150.2. 
149.8. 144.6, 144.2, 142.9. 140.9. 137.0. 132.7. 130.2. 129.6. 129.0, 127.7. 124.8. 124.5. 
122.6. 119.3. 116.0. 114.5. 112.6. 111.5. 62.9. 56.1: lRMS (EI) mlz 515.4 (M + H) M+ 
C2sH2oClFN403 requires 514.2; Anal. Caled. for C2sH2oCIFN403 C 65.3%. H 3.9%. N 
10.9%; found C 64.9%. H 4.1%. N 10.6%. 
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1-{4-[1-(7-Chloro-quinolin4-yl)-lH-[1.2.3]triazol-4-ylmethoxyJ-3-methoxy-phenyI}-3-C2,4-
difluoro-phenyl)-propenone. 3. t 7 e 
F o 
F 3' 
9 (I 
Yellow solid (202.5 mg. 38%); mp 106 - 108°C 
(from EtOAc); R, (EtOAc:Hex 6:4) 0.3; IR V max 
(CHCh)/cm-
' 
3000 (Ar C-H), 1657 (C=O). 1595 
CAr C=C); OH (300 MHz, CDCh) 9.06 (tH. d, J 
4.4. H-8), 8.27 (tH. d, J 1.9, H-9), 8.16 (tH. s, H-
6), 7.96 (tH, d. J 9.3, H-n), 7.85 (tH, d, J 15.6, 
H-a), 7.69 - 7.65 (2H, m, H-i, 3), 7.59 (tH. dd, J 
1.9 and 9.3. H-lO). 7.55 (tH. d, J 8.3, H-2'), 7.52 
(tH. d. 115.6, H-b), 7.51 (tH. d, J 4.4, H-7), 7.19 
(lH, d, J 8.8. H-2), 6.73 (tH. dd. J 2.4 and 8.3. 
H-3'), 6.64 (tH. d. J2.4. H-1'). 5.53 (2H. s. H-5). 3.96 (3H. s, H-4): oc(75 MHz. CDCh) 
151.0. 149.8. 144.6. 137.2. 132.5. 130.9. 129.7. 128.8. 124.8. 124.6, 122.9. 122.7. 121.7. 
116.0. 112.6. 111.4. nO.8. 102.2. 101.9. 98.5. 62.8, 56.1: lRMS (EI) m/z 533.4 eM + H) M+ 
C2sH9CIF2N403 requires 532.1: Anal. Caled. for C2sH9CIF2N403 C 63.1%, H 3.6%, N 
10.5%: found C 63.4 %, H 4.0%, N 10.2%. 
Synthesis of the vanillin-triazole enone- derivatives 3.18 and 3.19: 
These were synthesized as described under General method III, applying the alkylated 
vanillin-acetone enone 3.n (2.3 g. 10 mmol). the appropriate azide (AZT or 3.13. 15 
mmol). 1 M Na ascorbate (4 mL 4 mmol) and 1 M CUS04 (2 ml. 20 mol%). 
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C:-iAPTER E1C,HT: EXPERltv1ENT,\L 
1-(5-Hydroxymethyl-4-{4-[2-methoxy-4-(3-oxo-but-I-enyl)-phenoxymethylJ-{1.2.3]triazol-
l-yl)-tetrahydro-furan-2-yl)-5-methyl-1 H-pyrimidine-2.4-dione, 3.18 
Fluffy white solid (3.9 g, 80%): mp 177 - 179°C 
(from MeOH/EtOAe); Rr (MeOH: CH2Cb 5:95) 
0.42; IR V max (KBr)/em-' 3072 (Ar C-H), 1627 
(C=O), 1595(Ar C=C); OH (400 MHz. DMSO-d6) 
11.30 (tH. s. H-14). 8.41 (tH. s, H-6). 7.80 (tH. s. 
H-12). 7.56 (1H. d. )16.3. H-a). 7.33 (tH. d, )1.6. 
H-l), 7.25 (1H. dd. ) 1.8 and 8.3. H-2). 7.21 (1H. 
d. ) 8.4. H-3), 6.74 (1H. d. 116.3, H-b), 6.42 (1H, 
t, ) 6.5, H-9), 5.42 - 5.37 (tH. m, H-7l, 5.19 (2H. 
s, H-5), 4.25 - 4.22 (1H, m. H-lO), 3.80 (3H, s, 
H-4), 3.75 - 3.61 (2H, m, H-ll), 2.78 - 2.62 (2H, 
m, H-8), 2.30 (3H, S, H-b'), 1.8 (3H, s, H-B); Oc (100 MHz, DMSO-~) 197.8, 163.6, 
150.4, 149.6, 149.1, 143.3. 142.5, 136.1, 127.6. 125.4, 124.4, 122.7, 113.2, nO.7. 109.5, 
84.4. 83.9. 61.6. 60.7. 59.2, 55.5, 37.1, 27.1, 12.1; lRMS (EI) m/z 498.5 (M + H) M+ 
C24H27Ns07 requires 497.2: Anal.Calcd. for C24H27Ns07.1H20 - C 55.9%, H 5.6°/0, N 
13.6%; found C 55.6%. H 5.4%. N 14.0%. 
4-{4-{1-(7-Chloro-quinolin-4-yl)-IH-{1.2.3]triazol-4-y/methoxy]-3-methoxy-phenyl)-but-3-
en-2-one.3.19 
9 
(I 
Off-white to pale brown solid (2.7 g. 62%); mp 
82 - 84°C (from EtOAe); Rr (EtOAe:Hex 8:2) 0.20; 
IR Vmax (KBr)/em! 2927 CAr C-H), 1663 (C=O). 
1595 (Ar C=C); ~ (300 MHz. CDCh) 9.05 (1H. 
d, 4.9, H-8), 8.24 (tH, d, )2.0, H-9), 8.14 (1H, s, 
H-6), 7.94 (lH, d, )9.3, H-ll), 7.58 (tH, dd, )2.0 
and 9.3, H-lO), 7.48 (tH, d, )4.9, H-7), 7.46 (lH, 
d, ) 15.6, H-a), 7.15 - 7.10 (3H, m, H-t 2, 3), 
6.62 (1H, d, ) 15.6. H-b), 5.48 (2H. s, H-5), 3.91 
(3H, s. H-4). 2.37 (3H, s, H-b'); oc (75 MHz, 
CDCb) 198.2. 151.4, 149.9. 149.7. 144.7. 143.0, 140.8, 137.0, 129.5. 129.1. 128.6. 125.9. 
124.8. 124.5, 122.7. 120.5, 116.0 (2C), 113.9, nO.4. 62.9, 55.9. 27.4: lRMS (EI) mlz 
435.2 eM + H) M+ C23H9CIN40 3 requires 434.1; Anal. Caled. for C23H9CIN4032H20 C 
58.6%, H 4.9%, N 11.9%; found C 58.4%, H 4.6%, N 11.6%. 
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EiGHT: EXPERl.'v\ENT,'~L 
Synthesis of the dienone-triazole derivatives 3.20 - 3.21: 
These were synthesized as described under General method IV. applying of the triazole 
enone 3.18 or 3.19 (l mmol). the appropriately substituted benzaldehyde (l mmol) and 
BF3-EhO (0.2mL 1.5 mmol). 
1-{5-Hydroxymethyl-4-(4-(2-methoxy-4-{5-(4-methoxy-phenyl)-3-oxo-penta-l.4-dienyIJ-
phenoxy methylj-{I.2.3Jtriazol-l-ylj-tetrahydro-furan-2-yIJ-5-methyl-l H-pyrimidine-2. 4-
dione,3JOa 
o 
1:/' 
3' 
Yellow solid (258 mg. 42%); mp: 192 - 194°C 
'(from MeOH/EtOAc); Rt (MeOH:EtOAc 5:95) 
0.30; IR Vm"" (KBr)/c:m-1 3340 (O-H), 3057 (Ar 
oJ~ C-H). 1689 (C=O). 1584(Ar C=C); OH (400 
MHz. DMSO-d6) 11.31 (lH. s, H-14), 8.43 (lH. 
s. H--6). 7.81 (lH. s. H-12). 7.75 (4H. m. H-a. 
a', r, 4'). 7.41 (lH, d. ) 1.7, H-l), 7.33 (tH. 
dd. lt8 and 8.3. H-2). 7.22 (lH. d. li5.8. H-
b'). 7.19 (l H. d. l15.9. H-b). 7.02 (2H. d. 1 
8.7. H-2" 3'). 6.43 (lH, t, l6.4, H-9). 5.43 -
5.38 (lH. m. H-7). 5.21 (2H. s. H-5). 4.26 -
4.23 (lH. m. H-lO). 3.83 (3H. s. H-S'). 3.82 
(3H. s. H-4. 3.74 - 3.62 (2H. m. H-ll). 2.79 - 2.63 (2H. m. H-8), 1.81 (3H. s. H-B); oc 
(100 MHz. DMS04) 188.0, 163.6. 161.1. 150.8. 150.4. 149.6. 149.2. 142.5, 142.4, 142.0, 
136.1. 130.2. 128.1. 127.3. 124.4. 124.1. 123.4, 122.8. 114.4. 113.9. 113.2, nO.9, 109.5, 
84.4. 83.9. 61.6, 60.7. 59.3. 55.6. 55.3. 37.1. 12.1; LRMS (EI) m/z 616.2 (M + H) M+ 
C32H33NsOs requires 615.2; Anal. Caled. for C32H33NsOs.l1hH20 C 59.8%. H 5.6%, N 
10.9%; found C 59.7%. H 5.6%, N 10.5%. 
~_RiC M. GLIANTAI - Ph.D fHt:SIS :Cl! 
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CHAPTER EIGHT: EXP!'"RII"~!'"NT AL 
1-[4-(4-{4-[5-(2. 4-Dimethoxy-phenyl)-3-oxo-penta-l. 4-dienylj-2-methoxy-
phenoxymethyl)-fl.2.3j-triazol-I-yl}-5-hydroxymethyl-tetrahydro-furan-2-ylj-5-methyl-IH-
pyrimidine-2.4-dione.3.20b 
o 
Yellow solid (337 mg, 52%); mp 129 - 131°C 
(from MeOH/EtOAc): Rf (MeOH:EtOAc 
5:95) 0.30; IR v""", (KBr}/cm' 3384 (O-H), 
3057 (Ar C-H), 1692 (C=O). 1595 CAr C=C); 
OH (300 MHz, DMSO-d6) 11.20 (1H, s, H-14), 
8.39 (1H. s, H-6), 7.87 (1H. d, J 16.0, H-a'), 
7.78 (tH, s, H-12), 7.72 (1H, d, J 8.3, H-3'). 
7.66 (lH, d. ) 16.0. H-al, 7.56 (tH. dd. ) 1.9 
and 8.3. H-2), 7.43 (tH, d, J 1.9. H-l), 7.39 
(lH, d, ) 1.9, H-l') , 7.30(lH, dd. J 1.9 and 
8.4, H-2'), 7.23 (lH. d, J 8.4, H-3), 7.21 (tH, 
d, J 16.0, H-b'), 7.11 (lH. d. ) 16.0, H-b), 
6.42 (tH, t. ) 6.5, H-9), 5.43 - 5.36 (1H. m, H-7). 5.22 (2H. s, H-5), 4.28 - 4.24 (1H, m, 
H-l0). 3.90 (3H. s. H-4'). 3.84 (3H, s, H-5'), 3.82 (3H, s, H-4), 3.81 - 3.57 (2H. m, H-
11). 2.82 - 2.62 (2H. m. H-8), 1.82 (3H. s. H-B); oc (75 MHz, DMSO-~) 191.0, 187.9, 
163.4, 162.7. 159.7. 150.2. 149.5. 142.5. 141.9. 136.8. 135.9. 129.7. 128.1. 125.3. 124.7, 
124.3. 124.1, 123.1, 122.5. 113.6. n1.1. 109.4. 106.2. 98.3. 84.3. 83.9, 61.7. 60.6. 59.2. 
55.6, 55.3, 36.9, n.9; lRMS (EI) mlz 646.2 (M + H) M+ C33H3SNs09 requires 645.2; 
Anal.Calcd. for C33H3SNs09 - C 61.4%, H 5'sc'/o. N 10.9%; found C 61.7%. H 5.6%. N 
10.6%. 
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(HAPTER EIGHT: EXPE~IME1',;T AL 
1-[S-Hydroxymethyl-4-(4-{2-methoxy-4-[3-oxo-S-(2.3.4-trimethoxy-phenyl)-penta-l.4-
dienylJ-phenoxymethyl)-{1.2.3 Jtriazol-l-yl)-tetrahydro-furan-2-yIJ-S-methyl-l H-
pyrimidine-2.4-dione.3.20c 
o 
4' 
Yellow solid (263 mg, 40%); mp 144 -146°C 
(from MeOH/EtOAc): Rf (MeOH:EtOAc 
OCH3 5:95) 0.33; IR Vrnax (KBr)/cm-1 3391 (O-H), 
5' 2934 (Ar C-H). 1689 (C=O). 1584 CAr C=C); OCH3 
OH (300 MHz. DMSO-d6) 11.21 (1H, s, H-14), 
8.38 (1H, s, H-6), 7.79 (1H. d. J 16.0. H-a'). 
7.78 (1H, s, H-12). 7.69 (lH. d, J 16.0. H-a). 
7.56 (1 H, d, J 8.8, H-2'), 7040 (1 H. d, J 1.8 
H-1), 7.32 (1 H. dd, J 1.8 and 804. H-2), 7.24 
(1H, d, 116.0, H-b'), 7.23 (1H. d. J8A, H-3), 
7.14 (1H, d, J 16.1, H-b), 6.91 (1H, d, J 8.9, 
H-t'), 6.42 (1H. t, J 6.6, H-9), 5043 - 5.37 
(1H, m, H-7), 5.22 (2H, s, H-5), 4.28 - 4.24 (1H, m, H-lO), 3.87 (6H. S, H-3', 5'). 3.84 
(3H. s, H-4'). 3.79 (3H. s, H-4). 3.76 - 3.64 (2H, m, H-ll). 2.82 - 2.63 (2H. m, H-8). 
1.82 (3H. s. H-13); Oe (75 MHz. DMSO-~) 187.9. 163.4. 155.3. 152.7. 150.2. 149.6, 
149.2. 142.5. 142.3. 141.8. 136.5, 135.9, 128.1, 124.7, 124.2, 124.1, 122.9. 122.6. 120.9. 
113.6. 111.2. 109.4, 108.4. 84.3. 83.9, 61.7. 61.1, 60.6. 60.2, 59.2, 55.9, 55.5, 36.9, 11.9; 
lRMS (EI) mlz 676.5 (M + H) M+ C34H37NsOlO requires 675.3; Anal.Calcd. for 
C34H37NsOlOJY.2H20 - C 58.0%, H 5.7%. N 9.9%; found C 57.5%, H 5.7%. N 9.5%. 
[:l.IC M. GUANTAI - r~1.D rl·i!~;:S ::C]r 
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1-{4-(4-{4-{5-(2. 4-Dichloro-phenyl)-3-oxo-penta-l.4-dienyIJ-2-methoxy-phenoxymethyl)-
{1.2.3J triazol-l-yI)-5-hydroxymethyl-tetrahydro-furan-2-yl]-5-methyl-IH-pyrimidine-2.4-
dione. 3.20d 
0:i~ 2 
5 N 
'I II 
6 .... N 
N 7ha 
15 :}-o19 
HO n~l N1~;.O 
I NH 14 
13 
o 
o 
2' 
Yellow solid (379 mg, 58%); mp 239 - 241°C 
(from MeOH/EtOAc); R, (MeOH:EtOAc 
5:95) 0.50; IR V max (KBr}/cm-l 3442 (O-H), 
3057(Ar C-H), 1692 (C=O), 1580 (Ar C=C): 
OH (400 MHz, DMSO-d6) 11.31 (1H. s, H-14), 
8.43 (1H. s. H-6). 8.07 (1H, d, ) 8.6, H-3'). 
7.86 (1H, d. 115.8. H-a'). 7.84 (1H. d, 116.1. 
H-a). 7.81 (1H. s. H-12), 7.74 (tH. d, 12.1. H-
1), 7.55 (1H. d. ) 15.5. H-b'), 7.54 (1H, dd. 1 
2.1 and 8.5. H-2). 7.41 (1H. d. 11.7. H-r). 
7.33 (1H. dd. 11.7 and 8.5, H-2'). 7.26 (1H. 
d. )8.4. H-3), 7.13 (1H, d. 116.1, H-b), 6.43 
(1H. t, 16.6, H-9). 5.43 - 5.38 (tH. m. H-7), 5.22 (2H, s, H-5), 4.26 - 4.23 (tH, m, H-
10). 3.82 (3H. s. H-4), 3.78 - 3.61 (2H. m. H-n), 2.79 - 2.63 (2H. m, H-8l. 1.81 (3H. s. 
H-13); Oe (100 MHz, DMSO~) 187.9. 164.6, 163.6. 150.4. 149.9. 149.2, 145.4, 144.1, 
142.5, 140.9. 136.1, 134.8, 131.8, 131.6, 129.5, 128.0, 126.9. 124.5, 123.1. 114.7, 110.9, 
109.5, 100.8, 84.4. 83.9.61.6.60.7,59.3.55.5,37.1. 12.1; LRMS (EI) mlz 654.6 (M + H) 
M+ C31H29CbNs01 requires 653.1; Anal.Calcd. for C31H29CbNs01.1hH20 - C 56.1%, H 
4.5%, N 1O.6%~ found C 56.0%. H 4.6%, N 10.7%. 
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CHAPTER EIGHT: EXPERIMENTAL 
1-[4-{4-[4-[5-{4-Fluoro-phenyl)-3-oxo-penta-l.4-dienylJ-2-methoxy-phenoxymethyl}-
[1.2.3J-fnazol-l-yl)-5-hydroxymethyl-tetrahydro-furan-2-yIJ-5-methyl-lH-pynmidine-2.4-
dione. 3.20e 
I O):~ 1 
5 N 7 II 
6 ,.N 
N 
~8 10 9 15 0 
o 
HO t~12 NyO 
I NH 14 
13 
o 
3' 
Yellow solid (193 mg. 32%); mp °C (from 
MeOH/EtOAc): R, (MeOH:EtOAc 5:95) 
0.50; IR Vmax (KBr)/cm-1 3387 (O-H) , 3010 
(Ar C-H), 1688 (C=O), 1602 (Ar C=C); OH 
(400 MHz, DMSO-d6) 11.30 (lH, s, H-14), 
8.43 (lH, s. H-6), 7.86 (lH. d, J 8.9, H-l'), 
7.85 (lH, d, J 8.8, H-4'), 7.81 (lH, s, H-12), 
7.75 (1H, d. J16.0, H-a'), 7.72 (tH. d, J16.0, 
H-a).7.41 (lH. d, J 1.9, H-l), 7.34 (lH, dd, J 
1.9 and 8.5, H-2), 7.32 (tH, d, J 16.1. H-b'), 
7.30 (lH, d. J 8.9. H-2'), 7.29 (1H, d. J 8.9, 
H-3'). 7.25 (tH. d. J 8.4. H-3), 7,20 (lH, d, J 
16.0, H-b), 6.43 (I H, t. J 6.5. H-9), 5.42 - 5.38 (1 H. m. H-7), 5.21 (2 H. s. H-5). 4.26 -
4.22 (1H. m. H-1O). 3.83 (3H, s. H-4), 3.77 - 3.61 (2H. m. H-n). 2.78 - 2.63 (2H. m. H-
8). 1.81 (3H. s. H~t3); &: (100 MHz. DMSO-d6 188.2. 163.6, 150.4, 149.8, 149.2, 145.4, 
144.1, 143.1. 142.5. 137.6. 136.1. 131.4. 130.6, 127.9. 125.4. 124.4. 124.0. 122.9. 116.0, 
113.2. 110.9, 109.5, 84.4, 83.9, 67.8, 61.6, 60.7, 59.3. 55.5, 37.1. 12.1; LRMS (El) mlz 
604.4 (M + H) M+ C31H30FNs07 requires 603.2; Anal.Calcd. for C31H30FNs07 - C 61.7%. 
H 5.0%. N n.6%; found C 61.4%, H 5.2%, N 11.5%. 
ERIC M. GUANTAI - i'hD rt-1I:S:$ 2Cln 
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CHAPTER EIGHT: EXPERIMENTAL 
1-[4-(4-(4-[5-(2.4-Difluoro-phenyl)-3-oxo-penta-l.4-dienylj-2-methoxy-phenoxymethyl}-
fl.2.3j-triazol-l-yl)-5-hydroxymethyl-tetrahydro-furan-2-ylj-5-methyl-1 H-pyrimidine-2, 4-
dione, 3.2Of 
o F 
F 
Yellow solid (191 mg, 31%): mp 197 - 199°C 
(from MeOH/EtOAe): R, (MeOH:EtOAe 5:95) 
0.50; IR V max (KBr)/cml 3434 (O-H), 3065 CAr 
C-H), 1696 (C=O). 1609 CAr C=C): OH (400 
MHz. DMSO-d6) n.31 (1H, s, H-14), 8.43 (1H. 
s. H-6), 8.02 (tH. d, ) 8.7, H-3'), 7.81 (tH, s. 
H-12), 7.77 (1H, d. 116.0, H-a'). 7.70 (tH. d. 
116.1. H-a), 7.43 (1H. d. )1.9, H-n, 7.42 (tH. 
d. 116.1. H-b'). 7.37 (1H. d. ) 2.1. H-i'), 7.35 
(tH. dd, J 1.9 and 8.4, H-2). 7.25 (tH. d. J 
8.5, H-3), 7.21 (1H, dd, ) 2.1 and 8.5, H-2'), 
7.19 (1H, d, 116.1, H-b), 6.43 (tH. t. ) 6.6, H-
9). 5.42 - 5.38 (tH. m, H-7), 5.21 (2H, s, H-5), 4.26 - 4.22 (tH, m. H-lD). 3.82 (3H, s. 
H4), 3.77 - 3.61 (2H, m. H-ll). 2.78 - 2.63 (2H. m. H-8), 1.81 (3H, s, H-B); oc (100 
MHz. DMSO-d6) 188.1. 163.6. 153.2, 150.4. 149.9. 149.2, 143.6, 140.9, 139.7. 136.1. 
132.7, 130.8, 127.9, 127.4, 124.5, 124.2, 123.1. 113.2, 112.6. 112.4. 110.9, 109.5, 104.6, 
84.4, 83.9, 61.6, 60.7, 59.3, 55.5, 37.1, 12.1; lRMS (EI) mlz 622.3 (M + H) M+ 
C31H29F2Ns07 requires 621.2: Anal.Calcd. for C31H29F2Ns07.'hH20 - C 59.0%, H 4.8%, N 
11.1%: found C 59.2%, H 5.0%, N 11.3%. 
l-{4-[1-(7-Chloro-quinolin-4-yl)-lH-fl.2.3jtriazol-4-ylmethoxyj-3-methoxy-phenyI}-5-(4-
methoxy-phenyl)-penta-l.4-dien-3-one. 3.21a 
° 
b' 
0):3 
5 N 
'I II 
6 /N 
N 
I' 
3' 
Yellow solid (199 mg, 36%); mp: 173 - 175°C 
(from EtOAe); Rr CEtOAe:Hex 7.3) 0.50; IR V max 
(KBr)/em1 3036 (Ar C-H). 1642 (C=O), 1580 
(Ar C=C); OH (400 MHz. CDCb) 9.08 (tH. d. ) 
4.6. H-8), 8.27 (tH, d, J 2.0. H-9), 8.13 (1H. s. 
H-6). 7.96 (lH. d, ) 9.1, H-ll). 7.71 (1H, d. ) 
15.6, H-a'), 7.68 (1H, d. )15.8, H-al, 7.60 (tH. 
dd, ) 2.0 and 9.1, H-lD), 7.58 (2H. d, ) 8.8, H-
r. 4'). 7.51 (tH, d, ) 4.6, H-7), 7.23 (tH, dd, ) 
--~!C M. GUANTAI - PhD TiIISI) 2()1!) 
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CHAPTER EiGHT: EXfJERJ,\\ENTAL 
1.8 and 8.3, H-2), 7.19 (1H, d, )1.7, H-U, 7.16 (1H, d, )8.1, H-3), 6.97 (1H, d, )15.8 H-
b'). 6.96 (1H. d, ) 15.8, H-b), 6.95 (2H, dd, ) 2.1 and 8.8, H-2', 3'), 5.50 (2H, s, H-5), 
3.96 (3H. s, H-5'), 3.87 (3H, s. H-4); OC (100 MHz, CDCb) 161.7. 151.4. 150.3. 147.3, 
144.8, 142.9, 142.5. 137.0, 136.8, 130.1. 129.5, 129.1. 128.6, 124.8, 124.5 (2C), 124.2, 
123.2. 122.8, 122.6, 120.6, 116.1, 114.5. 114.0. 113.6. 111.3, 110.8, 110.4, 62.9. 56.0, 55.4: 
lRMS (EI) mlz 553.2 (M + H) M+ C31H2SCIN404 requires 552.1; Anal. Calcd. for 
C31H2sCIN404.1H20 - C 65.1%. H 4.7%. N 9.8%; found C 64.9%, H 4.70/0, N 9.4%. 
1-{4-[1-(7-Chloro-quinolin-4-yl)-1 H-[1.2.3 ]triazol-4-ylmethoxy]-3-methoxy-phenyI}-5-(2. 4-
dimethoxy-phenyl)-penta-l.4-dien-3-one. 3.21b 
o~~ 2 
.5 N 
'I II 
6 "N N 
9 
o 
b' 
(I 
Yellow solid (192 mg. 33%); mp: 103 - 105"C 
(from EtOAc): Rf (EtOAc:Hex 8:2) 0.30; IR 
Vmax (KBr)/cm-1 3079(Ar C-H), 1656(C=O). 
1602 (Ar C=C); OH (300 MHz, CDCI3) 9.07 
(tH, d, ) 4.6. H-8). 8.24 (tH. d, ) 1.9, H-9) • 
8.14 (1H, s, H-6), 7.99 (tH, d. ) 16.0, H-a'). 
7.96 (tH, d, ) 8.9. H-ll), 7.65 (tH, d, ) 15.8. 
H-a). 7.60 (tH. dd, )2.1 and 9.1. H-lO), 7.55 
(tH, d, ) 8.6, H-3'), 7.49 (tH. d, ) 4.6, H-7), 
7.21 (tH, dd, )1.9 and 8.3, H-2), 7.16 (tH, d, 
)1.9, H-1), 7.14 (tH, d, )8.3, H-3), 7.05 (1H, 
d, 116.0 H-b'), 6.98 (tH, d, )15.8, H-b), 6.52 (tH, dd, )2.3 and 8.6, H-2'), 6.47 (tH, d, 
)2.3, H-1'), 5.49 (2H, S, H-5). 3.94 (3H. s, H-4'), 3.89 (3H, s, H-5'), 3.85 (3H, 5, H-4); 
oc (75 MHz, CDCh) 183.9, 151.4, 142.0. 138.7, 137.1, 134.2, 132.6, 131.1, 130.4, 129.5, 
129.1. 127.3, 124.8, 124.6, 123.9, 122.4, 120.6, 117.1, 116.5, 116.1, 114.8, 114.0, 112.8, 
nO.9, 109.6, 105.6, 103.6, 98.5, 63.0, 56.0, 55.6, 55.5; lRMS (EI) mlz 583.4 (M + H) 
M+ CnH2;oCIN40 S requires 582.2; Anal. Calcd. for C32H27ClN40S.11hH20 - C 63.0%. H 
4.9%, N 9.2%; found C 62.9%. H 4.9%, N 9.8%. 
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1-{4-{1-(7-Chloro-quinolin-4-yl)-lH-{1.2.3Jtriazol-4-ylmetooxyJ-3-methoxy-phenyI}-5-
(2.3. 4-trimethoxy-phenyl)-penta-l. 4-dien-3-one. 3.21 e 
b 
o 
);
3 
5 N r II 
6 /N 
N 
9 
o 
0' 
d 
" 
Yellow solid (202 mg. 33%): mp: 96 - 98"C 
(from EtOAe); R, (EtOAe:Hex 8:2) 0.30: IR 
V max (KBr)/em' 3086{Ar C-H). 1660 (C=O). 
1588 CAr C=C); OH (400 MHz, CDCh) 9.08 
(1H, d, 14.6, H-8). 8.27 (1H, d. 11.9, H-9). 
8.16 (tH. s, H-6). 7.99-7.93 (2H. m, H-ll. a'), 
7.66 (1H, d, 115.8, H-a), 7.62 (1H, dd, 12.0 
and 9.1, H-lO). 7.51 (1H. d. 14.6, H-7). 7.38 
(1H. d, 18.8, H-2'). 7.23 (tH. dd, 11.7 and 
8.3, H-2), 7.18-7.16 (2H, m. H-l. 3). 7.09 (1H, 
d, 116.0, H-b'), 6.97 (1H, d, 115.9 H-b), 6.72 
(tH. d. 18.8, H-n, 5.51 (2H. s, H-5), 3.97 (3H, S, H-3'), 3.96 (3H. s, H-5'). 3.92 (3H, s. 
H-4'). 3.90 (3H. s, H-4); eSc (100 MHz. CDCh) 189.1. 151.4. 150.3, 149.9, 149.5. 144.8. 
142.4, 140.9, 138.3, 129.5. 129.3. 129.1. 125.9. 124.9, 124.8. 124.5, 124.4, 123.5. 122.5, 
121.9, 120.9, 116.1. 114.1. 111.6. 110.9. 110.5, 109.4. 107.7. 62.9. 61.5. 60.9. 56.1. 56.0; 
LRMS (EI) mlz 613.3 (M + H) M+ C33H29CIN406 requires 612.2; Anal. Caled. for 
CnH29C1N406.1H20 - C 62.7%. H 4.9%, N 8.9%: found C 62.5%. H 4.9%. N 9.4%. 
1-{4-{1-(7-Chloro-quinolin-4-yl)-lH-{1.2.3Jtriazol-4-ylmetooxyJ-3-methoxy-phenyI}-5-f2.4-
dichloro-phenyl)-penta-l.4-dien-3-one. 3.21d 
o);~ 2 
5 N 
r II 
6 ,.N 
N 
o 
0' 
(I 
d 
2' 
Yellow solid (248 mg. 42%); mp: 159 - 161°C 
(from BOAc); Rf (BOAc:Hex 8:2) 0.33; IR 
Vmax (KBr)/em-! 3050 (Ar C-H), 1653 (C=O). 
1584 (Ar C=C); OH (400 MHz. CDCh) 9.08 
(1H. d. 14.6, H-8). 8.26 (1H. d. 12.1. H-9), 
8.16 (1H. s. H-6), 8.04 (lH, d. 116.0, H-a'), 
7.98 (1H. d, 19.1, H-ll), 7.71 (1H, d. 115.9. 
H-a). 7.66 (tH, d. 18.5. H-3'), 7.61 (1H. dd. 
12.1 and 9.1. H-l0). 7.5t (lH, d, 14.6. H-7), 
7.48 (1H. d, 12.0. H-t), 7.30 (1H, dd, 12.1 
and 8.5. H-2). 7.25 (1H. dd. 11.9 and 8.4. H-
2'). 7.20-7.18 (2H. m, H-l', 3). 7.04 (lH. d. ltS.9, H-b'). 6.98 (tH, d, ltS.9. H-b), 5.51 
(2H, s. H-5). 3.96 (3H. s, H-4); Oe (100 MHz. CDCh) 188.3. 154.9. 153.2. 151.4. 150.3. 
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149.9, 144.7, 143.6, 140.9, 138.6. 137.5. 137.0, 136.4. 135.9, 131.8. 130.1. 129.5. 129.1, 
128.4, 128.2 127.6. 124.8. 124.4. 123.8. 122.8. 120.6, 116.1. nO.9, 62.9, 56.1: lRMS (EI) 
m/z 591.1 (M + H) M+ C30H21CbN403 requires 590.1; Anal. Calcd. for C30H21ChN403. - C 
60.9%. H 3.6%. N 9.5%: found C 60.4%. H 3.7%. N 9.5%. 
l-(4-/l-(7-Chloro-quinolin-4-yl)-l H-{1.2.3 Jtriazol-4-ylmethoxyJ-3-methoxy-phenyI)-5-(4-
fluoro-phenyl)-penta-l.4-dien-3-one. 3.21e 
o 
b' 
3' 
F 
a 
Yellow solid (206 mg, 38%); mp: 107 -lQgoC 
(from EtOAc); R, (EtOAc:Hex 7.3) 0.30; IR 
Vmax (KBr)/em1 3036 (Ar C-H), 1653 (C=O), 
1588 CAr C=C): OH (400 MHz, CDCh) 9.08 
(tH, d. J 4.6. H-8), 8.26 (tH. d, J 2.1, H-9). 
8.16 (tH. s, H-6). 7.97 (tH, d, J 9.1, H-ll>, 
7.78 (tH, d, 116.1. H-a'), 7.70 (tH, d, J15.9. 
H-a). 7.64 (tH, d, J 8.5, H-1'). 7.62 (tH, d, J 
8.5, H4'), 7.60 (tH. dd. J 2.2 and 9.1. H-
10). 7.50 (tH. d. J 4.6, H-7), 7.24 (tH. dd. J 
1.8 and 8.5, H-2), 7.18-7.16 (2H. m. H-1. 3). 
7.14 (tH. d. 116.1 H-b'), 6.95 (tH, d, 115.9, H-b), 6.91 (tH. dd, J2.1 and 8.6. H-2'). 6.88 
(lH. dd. J 2.5 and 8.5. H-3'). 5.50 (2H. s. H-5), 3.95 (3H, s. H4); oc (tOO MHz. CDCh) 
188.5. 151.4. 150.3, 149.9. 144.7. 143.4. 140.9, 138.5. 137.0. 135.3. 134.7, 130.7, 129.5, 
129.1. 127.2~ 124.8. 124.5. 124.2. 122.9. 120.6. 116.0. 113.9. 112.3, 112.1. 110.8, 104.9, 
104.7. 104.5. 62.9. 56.0 ; lRMS (EI) m/z 541.4 (M + H) M+ C30H22CIFN40 3 requires 
540.1; Anal. Calcd. for C30H22CIFN403.1hH20 - C 65.5%. H 4.2%. N 10.2%; found C 
65.9%. H 4.2%. N 10.0%. 
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1-{4-[1-(7-Chloro-quinolin-4-yl)-IH-[1.2.3Jtnazol-4-ylmethoxyJ-3-methoxy-phenyI}5-(2.4-
difluoro-phenyl)-penta-l.4-dien-3-one. 3.21 f 
o 
o~ 5 N 
~ II 
6 "N N 
d 
F 
b' 
F 
Yellow solid (173 mg, 31%): mp: 124 - 126°C 
(from BOAc); R, (EtOAc:Hex 8:2) 0.30; IR 
Vmax (KBr)/cm' 3043 (Ar C-H), 1653 (C=O), 
1580 (Ar C=C); OH (400 MHz, CDCh) 9.08 
(1H, d, J 4.6, H-8), 8.26 (1H, d, J 2.1. H-9). 
8.16 (1H. s. H-6). 7.97 (1H. d, J 9.1. H-n), 
7.71 (1H. d. J15.9. H-a'). 7.69 (lH. d, 115.9, 
H-a), 7.62 (1H. d. J 8.5. H-3'). 7.60 (1H. dd. 
J2.1 and 9.1, H-l0). 7.50 (1H. d, J4.6. H-7). 
7.24 (1H. dd, J1.9 and 8.3. H-2). 7.18 (1H. d, 
J1.9, H-l). 7.17 (1H. d. J8.3, H-3), 7.13 (1H. 
d, Jt9. H-r). 7.11 (1H, dd, Jt8 and 8.5, H-2'). 7.03 (1H. d. 115.9. H-b'). 6.95 (1H, d, 1 
15.9, H-b). 5.51 (2H. s, H-5). 3.95 (3H. s, H-4); Oc (100 MHz, CDCh) 188.5, 151.4. 
150.3, 149.9, 149.8. 146.5, 144.7, 143.7. 140.9. 137.0. 132.2. 131.1. 130.3. 129.5, 129.1. 
125.0. 124.8, 124.5, 124.3. 122.8. 120.6, 118.6. 116.2. 116.0. 115.2. 114.0. 110.8, 105.9. 
62.9.56.0; LRMS (El) mlz 559.3 (M + H) M+ C30H21C1F2N403 requires 558.1: Anal. Calcd. 
for C30H21ClF2N403 - C 64.5%. H 3.5%, N 10.0%; found C 64.6%, H 3.7%. N 10.2%. 
8.1.4.3:Experimental details pertaining to Chapter 5 
General method V: synthesis of hydroxylated enones 5.1 and 5.3: 
Vanillin or 4-hydroxybenzaldehyde (20 mmol) was dissolved in 30 mL acetone, and 5 mL 
of 5 M HCI was then added gradually to the stirring mixture. The reaction mixture was 
then stirred at room temperature for 24 hours. 
The reaction mixture was then neutralized with 2.5 M NaOH. after which the acetone in 
the mixture was removed at reduced pressure. The remaining compound mixture was 
then taken up in 100 mL EtOAc, washed three times with water. dried over anhydrous 
Na2S04. concentrated in vacuo and purified by column chromatography (EtOAclHex) to 
yield the pure target compound. 
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4-(4-Hydroxy-3-methoxy-phenylJ-but-3-en-2-one.5.1 
Pale yellow solid (3.2 g. 84%): mp 124 - 125°C (from 
EtOAc/Hex); R, (EtOAc:Hex 4:6) 0.30; IR Vmax (KBr)/cm1 
3261 (Ar O-H), 3000 (Ar C-H), 1668 (C=O). 1581 (Ar C=C): 
OH (400 MHz, CDCb) 7.46 (1H. d. 116.2. H-a). 7.09 (tH. dd. 
11.9 and 8.2. H-2), 7.07 (1H, d, lt9, H-l), 6.94(1H. d, l8.l. H-3). 6.60 (tH. d. Jt6.2, 
H-b). 5.98 (1H, s. H-5). 3.95 (3H. s. H-4), 2.37 (3H. s, H-b'); Oc (100 MHz. CDCb) 
198.3, 150.4, 146.9, 143.5, 126.5, 125.0, 123.8. 114.9. 109.4, 55.8. 24.5: LRMS (El) mlz 
193.1 (M + H) M+ CnH 203 requires 192.1; Anal. Caled. for Cll H 203 - C 68.7%. H 6.3%; 
found C 68.3%, H 6.1%. 
4-(4-Hydroxy-phenylJ-but-3-en-2-one. 5.3 
o 
b b' 
Dark yellow solid (2.4 g, 76%); mp 81 - 82"C (from 
EtOAc/Hex): R, (EtOAc:Hex 4:6) 0.40; IR V max (KBr)/cml 
3150 CAr C-H), 1666 (C=O). 1590 (Ar C=C): OH (400 MHz. 
CDCI3) 7.50 (1H. d. Jt6.2. H-a). 7.42 (2H. d. l8.7. H-l, 2). 
6.88 (2H. d. l8.7. H-3. 4). 6.58 (tH. d, l16.2. H-b). 2.35 (3H, s. H-b'); Oc (100 MHz, 
CDCb) 200.0. 159.1, 144.8. 130.4 (2 C), 126.5, 124.3 (2C), 116.2. 27.2: LRMS (EI) m/z 
163.3 (M + H) M+ ClOHo02 requires 162.1; Anal. Caled. for ClOHo02 - C 74.1%, H 6.2%; 
found C 74.6%, H 6.0%. 
General method VI: synthesis of hydroxylated chalcones 5.2 and 5.4: 
Vanillin or 4-hydroxybenzaldehyde (20 mmol) and 2.4..cfimethoxyacefophenone (4.0 g, 
22 mmol) were dissolved in 20 mL MeOH. 5 mL of 5 M HCI was then added gradually 
to the stirring mixture. The reaction mixture was then stirred at 50GC for 24 hours. 
The reaction mixture was then allowed to cool to ambient temperature and neutralized 
with 2.5 M NaOH. after which the MeOH in the mixture was removed under reduced 
pressure. The remaining compound mixture was then taken up in 100 mL EtOAc, washed 
three times with water. dried over anhydrous Na2S04. concentrated in vacuo and purified 
by column chromatography (EtOAc/Hex) to yield the pure target compound. 
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1-{2.4-Dimethoxy-phenyl)-3-{4-hydroxy-3-methoxy-phenyl}-propenone. 5.2 
Yellow solid (4.3 g. 68%); mp 92 - 94°C (from 
EtOAc/Hex); ~ (EtOAc:Hex 4:6) 0.30; IR Vm"" 
(KBr)/cm-1 3506 (Ar O-H), 3113 (Ar C-H), 1640 
(C=O), 1598 (Ar C=C): OH (400 MHz. CDCh) 7.74 
(1H. d. ) 8.6, H-3'). 7.61 (1H, d. ) 15.7, H-a), 7.35 
(1H. d. ) 15.7. H-b}. 7.17 (lH. dd, ) 1.9 and 8.3, H-2}. 7.10 (1H. d, ) 1.9, H-t), 6.94 (tH, 
5 
HO 
.3 2' 
d. )8.3. H-3). 6.58 (1H. dd. J2.3 and 8.6, H-2'), 6.51 (tH. d. )2.3. H-r). 5.93 (tH, s, H-
5). 3.94 (3H. s. H-4'). 3.91 (3H. s, H-S'), 3.88 (3H. s. H-4): Oc 000 MHz. CDCh) 190.8. 
163.9. 160.2, 147.8. 146.7. 142.6. 132.6. 128.0. 125.1. 122.8. 122.5, 114.8. 110.2. 105.1. 
98.8. 55.9, 55.8, 55.5; lRMS (EI) mlz 314.0 M+ C1sHsOs requires 314.1; Anal. Caled. for 
Cu!HaOs_ - C 68.8% , H 5.8%; found C 68.7%. H 5.9%. 
1-{2.4-Dimethoxy-phenyl)-3-(4-hydroxy.phenyl)-propenone. 5.4 
.3 a' 
Yellow solid (3.2 g. 59%); mp 135 - 13rC (from 
EtOAc/Hex); R, (EtOAc:Hex 4:6) 0.27; IR Vmax 
(KBr)/cm-1 3204 (Ar O-H). 1635 (C=O). 1600(Ar 
C=C): OH (400 MHz. CDCI)} 7.53 (2H. d. J8.7. H-1 . 
2). 7.51 (tH. d, ) 8.7. H-3'}. 7.43 (1H. d. 115.8. H-
a). 7.28 (tH, d. J 15.7. H-b). 6.78 (2H. d. J 8.5. H-
3,4).6.62 (tH. d, )2.1. H-r), 6.58 (tH. dd, J2.0 and 8.6, H-2'), 3.83 (3H. s, H-4'), 3.79 
(3H, s. H-S'); oc (100 MHz, CDCI3) 189.9. 164.1. 160.4, 160.3, 142.4. 132.3. 130.8. 126.3, 
124.3. 122.3. 116.4, 106.4. 99.2. 56.4. 56.0; lRMS (EI) m/z 284.0 M+ C17H1604 requires 
284.1; Anal. Caled. for CI7H 604 - C 71.8%. H 5.7%; found C 72.1%. H 5.9%. 
2-(7 -Chloro-quinolin-4-ylamino)-ethanol. 5.5 
4.7-dkhloroquinoline (2 g. lOmmol) was heated with stirring in 
neat ethanolamine (10 ml) at 130°C for 5 hours. The mixture 
was then allowed to cool to room temperature. during which 
the product precipitated. This crude mixture was then suspended 
in water. filtered and crystallized from hot MeOH to yield pure 
5.5 as a white solid (1.97 g. 89%). Mp 215-216"C (from MeOH) 
(lit. 214 "C) [11. Rf (MeOH/EtOAc. 1:9) 0.20; 5H (400 MHz; 
DMSO-d6) 8.41 (1H. d. J 5.4. H2). 8.30 (tH. d. ) 9.0, H5). 7.81 (tH. d. ) 2.2. H3). 7.46 
_ ',1. C;;AN r;\i· l'hD n j [SIS 2010 
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(1H, dd, J 2.2 and 8.9, H4), 7.26 (1H, t. J 5.2, H-6). 6.52 (1H. d,.) 5.5, H1), 4.85 (1H. s. 
H-9), 3.70 (2H. t, J 5.9. H8), 3.38 (2H, q. J 5.8, H7). 
2-[4-{7-Chloro-quinoJin-4-yl}-piperazin-l-yIJ-ethanol.5.6 
4,7 -dkhloroquinoline (2 g, lOmmol) was dissolved in 10 mL 
anhydrous DMF, after which I<;zC03 (2.1 g, 15 mmol) and 1-(2-
hydroxyethyl)piperazine (1.3 g. 10 mmol) were added. This reaction 
mixture was then stirred at 80 "c for 24 hrs. upon 'which TlC 
indicated completion of the reaction. The mixture was then diluted in 
100 ml EtOAc. washed with water (2 x 30 ml). dried over anhydrous 
Na2S04 and concentrated under reduced pressure. The resultant oily 
product crystallized on standing. and these crystals were washed with hexane and dried 
to yield 5.6 as pale yellow crystals (1.83 g. 63%). M.p. 111-112 "c (from EtOAc): Rf 
(MeOH/EtOAc. 1:9) 0.24: IR VrnaJ< (CHCI3)/cm-1 3222 (O-H), 2903 (C-H), 1677 (C=O). 
1569 (Ar C=C): OH (400 MHz, DMSO-d6) 8.66 (1H. d. J5.0. H-2). 7.99 (1H. d. J9.0. H-
5), 7.95 (1H. d. J 2.2. H-3). 7.51 (1H. dd. J 2.2 and 9.0. H-4). 6.96 (1H. d. J 5.1. H-l). 
4.33 (1H. t. J5.3, H-12). 3.55 (2H. q. J6.0. H-l1). 3.17 (4H. t. J4.8, H-6, 9). 2.70 (4H, t, 
J 4.8. H-7. 8). 2.51 (2H. t. J 6.2. H-lO); oc (100 MHz. CDCb) 156.2, 151.9, 149.6. 133.4, 
127.9. 125.9. 125.5. 121.3. 109.1. 60.0. 58.5 (2C). 52.8 (2C), 51.7; lRMS (EI) m/z 290.5 
(M - H) M+ ClsHaCIN30 requires 291.1; Anal. Calcd. for C1sH aCIN30 - C 61.8%. H 6.2%. 
N 14.4%; found C 61.7%. H 6.1%. N 14.5%. 
7-Chlor0-4-piperazin-l-yl-quinoline. 5.7 
4.7-dichloroquinoline (2 g, lOmmol) was dissolved in 15 mL 
anhydrous NMP, after which I<;zC03 (2.8 g. 20 mmol) and 
piperazine (5.2 g. 60 mmol) were added. This reaction mixture was 
then stirred at 135 "c for 4 hrs. upon which TlC indicated 
completion of the reaction. The. mixture was then diluted in 100 ml 
EtOAc. washed with water (2 x 30 mL). dried over anhydrous 
Na2S04. concentrated under reduced pressure and purified by column chromatography 
(NH40H/MeOH/EtOAC. 1:9:90) to yield 5.7 as an off-white solid (1.9 g. 78%). M.p. 111-
113 "C (lit. 113 -115 <lC) [2]; OH (400 MHz. DMSO-d~ 8.68 (1H, d. J 5.0, H-2), 8.01 (1H, 
d, J 9.0, H-3), 7.89 (1H. d. J 2.0, H-5), 7.52 (lH. dd. J 2.1 and 9.0. H-4), 6.95 (1H. d. J 
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5.0, H-t), 3.05 - 3.11 (4H, m, H-6, 9), 2.92 - 2.97 (4H, m. H-7. 8). 3.19 (tH, br s. H-lO): 
oc (tOO MHz. DMSO-d6) 157.4. 152.6, 15.0.2. 133.9. 128.5, 126.6, 121.9, 109.7. 53.7 
(2C), 45.9 (2C). 
General method VU: synthesis of analogues 5.8 - 5.11: 
Hydroxylated chloroquinoline intermediate 5.5 or 5.6 (t eq.), enone 5.1 or chalcone 5.2 
(1 eq.) and triphenylphosphine (t.2 eq.) were dissolved in anhydrous CH2Cb under a N2 
atmosphere. The solution was cooled to O"C, and di-isopropyl azodicarboxylate (DIAD, 
1.2 eq.) was added slowly over 5 min. The stirred reaction mixture was then allowed to 
warm to ambient temperature. and was further stirred for 6 hrs. The mixture was then 
concentrated under reduced pressure, and the target compound purified by silica column 
chromatography (5% MeOH in EtOAc). 
4-{4-[2-(7-Chloro-quinolin-4-ylamino)-ethoxyj-3-methoxy-phenyl}-but-3-en-2-one. 5.8 
Yellow solid (289 mg, 73%); mp 143 - 144"C (from 
MeOH/EtOAc): Rf (MeOH/EtOAc 1:9) 0.23: IR V max 
(KBr)/cm-1 3420 (N-H). 2972 (Ar C-H). 1686 (C=O), 
1584 (Ar C=C); OH (400 MHz. CDCh) 8.57 (lH. d. ) 5.3. 
H-9), 7.99 (tH, d, 11.8, H-lO), 7.76 (lH. d. )8.9. H-12). 
7.46 (tH. d, 116.2. H-a). 7.39 (tH. dd. )1.9 and 8.9. H-
11). 7.13-7.11 (2H, m. H-t, 2). 6.98 (tH, d. ) 8.0. H-3), 
6.63 (lH, d. 116.2, H-b), 6.49 (tH. d. ) 5.3. H-8). 5.70 (lH. s. H-7). 4.39 (2H. t. H-5.0, 
H-5), 3.92 (3H. s, H-4), 3.73 (2H. q. ) 5.0, H-6), 2.37 (3H. s, H-a'); oc (100 MHZ, 
CDCh) 198.2. 151.7, 150.1, 149.8. 148.9. 142.9, 135.1, 128.9, 125.9, 125.5, 122.6, 121.2, 
117.4, 114.7, 110.5, 99.3, 67.7, 55.8, 42.3. 27.4. 21.9; lRMS (EI) m/z 395.3 (M - H) M+ 
C22H21ClN203 requires 396.1; Anal. Caled. for C22H21CIN203 - C 66.6%, H 5.3%, N 7.1%; 
found C 66.5%, H 5.6%, N 7.3%. 
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3-{4-/2-(7-Chloro-quinolin-4-ylamino)-ethoxy]-3-methoxy-phenyl}-1-f2,4-dimethoxy-
phenyl)-propenone, 5.9 
5(0 :I 
7 )6 
HN 
8~1I 9~)~ 
N 10 (I 
Pale yellow solid (310 mg, 60%): mp 164 -
166°C (from MeOH/EtOAc); Rf (MeOH: 
EtOAc 1:9) 0.27; IR Vmax (KBr)/cm-1 3406 (N-
H), 2942 CAr C-H), 1646 (C=O). 1584 (Ar 
C=C): OH (400 MHz, CDCh) 8.57 (1H. d. J 
5.3. H-9), 7.98 (tH, d, J 2.1, H-lO). 7.78-7.74 
(2H, m, H-3', 12). 7.61 (1H. d, J 15.7. H-a). 
7.39 (1H, d, J 15.7, H-b). 7.38 (1H. dd, J 2.1 
and 8.9, H-B), 7.17 (1H, dd, J 1.7 and 8.2. H-2), 7.14 (1H, d, J 1.7, H-l), 6.96 (1H, d, J 
8.2, H-3), 6.57 (1H, dd, 2.2 and 8.6, H-2'). 6.52 (lH, d, J 2.2, H-1'), 6.48 (lH, d, J 5.3, 
H-8), 5.78 (lH, t, J5.5. H-7l, 4.39 (2H. t, J5.2, H-5), 3.92 (3H, s, H-4'), 3.90 (3H, s, H-
5'),3.88 (3H, s, H-4), 3.72 (2H, q, J 5.2, H-6); Oe (100 MHZ. CDCI3) 190.5, 164.1, 160.3, 
152.0, 150.1, 149.6, 149.4, 149.2. 141.8, 134.9, 132.7, 130.2, 128.9. 126.1. 125.4. 122.3, 
122.2. 121.2, 117.5, 115.0, 111.2. 105.2, 99.3, 98.8, 67.8, 55.9, 55.7. 55.5, 42.3; LRMS 
(EI) m/z 517.1(M - H) M+ C29H27C1N20S requires 518.2; Anal. Caled. for C29H.l7(IN20 S - C 
67.1%, H 5.2%, N 5.4%; found C 66.8%, H 5.6%, N 5.3%. 
4-(4-{2-/4-(7-Chloro-quinolin-4-yl)-piperazin-l-yl]-ethoxy}-3-methoxy-phenyl)-but-3-en-2-
one, 5.10 
Pale yellow (316 mg, 68%); mp 61 - 62°C (from 
MeOH/EtOAc): R, (MeOH/EtOAc 1:9) 0.26; IR V max 
(KBr)/cm- 2977 (Ar C-H), 1714 «=0), 1594 (Ar C=C): OH 
(300 MHz, CD(h) 8.72 (lH, d, J 5.0, H-12), 8.04 (1H, d, J 
2.0, H-13). 7.93 (lH. d, J 8.9, H-15). 7.46 (lH, d, 116.1. H-
a), 7.41 (tH. dd, J 2.2 and 9.0, H-14), 7.12 (tH, dd, J 1.9 
and 8.3, H-2), 7.09 (1H, d, J 1.9, H-1), 6.92 (1H, d. J 8.2, 
H-3). 6.83 (1H, d, J 5.0, H-ll). 6.61 (tH. d. J 16.1. H-b), 
4.25 (2H, t. J 5.9. H-5). 3.90 (3H. s, H-4), 3.28-3.25 (4H, m. H-8. 9). 2.99 (2H. t. J 5.9. 
H-6), 2.91-2.88 (4H. m. H-7. 10), 2.36 (3H. s, H-a'); Oe (75 MHZ. (DCb) 198.0, 156.9, 
151.9, 150.5, 150.1, 149.7, 143.2, 134.8, 128.8, 127.8, 126.1. 125.4. 125.1. 122.7, 113.0. 
110.3, 108.9. 67.0, 56.8, 55.9, 53.4, 52.9, 52.1. 27.3. 21.9; LRMS (EI) m/z 464.2 eM - H) 
M+ ( 26H2sC1N 303 requires 465.2; Anal. Caled. for C26H:;!8CIN~3 - C 67.0%. H 6.1%. N 
9.0%; found (66.7%, H 5.8%, N 9.3%. 
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3-(4-{2-[4-(7-Chloro-quinolin-4-y/}-piperazin-l-ylj-ethoxy}-3-methoxy-pheny/}-I-(2.4-
dimethoxy-pheny/}-propenone. 5. n 
Yellow solid (435 mg, 74%); mp 62 - 63°C (from 
MeOH/EtOAc); Rr (MeOH/EtOAc 1:9) 0.30; IR 
V max (KBr)/cml 2938 (C-H). 1648 (C=O). 1600 
(Ar C=C); OH (300 MHz, CDCh) 8.66 (1H. d. J 
5.0. H-12). 8.01 (1H. d. J9.0. H-15). 7.95 (1H. d. 
J 2.1, H-13), 7.56 (1H. d, J 8.5, H-3'). 7.53 (1H. 
dd. J 2.3 and 9.0, H-14), 7.46 (1H. d. J 15.8, H-
al, 7.37 (1H, d, J 15.8. H-b), 7.30 (lH. d, J t.9, 
H-U. 7.23 (1H. dd, J1.9 and 8.4, H-2). 7.05 (1H. 
d. J 8.4. H-3). 6.99 (1H. d. J 5.1. H-ll), 6.67 (1H. d, J 2.2. H-r). 6.62 (1H. dd, J 2.2 and 
8.6. H-2'). 4.19 (2H. t. J 5.8 H-5). 3.87 (3H, s, H-4'), 3.84 (3H. s, H-5'), 3.83 (3H, s. H-
4), 3.19 (4H, t. J 4.8, H-8. 9). 2.85 (2H. t. J 5.8. H-6). 2.79 (4H. t. J 4.8. H-7, 10); oc (75 
MHZ, CDCh) 189.7, 163.5. 159.9. 156.2. 151.9. 150.1. 149.6. 149.2. 141.6. 133.4. 131.5. 
127.9,125.8, 125.5. 125.1. 122.3. 121.7. 121.2. 113.3. 111.4. 109.2. 105.8. 98.7. 65.6. 56.3. 
55.8 (2C), 52.8 (2C), 51.7 (2C); lRMS (EI) mlz 586.0 (M - H) M+ CnH)4CIN30 s requires 
587.2; Anal. Caled. for C33H)4CIN30s - C 67.4%. H 5.8%. N 5.2%; found C 67.3%, H 
5.9%, N 5.3%. 
General method VIII: synthesis of analogues 5.12 - 5.15: 
The appropriate hydroxylated chalcone or enone (5.1 - 5.4) (1 eq.) and the 
piperazinylquinoline intermediate. 5.7 (1 eq) were dissolved in EtOH. Formaldehyde 
(37% solution in water, 10 eq.) was then added to the stirring solution. which was then 
refluxed at ll00C for 12 hrs. 
The reaction mixture was then allowed to cool to ambient temperature, after which it 
was concentrated under reduced pressure and purified by column chromatography 
(EtOAc) to yield the pure target compounds. 
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4-{3-[4-(7-Chloro-quinolin-4-yl)-piperazin-I-ylmethylj-4-hydroxy-5-methoxy-phenyl}-but-
3-en-2-one.5.12 
3 
Yellow solid (58%); mp 91 - 92°C (from EtOAe): R, 
(EtOAe) 0.15; IR V max (KBr)/eml 2943 (C-H), 1662 (C=O), 
1575 (Ar C=C): OH (300 MHz. CDCh) 8.73 (tH, d. ) 5.0, 
H-ll), 8.06 (1H, d, ) 2.1. H-12), 7.89 (tH, d, ) 9.0, H-14), 
7.43 (tH. d. ) 16.1, H-a). 7.40 (1H. dd. ) 2.1 and 9.0, H-
13).7.03 (1H, d, )1.5, H-2). 6.91 (tH, d, )1.5. H-l), 6.82 
(tH, d, ) 5.0, H-l0), 6.58 (tH, d. ) 16.1, H-b), 3.91 (3H. s, 
H-3), 3.89 (2H, s. H-5), 3.28 - 3.34 (4H, m, H-7. 8), 2.90 
- 2.96 (4H, m. H-6, 9), 2.35 (3H, s. H-a'); oc (75 MHz. 
CDC(3) 198.1, 156.4. 151.6. 149.9, 149.6, 148.4, 143.5, 135.2, 128.8, 126.5, 125.8, 124.9, 
124.8. 122.5. 121.7, 120.9. nO.1, 109.1. 60.7. 55.9, 52.4 (2C). 51.9 (2C). 27.4; lRMS (EI) 
m/z 450.7 (M - H) M+ C25H26CIN303 requires 451.9; Anal. Caled. for C2sH26CIN303.H20-
C 63.8%, H 6.0%, N 8.9%: found C 64.0%, H 6.2%, N 8.7%. 
3-{3-[4-(7-Chloro-quinolin-4-yl)-piperazin-l-ylmethyIJ-4-hydroxy-5-methoxy-phenyl}-I-
(2.4-dimethoxy-phenyl)-propenone. 5.13 
5 
:c) 
6Y4 10 I ~ ~ 13 11 N"": h (I 
12 
2' 
o 
5' 
Deep yellow solid (66%); mp 95 - 97°C (from 
EtOAe); R, (EtOAe) 0.20; IR Vmax (KBr)/em! 
2938 (C-H), 1648 (C=O). 1597 (Ar C=C); OH 
(400 MHz. CDCh) 8.71 (1H. d. ) 5.1, H-U). 
8.10 (1H. d. ) 1.9. H-12). 7.89 (1H, d, ) 9.0, H-
14). 7.72 (tH. d, ) 8.6. H-3'), 7.58 (lH. d. ) 
15.8. H-a). 7.44 (lH. dd. ) 1.9 and 8.9, H-13). 
7.33 (tH, d. 115.7. H-b). 7.09 (tH. d. )1.8. H-
2), 6.97 (t H. d, ) 1.8. H-l), 6.84 (tH. d. ) Sol, 
H-lO), 6.57 (tH. dd, )1.7 and 8.6. H-2'), 6.51 (tH. d. 11.8. H-1'). 3.92 (3H. s, H4'). 3.91 
(5H. s. H-5. 5'), 3.87 (3H. s. H-3). 3.32 - 3.55 (4H. m. H-7, 8),2.90 - 2.96 (4H, m. H-6. 
9); oc (tOO MHz. CDCh) 190.9. 163.9. 160.3, 156.7. 151.2, 149.4. 149.2, 148.3. 142.5, 
135.5, 132.6, 128.4, 126.6, 124.9. 124.8. 122.7, 122.6, 121.6. 120.7, 110.8, nO.5, 109.0, 
105.2, 98.8, 60.6, 56.0, 55.8, 55.5, 52.3 (2C), 51.8 (2C); lRMS (EI) m/z 572.7 (M - H) 
M+ C32H32C1N30S requires 573.2; Anal. Caled. for C32H32C1N 30s.H20 - C 64.8%, H 
5.7%, N 7.1%; found C 64.4%, H 6.0%, N 6.7%. 
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4-{3-[4-(7-Ch/oro-quinolin-4-ylj-piperazin-l-ylmethyIJ-4-hydroxy-phenyl}-but-3-en-2-one. 
5.14 
4 3 
HoN;y1. I b iJ' 
5 ~ ~ 
6(N)" • 0 
7 N 8 
6:):4 10 ~ ~ 13 I .....: "" 
11 N // (I 
U 
Pale yellow solid (45%); mp 83 - 85 "C (from EtOAe); Rf 
(EtOAc) 0.35: IR Vmax (KBr)/cm-! 2823 (C-H), 1663 (C=O). 
1578 CAr C=C): OH (300 MHz. CDCh) 8.71 (1H. d.) 5.1. H-
11). 8.07 (lH. d. ) 2.1, H-12), 7.89 (1H, d, ) 9.0. H-14), 
7.44 (tH. d, ) 16.4. H-a). 7.43 (tH. dd, ) 2.1 and 9.0, H-
B), 7.41 (1H. dd. ) 2.3 and 8.4, H-2), 7.30 (tH, d, ) 2.3. 
H-t). 6.86 (1H. d, ) 8.4, H-3). 6.85 (tH. d. ) Sol, H-10), 
6.58 (1H, d, ) 16.3, H-b), 3.88 (2H, s, H-5), 3.28 - 3.35 
(4H, m, H-7, 8), 2.85 - 2.93 (4H, m, H-6, 9), 2.34 (3H, s, 
H-a'); oc (75 MHz. CDCh) 198.2. 160.1. 156.5. 151.5. 149.7. 143.2. 135.3, 129.8. 129.1, 
128.7. 126.5. 126.0, 124.8. 124.6. 121.7. 121.1. 116.9. 109.1. 61.2. 52.4 (2C), 51.9 (2 C). 
27.4; lRMS (EI) mlz 420.7 (M - H) M+ C24H24C1N]02 requires 421.9; Anal. Calcd. for 
C24H24CIN)02.H20 - C 65.5%, H 5.9%. N 9.5%; found C 65.7%. H 6.0%. N 9.4%. 
3-{3-[4-(7-Chloro-quinolin-4-ylj-piperazin-I-y/methy/J-4-hydroxy-pheny!}-1-(2.4-
dimethaxy-p/7enylj-propenone. 5.15 
5 
:c): 
6&4 10 ~ ~ 13 I .....: ..", 11 N ,r", (I 11. 
l' 
5' 
Yellow solid (49%): mp 85 - 87 .. c (from 
EtOAc); Rt (EtOAe) 0.40; IR V max (KBr)/em! 
2935 (C-H), 1649 (C=O), 1598 (Ar C=C): OH 
(400 MHz, CDCh) 8.68 (1H, d, ) 5.0, H-n>, 
8.07 (tH. d. ) 1.8, H-12), 7.89 (1H, d, ) 9.0, H-
14). 7.69 (lH, d, ) 8.6, H-3'), 7.57 (lH, d, ) 
15.7, H-a). 7.46 (1H, dd, ) 1.9 and 8.5, H-2), 
7.41 (1H, dd, )1.8 and 8.9, H-13), 7.32 (lH, d, ) 
15.7, H-b), 7.24 (1H. d, )1.9. H-t). 6.83 (1H. d. 
) 8.3. H-3), 6.82 (1H, d, ) 4.9. H-1O), 6.52 (tH, dd. ) 2.0 and 8.6. H-2'). 6.47 (tH, d, ) 
2.0. H-n, 3.87 (3H. s. H4'). 3.85 (2H. s. H-5), 3.83 (3H, s. H-5'). 3.28 - 3.34 (4H. m, 
H-7. 8). 2.84 - 2.90 (4H. m. H-6. 9); oc (100 MHz. CDCh) 190.6. 163.9. 160.2. 159.6. 
156.7, 151.1. 149.3, 142.1. 135.5. 132.6. 129.6. 129.3. 128.4. 127.1. 126.6. 124.8. 124.6, 
122.5, 121.5. 120.8. 116.9. 108.9, 105.1, 98.7. 61.55. 55.7. 55.4, 52.4 (2 C), 51.8 (2 C): 
LRMS (EI). m/z 542.8 M+ C31 H30ClN)04 requires 543.2; Anal. Cakd. for 
C31H3oCIN)04.H20 - C 66.2%. H 5.7%. N 7.5%: found C 66.4%, H 5.6%, N 7.2%. 
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8.2 Biological evaluation 
The biological evaluation procedures not described in the main text are outlined below. 
8.2.1 p-hematin inhibition assay 
This assay was carried out as described by Kanyile and Egan. 2.004 [3}. and is based on 
the pyridine-hemochrome method of quantifying heme. Briefly. serial dilutions of the 
drug solutions were carried out in triplicate across a 96-well plate such that each well 
contained 10.12 III of drug solution. Concentrations of drug solution corresponded to 0-
1.0 equivalents relative to hematin in the final mixture. 1.01.2 III of hematin stock solution 
(1.68.0 mM in .0.1 M NaOH) was then added to each well. and the solutions mixed. 
Subsequently. 58.7 III of sodium acetate solution (12.9 M. pH 5 . .0) preincubated at 6.0 °C 
was added and the plates incubated at 6.0 °C for 6.0 min. Thereafter, 8.0 III of 3.0% (v/v) 
pyridine solution in 2.0 mM HEPES buffer pH 7.5 was added at ambient temperature. 
Solids were resuspended and then allowed to settle for 15 minutes. after which 38 III of 
supernatant was transferred to another plate and diluted to 25.0 III with 3.0% (v/v) 
pyridine solution (pH 7.5.2.0 mM HEPES buffer). The plates were then read on a 
microplate reader. and the resulting data was plotted and analyzed. 
8.2.2 Falcipain2 inhibition assay 
This assay was carried out as described by Rosenthal et al. 1996 [4], with modifications 
described by Greenbaum et al. 2.004 [5]. This assay is based on the quantifiable 
fluorescence caused by the cleavage of benzyloxycarbonyl-Phe-Arg-7-amin0-4-methyl-
coumarin (Z-Phe-Arg-AMC) by Fakipain 2. The assays were carried out in 96-well plates. 
Briefly, different concentrations of each test compound (prepared from stock solutions in 
DMSO by dilution with .O.1M sodium acetate) were incubated in duplicate or triplicate 
with equal amounts of recombinant Falcipain 2 (in .OJ M sodium acetate and 10 mM 
dithiothreitol [pH 5.5]) for 3.0 min at room temperature. Positive controls were 
incubated with E-64 (1.0 mM). The substrate (Z-Phe-Arg-AMC) was then added in the 
same buffer to give a final concentration of 15 11M. and the fluorescence caused by the 
cleavage of Z-Phe-Arg-AMC was monitored continuously over 15 min at room 
temperature. ICso values were determined from plots of percentage activity versus 
compound concentrations . 
. ~!C M. GUANTAI - f'h.D THESIS 201() 
240 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
CHAPTER EIGHT: EXPERIMENTAL 
References 
1. R C Elderlield. W J Gensler. 0 Birstein. F J Kreysa. J T Maynard. and J Galbreath. Synthesis of Certain Simple 4-
Aminoquinoline Derivatives. J. Am. Chern. Soc. (1946) 68 1250-1251. 
2. T Singh. R G Stein. J F Hoops. J H Biel. W K Hoya. and 0 R Cruz. Antimalarials. 7-Chlor0-4-(substituted 
amino)quinolines. J. Med. Chem. (1971) 14 (4) 283-286. 
3. K Ncokazi and T Egan. A colorimetric high-throughput li-hematin inhibition scree'ling assay for use in the searm 
for antimalarial compounds. Anal. Biochem. (2004) 338 306-319. 
4. P J Rosenthal. J E Olson. G K lee. J T Palmer. J l Klaus. and 0 Rasnick. Antimalarial Effects of Vinyl Sulfone 
Cysteine Proteinase Inhibitors. Antimicrob. Agents Chemother. (1996) 40 (7) 1600-1603. 
5. 0 C Greenbaum. Z Mackey. E Hansell. P Doyle. J Gut. C R Caffrey, J Lehrman. P J Rosenthal. J H McKerrow. 
and K Chibale. Synthesis and Strudure-Activity Relationships of Parasiticidal Thlosemiollbazone Cysteine 
Protease Inhibitors against Plasmodium taldparulTJ, Trypanosoma brucei. and Tlypanosoma cruzi. J. Med. 
Chern. (2004) 47 3212-3219. 
'RIC M. CUANTAI PhD nilSIS 2010 
241 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
" 
APP[ NDI([S 
AP PENDIX A: TABIH or RCi ULTS rROM PHARMACOK1NFTIC STUDIES 
Tab le AI: Tobie of the determined W<1"",( rJtiorll Inv'r,,!.) of compound 3.15b In the J1l0u<e 
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la l~~ A3 ' f3ble 01 (h" de!ermined (0I1(entr~t ioo5 (nyml ) of compound 5.7 in 1he moo'~ 
I' ,me MCl"€ Moo. Moo, Moo< MO\lsC 
(houT<) , , ; , , A", ~Id [)e.... 
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